WO2013184757A1 - Compounds and compositions for modulating egfr activity - Google Patents

Compounds and compositions for modulating egfr activity Download PDF

Info

Publication number
WO2013184757A1
WO2013184757A1 PCT/US2013/044247 US2013044247W WO2013184757A1 WO 2013184757 A1 WO2013184757 A1 WO 2013184757A1 US 2013044247 W US2013044247 W US 2013044247W WO 2013184757 A1 WO2013184757 A1 WO 2013184757A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
enoyl
azepan
alkyl
benzo
Prior art date
Application number
PCT/US2013/044247
Other languages
French (fr)
Inventor
Gerald Lelais
Robert Epple
III Thomas H. MARSILJE
Pierre-Yves Michellys
Matthew H. Mcneill
Yun LONG
Wenshuo Lu
Bei Chen
Badry Bursulaya
Songchun Jiang
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013184757(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK13729219.9T priority Critical patent/DK2773635T3/en
Priority to LTEP13729219.9T priority patent/LT2773635T/en
Priority to EP13729219.9A priority patent/EP2773635B1/en
Priority to BR112014030386-0A priority patent/BR112014030386B1/en
Priority to KR1020147037047A priority patent/KR101817829B1/en
Priority to MA37739A priority patent/MA37739B1/en
Priority to AU2013271733A priority patent/AU2013271733B2/en
Priority to JP2015516156A priority patent/JP6039800B2/en
Priority to MX2014014961A priority patent/MX345630B/en
Priority to ES13729219.9T priority patent/ES2645973T3/en
Priority to CA2875966A priority patent/CA2875966C/en
Priority to UAA201412612A priority patent/UA113543C2/en
Priority to NZ627661A priority patent/NZ627661A/en
Priority to SG11201407793TA priority patent/SG11201407793TA/en
Priority to PL13729219T priority patent/PL2773635T3/en
Priority to RS20170954A priority patent/RS56396B1/en
Priority to AP2014008083A priority patent/AP3909A/en
Priority to MEP-2017-232A priority patent/ME02844B/en
Priority to SI201330801T priority patent/SI2773635T1/en
Priority to CN201380029790.XA priority patent/CN104379575B/en
Priority to US14/405,773 priority patent/US9440957B2/en
Priority to EA201492219A priority patent/EA026269B1/en
Application filed by Irm Llc filed Critical Irm Llc
Publication of WO2013184757A1 publication Critical patent/WO2013184757A1/en
Priority to TN2014000487A priority patent/TN2014000487A1/en
Priority to IL235974A priority patent/IL235974A/en
Priority to PH12014502704A priority patent/PH12014502704A1/en
Priority to CR20140563A priority patent/CR20140563A/en
Priority to CUP2014000139A priority patent/CU20140139A7/en
Priority to HRP20171670TT priority patent/HRP20171670T1/en
Priority to CY20171101147T priority patent/CY1119531T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Definitions

  • the invention relates to compositions and methods for modulating the activity of the epidermal growth factor receptor (EGFR, Erb-Bl).
  • EGFR epidermal growth factor receptor
  • Erb-Bl epidermal growth factor receptor
  • the epidermal growth factor receptor belongs to a family of proteins involved in the proliferation of normal and malignant cells. Overexpression of EGFR is found in over 70 percent of human cancers, including without limitation non-small cell lung carcinomas (NSCLC), breast cancers, gliomas, squamous cell carcinoma of the head and neck, and prostate cancer.
  • NSCLC non-small cell lung carcinomas
  • breast cancers gliomas
  • squamous cell carcinoma of the head and neck and prostate cancer.
  • anti-EGFR targeted molecules such as gefitinib and erlotinib.
  • a secondary EGFR mutation, T790M can render gefitinib and erlotinib ineffective inhibitors of EGFR kinase activity.
  • Another major limitation of current EGFR inhibitors is the development of toxicity in normal tissues. Because ATP affinity of EGFR T790M is similar to wild type EGFR, the concentration of an irreversible EGFR inhibitor required to inhibit EGFR T790M may also effectively inhibit wild type EGFR.
  • the class-specific toxicities of current EGFR kinase inhibitors are a result of inhibiting wild type EGFR in non-cancer tissues. These toxicities preclude dose escalation of current agents to plasma levels that can effectively inhibit EGFR T790M.
  • the invention provides compositions and methods for modulating the activity of the epidermal growth factor receptor (EGFR).
  • the invention provides compounds which act as inhibitors of EGFR.
  • EGFR epidermal growth factor receptor
  • Ring A is a 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and optionally substituted with oxo;
  • Ring B is phenyl; a 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S; or a 5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted by oxo;
  • E is NH or CH 2 ;
  • R ⁇ R r and R 2 are independently hydrogen; halo; cyano; Ci_ 6 alkyl; Ci_ 6 haloalkyl;
  • heteroaryl comprising 1-4 heteroatoms selected from N, O and S; phenyl,
  • heterocyclyl comprising 1-2 heteroatoms selected from N, O, S and P, and optionally substituted by oxo; - X 1 -C(0)OR 3 ; -X 1 -0-C(0)R 3 ; -X 1 -C(0)R 3 ;
  • each phenyl, heteroaryl, or heterocyclyl in R 1 or R 2 is unsubstituted or substituted by 1-3 groups selected from OH, halo, Ci_6 alkyl, Ci_6 haloalkyl and Ci_6 haloalkoxy;
  • R 3 , R 4 and R 5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R 4 and R 5 together with N in NR 4 R 5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R 7 ;
  • R 6 is Ci_6 alkyl or Ci_ 6 haloalkyl
  • R 6a and R 6b are independently hydroxy, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 alkoxy, Ci_6 haloalkoxy, 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and o tionally substituted with oxo;
  • R 9 and R 10 are independently hydrogen, halo, Ci_ 6 alkyl, Ci_ 6 haloalkyl, OH, cyano, Ci_6 alkoxy, Ci_6 haloalkoxy;
  • R lla , R llb , R llc , R lld , R lle , R llf , R llg , R llh , R ni , R llj , R llk and R 111 are
  • Ci_6 alkyl or Ci_6 haloalkyl independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl
  • R 12 and R 13 are independently hydrogen, halo, cyano, Ci_6 alkyl or Ci_6 haloalkyl;
  • R 14 and R 15 are independently hydrogen, Ci_ 6 alkyl, -L ] -R 23 , -(CR a R b ) 2 - 3 -R c or -L 2 - R d ; or R 14 and R 15 together with N in NR 14 R 15 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R 18 groups;
  • R and R are independently hydrogen or Ci_ 6 alkyl; or R and R together with the carbon to which they are attached may form a C3-6 cycloalkyl;
  • X 1 and X 2 are independently a bond or Ci_6 alkyl
  • X 3 is Ci_6 alkyl
  • X 4 is C 2 -6 alkyl
  • R 19 hydrogen, Ci_ 6 alkyl, COR 20 , COOR 20 , CONR 20 R 21 or S(0) 2 R 2 °;
  • R 20 is Ci-6 alkyl, Ci_6 haloalkyl or cycloalkyl
  • R 21 is hydrogen or Ci_ 6 alkyl; or R 20 and R 21 together with the N in NR 20 R 21 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S, P and optionally substituted with 1-4 R 22 groups;
  • R 7', R 1 1 8 0 and R 2 ⁇ 2 are independently oxo, halo, hydroxy, Ci_6 alkyl, Ci_6 haloalkyl, Ci-6 alkoxy or Ci_6 haloalkoxy;
  • R 23 is independently C3-7 cycloalkyl, or a 4-10 membered heterocyclyl comprising 1-3 heteroatoms selected from N, O and S, and is optionally substituted with oxo; and R 23 is unsubstituted or substituted with Ci_ 6 alkyl, Ci_ 6 haloalkyl, -L 3 -R e or -L 4 -R f ;
  • R c and R e are independently halo, cyano, hydroxy, -OR 24 , -NRR 25 , -NR-C0 2 R 24 , - NR-SO2-R 26 , -NR-COR 26 , -NR-C(0)-NRR 25 , -OC(0)-NRR 25 , or Ci_ 6 alkyl substituted with halo, Ci_6 alkoxy, hydroxy or cyano;
  • R d and R f are independently -S0 2 NRR 25 , -CONRR 25 , -C(0)OR 24 , -S0 2 R 26 or C(0)R 26 ;
  • R 24 is Ci_6 alkyl, Ci_ 6 haloalkyl, -L 2 -R 23a or -(CR a R b ) 2 _ 3 -N(R a R b ) 2 ;
  • R 25 is hydrogen, Ci_ 6 alkyl, Ci_ 6 haloalkyl, -L 2 -R 23b or-(CR 2 ) 2 _ 3 -N(R a R b ) 2 ;
  • R 26 is Ci_6 alkyl, Ci_ 6 haloalkyl, -L 2 -R 23c or -(CR a R b )i_ 3 -N(R a R b ) 2 ;
  • R 23a , R 23b and R 23c are independently selected from R 23 ;
  • R, R a and R b are independently hydrogen or Ci_6 alkyl
  • L 1 , L 2 , L 3 and L 4 are independently a bond or -(CR a R b )i_3;
  • n and m are independently 1-3; and p and q are 1-4;
  • Ring A is a 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 5- membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo;
  • R 1 and R r are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl; -X ] -NR 4 R 5 ; -X ] -OR 3 ; -X 1 -S(O) 0 - 2 R 6 ; -X 1 -P(0)R 6a R 6b ; phenyl unsubstituted or substituted by Ci-6 alkyl; or a 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S;
  • R 3 , R 4 and R 5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R 4 and R 5 together with N in NR 4 R 5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R 7 groups;
  • R 6 , R 6a and R 6b are Ci_ 6 alkyl
  • Z is ; provided Z is a 4-7 membered
  • Y is O or NR 19.
  • R 9 , R 10 , R Ua , R U , R nc , R nd , R l le , R uf , R Ug , R nh , R 1 H , R l lj , R l lk and R 111 are hydrogen;
  • R 12 , R 13 , R 16 and R 17 are independently hydrogen or Ci_6 alkyl
  • R 14 and R 15 are independently hydrogen; Ci_ 6 alkyl; -C(0)0-(Ci_ 6 alkyl); C3-7 cycloalkyl unsuhstituted or substituted with Ci_6 alkyl; or R 14 and R 13 together with N in NR 14 R 15 may form may form a 4-7 membered ring containing 1-2 heteroatoms selected
  • R 7 and R 18 are independently oxo, halo, hydroxy, Ci_6 alkyl or Ci- 6 alkoxy;
  • R 19 hydrogen, COR 20 or COOR 20 ;
  • R 20 is Ci-6 alkyl
  • p 1 ;
  • n and q are independently 1-2;
  • Ring B, X 1 , X 2 , X 3 and X 4 and n are as defined in any of the embodiments described herein.
  • Y is O or NR ;
  • R 1 , R r , R 2 , R 8 , R 19 , A, B, Y, m and n are as defined in any of the embodiments described herein.
  • W 1 , W 2 , W 3 and W 4 are independently CR 1 or N; and R 1 , R r , R 2 , R 8 , Y and m are as defined in any of the embodiments described herein.
  • at least two of W 1 , W 2 , W 3 and W 4 are CR 1 , and the others are N.
  • W 1 and W 2 are independently CR 1 or N; and R 1 , R 1 , R 2 , R 8 and m are as defined in any of the embodiments described herein.
  • a compound of Formula (4) or (5) as described herein, or a pharmaceutically acceptable salt thereof wherein: (i) W 1 is CR 1 and W 2 is N; (ii) W 2 is CR 1 and W 1 is N; (iii) W 1 and W 2 are CR 1 ; or (iv) W 1 and W 2 are N.
  • R 1 and R 1' are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl; - X ] -NR 4 R 5 ; -X ] -OR 3 ; -X 1 -S(O) 0 - 2 R 6 ; phenyl unsubstituted or substituted by d_ 6 alkyl; tetrazolyl or pyrrolyl;
  • each X 1 is a bond or CH 2 ;
  • R 3 , R 4 and R 5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R 4 and R 5 together with N in NR 4 R 5 form piperidinyl; and
  • R 6 is as defined in Formula (1) or (2).
  • R 1 is hydrogen, halo, cyano, Ci_6 alkyl, Ci_6 haloalkyl, tetrazolyl, pyrrolyl, -X 1 -
  • R 1 is hydrogen, halo or Ci_6 alkyl
  • R 3 , R 4 and R 5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R 4 and R 5 together with N in NR 4 R 5 form piperidinyl;
  • X 1 is a bond or CH 2 ;
  • R 6 is as defined in Formula (1) or (2).
  • R 1 and R 1 are independently hydrogen; methyl; t-butyl; trifluoromethyl; methoxy; ethoxy; trifluoromethoxy; difluoromethoxy; fluoro; chloro; cyano; dimethylamino; methylsulfonyl; dimethylphosphoryl; tetrazolyl; pyrrolyl; phenyl unsubstituted or substituted by methyl; or piperidinyl.
  • methylsulfonyl methylcarbonyl; carboxy; methoxycarbonyl; carbamoyl;
  • R 2 is -CH 2 -N(CH 3 )-C(0)-CH 3 ; -CH
  • R 2 is halo
  • a pharmaceutical composition comprising a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3 A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a combination comprising a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a
  • EGFR epidermal growth factor receptor
  • EGFR epidermal growth factor receptor
  • the EGFR is a mutant EGFR; for example, wherein the mutant EGFR comprises G719S, G719C, G719A, L858R, L861Q, an exon 19 deletion mutation or an exon 20 insertion mutation.
  • the mutant EGFR further comprises an EGFR T790M, T854A or D761Y resistance mutation; more particularly, the mutant EGFR comprises L858R or an exon 19 deletion, each of which may further comprise an EGFR T790M.
  • NSCLC non-small cell lung cancer
  • a method for inhibiting epidermal growth factor comprising administering to a system or subject a therapeutically effective amount of a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3 A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof.
  • Also provided herein is a method for treating a condition mediated by epidermal growth factor receptor, comprising administering to a system or subject in need of such treatment an effective amount of a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof,
  • mutant specific EGFR inhibitors that are less effective against wild type EGFR.
  • Ci_ 6 alkyl denotes a saturated or unsaturated alkyl radical having from 1 up to 6 carbon atoms, the radicals being either linear or branched with single or multiple branching; for example, butyl, such as n-butyl, sec-butyl, isobutyl, tert- butyl; propyl, such as n-propyl or isopropyl; ethyl or methyl.
  • the Ci- 6 alkyl is a saturated alkyl radical, and where specified, may be unsubstituted or substituted, for example by halo (i.e., haloalkyl such as trifluoromethyl, and the like), hydroxy (hydroxyalkyl such as hydroxymethyl, hydroxyethyl, 2-hydroxy-2-propyl and the like) or cyano (cyanoalkyl such as cyanomethyl, cyanoethyl and the like).
  • halo i.e., haloalkyl such as trifluoromethyl, and the like
  • hydroxy hydroxyalkyl such as hydroxymethyl, hydroxyethyl, 2-hydroxy-2-propyl and the like
  • cyano cyanoalkyl such as cyanomethyl, cyanoethyl and the like
  • Ci- 6 alkoxy refers to the group -OR a , where R a is Ci_ 6 alkyl group as defined herein.
  • alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butyloxy, t-butyloxy, pentyloxy, hexyloxy and the like.
  • Ci_ 6 haloalkyl refers to Ci_ 6 alkyl group as defined herein, substituted with one or more halo groups, which may be the same or different.
  • the haloalkyl can be monohaloalkyl, dihaloalkyl or polyhaloalkyl, including perhaloalkyl.
  • a haloalkyl group is trifluoromethyl.
  • cycloalkyl refers to a saturated or unsaturated monocyclic hydrocarbon group.
  • C3_ 7 cycloalkyl or “Cs_ 6 cycloalkyl” as used herein refer to a cycloalkyl having from 3 up to 7 carbon atoms, or from 5 to 6 carbon atoms, respectively; for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • aryl refers to an aromatic hydrocarbon group having 6-10 carbon atoms in the ring portion, and can be a single or bicyclic aromatic ring. Non- limiting examples include phenyl, naphthyl or tetrahydronaphthyl.
  • heteroaryl refers to a 5-10 membered heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, which may be a 5-6 membered monocyclic ring or an 8-10 membered fused bicyclic ring where at least one of the rings is aromatic.
  • Such bicyclic ring systems may be fused to one or more aryl, cycloalkyl, or heterocycloalkyl rings.
  • heteroaryl groups include 2- or 3-furyl; 1-, 2-, 4-, or 5-imidazolyl; 3-, 4-, or 5-isothiazolyl; 3-, 4-, or 5-isoxazolyl; 2-, 4-, or 5-oxazolyl; 4- or 5-1,2,3-oxadiazolyl; 2- or 3-pyrazinyl; 1-, 3-, 4-, or 5- pyrazolyl; 3-, 4-, 5- or 6-pyridazinyl; 2-, 3-, or 4- pyridyl; 2-, 4-, 5- or 6-pyrimidinyl; 1-, 2- or 3-pyrrolyl; 1- or 5-tetrazolyl; 2- or 5-1,3,4- thiadiazolyl; 2-, 4-, or 5-thiazolyl; 2- or 3-thienyl; 2-, 4- or 6-1,3,5-triazinyl; 1-, 3- or 5- 1,2,4-triazolyl; 1-, 4- or 5-1,2,3-triazolyl; 2-,
  • heterocyclyl or “heterocyclic” refer to a saturated or unsaturated non-aromatic ring or ring system, e.g., which is a 4-, 5-, 6-, or 7-membered monocyclic, or 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring system and contains at least one heteroatom selected from O, S, P and N, where the N, S and P can also optionally be oxidized to various oxidation states.
  • the heterocyclic group can be attached at a heteroatom or a carbon atom. Examples of heterocycles include tetrahydrofuran
  • THF dihydrofuran, 1, 4-dioxane, morpholine, 1,4-dithiane, piperazine, piperidine, 1,3- dioxolane, imidazolidine, imidazoline, pyrroline, pyrrolidine, azetidinyl, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane, 1,3-dithiane, oxathiane,
  • heterocyclyl further refers to heterocyclic groups that is substituted by oxo; for example, pyrrolidin-2-one, 1,6-dihydro- pyridin-2(3H)-one, pyridin-2-(3H)-one, and the like.
  • heteroatoms refers to nitrogen (N), oxygen (O), sulfur (S) or phosphorus (P) atoms, wherein the N, S and P can optionally be oxidized to various oxidation states.
  • acceptable with respect to a compound, formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.
  • administering means providing a compound of the invention, a pharmaceutically acceptable salt, a
  • co-administration or “combined administration” or the like as used herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • dilute a compound described herein prior to delivery refers to chemical compounds that are used to dilute a compound described herein prior to delivery. Diluents can also be used to stabilize compounds described herein.
  • an “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of a compound described herein being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
  • an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms.
  • An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study.
  • the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • pharmaceutically acceptable refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compounds described herein. Such materials are administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • carrier refers to chemical compounds or agents that facilitate the incorporation of a compound described herein into cells or tissues.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts,
  • pharmaceutically acceptable salt refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compounds described herein.
  • combination means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non- fixed combinations of the active ingredients.
  • fixed combination means that the active ingredients, by way of example, a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients, by way of example, a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5) or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient.
  • cocktail therapy e.g. the administration of three or more active ingredients.
  • composition refers to a mixture of at least one compound, such as a compound Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof, with at least one and optionally more than one other pharmaceutically acceptable chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
  • subject or "patient,” as used herein, encompasses mammals and non- mammals.
  • mammals include, but are not limited to, humans, chimpanzees, apes, monkeys, cattle, horses, sheep, goats, swine; rabbits, dogs, cats, rats, mice, guinea pigs, and the like.
  • non-mammals include, but are not limited to, birds, fish and the like.
  • the subject is a human, and may be a human who has been diagnosed as in need of treatment for a disease or disorder disclosed herein.
  • a subject is "in need of a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • an optical isomer or "a stereoisomer”, as used herein, refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom.
  • the term “chiral” refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound.
  • “Enantiomers” are a pair of stereoisomers that are non- superimposable mirror images of each other. A 1 : 1 mixture of a pair of enantiomers is a "racemic" mixture. The term is used to designate a racemic mixture where appropriate.
  • Diastereoisomers are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
  • the absolute stereochemistry is specified according to the Cahn- lngold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
  • Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
  • Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
  • a therapeutically effective amount of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a subject, is effective to: (a) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by EGFR kinase, (ii) associated with EGFR kinase activity, or (iii) characterized by activity (normal or abnormal) of EGFR kinases; (b) reducing or inhibiting the activity of EGFR kinase; or (c) reducing or inhibiting the expression of EGFR kinase.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of EGFR kinase; or at least partially reducing or inhibiting the expression of EGFR kinase.
  • treat refers to methods of alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.
  • the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat”, “treating” or “treatment” refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • treatment refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • the term "compound(s) of the invention” or “compound(s) provided herein” refers to compounds of Formula (1) and subformulae thereof (Formula (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5)), a pharmaceutically acceptable salt thereof, a prodrug thereof, a stereoisomer thereof (including diastereoisomers and enantiomers), a tautomer thereof, an isotopically labeled compound thereof (including deuterium substitutions), as well as inherently formed moieties (e.g., polymorphs, solvates and/or hydrates).
  • the invention provides compositions and methods for modulating the activity of the epidermal growth factor receptor (EGFR).
  • EGFR epidermal growth factor receptor
  • the invention provides compounds which act as inhibitors of EGFR.
  • Various embodiments of the invention are described herein.
  • a compound of Formula (1) in one aspect, provided herein is a compound of Formula (1), a tautomer thereof, or a pharmaceutically accep
  • Ring A is a 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and optionally substituted with oxo;
  • Ring B is phenyl; a 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S; or a 5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted by oxo;
  • E is NH or CH 2 ;
  • R r and R 2 are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl; 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; phenyl, 5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O, S and P, and optionally substituted by oxo; - X 1 -C(0)OR 3 ; -X 1 -0-C(0)R 3 ; -X ] -C(0)R 3 ;
  • each phenyl, heteroaryl, or heterocyclyl in R 1 or R 2 is unsubstituted or substituted by 1-3 groups selected from OH, halo, Ci_6 alkyl, Ci_6 haloalkyl and Ci_6 haloalkoxy;
  • R 3 , R 4 and R 5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R 4 and R 5 together with N in NR 4 R 5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R 7 ;
  • R 6 is Ci-6 alkyl or Ci_6 haloalkyl
  • R 6a and R 6b are independently hydroxy, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 alkoxy, Ci_6 haloalkoxy, 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and o tionally substituted with oxo;
  • Ci_6 alkyl or Ci_6 haloalkyl independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl
  • R 12 and R 13 are independently hydrogen, halo, cyano, Ci_6 alkyl or Ci_6 haloalkyl;
  • R 14 and R 15 are independently hydrogen, Ci_ 6 alkyl, -L ] -R 23 , -(CR a R b ) 2 - 3 -R c or -L 2 - R d ; or R 14 and R 15 together with N in NR 14 R 15 may form a 4-7 membered ring containing
  • R and R are independently hydrogen or Ci_6 alkyl; or R and R together with the carbon to which they are attached may form a C3-6 cycloalkyl;
  • X 1 and X 2 are independently a bond or Ci_6 alkyl
  • X 3 is Ci_6 alkyl
  • X 4 is C 2 _6 alkyl
  • R iy hydrogen, Ci_ 6 alkyl, COR , COOR , CONR zu R zl or S(0) 2 R ;
  • R 20 is Ci-6 alkyl, Ci_6 haloalkyl or cycloalkyl
  • R 21 is hydrogen or Ci_ 6 alkyl; or R 20 and R 21 together with the N in NR 20 R 21 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S, P and optionally substituted with 1-4 R 22 groups;
  • R 7 , R 18 and R 22 are independently oxo, halo, hydroxy, Ci_6 alkyl, Ci_6 haloalkyl, Ci-6 alkoxy or Ci_6 haloalkoxy;
  • R 23 is independently C3-7 cycloalkyl, or a 4-10 membered heterocyclyl comprising 1-3 heteroatoms selected from N, O and S, and is optionally substituted with oxo; and R 23 is unsubstituted or substituted with Ci_6 alkyl, Ci_6 haloalkyl, -L 3 -R e or -L 4 -R f ;
  • R c and R e are independently halo, cyano, hydroxy, -OR 24 , -NRR 25 , -NR-C0 2 R 24 , - NR-S0 2 -R 26 , -NR-COR 26 , -NR-C(0)-NRR 25 , -OC(0)-NRR 25 , or Ci_ 6 alkyl substituted with halo, Ci_6 alkoxy, hydroxy or cyano;
  • R d and R f are independently -S0 2 NRR 25 , -CONRR 25 , -C(0)OR 24 , -S0 2 R 26 or C(0)R 26 ;
  • R 24 is C ⁇ g alkyl, d_ 6 haloalkyl, -L 2 -R 23a or -(CR a R b ) 2 - 3 -N(R a R b ) 2 ;
  • R 25 is hydrogen, Ci_ 6 alkyl, Ci_ 6 haloalkyl, -L 2 -R 23b or-(CR 2 ) 2 _ 3 -N(R a R b ) 2 ;
  • R 26 is Ci_6 alkyl, Ci_ 6 haloalkyl, -L 2 -R 23c or -(CR a R b )i_ 3 -N(R a R b ) 2 ;
  • R 23a , R 23b and R 23c are independently selected from R 23 ;
  • R, R a and R b are independently hydrogen or Ci_6 alkyl
  • L 1 , L 2 , L 3 and L 4 are independently a bond or -(CR a R b )i_3 ;
  • n and m are independently 1-3; and p and q are 1-4;
  • Ring A is a 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo;
  • R 1 and R r are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl; -X ] -NR 4 R 5 ; -X ] -OR 3 ; -X 1 -S(O) 0 - 2 R 6 ; -X 1 -P(0)R 6a R 6b ; phenyl unsubstituted or substituted by Ci-6 alkyl; or a 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S;
  • R 2 is selected from hydrogen, halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl;
  • R 3 , R 4 and R 5 are independently hydrogen, Ci_ 6 alkyl or Ci_ 6 haloalkyl; or wherein R 4 and R 5 together with N in NR 4 R 5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R 7 groups;
  • R 6 , R 6a and R 6b are Ci_ 6 alkyl
  • R 9 , R 10 , R lla , R llb , R llc , R lld , R lle , R llf , R llg , R llh , R ni , R llj , R llk and R 111 are hydrogen;
  • R 1 i 2 A , R 1 ⁇ 3 R 1 ⁇ 6 and R I 1 V' are independently hydrogen or Ci_6 alkyl;
  • R 14 and R 15 are independently hydrogen; Ci_ 6 alkyl; -C(0)0-(Ci_ 6 alkyl); C 3 - 7 cycloalkyl unsubstituted or substituted with Ci_6 alkyl; or R 14 and R 15 together with N in NR 14 R 15 may form may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R 18 groups;
  • R 7 and R 18 are independently oxo, halo, hydroxy, Ci_ 6 alkyl or Ci_ 6 alkoxy; R 19 hydrogen, COR 20 or COOR 20 ;
  • R 20 is Ci_6 alkyl
  • p 1;
  • n 1 , X 2 , X 3 and X 4 and n are as defined in any of the embodiments described herein.
  • R 1 , R r , R 2 , R 8 , R 19 , A, B, Y, m and n are as defined in any of the embodiments described herein.
  • W 1 , W 2 , W 3 and W 4 are independently CR 1 or N; and R 1 , R r , R 2 , R 8 , Y and m are defined in any of the embodiments described herein. In a particular embodiment, at least two of W 1 , W 2 , W 3 and W 4 are CR 1 , and the others are N.
  • W 1 and W 2 are independently CR 1 or N; and R 1 , R 1 , R 2 , R 8 and m are as defined in any of the embodiments described herein.
  • Certain of the compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
  • the present invention is meant to include all possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures.
  • Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, n C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S, 36 C1 and 125 I respectively.
  • the invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H, 13 C, and 14 C, are present.
  • isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or labeled compound may be particularly desirable for PET or SPECT studies.
  • Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
  • a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Processes using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
  • solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 0, d 6 - acetone, d 6 -DMSO.
  • Compounds of the invention i.e. compounds of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co- crystal formers.
  • These co-crystals may be prepared from the compounds of the invention by known co-crystal forming procedures. Such procedures include grinding, heating, co- subliming, co-melting, or contacting in solution a compound of the invention with the co- crystal former under crystallization conditions and isolating co-crystals thereby formed.
  • Suitable co-crystal formers include those described in WO 2004/078163.
  • the invention further provides co-crystals comprising a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5).
  • any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomeric ally enriched, for example the (R)-, (S)- or (R,S)- configuration.
  • each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration.
  • Substituents at atoms with unsaturated bonds may, if possible, be present in cis- (Z)- or trans- (E)- form.
  • a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof. Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
  • any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
  • a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-0,0'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid.
  • Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
  • HPLC high pressure liquid chromatography
  • the invention also provides for a method of inhibiting EGFR kinase activity in a cell comprising contacting the cell with an effective amount of an EGFR antagonist.
  • the administered amount is a therapeutically effective amount and the inhibition of EGFR kinase activity further results in the inhibition of the growth of the cell.
  • the cell is a cancer cell.
  • Inhibition of cell proliferation is measured using methods known to those skilled in the art.
  • a convenient assay for measuring cell proliferation is the CellTiter- GloTM Luminescent Cell Viability Assay, which is commercially available from Promega (Madison, Wis.). That assay determines the number of viable cells in culture based on quantitation of ATP present, which is an indication of metabolically active cells. See Crouch et al (1993) J. Immunol. Meth. 160:81-88, U.S. Pat. No. 6,602,677. The assay may be conducted in 96- or 384-well format, making it amenable to automated high- throughput screening (HTS).
  • HTS high- throughput screening
  • the assay procedure involves adding a single reagent (CellTiter-Glo® Reagent) directly to cultured cells. This results in cell lysis and generation of a luminescent signal produced by a luciferase reaction.
  • the luminescent signal is proportional to the amount of ATP present, which is directly proportional to the number of viable cells present in culture. Data can be recorded by luminometer or CCD camera imaging device.
  • the luminescence output is expressed as relative light units (RLU). Inhibition of cell proliferation may also be measured using colony formation assays known in the art.
  • the invention provides for methods of treating a condition mediated by EGFR in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of an EGFR antagonist.
  • the condition is a cell proliferative disease.
  • Treatment of the cell proliferative disorder by administration of an EGFR antagonist results in an observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of cancer cells or absence of the cancer cells;
  • the EGFR antagonist may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. Reduction of these signs or symptoms may also be felt by the patient.
  • efficacy can be measured, for example, by assessing the time to disease progression (TDP) and/or determining the response rate (RR).
  • TDP time to disease progression
  • RR response rate
  • Metastasis can be determined by staging tests and by bone scan and tests for calcium level and other enzymes to determine spread to the bone.
  • CT scans can also be done to look for spread to the pelvis and lymph nodes in the area.
  • Chest X-rays and measurement of liver enzyme levels by known methods are used to look for metastasis to the lungs and liver, respectively.
  • Other routine methods for monitoring the disease include transrectal ultrasonography (TRUS) and transrectal needle biopsy (TRNB).
  • TRUS transrectal ultrasonography
  • TRNB transrectal needle biopsy
  • the administration of an EGFR antagonist decreases tumor burden (e.g., reduces size or severity of the cancer).
  • the administration of an EGFR antagonist kills the cancer.
  • a compound of Formula (1) can be prepared according to any one of the following schemes illustrated below, wherein A, B, R 1 , R 1 , R 2 , R 8 , E, n and m are as defined in the Summary of the Invention, and Z* is the same as Z, except each N-R 8 moiety has been replaced with an N-H.
  • E is NH.
  • a radical as defined encompasses any protecting groups thereof.
  • a compound of Formula (1) can be prepared according to Scheme
  • an intermediate of formula (I-l) is reacted with an intermediate of formula (1-2), in the presence of a base in a suitable solvent.
  • a compound of Formula (1) can be prepared from the reaction of an intermediate of formula (I-l) with an intermediate of formula (1-3), in the presence of a coupling reagent and a base in a suitable solvent. The reaction proceeds in a temperature range of about -30 °C to about 50 °C.
  • Suitable bases include but are not limited to, DIEA, K2CO 3 , NaHCC>3, and the like.
  • a compound of Formula (1) can be prepared according to Scheme 2, wherein A, R 1 , R 1 , R 2 , E, n and m are as defined in the Summary of the In
  • a compound of Formula (1) is prepared from the reaction of an intermediate of formula (1-8) with an intermediate of formula (1-9) in the presence of a coupling reagent and a base (for example, DIEA, triethylamine, K2CO 3 , NaHCC>3, and the like) in a suitable solvent.
  • a compound of Formula (1) can be prepared from the reaction of an intermediate of formula (1-8) with an intermediate of formula (I- 10) in the presence of base (for example, DIEA, K2CO 3 , NaHCC>3, and the like) in a suitable solvent.
  • the reaction proceeds in a temperature range of about -30 °C to about 50
  • Suitable coupling agents for use in the schemes described above include, but are not limited to, 2-(7-aza-lH- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium
  • HATU hexafluorophosphate
  • HBTU O-benzotriazole- ⁇ , ⁇ , ⁇ ' ,N'-tetramethyl-uronium- hexafluoro-phosphate
  • EDCI/HOBt l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride/hydroxybenzotriazole
  • Suitable solvents include but are not limited to, CH2CI2, DMF, THF and the like.
  • an intermediate of formula (1-4) (where X is a leaving group such as fluoro, chloro, bromo, methoxy, ethoxy and the like) is reacted with an intermediate of the formula (1-5) in the presence or absence of a base (for example, DIEA, triethylamine, K2CO 3 , NaHCC>3, and the like), either neat or in a suitable solvent such as DMF, DMA, N-methylpyrrolidine and the like, to generate an intermediate of formula (1-6).
  • a base for example, DIEA, triethylamine, K2CO 3 , NaHCC>3, and the like
  • a suitable solvent such as DMF, DMA, N-methylpyrrolidine and the like
  • An intermediate of formula (1-6) can further be converted to an intermediate of formula (1-7) by means of hydrogenation conditions known in the art (for example H 2 , Pd/C, MeOH or H 2 , Raney-Ni, MeOH and the like) or in the presence of a reducing agents such as iron, zinc and the like in a suitable solvent such as acetic acid or the like.
  • An intermediate of formula (1-7) can then be converted to an intermediate of formula (1-8) in the presence of cyanogen bromide in a suitable solvent such as a mixture of water, MeCN and MeOH at a temperature ranging from about room temperature to about 60 °C.
  • an intermediate of formula (1-11) can be prepared from the reaction of an intermediate of formula (1-7) with a condensation partner such as trimethyl orthoformate, triethyl orthoformate, 1,3,5-triazine, formamide, N,N-dimethylformamide dimethyl acetal, formic acid and the like in the presence or absence of an acid (for example AcOH, p-TSA, H 2 S0 4 , HC0 2 H and the like) either neat or in a suitable solvent such as DMF, DMA, MeOH, THF, toluene and the like.
  • the reaction proceeds in a temperature range of about room temperature to about 150 °C.
  • An intermediate of formula (1-11) can further be deprotonated with a base such as BuLi, LDA, LHMDS and the like, and reacted with an azide source such as p-toluenesulfonyl azide,
  • the reaction proceeds in a temperature range of about - 30 °C to about 60 °C.
  • the invention also relates to those forms of the process in which a compound obtainable as an intermediate at any stage of the process is used as a starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, for example in a protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ.
  • Compounds of the invention and intermediates can also be converted into each other according to methods generally known to those skilled in the art. Intermediates and final products can be worked up and/or purified according to standard methods, e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like.
  • reactive functional groups for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, may be protected to avoid their unwanted participation in the reactions.
  • a characteristic of protecting groups is that they can be removed readily (i.e. without the occurrence of undesired secondary reactions) for example by solvolysis, reduction, photolysis or alternatively under physiological conditions (e.g. by enzymatic cleavage).
  • Conventional protecting groups may be used in accordance with standard practice (see e.g., T.W.
  • mixtures of isomers that are formed can be separated into the individual isomers, for example diastereoisomers or enantiomers, or into any desired mixtures of isomers, for example racemates or mixtures of diastereoisomers.
  • Mixtures of isomers obtainable according to the invention can be separated in a manner known to those skilled in the art into the individual isomers; diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallisation and/or chromatographic separation, for example over silica gel or by e.g.
  • medium pressure liquid chromatography over a reversed phase column and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials.
  • solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate; ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydrofuran or dioxane; liquid aromatic hydrocarbons, such as benzene or toluene; alcohols, such as methanol, ethanol or 1- or 2-propanol; nitriles, such as acetonitrile; halogenated hydrocarbons, such as methylene chloride or chloroform; acid amides, such as dimethylformamide or dimethyl acetamide; bases, such as heterocyclic or heteroaromatic nitrogen bases, for example pyridine or N-methylpyrrolidin-2-one; carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic
  • the compounds of the present invention are either obtained in the free form, as a salt thereof, or as prodrug derivatives thereof.
  • the compounds of the present invention may also form internal salts, e.g., zwitterionic molecules.
  • salt refers to an acid addition or base addition salt of a compound of the invention.
  • Salts include in particular “pharmaceutical acceptable salts”.
  • pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
  • the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids.
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
  • the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
  • Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and
  • the invention provides a compound of Formula (1), (2), (2A),
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
  • Lists of additional suitable salts can be found, e.g., in “Remington: The Science and Practice of Pharmacy,” 21 st Ed., Pharmaceutical Press 2011; and in “Pharmaceutical Salts: Properties, Selection, and Use,” by Stahl and Wermuth, 2 nd Rev. Ed., Wiley- VCH 2011, and subsequent versions thereof).
  • the present invention also provides pro-drugs of the compounds of the present invention that converts in vivo to the compounds of the present invention.
  • a pro-drug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a subject.
  • the suitability and techniques involved in making and using pro-drugs are well known by those skilled in the art.
  • Bioprecursor prodrugs can be conceptually divided into two non-exclusive categories, bioprecursor prodrugs and carrier prodrugs. (See, “The Practice of Medicinal Chemistry,” Ch. 31-32 Ed. Wermuth, Academic Press, San Diego, Calif., 2001, and subsequent versions thereof).
  • bioprecursor prodrugs are compounds, which are inactive or have low activity compared to the corresponding active drug compound, that contain one or more protective groups and are converted to an active form by metabolism or solvolysis. Both the active drug form and any released metabolic products should have acceptably low toxicity.
  • Carrier prodrugs are drug compounds that contain a transport moiety, e.g., that improve uptake and/or localized delivery to a site(s) of action.
  • a transport moiety e.g., that improve uptake and/or localized delivery to a site(s) of action.
  • the linkage between the drug moiety and the transport moiety is a covalent bond
  • the prodrug is inactive or less active than the drug compound
  • any released transport moiety is acceptably non-toxic.
  • the transport moiety is intended to enhance uptake
  • the release of the transport moiety should be rapid.
  • it is desirable to utilize a moiety that provides slow release e.g., certain polymers or other moieties, such as cyclodextrins.
  • Carrier prodrugs can, for example, be used to improve one or more of the following properties: increased lipophilicity, increased duration of pharmacological effects, increased site-specificity, decreased toxicity and adverse reactions, and/or improvement in drug formulation (e.g., stability, water solubility, suppression of an undesirable organoleptic or physiochemical property).
  • lipophilicity can be increased by esterification of (a) hydroxyl groups with lipophilic carboxylic acids (e.g., a carboxylic acid having at least one lipophilic moiety), or (b) carboxylic acid groups with lipophilic alcohols (e.g., an alcohol having at least one lipophilic moiety, for example aliphatic alcohols).
  • prodrugs are, e.g. , esters of free carboxylic acids and S-acyl derivatives of thiols and O-acyl derivatives of alcohols or phenols, wherein acyl has a meaning as defined herein.
  • Suitable prodrugs are often pharmaceutically acceptable ester derivatives convertible by solvolysis under physiological conditions to the parent carboxylic acid, e.g.
  • amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde
  • the compounds of the present invention may also be obtained in the form of hydrates, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present.
  • the compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
  • solvate refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof) with one or more solvent molecules.
  • solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
  • hydrate refers to the complex where the solvent molecule is water.
  • the compounds of the present invention, including salts, hydrates and solvates thereof may inherently or by design form polymorphs.
  • Compounds of the invention in unoxidized form may be prepared from N-oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C.
  • a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
  • a suitable inert organic solvent e.g. acetonitrile, ethanol, aqueous dioxane, or the like
  • the invention provides compounds and compositions that are able to modulate the activity of epidermal growth factor receptor (EGFR).
  • EGFR epidermal growth factor receptor
  • the invention provides the use of a compound of the invention for treating a condition mediated by EGFR.
  • the invention provides compounds and compositions for treating cancer, including but not limited to the following cancers: non-small cell lung cancer (NSCLC), head and neck cancer, colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, gastric cancer, glioma and prostate cancer.
  • NSCLC non-small cell lung cancer
  • head and neck cancer colorectal cancer
  • breast cancer pancreatic cancer
  • ovarian cancer gastric cancer
  • gastric cancer glioma and prostate cancer.
  • cancers include but are not limited to : epidermoid, Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma,
  • Lung bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma;
  • Gastrointestinal esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small
  • medulloblastoma glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanom
  • carcinoma carcinoma
  • breast Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma] hairy cell; lymphoid disorders; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma;
  • a cancerous cell includes a cell afflicted by any one of the above-identified conditions.
  • cancers include but are not limited to, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, thyroid cancer (medullary and papillary thyroid carcinoma), renal carcinoma, kidney parenchyma carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, testis carcinoma, urinary carcinoma, melanoma, brain tumors such as glioblastoma, astrocytoma, meningioma,
  • medulloblastoma and peripheral neuroectodermal tumors gall bladder carcinoma, bronchial carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroidea melanoma, seminoma, rhabdomyosarcoma, craniopharyngeoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmocytoma.
  • the invention provides compounds and compositions for treating lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphoma, myeloma, a solid tumor, or a cancer comprising an EGFR activated tumor.
  • the EGFR activated tumor can be from a mutation of EGFR; for example, from a mutation of EGFR located at G719S, G719C, G719A, L858R, L861Q, an exon 19 deletion mutation or an exon 20 insertion mutation.
  • the EGFR activated tumor can also be from an amplification of EGFR, expression of EGFR, and/or ligand mediated activation of EGFR.
  • the invention also provides compounds and compositions for treating a condition that is resistant to EGFR targeted therapy.
  • the EGFR targeted therapy may comprise treatment with gefitinib, erlotinib, lapatinib, XL-647, HKI-272 (Neratinib), BIBW2992 (Afatinib), EKB-569 (Pelitinib), AV-412, canertinib, PF00299804, BMS 690514, HM781-36b, WZ4002, AP-26113, cetuximab, panitumumab, matuzumab, trastuzumab, or pertuzumab.
  • the invention also provides compounds and compositions for treating a condition that is resistant to ALK-targeted therapy.
  • the ALK targeted therapy may comprise treatment with crizotinib, SP-3026, AF802, X-396, or AP-26113.
  • the invention provides compounds and compositions for treating a proliferative disease.
  • the compounds of the invention may be used to inhibit cell proliferative disease such as hyperplasias, dysplasias and pre- cancerous lesions.
  • pre-cancerous lesions may occur in skin, esophageal tissue, breast and cervical intra-epithelial tissue.
  • Inhibition may be assessed by delayed appearance of primary or secondary tumors, slowed development of primary or secondary tumors, decreased occurrence of primary or secondary tumors, slowed or decreased severity of secondary effects of disease, arrested tumor growth and regression of tumors, among others. In the extreme, complete inhibition is observed, and may be referred to as prevention or chemoprevention.
  • the invention provides compounds and compositions for treating an autoimmune disease, inflammatory disease, immunologically-mediated disease, bone disease, metabolic disease, neurological or neurodegenerative disease, cardiovascular disease, hormone related disease, allergy, or asthma.
  • the invention provides compounds and compositions for treating a condition selected from inflammation, arthritis, rheumatoid arthritis,
  • spondylarthropathies gouty arthritis, osteoarthritis, juvenile arthritis, and other arthritic conditions, systemic lupus erthematosus (SLE), skin-related conditions, psoriasis, eczema, burns, dermatitis, neuroinflammation, allergy, pain, neuropathic pain, fever, pulmonary disorders, lung inflammation, adult respiratory distress syndrome, pulmonary sarcoisosis, asthma, silicosis, chronic pulmonary inflammatory disease, and chronic obstructive pulmonary disease (COPD), cardiovascular disease, arteriosclerosis, myocardial infarction (including post-myocardial infarction indications), thrombosis, congestive heart failure, cardiac reperfusion injury, as well as complications associated with hypertension and/or heart failure such as vascular organ damage, restenosis, cardiomyopathy, stroke including ischemic and hemorrhagic stroke, reperfusion injury, renal reperfusion injury, ischemia including stroke and brain isch
  • AIDS AIDS related complex
  • pneumonia herpes virus
  • myalgias due to infection influenza, autoimmune disease, graft vs. host reaction and allograft rejections, treatment of bone resorption diseases, osteoporosis, multiple sclerosis, angiogenesis including neoplasia, metastasis, a central nervous system disorder, a central nervous system disorder having an inflammatory or apoptotic component, Alzheimer's disease,
  • Parkinson's disease Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, and peripheral neuropathy, or Canine B-Cell Lymphoma.
  • Parkinson's disease Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, and peripheral neuropathy, or Canine B-Cell Lymphoma.
  • the condition is inflammation, arthritis, rheumatoid arthritis,
  • spondylarthropathies gouty arthritis, osteoarthritis, juvenile arthritis, and other arthritic conditions, systemic lupus erthematosus (SLE), skin-related conditions, psoriasis, eczema, dermatitis, pain, pulmonary disorders, lung inflammation, adult respiratory distress syndrome, pulmonary sarcoisosis, asthma, chronic pulmonary inflammatory disease, and chronic obstructive pulmonary disease (COPD), cardiovascular disease, arteriosclerosis, myocardial infarction (including post-myocardial infarction indications), congestive heart failure, cardiac reperfusion injury, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, leukemia, or lymphoma.
  • SLE systemic lupus erthematosus
  • COPD chronic obstructive pulmonary disease
  • cardiovascular disease arteriosclerosis
  • myocardial infarction including post-myocardial infarction indication
  • the invention provides compounds and compositions for treating a neurodegenerative disease.
  • neurodegenerative diseases include, without limitation, Adrenoleukodystrophy (ALD), Alexander's disease, Alper's disease,
  • Alzheimer's disease Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjoegren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia,
  • Batten disease also known as Spielmeyer-Vogt-Sjoegren-Batten disease
  • BSE Bovine spongiform encephalopathy
  • Canavan disease Cockayne syndrome
  • Corticobasal degeneration Corticobasal degeneration
  • Creutzfeldt- Jakob disease Familial fatal insomnia
  • Frontotemporal lobar degeneration Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado- Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Progressive
  • Supranuclear Palsy Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer- Vogt-Sjogren-Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson- Olszewski disease, Tabes dorsalis, and Toxic encephalopathy.
  • the invention also provides a method of preventing resistance to gefitinib or erlotinib in a disease, comprising administering to a subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt, ester, or prodrug thereof.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier, diluent or excipient.
  • the pharmaceutical compositions can be formulated for oral, intravenous, intradermal, intramuscular, intraperitoneal, subcutaneous, intranasal, epidural, sublingual, intracerebral, intravaginal, intraventricular, intrathecal, epidural, transdermal, rectal, by inhalation, or topical administration.
  • the pharmaceutical composition is formulated for oral administration.
  • the pharmaceutical compositions can take the form of solutions, suspensions, emulsions, tablets, pills, pellets, capsules, capsules containing liquids, powders, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use.
  • the compositions can be formulated for immediate release, sustained release, or controlled release of the compounds of the invention.
  • Suitable pharmaceutical excipients include, for example, a) diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine); b) lubricants (e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol); for tablets also c) binders (e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone); if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
  • diluents e.g., lactose, dextrose, sucrose, mannitol, sorbi
  • Additional suitable pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • the pharmaceutical excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like.
  • auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used.
  • the pharmaceutically acceptable excipients are sterile when administered to a subject. Water is a useful excipient when the compound of the invention is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, specifically for injectable solutions.
  • suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the present compositions if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • Additional suitable pharmaceutical excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene -block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch;
  • cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes, oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water, isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming
  • compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs for example.
  • Orally administered compositions can contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation.
  • compositions in tablet or pill forms can be coated to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over an extended period of time.
  • Selectively permeable membranes surrounding an osmotically active substance driving a compound of the invention are also suitable for orally administered compositions.
  • fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture.
  • delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations.
  • a time-delay material such as glycerol monostearate or glycerol stearate can also be useful.
  • Oral compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment, the excipients are of pharmaceutical grade.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents, e
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents.
  • compositions can be formulated for parenteral administration by various routes, including but not limited to, intravenous (including bolus injection), subcutaneous, intramuscular, and intra-arterial administration.
  • parenteral dosage forms are administered in the form of sterile or sterilizable injectable solutions, suspensions, dry and/or lyophylized products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection (reconstitutable powders) and emulsions.
  • Vehicles used in such dosage forms include, but are not limited to, Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium
  • Chloride Injection Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
  • water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol
  • non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • compositions can be formulated for intranasal form via use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
  • the dosage administration can be continuous rather than intermittent throughout the dosage regimen.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • compositions for rectal or vaginal administration can be formulated for rectal or vaginal administration.
  • Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present compositions can contain, in one embodiment, from about 0.1 percent to about 99 percent; and in another embodiment from about 1 percent to about 70 percent of the compound of the invention by weight or volume.
  • the present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g., vials), blister packs, and strip packs.
  • compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose.
  • agents which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
  • compositions further comprise one or more additional therapeutic agents.
  • the compounds of the invention and the additional therapeutics agent(s) may act additively or synergistically.
  • the compounds may be administered in combination with one or more therapeutic agents (e.g. small molecules, monoclonal antibodies, antisense RNA, and fusion proteins) that modulate protein kinase signaling involved in various disease states.
  • therapeutic agents e.g. small molecules, monoclonal antibodies, antisense RNA, and fusion proteins
  • kinases may include, but are not limited to: serine/threonine specific kinases, phosphatidylinositol-3-kinases (PI3 kinases), Phosphatidylinositol-3 kinase -related kinases, mTOR, receptor tyrosine specific kinases and non-receptor tyrosine specific kinases.
  • Serine/threonine kinases include mitogen activated protein kinases (MAPK), meiosis specific kinase (MEK), AKT, RAF PLK1, and aurora kinase.
  • mitogen activated protein kinases MAPK
  • MEK meiosis specific kinase
  • AKT AKT
  • RAF PLK1 AKT
  • aurora kinase AKT
  • receptor kinase families include epidermal growth factor receptor (EGFR) (e.g. HER2/neu, HER3, HER4, ErbB, ErbB2, ErbB3, ErbB4, Xmrk, DER, Let23);
  • FGF fibroblast growth factor
  • FGF-R1, GFF-R2/BEK/CEK3 , FGF- R3/CEK2, FGF-R4/TKF, KGF-R hepatocyte growth/scatter factor receptor
  • HGFR/SF hepatocyte growth/scatter factor receptor
  • insulin receptor e.g. Ins-R, IGFI-R, ALK, ROS
  • Eph e.g. CEK5, CEK8, EBK, ECK, EEK, EHK-1, EHK-2, ELK, EPH, ERK, HEK, MDK2, MDK5, SEK
  • Axl e.g.
  • Non-receptor tyrosine kinase families include, but are not limited to, BCR-ABL (e.g. p43, ARG); BTK (e.g. ITK/EMT, TEC); CSK, FAK, FPS, JAK, SRC, BMX, FER, CDK and SYK.
  • the compounds of the invention may also be administered in combination with one or more agents that modulate non-kinase biological targets or processes.
  • targets include histone deacetylases (HDAC), DNA methyltransferase (DNMT), thrombin, TLR9, hedgehog pathway, COX-2, Aromatase, heat shock proteins (e.g. HSP90), and proteosomes.
  • the compounds of the invention may be combined with antineoplastic agents (e.g. small molecules, monoclonal antibodies, antisense RNA, and fusion proteins) that inhibit one or more biological targets such as vorinostat, erlotinib, gefitinib, lapatinib, sunitinib, dasatinib, sorafenib, MGCD265, Pazopanib, Regorafenib, , Rapamycin, Temsirolimus (CCI-779), Ridaforolimus (MK8669), PF-04691502, DS- 7423, Tanespimycin, GDC-0449, PF-04449913, IPI-926, XL139, TAK-441, MK-2206, GSK2110183, AZD6244, GDC-0941, XL765, CAL-101, BAY80-6946, XL147, PX-866, AMG 319, Volasertib, B
  • MSC1936369B Selumetinib (AZD6244), PD-325901, BAY86-9766, RDEA119, TAK- 733, R04987655, , EMD 1214063, AMG 208, XL880, AMG 337, tivantinib (ARQ 197), , AZD6244, BMS-908662, BAY 43-9006, XL281, R05126766, GSK2118436,
  • Vemurafenib (R05185426, PLX4032), MetMAb, Crizotinib, ASP-3026, AF802, X-396, AP-26113, CNF2024, RG108, BMS387032, Isis-3521, bevacizumab, trastuzumab, pertuzumab, MM-121, U3-1287 (AMG 888), cetuximab, panitumumab, zalutumumab, nimotuzumab, matuzumab, AV-299, PR0143966, IMC-A12, R1507, AVE- 1642, Figitumumab, OSI-906, Intedanib, AMG 102, AMG 900, MLN8237, AG24322, PD325901, ZD6474 (vandetanib), PD184322, Obatodax, ABT737, XL-647, neratin
  • the compounds of the invention may also be administered in combination with a chemotherapeutic agent at various stages of the disease for the purposes of shrinking tumors, destroying remaining cancer cells left over after surgery, inducing remission, maintaining remission and/or alleviating symptoms relating to the cancer or its treatment.
  • chemotherapeutic agents include, but are not limited to, alkylating agents such as mustard gas derivatives (Mechlorethamine, cylophosphamide, chlorambucil, melphalan, ifosfamide), ethylenimines (thiotepa, hexamethylmelanine), Alkylsulfonates (Busulfan), Hydrazines and Triazines (Altretamine, Procarbazine, dacarbazine and Temozolomide), Nitrosoureas (Carmustine, Lomustine and Streptozocin), Ifosfamide and metal salts (Carboplatin, Cisplatin, and Oxaliplatin); plant alkaloids such as mustard gas derivatives (Mechlorethamine, cylophosphamide, chlorambucil, melphalan, ifosfamide), ethylenimines (thiotepa, hexamethylmelanine), Alkylsulf
  • Podophyllotoxins Etoposide and Tenisopide
  • Taxanes Paclitaxel and Docetaxel
  • Vinca alkaloids Vincristine, Vinblastine, Vindesine and Vinorelbine
  • Camptothecan analogs Irinotecan, SN38, and Topotecan
  • anti-tumor antibiotics such as Chromomycins (Dactinomycin and Plicamycin), Anthracyclines (Doxorubicin, Daunorubicin, Epirubicin, Mitoxantrone, Valrubicin and Idarubicin), and miscellaneous antibiotics such as
  • Mitomycin, Actinomycin and Bleomycin anti-metabolites such as folic acid antagonists (Methotrexate, Pemetrexed, Raltitrexed, Aminopterin), pyrimidine antagonists (5- Fluorouracil, Floxuridine, Cytarabine, Capecitabine, and Gemcitabine), purine antagonists (6-Mercaptopurine and 6-Thioguanine) and adenosine deaminase inhibitors (Cladribine, Fludarabine, Mercaptopurine, Clofarabine, Thioguanine, Nelarabine and Pentostatin); topoisomerase inhibitors such as topoisomerase I inhibitors (Ironotecan, topotecan) and topoisomerase II inhibitors (Amsacrine, etoposide, etoposide phosphate, teniposide); interferons (interferon-oc, interferon- ⁇ , interferon- ⁇ ); monoclonal antibodies (for
  • the compounds of the invention are administered in combination with a chemoprotective agent.
  • chemoprotective agents act to protect the body or minimize the side effects of chemotherapy. Examples of such agents include, but are not limited to, amfostine, mesna, and dexrazoxane.
  • the compounds of the invention are administered in combination with radiation therapy. Radiation is commonly delivered internally
  • the combination therapy further comprises radiation treatment
  • the radiation treatment may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and radiation treatment is achieved. For example, in appropriate cases, the beneficial effect is still achieved when the radiation treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.
  • compounds of the invention can be used in combination with an immunotherapeutic agent, such as agents used to transfer the immunity of an immune donor, e.g., another person or an animal, to a host by inoculation.
  • an immunotherapeutic agent such as agents used to transfer the immunity of an immune donor, e.g., another person or an animal, to a host by inoculation.
  • the term embraces the use of serum or gamma globulin containing performed antibodies produced by another individual or an animal; nonspecific systemic stimulation; adjuvants; active specific immunotherapy; and adoptive immunotherapy.
  • Adoptive immunotherapy refers to the treatment of a disease by therapy or agents that include host inoculation of sensitized lymphocytes, transfer factor, immune RNA, or antibodies in serum or gamma globulin.
  • One form of immunotherapy is the generation of an active systemic tumor-specific immune response of host origin by administering a vaccine composition at a site distant from the tumor.
  • Various types of vaccines have been proposed, including isolated tumor- antigen vaccines and anti-idiotype vaccines.
  • Another approach is to use tumor cells from the subject to be treated, or a derivative of such cells (Schirrmacher et al. (1995) J. Cancer Res. Clin. Oncol. 121:487).
  • Schirrmacher et al. (1995) J. Cancer Res. Clin. Oncol. 121:487) In U.S. Pat. No. 5,484,596, Hanna Jr. et al.
  • a method for treating a resectable carcinoma to prevent recurrence or metastases comprising surgically removing the tumor, dispersing the cells with collagenase, irradiating the cells, and vaccinating the patient with at least three consecutive doses of about 10 7 cells.
  • the compounds of the invention can be used in conjunction with such techniques. It will be appreciated that the compounds of the invention may advantageously be used in conjunction with one or more adjunctive therapeutic agents.
  • suitable agents for adjunctive therapy include a 5HT] agonist, such as a triptan (e.g.
  • adenosine Al agonist such as an EP ligand; an NMDA modulator, such as a glycine antagonist; a sodium channel blocker (e.g. lamotrigine); a substance P antagonist (e.g. an NKi antagonist); a cannabinoid; acetaminophen or phenacetin; a 5-lipoxygenase inhibitor; a leukotriene receptor antagonist; a DMARD (e.g. methotrexate); gabapentin and related compounds; a tricyclic antidepressant (e.g.
  • amitryptilline a neurone stabilizing antiepileptic drug
  • a mono-aminergic uptake inhibitor e.g. venlafaxine
  • a matrix metalloproteinase inhibitor e.g. a nitric oxide synthase (NOS) inhibitor, such as an iNOS or an nNOS inhibitor
  • NOS nitric oxide synthase
  • an antibody therapy such as a monoclonal antibody therapy
  • an antiviral agent such as a nucleoside inhibitor (e.g. lamivudine) or an immune system modulator (e.g.
  • an opioid analgesic e.g. a local anesthetic
  • a stimulant including caffeine
  • an H2-antagonist e.g. ranitidine
  • a proton pump inhibitor e.g. omeprazole
  • an antacid e.g. aluminum or magnesium hydroxide
  • an antiflatulent e.g. simethicone
  • a decongestant e.g.
  • phenylephrine phenylpropanolamine
  • pseudoephedrine oxymetazoline, epinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine
  • an antitussive e.g. codeine, hydrocodone, carmiphen, carbetapentane, or dextromethorphan
  • a diuretic or a sedating or non-sedating antihistamine.
  • therapeutic agents include, without limitation: treatments for Alzheimer's Disease such as ARICEPT® and EXCELON®; treatments for Parkinson's Disease such as L- DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., AVONEX® and REBIF®, COPAXONE®, and mitoxantrone; treatments for asthma such as albuterol and SINGULAIR®; agents for treating schizophrenia such as ZYPREXA®, RISPERDAL®, SEROQUEL®, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, interleukin 1 receptor antagonist (IL-1RA), azathioprine, cyclophosphamide, and sulfasalazine;
  • MS Multiple Sclerosis
  • beta interferon
  • immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and antiparkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, antileukemic agents, and growth factors; and agents for treating immunodeficiency disorders such as gamma globulin.
  • neurotrophic factors such as acetylcholineste
  • the pharmaceutical composition comprising a compound of the invention and one or more additional therapeutic agent may be provided as a combined preparation for simultaneous, separate or sequential use, by the same or different route of administration, in the treatment of a disease or condition mediated by EGFR kinase activity.
  • Products provided as a combined preparation include a composition comprising a compound of the invention, and the other therapeutic agent(s) together in the same pharmaceutical composition; or a compound of the invention and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound provided herein.
  • the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • the kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit of the invention typically comprises directions for administration.
  • the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.
  • the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated, and can be determined by standard clinical techniques.
  • in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges.
  • the precise dose to be employed can also depend on the route of administration, and the seriousness of the condition being treated and can be decided according to the judgment of the practitioner and each subject's circumstances in view of, e.g., published clinical studies. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5 mg/kg per body weight.
  • An indicated daily dosage in the larger mammal, e.g. humans is in the range from about 0.5 mg to about 100 mg, conveniently administered, e.g. in divided doses up to four times a day or in retard form.
  • Suitable unit dosage forms for oral administration comprise from ca. 1 to 50 mg active ingredient.
  • a therapeutic amount or dose of the compounds of the present invention may range from about 0.1 mg/kg to about 500 mg/kg, alternatively from about 1 to about 50 mg/kg.
  • treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in single or multiple doses (such as two, three, or four times daily).
  • Therapeutic amounts or doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.
  • a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary.
  • the dosage or frequency of administration, or both may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease.
  • the subject may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
  • the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific inhibitory dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. Examples
  • Step A To a solution of (R)-lysine HQ salt (100 g, 0.68 mol) in xylene (1 L) was added hexamethyldisilazane (1000 mL, 4.76 mol) and chlorotrimethylsilane (10 mL, 78.8 mmol). The mixture was heated to 120 °C for 24h, then to 180 °C for 48 h. The solvent was then removed under reduced pressure and the crude material was purified by column chromatography (20:1 to 10:1 CH 2 Cl 2 /MeOH) to afford (R)-3-aminoazepan-2-one (I-la).
  • Step B To a suspension of L1AH 4 (51.13 g, 1.345 mol) in THF (1 L) at 0°C was added dropwise over 30 min a solution of I-la (34.44 g, 0.269 mol) in THF (400 mL). The mixture was then stirred at room temperature overnight, cooled to 0 °C, treated with H 2 0 (52 ml) and 2M NaOH (52 mL) and stirred for 0.5h. The resulting white precipitate was filtered through Celite and the filtrate evaporated under reduced pressure to afford (R)-azepan-3-amine (I- lb). The product was used in the next step without further purification.
  • Step A To the mixture of (E)-tert-butyl but-2-enoate (10.0 g, 70.4 mmol) and NBS (12.5 g, 70.4 mmol) in CC1 4 (150 mL) was added benzoyl peroxide (510 mg, 2.11 mmol), and the reaction was refluxed for 12 h. The mixture was cooled to room temperature, and the solid was filtered off. The filtrate was concentrated in vacuo, and purified by column chromatography to afford (E)-tert-butyl 4-bromobut-2-enoate (I-2a).
  • Step B A solution of I-2a (1.0 g, 4.55 mmol), (S)-pyrrolidin-3-ol HCI salt (561.7 mg, 4.55 mmol) and NEt 3 (1.27 mL, 9.1 mmol) in THF (35 mL) was stirred at room temperature overnight. The solid was filtered off, the filtrate was concentrated in vacuo, and purified by column chromatography to afford (S,E)-tert-butyl 4-(3- hydroxypyrrolidin-l-yl)but-2-enoate (I-2b).
  • Step C A solution of I-2b (584 mg, 2.57 mmol) in 4N aq. HCl solution was stirred at room temperature for 4 h. The mixture was then concentrated and dried in vacuo to afford (S,E)-4-(3-hydroxypyrrolidin- l-yl)but-2-enoic acid (1-2) as a HCl salt.
  • Step A A stirred solution of (S)-ieri-butyl 3-aminopiperidine-l-carboxylate (0.500 g, 2.49 mmol), l-fluoro-4-methyl-2-nitrobenzene (0.387 g, 2.49 mmol) and N,N- diisopropylethylamine (0.482 g, 3.74 mmol) in DMF under argon was heated to 110°C for 6 h (reaction completion monitored by TLC). The mixture was diluted with water and extracted with EtOAc (3 x 100 rriL).
  • Step B To a stirred solution of I- 15a (0.550 g, 1.64 mmol) in MeOH (35mL) was added Pd/C (0.090 g) and the mixture was stirred at room temperature under hydrogen atmosphere (balloon) for 2h (reaction completion monitored by TLC). The mixture was filtered through Celite, washed with MeOH and concentrated under reduced pressure to afford (S)-ieri-butyl 3-((2-amino-4-methylphenyl)amino)piperidine-l-carboxylate (I- 15b). MS calculated for C17H2 8 N 3 O2 (M+H + ) 306.22, found 306.2.
  • Step C To a stirred solution of (5)-tert-butyl 3-((2-amino-4- methylphenyl)amino)piperidine-l-carboxylate (I-15b) (0.500 g, 1.63 mmol) in MeOH (20 rriL) was added a solution of cyanogen bromide (0.208 g, 1.96 mmol) in 1 :2
  • Step A To the stirred solution of 1-15 (0.350 g, 1.06 mmol) in DMF (8 mL) were added sequentially 3-trifluoromethylbenzoic acid (0.221 g, 1.16 mmol), 2-(7-aza- lH- benzotriazole- l-yl)-l , l,3,3-tetramethyluronium hexafluorophosphate (0.483 g, 1.27 mmol) and ⁇ , ⁇ -diisopropylethylamine (0.410g, 3.18mmol). The mixture was stirred at room temperature for 16h (reaction completion monitored by TLC), diluted with H 2 0 (50 mL) and EtOAc (50 mL).
  • Step B To a stirred solution of I- 16a (0.300g, 0.59 mmol) in CH 2 C1 2 (25mL) at room temperature was added TFA (0.170 g, 1.49 mmol) and the mixture was stirred for 2h (reaction completion monitored by TLC). The mixture was then concentrated under reduced pressure, the crude material was basified with saturated aqueous NaHCC>3 solution and extracted with CH2CI2 (2 x 20mL). The combined organic layers were washed with brine, dried over anhydrous Na 2 S0 4 and concentrated under reduced pressure to afford the title compound (Intermediate 16) as a brown solid.
  • Steps A and B ieri-butyl 3-((3-aminopyridin-4-yl)amino)piperidine-l-carboxylate (I- 17b) was prepared from tert-butyl 3-((3-nitropyridin-4-yl)amino)piperidine-l- carboxylate (I-17a) following procedures analogous to 1-15 Steps A and B.
  • Step C A mixture of I-17b (1.5g, 0.34mmol), trimethylorthoformate (15mL) and p- toluene sulfonic acid (0.025g) was heated to reflux for 2h (reaction completion monitored by TLC). The mixture was concentrated under reduced pressure. The residue was diluted with EtOAc, washed with saturated aqueous NaHCC>3 and extracted with EtOAc (2 x 20mL). The combined organic layers were dried over Na 2 S0 4 and concentrated under reduced pressure. The crude material was purified by column chromatography to afford tert-butyl 3-(lH-imidazo[4,5-c]pyridin-l-yl)piperidine-l-carboxylate (I- 17c) as a white solid.
  • Step D To the stirred solution of I- 17c (0.2g, 0.66mmol) in dry THF (4mL) at -78°C was added sec -butyl lithium (1.38mL, 1.4M in cyclohexane) and the mixture was stirred at -78°C for 50 min. Dodecylbenzenesulfonyl azide (0.28g, 0.79 mmol) in THF (2 rriL) was slowly added over 10 min and allowed to stir at -78°C for 2h (reaction completion monitored by TLC). The mixture quenched with saturated aqueous NH 4 C1 solution and diluted with EtOAc (20mL).
  • Step E To a stirred solution of I-17d (0.4g) in MeOH (lOmL) was added Pd/C (O. lg) and the mixture was stirred at room temperature under hydrogen atmosphere (balloon) for 2h (reaction completion monitored by TLC). The mixture was filtered through Celite and concentrated under reduced pressure to afford the title compound (Intermediate 17).
  • Step A To a stirred solution of 3-fluoropyridine (20 g, 206 mmol) in AcOH (120 mL) at 85 °C was added under nitrogen concentrated H 2 S0 4 (1 mL). The mixture was then treated portion wise with H 2 0 2 (30% in water, 48 mL, 422 mmol) and stirred at reflux for 24 h (reaction completion monitored by TLC). The mixture was quenched with solid Na 2 SC>3, the solvent was removed under reduced pressure and the residue was dissolved in CH 2 C1 2 (500 mL). The mixture was neutralized with solid NaHCC>3 and stirred for 1 h. The mixture was filtered and concentrated under reduced pressure to afford crude 3-fluoropyridine 1-oxide (I- 19a).
  • Step B A solution of I- 19a in concentrated H 2 S0 4 (40 mL) was slowly treated over 15 min with a 2:3 HN0 3 H 2 S0 4 mixture (73 mL). The mixture was then heated to 90 °C and stirred for 4 h. The mixture was cooled to room temperature, poured into ice and extracted with CH 2 C1 2 (3x 300 mL). The combined organic phase was dried over Na 2 S0 4 and concentrated under reduced pressure. The crude material was washed with pentane and stirred in CH 2 CI 2 (30 mL). The resulting yellow precipitate was collected to afford 3- fluoro-4-nitropyridine 1-oxide (I-19b).
  • Step D To a stirred solution of I- 19c (7.5g, 22.1 mmol) in MeOH (450mL) was added Raney-Ni (cat.) and AcOH (7 mL) and the mixture was stirred at room temperature under hydrogen atmosphere (balloon) for 2h (reaction completion monitored by TLC). The mixture was filtered through Celite and concentrated under reduced pressure. The residue was dissolved in water, basified with 1M NaOH and extracted with Et 2 0 (2x 100 mL).
  • Step F tert-butyl 3-(2-azido-3H-imidazo[4,5-c]pyridin-3-yl)piperidine-l-carboxylate
  • Step A A mixture of methyl 4-fluoro-3-nitrobenzoate (l.OOg, 5.02mmol) and (R)- ieri-butyl 3-aminopiperidine-l -carboxylate (1.00 g, 5.02mmol) were heated to 130°C for 3h (reaction completion monitored by TLC). The mixture was cooled to room
  • Steps B and C The title compound (Intermediate 21) was prepared from I-21a in several steps following procedures analogous to 1-15, Steps B and C. MS calculated for C19H27N4O4 (M+H + ) 375.20, found 375.2.
  • Step A (R)-methyl l-(l-(tert-butoxycarbonyl)piperidin-3-yl)-2-(3-(trifluoromethyl) benzamido)-lH-benzo[d]imidazole-5-carboxylate (I-22a) was prepared from (/?)-methyl 2-amino-l-(l-(tert-butoxycarbonyl)piperidin-3-yl)-lH-benzo[d]imidazole-5-carboxylate (1-21) following procedures analogous to 1-16, Step A.
  • Step B To a stirred solution of I-22a (l.OOg, 1.83mmol) in THF (20mL) at 0°C was slowly added DIBAL-H (7.28mL, 12.82mmol) and the mixture was stirred for 2h (reaction completion monitored by TLC). The mixture was diluted with water and extracted with EtOAc (2 x 50 mL), the combined organic layers were washed with brine, dried over anhydrous Na 2 S0 4 and concentrated under reduced pressure.
  • Step A To a stirred solution of 1-22 (0.500g, 0.96mmol) in CH 2 C1 2 (30mL) at 0°C was added carbon tetrabromide (1.90g, 5.79mmol). The mixture was stirred for 15 min, PPI1 3 (0.758g, 2.89mmol) was added and the mixture was further stirred for 45 min at 0°C (reaction completion monitored by TLC).
  • Step C The title compound (Intermediate 23) was prepared from I-23b following procedures analogous to 1-16, Step B. MS calculated for C25H29F 3 N5O2 (M+H + ) 488.22, found 488.2.
  • Step A (R)-tert-butyl 3-((2-chloro-6-nitrophenyl)amino)azepane-l-carboxylate (I- 26a) was prepared following procedures analogous to 1-15, Step A, using the appropriate starting materials.
  • 1 H-NMR 400MHz, CDC1 3 ): d 8.00-7.91 (m, 1H), 7.58-7.49 (m, 1H), 7.02-6.51 (m, 2H), 4.31-4.03 (m, 1H), 3.84-2.98 (m, 4H), 1.98-1.60 (m, 5H), 1.46-1.39 (m, 10H); MS calculated for C17H25CIN 3 O4 (M+H + ) 370.15, found 370.10.
  • Step B A mixture of I-26a (7.5 g, 19.5 mmol) and Zn (12.8 mg, 195 mmol) in AcOH (22 mL) was stirred at room temperature for 2 h. The reaction was basified with saturated aqueous Na 2 CC>3 solution, filtered, and extracted with EtOAc (3 x 80 mL). The combined organic phase was washed with brine, dried with Na 2 S0 4 and concentrated in vacuo to afford (R)-tert-butyl 3-((2-amino-6-chlorophenyl)amino)azepane-l-carboxylate (I-26b). MS calculated for Ci7H 27 ClN 3 0 2 (M+H + ) 340.17, found 340.10. The crude was used in the next step without further purification.
  • Step C The title compound (Intermediate 26) was prepared from I-26b following procedures analogous to 1-15, Step C. ] H-NMR (400MHz, CDC1 3 ): d 7. ,34-7.26 (m, 1H), 7.04-6.97 (m, 2H), 6.05-5.85 (m, 1H), 5.84-5.72 (m, 1H), 5.50-5.37 (m, 0.5H), 5.10- 4.80(m, 0.5H), 4.41-4.23(m, 1H), 4.09-3.96(m, 0.5H), 3.94-3.81 (m, 1H), 3.76-3.57 (m, 1H), 3.22-3.14 (m, 0.5H), 2.84-2.63 (m, 1H), 2.34-2.17 (m, 1H), 2.07-1.84 (m, 1H), 1.82- 1.64 (m, 2H), 1.53 (s, 9H), 1.48-1.37 (m, 1H); MS calculated for Ci 8 H 26 ClN 4 0 2 (M+
  • Step A A mixture of 2-methylisonicotinic acid (3.371 g, 24.6 mmol) and 2-(7-aza- 1H- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (9.345 g, 24.6 mmol) in CH 2 C1 2 (120 ml) was treated at room temperature with NEt 3 (4.1 mL, 29.4 mmol). The reaction was stirred for 1 hour before it was slowly added into a CH 2 C1 2 solution (45 ml) of 1-26 (5.98 g, 16.4 mmol).
  • Step B A solution of I-27a (8.62 g, 16.4 mmol) in MeOH (67 mL) was treated with HCl in dioxane (4M, 67 mL) and the mixture was stirred at room temperature for 7 h. The mixture was then concentrated under reduced pressure to afford the title compound
  • Step A To a solution of 2-chloro-l,3-difluoro-4-nitrobenzene (1.3548 g, 7 mmol) in DMF (10 mL) was added N,N-diisopropylethylamine (0.9951 g, 1.341 mL) and 1-1
  • Step B (R)-tert-butyl 3-((6-amino-2-chloro-3-methoxyphenyl)amino)azepane-l- carboxylate (I-28b) was prepared from I -28a following procedures analogous to 1-26, Step B. MS calculated for C1 8 H29CIN 3 O 3 (M+H + ) 370.18, found 370.2.
  • Step C The title compound (Intermediate 28) was prepared from I-28b following procedures analogous to 1-15, Step C. MS calculated for C19H2 8 CIN4O 3 (M+H + ) 395.18, found 395.2.
  • Step A A solution of pyridazine-4-carboxylic acid (92.5 mg, 0.754) and 2-(7-aza-
  • Step B The title compound (Intermediate 29) was prepared from I-29a following procedures analogous to 1-27, Step B. MS calculated for C19H22CIN6O2 (M+H + ) 401.14, found 401.1.
  • Step A A mixture of 2,6-dimethylisonicotinic acid (927 mg, 6.1 mmol) and O- benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU) (4.65 g, 12.3 mmol) in DMF (15 ml) was treated with hydroxybenzotriazole (HOBt) (1.82 g, 13.5 mmol) and stirred at room temperature for 10 min. The resulting mixture was then added to a solution of 1-26 (1.12 g, 3.1 mmol) in DMF (4 mL), followed by addition of NEt 3 (1.7 mL, 12.3 mmol).
  • HBTU O- benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate
  • Step B A solution of I-30a (951 mg, 1.9 mmol) in CH 2 C1 2 (20 mL) was treated with HC1 in dioxane (4M, 20 mL) and the mixture was stirred at room temperature overnight. The yellow solid was filtered, washed with CH 2 CI 2 and dried to afford the title compound (Intermediate 30). MS calculated for C21H25CIN5O (M+H + ) 398.17, found: 398.2.
  • Step A (R)-tert-butyl 3-((2-methyl-6-nitrophenyl)amino)azepane-l-carboxylate (I- 31a) was prepared following procedures analogous to 1-15, Step A, using the appropriate starting materials.
  • Step B (R)-tert-butyl 3-((2-amino-6-methylphenyl)amino)azepane-l-carboxylate (I- 31b) was prepared from I-31a following procedures analogous to 1-15, Step B. MS calculated for C1 8 H 30 N 3 O2 (M+H + ) 320.23, found 320.2.
  • Step C The title compound (Intermediate 31) was prepared from I-31b following procedures analogous to 1-15, Step C. ] H-NMR (400MHz, CDC1 3 ): d 8.50 (br s, IH), 7.27-7.24 (m, IH), 7.18-7.14 (m, IH), 7.00-6.97 (m, IH), 5.10-5.05 (m, IH), 4.32-4.26 (m, IH), 3.99-3.92 (m, IH), 3.78-3.72 (m, IH), 2.99-2.87 (m, IH), 2.68 (s, 3H), 2.30-2.23 (m, IH), 2.13-2.08 (m, IH), 1.87 (br s, 3H), 1.50 (s, 9H), 1.39-1.38 (m, IH); MS calculated for C 19 H 29 N 4 O 2 (M+H + ) 345.22, found 345.2.
  • Step A (R)-tert-butyl 3-(7-methyl-2-(2-methylisonicotinamido)-lH- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-32a) was prepared from 1-31 following procedures analogous to 1-27, Step A. MS calculated for C26H 3 4N5O 3 (M+H + ) 464.26, found 464.2. Step B: Solid I-32a (363 mg, 0.78 mmol) was treated with 4.0 M HC1 in dioxane (5 mL) and the reaction mixture stirred until complete as determined by LC/MS analysis.
  • Step A A sample of racemate I-33a (prepared in several steps similarly to I- 16a, using the appropriate starting materials) is subjected to chiral chromatography (ChiralPak AD-H) with isocratic elution (75/25 C0 2 /iPrOH) using a Thar Technologies SFC Prep 80 system with SuperChrom v.5.3 software.
  • the first eluting peak is (/?)-tert-butyl 6-(7- methyl-2-(3-(trifluoromethyl)benzamido)-lH-benzo[d]imidazol-l-yl)-l,4-oxazepane-4- carboxylate (I-33b) and the second eluting peak is (S)-tert-butyl 6-(7-methyl-2-(3- (trifluoromethyl)benzamido)- lH-benzo[d]imidazol- 1 -yl)- 1 ,4-oxazepane-4-carboxylate (I- 33c). MS calculated for C 26 H 3 oF 3 N 4 0 4 (M+H + ) 519.21, found 519.2.
  • Step B The title compounds (Intermediate 33 and Intermediate 34) were prepared from I-33b and I-33c respectively, following procedures analogous to 1-32, Step B. MS calculated for C 2 iH 22 F 3 N 4 0 2 (M+H + ) 419.16, found 419.2. Intermediate 35
  • Step A Concentrated H 2 SO 4 (17.5 mL) was slowly added to methyl 4-fluoro-3- methylbenzoate (12.8 g, 76 mmol) and the mixture was cooled to 0 °C. A solution of fuming HNO 3 (69.5%, 11.6 mL) in concentrated H 2 SO 4 (17.5 mL) was then added drop- wise over 10 min. The mixture was stirred for 80 min while slowly warming up to room temperature (reaction completion monitored by TLC). The mixture was slowly poured into ice, the aqueous layer was extracted with CH 2 CI 2 (3 x 200 mL), dried over anhydrous Na 2 S0 4 and concentrated under reduced pressure. The crude was purified by column chromatography to afford methyl 4-fluoro-3-methyl-5-nitrobenzoate (I-35a) as a white solid. MS calculated for C 9 H 9 FNO 4 (M+H + ) 214.04, found 214.0.
  • Step B To a solution of I-35a (6.55g, 30.73 mmol) in THF (50 mL) at -10°C was slowly added DIBALH (92.2 mL of 1.0 M solution in hexanes) over 10 min. The mixture was stirred for 40 min at -10°C (reaction completion monitored by TLC) and quenched with Na 2 S0 4 - IOH 2 O. The mixture was then treated with Rochelle's salt (19.4 g, 95 mmol) in water (300 mL), CH 2 C1 2 (400mL) and EtOAc (200 ml) and stirred overnight. The organic phase was separated and the aqueous phase extracted with EtOAc (200 mL).
  • Step C A solution of I-35b (1.516 g, 8.20 mmol), (R)-tert-butyl 3-aminoazepane-l- carboxylate (1.844 g, 8.60 mmol) and N,N-diisopropylethylamine (1.16 g, 9.01 mmol) in DMF (30 rriL) was subjected to microwave irradiation (140 °C, 4.5 h).
  • Steps D and E The title compound (Intermediate 35) was prepared from I-35c in several steps following procedures analogous to 1-26, Steps B and C. MS calculated for C2 0 H 3 1N4O 3 (M+H + ) 375.23, found 375.2.
  • Step A (R)-tert-butyl 3-(2-benzamido-5-(hydroxymethyl)-7-methyl-lH- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-36a) as a clear oil was prepared from I- 35 following procedures analogous to 1-16, step A. MS calculated for C27H 3 5N4O4 (M+H + ) 479.26, found 479.2.
  • Step B To a solution of I-36a (540 mg, 1.128 mmol) in CH 2 C1 2 (65 rriL) were added N,N-diisopropylethylamine (436 mg, 3.385 mmol) and mesyl chloride (388 mg, 3.385 mmol). The mixture was stirred at RT for 16 h. Pyrrolidine (401 mg, 5.64 mmol) was added and the mixture was stirred for 30 min. The solvent was evaporated and the residue was re-dissolved in DMA. More pyrrolidine ((401 mg, 5.64 mmol) was added and the mixture was subjected to microwave irradiation (80 °C, 40 minutes).
  • Step C The title compound (Intermediate 36) was prepared from I-36b following procedures analogous to 1-27, Step B. MS calculated for C26H 3 4N5O (M+H + ) 432.27, found 432.2.
  • Step A A solution of I-37a (45 mg, 0.087 mmol; prepared in several steps following procedures analogous to 1-25, using the appropriate starting materials), NBS (23 mg, 0.131 mmol), benzoyl peroxide (3 mg, 0.012 mmol), and carbon tetrachloride (1 mL) in a 2 mL microwave reaction vessel was warmed to 100 °C by irradiation with a heat lamp for 6h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure.
  • Step B The title compound (Intermediate 37) was prepared following procedures analogous to 1-32, Step B. MS calculated for C26H 3 1F 3 N5O (M+H + ) 486.24, found 486.2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.

Description

COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of Indian provisional patent application serial number 1741/DEL/2012, filed June 6, 2012; and of U.S. provisional application serial number 61/770,752, filed February 28, 2013; each of which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
The invention relates to compositions and methods for modulating the activity of the epidermal growth factor receptor (EGFR, Erb-Bl).
BACKGROUND OF THE INVENTION
The epidermal growth factor receptor (EGFR, Erb-Bl) belongs to a family of proteins involved in the proliferation of normal and malignant cells. Overexpression of EGFR is found in over 70 percent of human cancers, including without limitation non-small cell lung carcinomas (NSCLC), breast cancers, gliomas, squamous cell carcinoma of the head and neck, and prostate cancer. The identification of EGFR as an oncogene has led to the development of anti-EGFR targeted molecules, such as gefitinib and erlotinib.
Despite the initial clinical benefits of gefitinib and erlotinib in NSCLC patients harboring EGFR mutations, many patients develop resistance. A secondary EGFR mutation, T790M, can render gefitinib and erlotinib ineffective inhibitors of EGFR kinase activity. Another major limitation of current EGFR inhibitors is the development of toxicity in normal tissues. Because ATP affinity of EGFR T790M is similar to wild type EGFR, the concentration of an irreversible EGFR inhibitor required to inhibit EGFR T790M may also effectively inhibit wild type EGFR. The class-specific toxicities of current EGFR kinase inhibitors, e.g., skin rash and diarrhea, are a result of inhibiting wild type EGFR in non-cancer tissues. These toxicities preclude dose escalation of current agents to plasma levels that can effectively inhibit EGFR T790M.
Accordingly, there continues to exist a need to develop novel EGFR inhibitors that is capable of giving an improved effect on EGFR tyrosine kinase mutants without the adverse side effects.
SUMMARY OF THE INVENTION
The invention provides compositions and methods for modulating the activity of the epidermal growth factor receptor (EGFR). In one aspect, the invention provides compounds which act as inhibitors of EGFR. In a first embodiment, provided herein is a compound of Formula (1), a tautomer thereof, or a pharmac
Figure imgf000003_0001
wherein Ring A is a 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and optionally substituted with oxo;
Ring B is phenyl; a 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S; or a 5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted by oxo;
E is NH or CH2;
R\ Rrand R2 are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl;
5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; phenyl,
5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O, S and P, and optionally substituted by oxo; - X1-C(0)OR3; -X1-0-C(0)R3; -X1-C(0)R3;
-X1-C(0)NR4R5; -X1-C(0)NR4-X3-C(0)OR3; -X1-C(O)NR4-X3-S(O)0-2 R6; -X]-NR4R5;
-X1NR4-X2-C(0)R3; -X1-NR4-X2-C(0)OR3; -X1-NR4-X2-C(0)NR4R5;
-X1-NR4-X3-S(0)o-2R6; -X1-NR4S(0)2R6; -X^OSCCXhR6; -X]-OR3; -X^O-X^OR3;
-X1-0-X4-S(0)o-2R6; -X1-0-X4-NR4R5; -X1-S(O)0-2R6; -X1-S(O)0-2-X3-NR4R5;
-X1-C(0)NR4-X3-P(0)R6aR6b; -X1-NR4-X1-P(0)R6aR6b; -X1-0-X1-P(0)R6aR6b;
-X1-P(0)R6a-X1-NR4R5; -X1-P(0)R6aR6b or -X^SCC zNR ; wherein each phenyl, heteroaryl, or heterocyclyl in R1 or R2 is unsubstituted or substituted by 1-3 groups selected from OH, halo, Ci_6 alkyl, Ci_6 haloalkyl and Ci_6 haloalkoxy;
R3, R4 and R5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R4 and R5 together with N in NR4R5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R7;
R6 is Ci_6 alkyl or Ci_6 haloalkyl;
R6a and R6b are independently hydroxy, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 alkoxy, Ci_6 haloalkoxy, 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and o tionally substituted with oxo;
Figure imgf000004_0001
R9 and R10 are independently hydrogen, halo, Ci_6 alkyl, Ci_6 haloalkyl, OH, cyano, Ci_6 alkoxy, Ci_6 haloalkoxy;
Rlla, Rllb, Rllc, Rlld, Rlle, Rllf, Rllg, Rllh, Rni, Rllj, Rllk and R111 are
independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl;
R12 and R13 are independently hydrogen, halo, cyano, Ci_6 alkyl or Ci_6 haloalkyl; R14 and R15 are independently hydrogen, Ci_6 alkyl, -L]-R23, -(CRaRb)2-3-Rc or -L2- Rd; or R14 and R15 together with N in NR14R15 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R18 groups; R and R are independently hydrogen or Ci_6 alkyl; or R and R together with the carbon to which they are attached may form a C3-6 cycloalkyl;
X1 and X2 are independently a bond or Ci_6 alkyl;
X3 is Ci_6 alkyl;
X4 is C2-6 alkyl;
R19 hydrogen, Ci_6 alkyl, COR20, COOR20, CONR20R21 or S(0)2R2°;
R 20 is Ci-6 alkyl, Ci_6 haloalkyl or cycloalkyl;
R21 is hydrogen or Ci_6 alkyl; or R20 and R21 together with the N in NR20R21 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S, P and optionally substituted with 1-4 R 22 groups;
R 7', R 1180 and R 2^2 are independently oxo, halo, hydroxy, Ci_6 alkyl, Ci_6 haloalkyl, Ci-6 alkoxy or Ci_6 haloalkoxy;
R23 is independently C3-7 cycloalkyl, or a 4-10 membered heterocyclyl comprising 1-3 heteroatoms selected from N, O and S, and is optionally substituted with oxo; and R23 is unsubstituted or substituted with Ci_6 alkyl, Ci_6 haloalkyl, -L3-Re or -L4-Rf;
Rc and Re are independently halo, cyano, hydroxy, -OR24, -NRR25, -NR-C02R24, - NR-SO2-R26, -NR-COR26, -NR-C(0)-NRR25, -OC(0)-NRR25, or Ci_6 alkyl substituted with halo, Ci_6 alkoxy, hydroxy or cyano;
Rd and Rf are independently -S02NRR25, -CONRR25, -C(0)OR24, -S02R26 or C(0)R26;
R24 is Ci_6 alkyl, Ci_6haloalkyl, -L2-R23aor -(CRaRb)2_3-N(RaRb)2;
R25 is hydrogen, Ci_6 alkyl, Ci_6haloalkyl, -L2-R23b or-(CR2)2_3-N(RaRb)2;
R26 is Ci_6 alkyl, Ci_6haloalkyl, -L2-R23c or -(CRaRb)i_3-N(RaRb)2;
R23a, R23b and R23c are independently selected from R23;
R, Ra and Rb are independently hydrogen or Ci_6 alkyl;
L1, L2, L3 and L4 are independently a bond or -(CRaRb)i_3; and
n and m are independently 1-3; and p and q are 1-4;
or a pharmaceutically acceptable salt thereof.
In a second embodiment, provided herein is a compound of Formula (2) or a pharmaceutically acceptable salt thereof:
Figure imgf000006_0001
wherein Ring A is a 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 5- membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo;
R1 and Rr are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl; -X]-NR4R5; -X]-OR3; -X1-S(O)0-2R6; -X1-P(0)R6aR6b; phenyl unsubstituted or substituted by Ci-6 alkyl; or a 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S;
selected from hydrogen, halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl;
- X1-C(0)OR3; -X1-C(0)R3; -X1-C(0)NR4R5; -X1-C(0)NR4-X3-C(0)OR3;
-X1-C(0)NR4-X3-S(0)o-2R6; -X]-NR4R5; -X1NR4-X2-C(0)R3; -X1-NR4-X3-S(O)0-2R6; -X]-OR3; -X^O-X^OR3; -X1-S(O)0-2R6; -X^O-X^NR ; or a 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S and is unsubstituted or substituted by Ci_6 alkyl;
R3, R4 and R5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R4 and R5 together with N in NR4R5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R7 groups;
R6, R6a and R6b are Ci_6 alkyl;
Z is ; provided Z is a 4-7 membered
heterocyclic
Figure imgf000006_0002
ring when Z is
Y is O or NR 19.
Figure imgf000007_0001
Figure imgf000007_0002
R9, R10, RUa, RU , Rnc, Rnd, Rl le, Ruf, RUg, Rnh, R1 H, Rl lj, Rl lk and R111 are hydrogen;
R12, R13, R16 and R17 are independently hydrogen or Ci_6 alkyl;
R14 and R15 are independently hydrogen; Ci_6 alkyl; -C(0)0-(Ci_6 alkyl); C3-7 cycloalkyl unsuhstituted or substituted with Ci_6 alkyl; or R14 and R13 together with N in NR14R15 may form may form a 4-7 membered ring containing 1-2 heteroatoms selected
18
from N, O, S and P, and optionally substituted with 1-4 R groups;
R7 and R18 are independently oxo, halo, hydroxy, Ci_6 alkyl or Ci-6 alkoxy;
R19 hydrogen, COR20 or COOR20;
R20 is Ci-6 alkyl;
p is 1 ;
m and q are independently 1-2; and
Ring B, X1, X2, X3 and X4 and n are as defined in any of the embodiments described herein.
In a third embodiment, provided herein is a compound of Formula (2A), (2B), (2C), (2D), (3A), (3B) or (3C) or a pharmaceutically acceptable salt thereof:
Figure imgf000007_0003
(2B)
Figure imgf000008_0001
or a pharmaceutically acceptable salt thereof;
wherein Y is O or NR ; and
R1, Rr, R2, R8, R19, A, B, Y, m and n are as defined in any of the embodiments described herein.
In a fourth embodiment, provided herein is a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B) or (3C) as described herein, or a pharmaceutically acceptable salt thereof, wherein Ring B together with the atoms to which it is attached forms a fused phenyl, pyridyl or piperidyl, each of which is unsubstituted or substituted by (R2)m; m is 1-2; and R2 is as defined in any of the embodiments described herein.
In a fifth embodiment, provided herein is a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B) or (3C) as described herein, or a pharmaceutically acceptable salt thereof, wherein Ring A is phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyridin-2- onyl, oxazolyl, furanyl, thiazolyl, imidazole[2,l-Z?]thiazolyl, imidazo[l,2-a]pyridinyl, imidazo[l,5-a]pyridinyl or naphthyl, each of which is unsubstituted or substituted by (R1),, and R1 ; wherein n is 1-3; and R1 and R1 are as defined in any of the embodiments described herein.
In a sixth embodiment, provided herein is a compound of Formula (4) or a pharmaceutically accep
Figure imgf000009_0001
(4) wherein W1, W2, W3 and W4 are independently CR1 or N; and R1, Rr, R2, R8, Y and m are as defined in any of the embodiments described herein. In a particular embodiment, at least two of W1, W2, W3 and W4 are CR1, and the others are N.
In a seventh embodiment, provided herein is a compound of Formula (5) or a pharmaceutically accep
Figure imgf000009_0002
wherein W1 and W2 are independently CR1 or N; and R1, R1 , R2, R8 and m are as defined in any of the embodiments described herein.
In a particular embodiment, provided herein is a compound of Formula (4) or (5) as described herein, or a pharmaceutically acceptable salt thereof , wherein: (i) W1 is CR1 and W2 is N; (ii) W2 is CR1 and W1 is N; (iii) W1 and W2 are CR1; or (iv) W1 and W2 are N.
In an eighth embodiment, provided herein is a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5) as described herein, or a
pharmaceutically acceptable salt thereof, wherein
R1 and R1' are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl; - X]-NR4R5; -X]-OR3; -X1-S(O)0-2R6; phenyl unsubstituted or substituted by d_6 alkyl; tetrazolyl or pyrrolyl;
each X1 is a bond or CH2;
R3, R4 and R5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R4 and R5 together with N in NR4R5 form piperidinyl; and
R6 is as defined in Formula (1) or (2).
In a ninth embodiment, provided herein is a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5) as described herein, or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, halo, cyano, Ci_6 alkyl, Ci_6 haloalkyl, tetrazolyl, pyrrolyl, -X1-
NR4R5, -X]-OR3, -X1-S(0)o-2R6 or phenyl unsubstituted or substituted by Ci_6 alkyl;
R1 is hydrogen, halo or Ci_6 alkyl;
R3, R4 and R5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R4 and R5 together with N in NR4R5 form piperidinyl;
X1 is a bond or CH2; and
R6 is as defined in Formula (1) or (2).
In a tenth embodiment, provided herein is a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5) as described herein, or a pharmaceutically acceptable salt thereof, wherein R1 and R1 are independently hydrogen; methyl; t-butyl; trifluoromethyl; methoxy; ethoxy; trifluoromethoxy; difluoromethoxy; fluoro; chloro; cyano; dimethylamino; methylsulfonyl; dimethylphosphoryl; tetrazolyl; pyrrolyl; phenyl unsubstituted or substituted by methyl; or piperidinyl.
In an eleventh embodiment, provided herein is a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5) as described herein, or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen; chloro; methyl; trifluoromethyl;
methoxy; isoproproxy; cyano; hydroxymethyl; methoxymethyl; ethoxymethyl;
methylsulfonyl; methylcarbonyl; carboxy; methoxycarbonyl; carbamoyl;
dimethylaminomethyl; pyrrolidinylmethyl unsubstituted or substituted by 1-2 hydroxy, halo or methoxy; morpholinomethyl; azeditinylmethyl unsubstituted or substituted by 1-2 halo or methoxy; piperidinylmethyl; ((4-methyl-3-oxo-piperazin-lyl)methyl); ((4- acetylpiperazin- 1 -yl)methyl) ; ( 1 , 1 -dioxidothiomorpholine-4-carbonyl) ; pyrrolidinyl carbonyl unsubstituted or substituted by 1-2 hydroxy; pyrrolidinylethoxy; (1,1- dioxidothiomorpholino)methyl; or 1 ,2,4-oxadiazolyl unsubstituted or substituted by Ci_6 alkyl; alternatively, R2 is -CH2-N(CH3)-C(0)-CH3; -CH2-0-(CH2)2-OCH3; -CH2-N(CH3)-(CH2)2-S02(CH3); -C(0)NH-(CH2)1.2-C(0)-OCH3;
-C(0)NH-(CH2)!_2-C(0)OH; or -C(0)NH-(CH2)2-S02(CH3). In a particular
embodiment, R2 is halo.
In an twelfth embodiment, provided herein is a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5) as described herein, or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000011_0001
R is
R and R are independently hydrogen, Ci_6 alkyl or C3-7 cycloalkyl; or R and R together with N in NR14R15 may form an azetidinyl, piperidyl, pyrrolidinyl or
morpholinyl; where said azetidinyl or pyrrolidinyl can be optionally substituted with 1-2 halo, methoxy or hydroxyl; and
R 12 , R 13 , R 16 , R IV and q are as defined in any of the embodiments described herein. In another embodiment, provided herein is a compound selected from:
N- { 7-chloro- 1 - [(3R)- 1 - [4-(pyrrolidin- 1 -yl)but-2-enoyl] azepan-3 -yl] - 1 H- 1 ,3 - benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- {7-chloro- l-[l-[4-(pyrrolidin-l-yl)but-2-enoyl]azepan-3-yl]-lH-l,3-benzodiazol-2- yl } -2-methylpyridine-4-carboxamide;
N- {7-chloro- 1 - [(3R)- 1 - [4-(3 -fluoroazetidin- 1 -yl)but-2-enoyl] azepan-3 -yl] - 1 H- 1 ,3 - benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[l-[4-(3-fluoroazetidin-l-yl)but-2-enoyl]azepan-3-yl]-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[(3R)-l-{4-[(3R)-3-fluoropyrrolidin-l-yl]but-2-enoyl}azepan-3-yl]- lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- {7-chloro- l-[l-{4-[3-fluoropyrrolidin-l-yl]but-2-enoyl}azepan-3-yl]-lH- 1,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[(3R)-l-{4-[(3S)-3-fluoropyrrolidin-l-yl]but-2-enoyl}azepan-3-yl]- lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[l-{4-[3-fluoropyrrolidin-l-yl]but-2-enoyl}azepan-3-yl]-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide; N-{7-chloro-l-[(3R)-l-[4-(3,3-difluoropyrrolidin-l-yl)but-2-enoyl]azepan-3-yl]-lH- l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- { 7-chloro- 1 - [ 1 - [4-(3 ,3 -difluoropyrrolidin- 1 -yl)but-2-enoyl] azepan-3 -yl] - 1 H- 1 ,3 - benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[(3R)-l-{4-[(3R)-3-methoxypyrrolidin-l-yl]but-2-enoyl}azepan-3-yl]- lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[l-{4-[3-methoxypyrrolidin-l-yl]but-2-enoyl}azepan-3-yl]-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N- { 7-chloro- 1 - [(3R)- 1 - { 4- [(3 S)-3 -methoxypyrrolidin- 1 -yl]but-2-enoyl } azepan-3 -yl] - 1 H- 1 ,3 -benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[l-{4-[3-methoxypyrrolidin-l-yl]but-2-enoyl}azepan-3-yl]-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N- { 7-chloro- 1 - [(3R)- 1 - { 4- [(3R)-3-hydroxypyrrolidin- 1 -yl]but-2-enoyl } azepan-3 -yl] - lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- { 7-chloro- 1 - [ 1 - { 4- [3-hydroxypyrrolidin- 1 -yl]but-2-enoyl } azepan-3 -yl] - 1 H- 1 ,3 - benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[(3R)-l-[(2E)-4-[(3S)-3-hydroxypyrrolidin-l-yl]but-2-enoyl]azepan-3- yl]-lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- { 7-chloro- 1 - [ 1 - [(2E)-4- [3-hydroxypyrrolidin- 1 -yl]but-2-enoyl] azepan-3 -yl] - 1H- l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- { 7-chloro- 1- [(3R)- 1- [(2E)-4-(pyrrolidin- 1 -yl)but-2-enoyl]azepan-3-yl]- 1H- 1,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N- { 7-chloro- 1 - [ 1 - [(2E)-4-(pyrrolidin- 1 -yl)but-2-enoyl] azepan-3 -yl] - 1H- 1 ,3 - benzodiazol-2-yl}pyridazine-4-carboxamide;
2-methyl-N- { 7-methyl- 1 - [(3R)- 1 - [(2E)-4-(pyrrolidin- 1 -yl)but-2-enoyl] azepan-3 -yl] - lH-l,3-benzodiazol-2-yl}pyridine-4-carboxamide;
2-methyl-N- {7-methyl- 1 - [ 1 - [(2E)-4-(pyrrolidin- 1 -yl)but-2-enoyl] azepan-3-yl] - 1 H- 1 ,3 -benzodiazol-2-yl } pyridine-4-carboxamide ;
N-{ l-[(3R)-l-[(2E)-4-[(3R)-3-fluoropyrrolidin-l-yl]but-2-enoyl]azepan-3-yl]-7- methyl- lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{ l-[l-[(2E)-4-[3-fluoropyrrolidin-l-yl]but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[(3R)-l-[(2E)-4-[(3R)-3-fluoropyrrolidin-l-yl]but-2-enoyl]azepan-3- yl]- 1H- l,3-benzodiazol-2-yl }pyridazine-4-carboxamide; N-{7-chloro-l-[l-[(2E)-4-[3-fluoropyrrolidin-l-yl]but-2-enoyl]azepan-3-yl]-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{ l-[(3R)-l-[4-(azetidin-l-yl)but-2-enoyl]azepan-3-yl]-7-chloro-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N- { 1 - [ 1 - [4-(azetidin- 1 -yl)but-2-enoyl] azepan-3 -yl] -7-chloro- 1 H- 1 ,3 -benzodiazol-2- yl } -2-methylpyridine-4-carboxamide;
N- {7-chloro- 1 - [(3R)- 1 - [4-(3 -hydroxyazetidin- 1 -yl)but-2-enoyl] azepan-3 -yl] - 1 H- 1 ,3 - benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N- {7-chloro- l-[l-[4-(3-hydroxyazetidin-l-yl)but-2-enoyl]azepan-3-yl]-lH- 1,3- benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- {7-chloro- 1 - [(3R)- 1 - [(2E)-4-(3 -methoxyazetidin- 1 - yl)but-2-enoyl] azepan-3 -yl] - lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[l-[(2E)-4-(3-methoxyazetidin-l-yl)but-2-enoyl]azepan-3-yl]-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[(3R)-l-[(2E)-4-(3,3-difluoroazetidin-l-yl)but-2-enoyl]azepan-3-yl]- lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- { 7-chloro- 1 - [ 1 - [(2E)-4-(3 ,3 -difluoroazetidin- 1 -yl)but-2-enoyl] azepan-3 -yl] - 1 H- l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{5-methyl-l-[(3S)-l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide;
N- { 5-methyl- 1 - [ 1 -(prop-2-enoyl)piperidin-3-yl] - 1 H- 1 ,3 -benzodiazol-2-yl } -3 - (trifluoromethyl)benzamide ;
N-{7-chloro-l-[(3R)-l-[(2E)-4-(dimethylarnino)but-2-enoyl]azepan-3-yl]-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N- { 7-chloro- 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] - 1 H- 1 ,3 - benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[(3R)-l-[(2E)-4-(dimethylarnino)but-2-enoyl]azepan-3-yl]-lH-l,3- benzodiazol-2-yl}-2,6-dimethylpyridine-4-carboxamide;
N- { 7-chloro- 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] - 1 H- 1 ,3 - benzodiazol-2-yl}-2,6-dimethylpyridine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide; N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -2-(trifluoromethyl)pyridine-4-carboxamide;
N- { 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -7-methyl- 1 H- 1 ,3- benzodiazol-2-yl } -2-(trifluoromethyl)pyridine-4-carboxamide;
N-{7-chloro-6-methoxy-l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2- yl}pyridazine-4-carboxamide;
N-{7-chloro-6-methoxy-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2- yl}pyridazine-4-carboxamide;
N-{ l-[(3R)-l-(ethenesulfonyl)azepan-3-yl]-7-methyl-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide;
N-{ l-[l-(ethenesulfonyl)azepan-3-yl]-7-methyl-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide ;
N-{ l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-7-(pyrrolidin-l-ylmethyl)-lH-l,3- benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
N- { 1 - [ 1 -(prop-2-enoyl)azepan-3 -yl] -7-(pyrrolidin- 1 -ylmethyl)- 1H- 1 ,3 -benzodiazol-2- yl } - 3 - (trifluoromethy l)benzamide ;
N- { 5 -methyl- 1 - [ 1 -(prop-2-enoyl)azepan-3-yl] - 1H- 1 ,3 -benzodiazol-2-yl } -3 - (trifluoromethy l)benzamide ;
N-{7-chloro-l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-6-methoxy- lH-l,3-benzodiazol-2-yl}pyridazine-4-carboxamide;
N- { 7-chloro- 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -6-methoxy- 1 H- l,3-benzodiazol-2-yl}pyridazine-4-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-2-fluorobenzamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]piperidin-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]piperidin-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-l,3-oxazole-5-carboxamide;
N- { 1 - [(6R)-4- [(2E)-4-(dimethylamino)but-2-enoyl] - 1 ,4-oxazepan-6-yl] -7-methyl- 1 H- 1 , 3 -benzodiazol-2-yl } -3 - (trifluoromethyl)benzamide ;
N-{ l-[4-[(2E)-4-(dimethylamino)but-2-enoyl]-l,4-oxazepan-6-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-3-(trifluoromethyl)benzamide; N-{ l-[(6S)-4-[(2E)-4-(dimethylamino)but-2-enoyl]-l,4-oxazepan-6-yl]-7-methyl-lH- l,3-benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
N- { 1 - [4- [(2E)-4-(dimethylamino)but-2-enoyl] - 1 ,4-oxazepan-6-yl] -7-methyl- 1 H- 1 ,3- benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
N-{ l-[l-(prop-2-enoyl)piperidin-3-yl]-lH-imidazo[4,5-c]pyridin-2-yl}-3- (trifluoromethyl)benzamide ;
N-{3-[l-(prop-2-enoyl)piperidin-3-yl]-3H-imidazo[4,5-c]pyridin-2-yl}-3- (trifluoromethyl)benzamide ;
N- { 7-methyl- 1 - [ 1 -(prop-2-enoyl)azepan-3-yl] - IH- 1 ,3 -benzodiazol-2-yl } -3 - (trifluoromethyl)benzamide;
N- { 7-methyl- 1 -[ 1 -(prop-2-enoyl)azepan-3-yl]- IH- 1 ,3-benzodiazol-2-yl Jbenzamide;
N-{ l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-7-(trifluoromethyl)-lH-l,3-benzodiazol-2- yl } - 3 - (trifluoromethy l)benzamide ;
N-{ l-[l-(prop-2-enoyl)azepan-3-yl]-7-(trifluoromethyl)-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethy l)benzamide ;
N-{ l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide ;
N- { 1 - [ 1 -(prop-2-enoyl)azepan-3 -yl] - 1 H- 1 ,3 -benzodiazol-2-yl } -3- (trifluoromethyl)benzamide ;
N- { 7-methyl- 1 - [4-(prop-2-enoyl)- 1 ,4-oxazepan-6-yl] - IH- 1 ,3 -benzodiazol-2-yl } -3 -
(trifluoromethy l)benzamide ;
N-{7-chloro-l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2- yl } pyridazine-4-carboxamide ;
N- { 7-chloro- 1 - [ 1 -(prop-2-enoyl)azepan-3-yl] - IH- 1 ,3 -benzodiazol-2-yl } pyridazine-4- carboxamide;
N-{7-chloro-l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N- { 7-chloro- 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] - 1 H- 1 ,3 - benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{7-chloro-l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2-yl}-2- methylpyridine-4-c arboxamide ;
N- { 7-chloro- 1 - [ 1 -(prop-2-enoyl)azepan-3-yl] - IH- 1 ,3 -benzodiazol-2-yl } -2- methylpyridine-4-c arboxamide ; N-{7-chloro-l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide ;
N-{7-chloro-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide ;
N- { 1 - [(3R)- 1 -(but-2-ynoyl)azepan-3 -yl] -7-methyl- 1 H- 1 ,3 -benzodiazol-2-yl } -3 -
(trifluoromethyl)benzamide ;
N-{ l-[l-(but-2-ynoyl)azepan-3-yl]-7-methyl-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide ;
N-{ l-[(3R)-l-[(2E)-but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide;
N- { 1 - [ 1 - [(2E)-but-2-enoyl] azepan-3-yl] -7-methyl- 1 H- 1 ,3 -benzodiazol-2-yl } -3 - (trifluoromethyl)benzamide ;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-3-fluorobenzamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-3,5-difluorobenzamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)pyridine-3-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)pyridazine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-4-fluorobenzamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-2,3-difluorobenzamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-2,4-difluorobenzamide;
N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1 H- 1 ,3- benzodiazol-2-yl)-2,5-difluorobenzamide;
N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1 H- 1 ,3 - benzodiazol-2-yl)-3,4-difluorobenzamide; 3-chloro-N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH- l,3-benzodiazol-2-yl)-2-fluorobenzamide;
3-chloro-N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH- 1 , 3 -benzodiazol-2-yl) -2 ,4-difluorobenzamide ;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-3,4,5-trifluorobenzamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)pyridine-2-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)pyridine-4-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)pyrimidine-2-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)pyrimidine-4-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)pyrazine-2-carboxamide;
N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1 H- 1 ,3- benzodiazol-2-yl)pyridazine-3-carboxamide;
N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1 H- 1 ,3 - benzodiazol-2-yl)benzamide;
N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1 H- 1 ,3 - benzodiazol-2-yl)-3-methylbenzamide;
3-cyano-N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH- 1 , 3 -benzodiazol-2-yl)benzamide ;
3-chloro-N-(l - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl } -7-methyl- 1H-
1 , 3 -benzodiazol-2-yl)benzamide ;
N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1 H- 1 ,3 - benzodiazol-2-yl)-3 -methoxybenzamide ;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-6-methoxypyridine-3-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-6-(trifluoromethyl)pyridine-3-carboxamide;
N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1 H- 1 ,3 - benzodiazol-2-yl)-6-methylpyridine-3-carboxamide; N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-2-methoxypyridine-4-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-l-methyl-2-oxo-l,2-dihydropyridine-4-carboxamide;
2-(dimethylamino)-N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7- methyl-lH-l,3-benzodiazol-2-yl)pyridine-4-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)imidazo[2, 1-b] [1 ,3]thiazole-6-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-3-methanesulfonylbenzamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-3-(lH-l,2,3,4-tetrazol-l-yl)benzamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-2-methylpyrimidine-4-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)imidazo[l,2-a]pyridine-6-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)furan-2-carboxamide;
N-(l-{ 1 (2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-2-(piperidin-l-yl)pyridine-4-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-2-fluoropyridine-4-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-4,5-dimethylfuran-2-carboxamide;
N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1H-1,3- benzodiazol-2-yl)-2-(lH-l,2,3,4-tetrazol-l-yl)pyridine-4-carboxamide;
2-tert-butyl-N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1 H- l,3-benzodiazol-2-yl)pyridine-4-carboxamide;
N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-2-methylpyridine-3-carboxamide;
N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1 H- 1 ,3- benzodiazol-2-yl)imidazo[l,5-a]pyridine-7-carboxamide;
N-( 1 - { 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl } -7-methyl- 1 H- 1 ,3- benzodiazol-2-yl)-2-methyl-l,3-thiazole-5-carboxamide; N-(l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-7-methyl-lH-l,3- benzodiazol-2-yl)-2-ethoxypyridine-4-carboxamide;
N-(l-{ l-[(2E)-4- (dimethylamino)but-2-enoyl] azepan- 3 -yl } -7 -methyl- 1 H- 1 , 3 - benzodiazol-2-yl)naphthalene-2-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-5-(trifluoromethyl)pyridine-3-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-5-(trifluoromethyl)pyridine-3-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } - 5 -methylpyridine- 3 -carboxamide ;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-5-methylpyridine-3-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-5-fluoropyridine-3-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-5-fluoropyridine-3-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -5-( lH-pyrrol- 1 -yl)pyridine-3-carboxamide;
N-{ l-[l-[(2E)-4-(din ethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -5-( lH-pyrrol- 1 -yl)pyridine-3-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-2-methoxypyridine-4-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-2-methoxypyridine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-2,6-dimethylpyridine-4-carboxamide;
N-{ l-[l-[(2E)-4-(din ethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-2,6-dimethylpyridine-4-carboxamide;
2-chloro-N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl- lH-l,3-benzodiazol-2-yl}pyridine-4-carboxamide;
2-chloro-N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH- l,3-benzodiazol-2-yl}pyridine-4-carboxamide;
2-chloro-N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl- lH-l,3-benzodiazol-2-yl}-6-methylpyridine-4-carboxamide; 2-chloro-N- { 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -7-methyl- 1 H- l,3-benzodiazol-2-yl}-6-methylpyridine-4-carboxamide;
2-chloro-N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl- 1 H- 1 ,3 -benzodiazol-2-yl } -6-methoxypyridine-4-carboxamide ;
2-chloro-N- { 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -7-methyl- 1 H- l,3-benzodiazol-2-yl}-6-methoxypyridine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-2-phenylpyridine-4-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-2-phenylpyridine-4-carboxamide;
6-chloro-N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl- lH-l,3-benzodiazol-2-yl}pyridine-3-carboxamide;
6-chloro-N- { 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -7-methyl- 1 H- 1 ,3 -benzodiazol-2-yl } pyridine-3 -carboxamide ;
5,6-dichloro-N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7- methyl- 1 H- 1 , 3 -benzodiazol-2-yl } pyridine- 3 -carboxamide ;
5 ,6-dichloro-N- { 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -7-methyl- lH-l,3-benzodiazol-2-yl}pyridine-3-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-5-methoxypyridine-3-carboxamide;
N- { 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -7-methyl- 1 H- 1 ,3- benzodiazol-2-yl}-5-methoxypyridine-3-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -2-(2-methylphenyl)pyridine-4-carboxamide;
N- { 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -7-methyl- 1 H- 1 ,3- benzodiazol-2-yl } -2-(2-methylphenyl)pyridine-4-carboxamide;
6-methyl-N- {7-methyl- l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2- yl}pyridazine-4-carboxamide;
6-methyl-N- {7-methyl- l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2- yl}pyridazine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-6-methylpyridazine-4-carboxamide;
N- { 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -7-methyl- 1 H- 1 ,3- benzodiazol-2-yl}-6-methylpyridazine-4-carboxamide; N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methoxy-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methoxy-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N- { 7-methoxy- 1 - [(3R)- 1 -(prop-2-enoyl)azepan-3 -yl] - 1 H- 1 ,3 -benzodiazol-2- yl } pyridazine-4-carboxamide ;
N-{7-methoxy-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2-yl}pyridazine- 4-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-(propan-2-yloxy)- lH-l,3-benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-(propan-2-yloxy)-lH- l,3-benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{ l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-7-(propan-2-yloxy)-lH-l,3-benzodiazol-2- yl } pyridazine-4-carboxamide ;
N-{ l-[l-(prop-2-enoyl)azepan-3-yl]-7-(propan-2-yloxy)-lH-l,3-benzodiazol-2- yl } pyridazine-4-carboxamide ;
N-{ l-[(3R)-l-[4-(dimethylamino)but-2-ynoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N- { 1 - [ 1 - [4-(dimethylamino)but-2-ynoyl] azepan-3 -yl] -7-methyl- 1 H- 1 ,3 -benzodiazol- 2-yl}pyridazine-4-carboxamide;
(R)-N-(7-methyl-l-(l-(2-methyl-4,4-dioxido-5,6-dihydro-l,4-oxathiine-3- carbonyl)azepan-3 -yl)- 1 H-benzo [d]imidazol-2-yl)pyridazine-4-carboxamide ;
N-(7-methyl-l-(l-(2-methyl-4,4-dioxido-5,6-dihydro-l,4-oxathiine-3- carbonyl)azepan-3 -yl)- 1 H-benzo [d]imidazol-2-yl)pyridazine-4-carboxamide ;
N-{ l-[(3R)-l-[(5,6-dihydro-l,4-dioxin-2-yl)carbonyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{ l-[l-[(5,6-dihydro-l,4-dioxin-2-yl)carbonyl]azepan-3-yl]-7 -methyl- lH-1, 3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N- { 7-methyl- 1 - [(3R)- 1 - [2-(piperidin- 1 -ylmethyl)prop-2-enoyl] azepan-3-yl] - 1 H- 1 ,3 - benzodiazol-2-yl}pyridazine-4-carboxamide;
N- { 7-methyl- 1 - [ 1 - [2-(piperidin- 1 -ylmethyl)prop-2-enoyl] azepan-3-yl] - 1 H- 1 ,3 - benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{7-methyl-l-[(3R)-l-[2-(pyrrolidin-l-ylmethyl)prop-2-enoyl]azepan-3-yl]-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide; N-{7-methyl-l-[l-[2-(pyrrolidin-l-ylmethyl)prop-2-enoyl]azepan-3-yl]-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{ l-[(3R)-l-{2-[(diethylamino)methyl]prop-2-enoyl}azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N- { 1 - [ 1 - { 2- [(diethylamino)methyl]prop-2-enoyl } azepan-3 -yl] -7-methyl- 1 H- 1 ,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{7-methyl-l-[(3R)-l-[2-(morpholin-4-ylmethyl)prop-2-enoyl]azepan-3-yl]-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N- {7-methyl- 1 - [ 1 - [2-(morpholin-4-ylmethyl)prop-2-enoyl] azepan-3 -yl] - 1 H- 1 ,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N- {7-methyl- 1 - [(3R)- 1 -(prop-2-enoyl)azepan-3 -yl] - 1 H- 1 ,3 -benzodiazol-2- yl}pyridazine-4-carboxamide;
N-{7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2-yl}pyridazine-4- carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}pyridazine-4-carboxamide;
methyl l-[l-(prop-2-enoyl)azepan-3-yl]-2-{[3-(trifluoromethyl)benzene]amido}-lH- 1,3 -benzodiazole-7 -carboxylate ;
N- { 5 -methyl- 1 - [ 1 -(prop-2-enoyl)piperidin-4-yl] - 1 H- 1 ,3-benzodiazol-2-yl } -3 - (trifluoromethyl)benzamide ;
N- { 5 -methyl- 1 - [ 1 -(prop-2-enoyl)pyrrolidin-3-yl] - 1 H- 1 ,3 -benzodiazol-2-yl } -3 - (trifluoromethyl)benzamide ;
N-{5-methyl-l-[l-(prop-2-enoyl)azetidin-3-yl]-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide ;
N-{5-methyl-l-[l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide ;
N- { 1 - [ 1 -(but-2-enoyl)azetidin-3 -yl] -5 -methyl- 1H- 1 ,3 -benzodiazol-2-yl } -3 - (trifluoromethyl)benzamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -2-(trifluoromethoxy)pyridine-4-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -2-(trifluoromethoxy)pyridine-4-carboxamide; 2-(difluoromethoxy)-N-{ l-[(3R)-l-[4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7- methyl-lH-l,3-benzodiazol-2-yl}pyridine-4-carboxamide;
2-(difluoromethoxy)-N- { 1 - [ 1 - [4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -7-methyl- lH-l,3-benzodiazol-2-yl}pyridine-4-carboxamide;
2-chloro-N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl- lH-l,3-benzodiazol-2-yl}-6-(trifluoromethoxy)pyridine-4-carboxamide;
2-chloro-N- { 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -7-methyl- 1 H- l,3-benzodiazol-2-yl}-6-(trifluoromethoxy)pyridine-4-carboxamide;
N- { 5 -methyl- 1 - [(3R)- 1 -(prop-2-enoyl)piperidin-3 -yl] - 1 H- 1 ,3 -benzodiazol-2-yl } -3 - (trifluoromethyl)benzamide;
N-{5-methyl-l-[l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide ;
N-{7-methyl-l-[(3R)-l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide ;
N- {7-methyl- 1 - [ 1 -(prop-2-enoyl)piperidin-3-yl] - 1 H- 1 ,3 -benzodiazol-2-yl } -3 -
(trifluoromethyl)benzamide ;
N- { 5-methyl- 1 - [ 1 -(prop-2-enoyl)azepan-4-yl] - 1H- 1 ,3 -benzodiazol-2-yl } -3 - (trifluoromethyl)benzamide ;
N- { 7-methyl- 1 - [(3R)- 1 -(prop-2-enoyl)piperidin-3 -yl] - 1H- 1 ,3 -benzodiazol-2- yl Jbenzamide;
N- { 7-methyl- 1 - [ 1 -(prop-2-enoyl)piperidin-3-yl] - 1 H- 1 ,3 -benzodiazol-2-yl Jbenzamide ;
2-methyl-N- {7-methyl- 1 - [(3R)- 1 -(prop-2-enoyl)piperidin-3 -yl] - 1 H- 1 ,3-benzodiazol- 2-yl}pyridine-4-carboxamide;
2-methyl-N- {7-methyl- 1 - [ 1 -(prop-2-enoyl)piperidin-3 -yl] - 1 H- 1 ,3 -benzodiazol-2- yl}pyridine-4-carboxamide;
methyl l-[(3R)-l-(prop-2-enoyl)piperidin-3-yl]-2-{[3- (trifluoromethyl)benzene] amido } - 1 H- 1 ,3 -benzodiazole-5 -carboxylate;
methyl 1 - [ 1 -(prop-2-enoyl)piperidin-3-yl] -2- { [3 -(trifluoromethyl)benzene] amido } - lH-l,3-benzodiazole-5-carboxylate;
N-{7-methyl-l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-5-(pyrrolidin-l-ylmethyl)-lH-l,3- benzodiazol-2-yl Jbenzamide;
N-{7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]-5-(pyrrolidin-l-ylmethyl)-lH-l,3- benzodiazol-2-yl Jbenzamide; N-[5-(morpholin-4-ylmethyl)-l-[(3R)-l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3- benzodiazol-2-yl]-3-(trifluoromethyl)benzamide;
N-[5-(morpholin-4-ylmethyl)-l-[l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3-benzodiazol- 2-yl]-3-(trifluoromethyl)benzamide;
2,6-dimethyl-N-{7-methyl-l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-5-(pyrrolidin-l- ylmethyl)-lH-l,3-benzodiazol-2-yl}pyridine-4-carboxamide;
2,6-dimethyl-N-{7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]-5-(pyrrolidin-l- ylmethyl)-lH-l,3-benzodiazol-2-yl}pyridine-4-carboxamide;
N-{7-[(3-hydroxypyrrolidin-l-yl)methyl]-l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-lH- 1,3 -benzodiazol-2-yl } benzamide ;
N- { 7- [(3-hydroxypyrrolidin- 1 -yl)methyl] - 1 - [ 1 -(prop-2-enoyl)azepan-3-yl] - 1 H- 1 ,3 - benzodiazol-2-yl}benzamide;
N-(l-(l-acryloylazepan-3-yl)-7-(l,l-dioxidothiomorpholine-4-carbonyl)-lH- benzo [d] imidazol-2-yl)benzamide ;
N-(7-cyano-l-{ l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl}-5- (hydroxymethyl) - 1 H- 1 , 3 -benzodiazol-2-yl) - 3 -(trifluoromethyl)benzamide ;
N-{ l-[(3R)-l-(prop-2-enoyl)piperidin-3-yl]-5-(pyrrolidin-l-ylmethyl)-lH-l,3- benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
N- { 1 - [ 1 -(prop-2-enoyl)piperidin-3 -yl] -5 -(pyrrolidin- 1 -ylmethyl)- IH- 1 ,3 -benzodiazol - 2-yl } -3-(trifluoromethyl)benzamide;
N-[5-(piperidin-l-ylmethyl)-l-[(3R)-l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3- benzodiazol-2-yl]-3-(trifluoromethyl)benzamide;
N-[5-(piperidin-l-ylmethyl)-l-[l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3-benzodiazol- 2-yl]-3-(trifluoromethyl)benzamide;
N- { 5- [(N-methylacetamido)methyl] - 1 - [(3R)- 1 -(prop-2-enoyl)piperidin-3 -yl] - 1 H- 1 ,3 - benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
N- { 5 - [(N-methylacetamido)methyl] - 1 - [ 1 -(prop-2-enoyl)piperidin-3-yl] - IH- 1 ,3 - benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
N-(5-{[(3R,4R)-3,4-dihydroxypyrrolidin-l-yl]methyl}-l-[(3R)-l-(prop-2- enoyl)piperidin-3-yl]-lH-l,3-benzodiazol-2-yl)-3-(trifluoromethyl)benzamide;
N-(5 - { [3 ,4-dihydroxypyrrolidin- 1 -yl]methyl } - 1 - [ 1 -(prop-2-enoyl)piperidin-3 -yl] - 1H- l,3-benzodiazol-2-yl)-3-(trifluoromethyl)benzamide;
N- [5 -(hydroxymethyl)- 1 - [(3R)- 1 -(prop-2-enoyl)piperidin-3 -yl] - 1 H- 1 ,3 -benzodiazol- 2-yl]-3-(trifluoromethyl)benzamide; N-[5-(hydroxymethyl)-l-[l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3-benzodiazol-2-yl]- 3-(trifluoromethyl)benzamide;
N- [5 -(methoxymethyl)- 1 - [(3R)- 1 -(prop-2-enoyl)piperidin-3 -yl] - 1 H- 1 ,3 -benzodiazol-
2- yl]-3-(trifluoromethyl)benzamide;
N- [5 -(methoxymethyl)- 1 - [ 1 -(prop-2-enoyl)piperidin-3 -yl] - IH- 1 ,3 -benzodiazol-2-yl] -
3- (trifluoromethyl)benzamide;
N- [5 -(ethoxymethyl)- 1 - [(3R)- 1 -(prop-2-enoyl)piperidin-3 -yl] - 1 H- 1 ,3-benzodiazol-2- yl] - 3 - (trifluoromethyl)benzamide ;
N-[5-(ethoxymethyl)-l-[l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3-benzodiazol-2-yl]-3- (trifluoromethyl)benzamide;
N-{5-[(2-methoxyethoxy)methyl]-l-[(3R)-l-(prop-2-enoyl)piperidin-3-yl]-lH-l,3- benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
N- { 5- [(2-methoxyethoxy)methyl] - 1 - [ 1 -(prop-2-enoyl)piperidin-3 -yl] - IH- 1 ,3 - benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
N-{5-[(3,3-difluoropyrrolidin-l-yl)methyl]-l-[(3R)-l-(prop-2-enoyl)piperidin-3-yl]- 1 H- 1 ,3 -benzodiazol-2-y 1 } - 3 - (trifluoromethyl)benzamide ;
N- { 5 - [(3 , 3 -difluoropyrrolidin- 1 -yl)methyl] - 1 - [ 1 - (prop-2-enoyl)piperidin- 3 -yl] - 1 H- 1 , 3 -benzodiazol-2-yl } -3 - (trifluoromethyl)benzamide ;
2-methyl-N- { 7-methyl- 1 - [(3R)- 1 -(prop-2-enoyl)azepan-3 -yl] -5 -(pyrrolidin- 1 - ylmethyl)-lH-l,3-benzodiazol-2-yl}pyridine-4-carboxamide;
2-methyl-N- {7-methyl- 1 - [ 1 -(prop-2-enoyl)azepan-3-yl] -5 -(pyrrolidin- 1 -ylmethyl)- lH-l,3-benzodiazol-2-yl}pyridine-4-carboxamide;
N-(5- {[(2-methanesulfonylethyl)(methyl)amino]methyl} -7-methyl- l-[(3R)-l-(prop-2- enoyl)azepan-3-yl]- IH- 1 ,3-benzodiazol-2-yl)benzamide;
N-(5- { [(2-methanesulfonylethyl)(methyl)amino]methyl } -7-methyl- 1 -[ 1 -(prop-2- enoyl)azepan-3-yl]- IH- 1 ,3-benzodiazol-2-yl)benzamide;
N- { 5 - [(2-methoxyethoxy)methyl] -7-methyl- 1 - [(3R)- 1 -(prop-2-enoyl)azepan-3 -yl] - 1 H- 1 , 3 -benzodiazol-2-y 1 } benzamide ;
N-{5-[(2-methoxyethoxy)methyl]-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3- benzodiazol-2-yl}benzamide;
N-{7-[(dimethylamino)methyl]-l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-lH-l,3- benzodiazol-2-yl}benzamide;
N-{7-[(dimethylamino)methyl]-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol- 2-yl} benzamide; N-{7-[(2-methoxyethoxy)methyl]-l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-lH-l,3- benzodiazol-2-yl}benzamide;
N-{7-[(2-methoxyethoxy)methyl]-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3- benzodiazol-2-yl}benzamide;
N-[7-(hydroxymethyl)- 1-[(3R)- l-(prop-2-enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2- yljbenzamide;
N-[7-(hydroxymethyl)-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2- yljbenzamide;
(R)-N-(l-(l-acryloylazepan-3-yl)-7-((l,l-dioxidothiomorpholino)methyl)-lH- benzo [d] imidazol-2-yl)benzamide ;
N-(l-(l-acryloylazepan-3-yl)-7-((l,l-dioxidothiomorpholino)methyl)-lH- benzo [d] imidazol-2-yl)benzamide ;
N-(7-{ [(2-methanesulfonylethyl)(methyl)amino]methyl}-l-[(3R)-l-(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl)benzamide;
N-(7- { [(2-methanesulfonylethyl)(methyl)amino]methyl } - 1 -[ 1 -(prop-2-enoyl)azepan-
3 -yl] - 1 H- 1 , 3 -benzodiazol-2-yl)benzamide ;
methyl 3-({2-benzamido-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-7- yl } formamido)propanoate ;
methyl 2-({2-benzamido-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-7- yl}formamido) acetate;
3-({2-benzamido-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-7- yl}formamido)propanoic acid;
2-({2-benzamido-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-7- yl}formamido)acetic acid;
N-[7-(3-methyl-l,2,4-oxadiazol-5-yl)-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3- benzodiazol-2-yl]benzamide;
l-(l-acryloylazepan-3-yl)-2-benzamido-N-(2-(methylsulfonyl)ethyl)-lH- benzo [d] imidazole-7 -carboxamide ;
N-(7-{ [(3R,4R)-3,4-dihydroxypyrrolidin-l-yl]carbonyl}-l-[l-(prop-2-enoyl)azepan- 3-yl]-lH-l,3-benzodiazol-2-yl)benzamide;
N-(7-{ [3,4-dihydroxypyrrolidin- l-yl]carbonyl}-l-[l-(prop-2-enoyl)azepan-3-yl]-lH- 1 , 3 -benzodiazol-2-yl)benzamide ;
N- [7-(3 -methyl- 1 ,2,4-oxadiazol-5-yl)- 1 - [4-(prop-2-enoyl)- 1 ,4-oxazepan-6-yl] - 1 H- l,3-benzodiazol-2-yl]benzamide; N-(l-{4-[(2E)-4-(dimethylamino)but-2-enoyl]-l,4-oxazepan-6-yl}-7-(3-methyl-l,2,4- oxadiazol-5-yl)-lH-l,3-benzodiazol-2-yl)benzamide;
N-{ 1-[(3R)-1- [(2E)-4-(dimethylamino)but-2-enoyl]piperidin-3 -yl] -5 - (hydroxymethyl) - 1 H- 1 , 3 -benzodiazol-2-yl } - 3 - (trifluoromethyl)benzamide ;
N- { 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl]piperidin-3 -yl] -5 -(hydroxymethyl)- 1H- l,3-benzodiazol-2-yl}-3-(trifluoromethyl)benzamide;
2-methyl-N-[7-methyl-5-(piperidin-l-ylmethyl)-l-[(3R)-l-(prop-2-enoyl)azepan-3- yl]-lH-l,3-benzodiazol-2-yl]pyridine-4-carboxamide;
2-methyl-N-[7-methyl-5-(piperidin-l-ylmethyl)-l-[l-(prop-2-enoyl)azepan-3-yl]-lH- 1 ,3-benzodiazol-2-yl]pyridine-4-carboxamide;
N-[5-(azetidin-l-ylmethyl)-7-methyl-l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-lH-l,3- benzodiazol-2-yl]-2-methylpyridine-4-carboxamide;
N- [5 -(azetidin- 1 -ylmethyl) -7 -methyl- 1 - [ 1 -(prop-2-enoyl)azepan-3 -yl] - 1 H- 1 ,3- benzodiazol-2-yl]-2-methylpyridine-4-carboxamide;
N-(5- { [(3S)-3-hydroxypyrrolidin- l-yl]methyl } -7-methyl- 1- [(3R)- l-(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl)-2-methylpyridine-4-carboxamide;
N-(5-{[3-hydroxypyrrolidin-l-yl]methyl}-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]- lH-l,3-benzodiazol-2-yl)-2-methylpyridine-4-carboxamide;
N-(5-{[(3S)-3-fluoropyrrolidin-l-yl]methyl}-7-methyl-l-[(3R)-l-(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl)-2-methylpyridine-4-carboxamide;
N-(5-{[3-fluoropyrrolidin-l-yl]methyl}-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]- lH-l,3-benzodiazol-2-yl)-2-methylpyridine-4-carboxamide;
N-(5-{[(3R)-3-fluoropyrrolidin-l-yl]methyl}-7-methyl-l-[(3R)-l-(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl)-2-methylpyridine-4-carboxamide;
N-(5-{[3-fluoropyrrolidin-l-yl]methyl}-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]- lH-l,3-benzodiazol-2-yl)-2-methylpyridine-4-carboxamide;
N-(5- {[(3S)-3-methoxypyrrolidin-l-yl]methyl} -7-methyl- 1-[(3R)-1 -(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl)-2-methylpyridine-4-carboxamide;
N-(5-{[3-methoxypyrrolidin-l-yl]methyl}-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]- lH-l,3-benzodiazol-2-yl)-2-methylpyridine-4-carboxamide;
N-(5-{[(3R)-3-methoxypyrrolidin-l-yl]methyl}-7-methyl-l-[(3R)-l-(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl)-2-methylpyridine-4-carboxamide;
N-(5-{[3-methoxypyrrolidin-l-yl]methyl}-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]- lH-l,3-benzodiazol-2-yl)-2-methylpyridine-4-carboxamide; N- { 5- [(3 ,3-difluoropyrrolidin- 1 -yl)methyl] -7-methyl- 1 - [(3R)- 1 -(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl }-2-methylpyridine-4-carboxamide;
N- { 5- [(3 ,3-difluoropyrrolidin- 1 -yl)methyl] -7-methyl- 1 - [ 1 -(prop-2-enoyl)azepan-3 - yl]-lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- { 5- [(3 -fluoroazetidin- 1 -yl)methyl] -7-methyl- 1 - [(3R)- 1 -(prop-2-enoyl)azepan-3 -yl] - lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- { 5- [(3 -fluoroazetidin- 1 -yl)methyl] -7-methyl- 1 - [ 1 -(prop-2-enoyl)azepan-3 -yl] - 1 H- l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{5-[(3,3-difluoroazetidin-l-yl)methyl]-7-methyl-l-[(3R)-l-(prop-2-enoyl)azepan- 3-yl]- 1H- 1 ,3-benzodiazol-2-yl }-2-methylpyridine-4-carboxamide;
N-{5-[(3,3-difluoroazetidin-l-yl)methyl]-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]- lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- { 5- [(3 -methoxyazetidin- 1 -yl)methyl] -7-methyl- 1 - [(3R)- 1 -(prop-2-enoyl)azepan-3 - yl]-lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- { 5- [(3 -methoxyazetidin- 1 -yl)methyl] -7-methyl- 1 - [ 1 -(prop-2-enoyl)azepan-3-yl] - lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
(R)-N-( 1 -( 1 -acryloylazepan-3 -yl)-5 -(( 1 , 1 -dioxidothiomorpholino)methyl)-7-methyl- lH-benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(l-(l-acryloylazepan-3-yl)-5-((l,l-dioxidothiomorpholino)methyl)-7-methyl-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(5- {[(3S)-3-methoxypyrrolidin-l-yl]methyl} -7-methyl- 1-[(3R)-1 -(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl)-2,6-dimethylpyridine-4-carboxamide;
N-(5-{[3-methoxypyrrolidin-l-yl]methyl}-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]- lH-l,3-benzodiazol-2-yl)-2,6-dimethylpyridine-4-carboxamide;
N-(5-{[(3R)-3-methoxypyrrolidin-l-yl]methyl}-7-methyl-l-[(3R)-l-(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl)-2,6-dimethylpyridine-4-carboxamide;
N-(5-{[3-methoxypyrrolidin-l-yl]methyl}-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]- lH-l,3-benzodiazol-2-yl)-2,6-dimethylpyridine-4-carboxamide;
N-(5-{[(3S)-3-fluoropyrrolidin-l-yl]methyl}-7-methyl-l-[(3R)-l-(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl)-2,6-dimethylpyridine-4-carboxamide;
N-(5-{[3-fluoropyrrolidin-l-yl]methyl}-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]- lH-l,3-benzodiazol-2-yl)-2,6-dimethylpyridine-4-carboxamide;
N-(5-{[(3R)-3-fluoropyrrolidin-l-yl]methyl}-7-methyl-l-[(3R)-l-(prop-2- enoyl)azepan-3-yl]- 1H- 1 ,3-benzodiazol-2-yl)-2,6-dimethylpyridine-4-carboxamide; N-(5-{[3-fluoropyrrolidin-l-yl]methyl}-7-methyl-l-[l-(prop-2-enoyl)azepan-3-yl]- lH-l,3-benzodiazol-2-yl)-2,6-dimethylpyridine-4-carboxamide;
2,3-difluoro-N-(5-{[(3R)-3-methoxypyrrolidin-l-yl]methyl}-7-methyl-l-[(3R)-l- (prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2-yl)benzamide;
2,3-difluoro-N-(5-{[3-methoxypyrrolidin-l-yl]methyl}-7-methyl-l-[l-(prop-2- enoyl)azepan-3-yl]- IH- 1 ,3-benzodiazol-2-yl)benzamide;
6-methyl-N- {7-methyl- l-[(3R)-l-(prop-2-enoyl)azepan-3-yl]-5-(pyrrolidin-l- ylmethyl)-lH-l,3-benzodiazol-2-yl}pyridazine-4-carboxamide;
6-methyl-N- {7-methyl- l-[l-(prop-2-enoyl)azepan-3-yl]-5-(pyrrolidin-l-ylmethyl)- lH-l,3-benzodiazol-2-yl}pyridazine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-but-2-enoyl]azepan-3-yl]-5-{ [(3S)-3-methoxypyrrolidin-l- yljmethyl } -7-methyl- IH- 1 ,3-benzodiazol-2-yl } -2,6-dimethylpyridine-4-carboxamide;
N- { 1 - [ 1 - [(2E)-but-2-enoyl] azepan-3-yl] -5 - { [3 -methoxypyrrolidin- 1 -yljmethyl } -7- methyl-lH-l,3-benzodiazol-2-yl}-2,6-dimethylpyridine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-but-2-enoyl]azepan-3-yl]-5-{ [(3R)-3-methoxypyrrolidin-l- yljmethyl } -7-methyl- IH- 1 ,3-benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N- { 1 - [ 1 - [(2E)-but-2-enoyl] azepan-3-yl] -5 - { [3 -methoxypyrrolidin- 1 -yljmethyl } -7- methyl-lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-but-2-enoyl]azepan-3-yl]-7-methyl-5-(pyrrolidin-l-ylmethyl)-lH- l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{ l-[l-[(2E)-but-2-enoyl]azepan-3-yl]-7-methyl-5-(pyrrolidin-l-ylmethyl)-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-but-2-enoyl]azepan-3-yl]-5-{ [(3S)-3-fluoropyrrolidin-l- yljmethyl } -7-methyl- IH- 1 ,3-benzodiazol-2-yl } -2,6-dimethylpyridine-4-carboxamide;
N- { 1 - [ 1 - [(2E)-but-2-enoyl] azepan-3-yl] -5 - { [3 -fluoropyrrolidin- 1 -yljmethyl } -7- methyl-lH-l,3-benzodiazol-2-yl}-2,6-dimethylpyridine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-but-2-enoyl]azepan-3-yl]-5-{ [(3S)-3-fluoropyrrolidin-l- yljmethyl } -7-methyl- IH- 1 ,3-benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N- { 1 - [ 1 - [(2E)-but-2-enoyl] azepan-3-yl] -5 - { [3 -fluoropyrrolidin- 1 -yljmethyl } -7- methyl- lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
methyl 1 - [ 1 -(prop-2-enoyl)piperidin-3-yl] -2- { [3 -(trifluoromethyl)benzene] amido } - lH,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carboxylate;
N-{5-methanesulfonyl-l-[l-(prop-2-enoyl)piperidin-3-yl]-lH,4H,5H,6H,7H- imidazo[4,5-c]pyridin-2-yl}-3-(trifluoromethyl)benzamide; N-{5-acetyl -[l-(prop-2-enoyl)piperidin-3-yl]-lH,4H,5H,6H,7H-imidazo[4,5- c]pyridin-2-yl}-3-(trifluoromethyl)benzamide;
methyl 3 - [ 1 -(prop-2-enoyl)piperidin-3-yl] -2- { [3 -(trifluoromethyl)benzene] amido } - 3H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carboxylate;
N-{5-methanesulfonyl-3-[l-(prop-2-enoyl)piperidin-3-yl]-3H,4H,5H,6H,7H- imidazo[4,5-c]pyridin-2-yl}-3-(trifluoromethyl)benzamide;
N-{5-acetyl-3-[l-(prop-2-enoyl)piperidin-3-yl]-3H,4H,5H,6H,7H-imidazo[4,5- c]pyridin-2-yl}-3-(trifluoromethyl)benzamide;
N-{5-methyl-3-[l-(prop-2-enoyl)piperidin-3-yl]-3H,4H,5H,6H,7H-imidazo[4,5- c]pyridin-2-yl}-3-(trifluoromethyl)benzamide;
N-{ l-[(3R)-l-[(2E)-but-2-enoyl]azepan-3-yl]-5-{ [(3S)-3-methoxypyrrolidin-l- yl]methyl}-lH-l,3-benzodiazol-2-yl}-2,6-dimethylpyridine-4-carboxamide;
N-{ l-[l-[(2E)-but-2-enoyl]azepan-3-yl]-5-{[(3S)-3-methoxypyrrolidin-l-yl]methyl}- lH-l,3-benzodiazol-2-yl}-2,6-dimethylpyridine-4-carboxamide;
N-(5-{[(3S)-3-methoxypyrrolidin-l-yl]methyl}-l-[(3R)-l-(prop-2-enoyl)azepan-3- yl]-lH-l,3-benzodiazol-2-yl)-2,6-dimethylpyridine-4-carboxamide;
N-(5-{[3-methoxypyrrolidin-l-yl]methyl}-l-[l-(prop-2-enoyl)azepan-3-yl]-lH-l,3- benzodiazol-2-yl)-2,6-dimethylpyridine-4-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methoxy-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methoxy-lH-l,3- benzodiazol-2-yl } -2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-6-methoxy- lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{7-chloro-l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-6-methoxy-lH- l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{6-chloro-l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-5-methoxy- lH-l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N- { 6-chloro- 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -5 -methoxy- 1 H- l,3-benzodiazol-2-yl}-2-methylpyridine-4-carboxamide;
N-{ 6-chloro- 1-[(3R)- l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-5-methoxy- lH-l,3-benzodiazol-2-yl}-2,6-dimethylpyridine-4-carboxamide;
N- { 6-chloro- 1 - [ 1 - [(2E)-4-(dimethylamino)but-2-enoyl] azepan-3 -yl] -5 -methoxy- 1 H- l,3-benzodiazol-2-yl}-2,6-dimethylpyridine-4-carboxamide; 1-[(3R)- l-(prop-2-enoyl)piperidin-3-yl]-2- { [3-(trifluoromethyl)benzene]amido} - 1H- 1 ,3 -benzodiazole-5 -carboxylic acid;
l-[l-(prop-2-enoyl)piperidin-3-yl]-2-{[3-(trifluoromethyl)benzene]amido}-lH-l,3- benzodiazole-5-carboxylic acid;
l-[(3R)-l-(prop-2-enoyl)piperidin-3-yl]-2-C-[3-(trifluoromethyl)benzene]-lH-l,3- benzodiazole-2, 5 -die arboxamide ;
l-[l-(prop-2-enoyl)piperidin-3-yl]-2-C-[3-(trifluoromethyl)benzene]-lH-l,3- benzodiazole-2, 5 -die arboxamide ;
1 - [ 1 -(prop-2-enoyl)azepan-3 -yl] -2- { [3 -(trifluoromethyl)benzene] amido } - 1H- 1 ,3 - benzodiazole-7-carboxylic acid;
N-{7-methyl-l-[(6R)-4-(prop-2-enoyl)-l,4-oxazepan-6-yl]-lH-l,3-benzodiazol-2-yl}- 3 - (trifluoromethyl)benzamide ;
N-{7-methyl-l-[(6S)-4-(prop-2-enoyl)-l,4-oxazepan-6-yl]-lH-l,3-benzodiazol-2-yl}- 3 - (trifluoromethyl)benzamide ;
N-{ l-[(3S)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl } -2-(trifluoromethyl)pyridine-4-carboxamide;
N-{ l-[(3S)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-2-methyl-l,3-thiazole-5-carboxamide;
N-{ l-[(3R)-l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-2-methyl-l,3-thiazole-5-carboxamide;
N-{ l-[l-[(2E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-7-methyl-lH-l,3- benzodiazol-2-yl}-2-methyl-l,3-thiazole-5-carboxamide;
N-{7-methyl-l-[(3S)-l-(prop-2-enoyl)azepan-3-yl]-lH-l,3-benzodiazol-2-yl}-3- (trifluoromethyl)benzamide; and
N- { 7-methyl- 1 - [(3R)- 1 -(prop-2-enoyl)azepan-3 -yl] - 1 H- 1 ,3 -benzodiazol-2-yl } -3 -
(trifluoromethyl)benzamide; or a pharmaceutically acceptable salt thereof.
(R)-N-(7-chloro-l-(l-(l-methyl-l,2,5,6-tetrahydropyridine-3-carbonyl)azepan-3-yl)- 1 H-benzo [d] imidazol-2-yl) -2-methylisonicotinamide ;
(N-(7-chloro-l-(l-(l-methyl-l,2,5,6-tetrahydropyridine-3-carbonyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(R)-N-(7-chloro-l-(l-(l-methyl- 1,2,3, 6-tetrahydropyridine-4-carbonyl)azepan-3-yl)- 1 H-benzo [d] imidazol-2-yl) -2-methylisonicotinamide ;
N-(7-chloro-l-(l-(l-methyl-l,2,3,6-tetrahydropyridine-4-carbonyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide; (R,E)-N-(7-chloro-l-(l-(4-(dimethylamino)-4-methylpent-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(dimethylamino)-4-methylpent-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
tert-butyl 4-acryloyl-6-(7-chloro-2-(2-methylisonicotinamido)- lH-benzo[d]imidazol-
1 -yl)- 1 ,4-diazepane- 1 -carboxylate;
N-(l-(l-acryloyl-l,4-diazepan-6-yl)-7-chloro-lH-benzo[d]imidazol-2-yl)-2- methylisonicotinamide;
N-(l-(l-acetyl-4-acryloyl-l,4-diazepan-6-yl)-7-chloro-lH-benzo[d]imidazol-2-yl)-2- methylisonicotinamide;
(R)-N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
(R,E)-N-(7-chloro-l-(l-(4-(dicyclopropylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(dicyclopropylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(R)-N-(l-(l-acryloylazepan-3-yl)-7-methyl-5-((4-methyl-3-oxopiperazin-l- yl)methyl)-lH-benzo[d]imidazol-2-yl)-2,6-dimethylisonicotinamide;
N-(l-(l-acryloylazepan-3-yl)-7-methyl-5-((4-methyl-3-oxopiperazin-l-yl)methyl)- 1 H-benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
(R)-N-(5-((4-acetylpiperazin-l-yl)methyl)-l-(l-acryloylazepan-3-yl)-7-methyl-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
N-(5-((4-acetylpiperazin-l-yl)methyl)-l-(l-acryloylazepan-3-yl)-7-methyl-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
(E)-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-(dimethylphosphoryl)-6-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2-(dimethylphosphoryl)-6-methylisonicotinamide;
(R,E)-tert-butyl 4-(3-(7-chloro-2-(2-methylisonicotinamido)-lH-benzo[d]imidazol-l- yl)azepan-l-yl)-4-oxobut-2-enyl(methyl)carbamate;
tert-butyl 4-(3-(7-chloro-2-(2-methylisonicotinamido)-lH-benzo[d]imidazol-l- yl)azepan-l-yl)-4-oxobut-2-enyl(methyl)carbamate; (R,E)-N-(7-chloro-l-(l-(4-(methylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(methylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol-2- yl)-2-methylisonicotinamide;
(R,E)-N-(7-chloro-l-(l-(4-(methylamino)but-2-enoyl)azepan-3-yl)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
N-(7-chloro-l-(l-(4-(methylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol-2- yl) -2 , 6-dimethylisonicotinamide ;
(R,E)-N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-(trifluoromethyl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-(trifluoromethyl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(R,E)-N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-(trifluoromethyl)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-(trifluoromethyl)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
(R,E)-N-(7-chloro-l-(l-(4-(cyclopropylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(cyclopropylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(R,E)-N-(l-(l-(4-(tert-butylamino)but-2-enoyl)azepan-3-yl)-7-chloro-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(l-(l-(4-(tert-butylamino)but-2-enoyl)azepan-3-yl)-7-chloro-lH-benzo[d]imidazol- 2-yl)-2-methylisonicotinamide;
(R,E)-N-(7-chloro-l-(l-(4-(l-methylcyclopropylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(l-methylcyclopropylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(R)-N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(R,E)-N-(l-(l-but-2-enoylazepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide; N-(l-(l-but-2-enoylazepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(R,E)-N-(l-(l-but-2-enoylazepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
N-(l-(l-but-2-enoylazepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
(S,E)-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2-methylisonicotinamide;
(S,E)-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2,6-dimethylisonicotinamide;
(S,E)-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-(dimethylphosphoryl)-6-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2-(dimethylphosphoryl)-6-methylisonicotinamide;
(R,E)-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-(dimethylphosphoryl)-6-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2-(dimethylphosphoryl)-6-methylisonicotinamide;
(S,E)-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-(dimethylphosphoryl)isonicotinamide;
N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2-(dimethylphosphoryl)isonicotinamide;
(R,E)-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-(dimethylphosphoryl)isonicotinamide; and
N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2-(dimethylphosphoryl)isonicotinamide;
or a pharmaceutically acceptable salt thereof.
In a particular embodiment, provided herein is a compound selected from:
(R,E)-N-(7-chloro-l-(l-(4-(pyrrolidin-l-yl)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide; N-(7-chloro- l-(l-(4-(pyrrolidin- l-yl)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2-methylisonicotinamide;
(R,E)-N-(7-chloro- l-(l-(4-(3-fluoroazetidin-l-yl)but-2-enoyl)azepan-3-yl)- lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro- l-(l-(4-(3-fluoroazetidin-l-yl)but-2-enoyl)azepan-3-yl)- lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(5')-N-(l-(l-acryloylpiperidin-3-yl)-5-methyl-lH-benzo[d]imidazol-2-yl)-3- (trifluoromethyl) benzamide;
N-(l-(l-acryloylpiperidin-3-yl)-5-methyl- lH-benzo[d]imidazol-2-yl)-3- (trifluoromethyl) benzamide;
(/?,£')-N-(7-chloro- l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro- l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)- lH-benzo[d]imidazol- 2-yl)-2-methylisonicotinamide;
(R,E)-N-(7-chloro- l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
N-(7-chloro- l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2,6-dimethylisonicotinamide;
(R,E)-N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl- lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl- lH-benzo[d]imidazol- 2-yl)-2-methylisonicotinamide;
(R,E)-N-(l-(l-(4- (dimethylamino)but-2-enoyl)azepan- 3 -yl) -7 -methyl- 1 H- benzo[d]imidazol-2-yl)-2-(trifluoromethyl)isonicotinamide;
N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl- lH-benzo[d]imidazol- 2-yl)-2-(trifluoromethyl)isonicotinamide;
(/?)-N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-methoxy- lH-benzo[d]imidazol-2- yl)pyridazine-4-carboxamide;
N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-methoxy- lH-benzo[d]imidazol-2- yl)pyridazine-4-carboxamide;
N-(7-methyl- l-(l-(vinylsulfonyl)azepan-3-yl)- lH-benzo[ii|imidazol-2-yl)-3- (trifluoromethyl)benzamide ;
N-(l-(l-acryloylazepan-3-yl)-7-(pyrrolidin-l-ylmethyl)-lH-benzo[(i]imidazol-2-yl)-3- (trifluoromethyl)benzamide ; tert-butyl 4-acryloyl-6-(7-chloro-2-(2-methylisonicotinamido)-lH-benzo[d]imidazol- 1 -yl)- 1 ,4-diazepane- 1 -carboxylate ;
N-(l-(l-acryloyl-l,4-diazepan-6-yl)-7-chloro-lH-benzo[d]imidazol-2-yl)-2- methylisonicotinamide;
N-(l-(l-acetyl-4-acryloyl-l,4-diazepan-6-yl)-7-chloro-lH-benzo[d]imidazol-2-yl)-2- methylisonicotinamide;
(R)-N-( 1 -( 1 -acryloylazepan-3 -yl)-7-chloro-6-(2-(pyrrolidin- 1 -yl)ethoxy)- 1 H- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
(R,E)-N-(7-chloro-l-(l-(4-(dicyclopropylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(dicyclopropylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(R)-l-(l-acryloylpiperidin-3-yl)-2-(3-(trifluoromethyl)benzamido)-lH- benzo [d]imidazole-5 -carboxylic acid;
1 -( 1 -acryloylpiperidin- 3 -yl) -2- (3 - (trifluoromethyl)benzamido) - 1 H- benzo [d]imidazole-5 -carboxylic acid;
(R)-l-(l-acryloylpiperidin-3-yl)-2-(3-(trifluoromethyl)benzamido)-lH- benzo[d]imidazole-5-carboxamide;
1 - ( 1 -acryloylpiperidin- 3 -yl) -2- (3 - (trifluoromethyl)benzamido) - 1 H- benzo[d]imidazole-5-carboxamide; and
1 - ( 1 -acryloylazepan- 3 -yl)-2- (3 - (trifluoromethyl)benzamido) - 1 H-benzo [d] imidazole- 7-carboxylic acid; or a pharmaceutically salt form thereof; particularly acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, subsalicylate, sulfate, tartrate, tosylate, trifenatate, trifluoroacetate or xinafoate; and more particularly, mesylate. In another aspect, provided herein is a pharmaceutical composition comprising a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3 A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
In another aspect, provided herein is a combination comprising a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a
pharmaceutically acceptable salt thereof, and a chemotherapeutic agent.
In another aspect, provided herein is the use of a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof, for inhibiting epidermal growth factor receptor (EGFR).
In another aspect, provided herein is the use of a compound of Formula (1), (2), (2A),
(2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a condition mediated by epidermal growth factor receptor (EGFR).
In another aspect, provided herein is the use of a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof, for treating a condition mediated by epidermal growth factor receptor (EGFR). In one embodiment, the EGFR is a mutant EGFR; for example, wherein the mutant EGFR comprises G719S, G719C, G719A, L858R, L861Q, an exon 19 deletion mutation or an exon 20 insertion mutation. In other embodiments, the mutant EGFR further comprises an EGFR T790M, T854A or D761Y resistance mutation; more particularly, the mutant EGFR comprises L858R or an exon 19 deletion, each of which may further comprise an EGFR T790M.
In another aspect, provided herein is the use of a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof, for treating a condition mediated by EGFR, wherein the condition is selected from non-small cell lung cancer (NSCLC), head and neck cancer, colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, gastric cancer, glioma and prostate cancer.
In another aspect, provided herein is a method for inhibiting epidermal growth factor, comprising administering to a system or subject a therapeutically effective amount of a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3 A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof.
Also provided herein is a method for treating a condition mediated by epidermal growth factor receptor, comprising administering to a system or subject in need of such treatment an effective amount of a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof,
In another aspect, provided herein are mutant specific EGFR inhibitors that are less effective against wild type EGFR.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
The term "Ci_6 alkyl" as used herein denotes a saturated or unsaturated alkyl radical having from 1 up to 6 carbon atoms, the radicals being either linear or branched with single or multiple branching; for example, butyl, such as n-butyl, sec-butyl, isobutyl, tert- butyl; propyl, such as n-propyl or isopropyl; ethyl or methyl. In particular embodiments, the Ci-6 alkyl is a saturated alkyl radical, and where specified, may be unsubstituted or substituted, for example by halo (i.e., haloalkyl such as trifluoromethyl, and the like), hydroxy (hydroxyalkyl such as hydroxymethyl, hydroxyethyl, 2-hydroxy-2-propyl and the like) or cyano (cyanoalkyl such as cyanomethyl, cyanoethyl and the like).
The term "Ci-6alkoxy" as used herein refers to the group -ORa, where Ra is Ci_6 alkyl group as defined herein. Non-limiting examples of alkoxy groups, as used herein, include methoxy, ethoxy, n-propoxy, isopropoxy, n-butyloxy, t-butyloxy, pentyloxy, hexyloxy and the like.
The term "Ci_6 haloalkyl" refers to Ci_6 alkyl group as defined herein, substituted with one or more halo groups, which may be the same or different. The haloalkyl can be monohaloalkyl, dihaloalkyl or polyhaloalkyl, including perhaloalkyl. In certain embodiments, a haloalkyl group is trifluoromethyl.
The term "cycloalkyl" as used herein, refers to a saturated or unsaturated monocyclic hydrocarbon group. The terms "C3_7cycloalkyl" or "Cs_6 cycloalkyl" as used herein refer to a cycloalkyl having from 3 up to 7 carbon atoms, or from 5 to 6 carbon atoms, respectively; for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
As used herein, the term "aryl" refers to an aromatic hydrocarbon group having 6-10 carbon atoms in the ring portion, and can be a single or bicyclic aromatic ring. Non- limiting examples include phenyl, naphthyl or tetrahydronaphthyl.
The term "heteroaryl," as used herein, refers to a 5-10 membered heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, which may be a 5-6 membered monocyclic ring or an 8-10 membered fused bicyclic ring where at least one of the rings is aromatic. Such bicyclic ring systems may be fused to one or more aryl, cycloalkyl, or heterocycloalkyl rings. Non-limiting examples of heteroaryl groups, as used herein, include 2- or 3-furyl; 1-, 2-, 4-, or 5-imidazolyl; 3-, 4-, or 5-isothiazolyl; 3-, 4-, or 5-isoxazolyl; 2-, 4-, or 5-oxazolyl; 4- or 5-1,2,3-oxadiazolyl; 2- or 3-pyrazinyl; 1-, 3-, 4-, or 5- pyrazolyl; 3-, 4-, 5- or 6-pyridazinyl; 2-, 3-, or 4- pyridyl; 2-, 4-, 5- or 6-pyrimidinyl; 1-, 2- or 3-pyrrolyl; 1- or 5-tetrazolyl; 2- or 5-1,3,4- thiadiazolyl; 2-, 4-, or 5-thiazolyl; 2- or 3-thienyl; 2-, 4- or 6-1,3,5-triazinyl; 1-, 3- or 5- 1,2,4-triazolyl; 1-, 4- or 5-1,2,3-triazolyl; 2-, 4-, 5- , 6-, or 7-benzoxazolyl; 1-, 2-, 4-, 5-, 6-, or 7-benzimidazolyl; 2-, 4-, 5-, 6-, or 7-benzothiazolyl; 2-, 3-, 4-, 5-, 6-, 7- benzo[b]thienyl; 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-benzo[b]oxepine; 2-, 4-, 5-, 6-, 7-, or 8- benzoxazinyl; 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8, or 9-carbazolyl; 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl;
2- , 4-, or 5-4H-imidazo[4,5-d] thiazolyl; 2-, 3-, 5-, or 6- imidazo[2,l-b] thiazolyl; 2-, 3-, 6-, or 7-imidazo[l,2-b][l,2,4]triazinyl; 1-, 3-, 4-, 5-, 6-, or 7-indazolyl; 1-, 2-, 3-, 5-, 6-, 7- , or 8-indolizinyl; 1-, 2-, 3-, 4-, 5-, 6-, or 7-indolyl; 1-, 2-, 3-, 4-, 5-, 6-, or 7-isoindolyl; 1-,
3- , 4-, 5-, 6-, 7-, or 8-isoquinoliyl; 2-, 3-, 4-, 5-, 6-, or 7-naphthyridinyl; 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl; 2-, 4-, 6-, or 7-pteridinyl; 2-, 6-, 7-, or 8- purinyl; 2-, 3-, 5-, 6-, or 7- furo[3,2-b]-pyranyl; 1-, 3-, or 5-lH-pyrazolo[4,3-d]-oxazolyl; 2-, 3-, 5-, or 8- pyrazino[2,3-d]pyridazinyl; 1-, 2-, 3-, 4-, 5-, or 8-5H-pyrido[2,3-d]-o-oxazinyl; 1-, 2-, 3-,
4- , 6-, 7-, 8-, or 9-quinolizinyl; 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl; 2-, 3- , 4-, 5-, 6-, 7-, or 8-quinazolinyl; and 2-, 3-, 4-, or 5-thieno[2,3-b]furanyl.
As used herein, the terms "heterocyclyl" or "heterocyclic" refer to a saturated or unsaturated non-aromatic ring or ring system, e.g., which is a 4-, 5-, 6-, or 7-membered monocyclic, or 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic ring system and contains at least one heteroatom selected from O, S, P and N, where the N, S and P can also optionally be oxidized to various oxidation states. The heterocyclic group can be attached at a heteroatom or a carbon atom. Examples of heterocycles include tetrahydrofuran
(THF), dihydrofuran, 1, 4-dioxane, morpholine, 1,4-dithiane, piperazine, piperidine, 1,3- dioxolane, imidazolidine, imidazoline, pyrroline, pyrrolidine, azetidinyl, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane, 1,3-dithiane, oxathiane,
thiomorpholine, and the like. Where specified, the term "heterocyclyl" further refers to heterocyclic groups that is substituted by oxo; for example, pyrrolidin-2-one, 1,6-dihydro- pyridin-2(3H)-one, pyridin-2-(3H)-one, and the like.
The term "heteroatoms," as used herein, refers to nitrogen (N), oxygen (O), sulfur (S) or phosphorus (P) atoms, wherein the N, S and P can optionally be oxidized to various oxidation states. The term "acceptable" with respect to a compound, formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.
The term "administration" or "administering" of the subject compound means providing a compound of the invention, a pharmaceutically acceptable salt, a
pharmaceutically acceptable solvate, or solvate thereof to a subject in need of treatment.
The terms "co-administration" or "combined administration" or the like as used herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
The term "diluent," as used herein, refers to chemical compounds that are used to dilute a compound described herein prior to delivery. Diluents can also be used to stabilize compounds described herein.
The terms "effective amount" or "therapeutically effective amount," as used herein, refer to a sufficient amount of a compound described herein being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study.
As used herein, the term "inhibit", "inhibition" or "inhibiting" refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
The term "pharmaceutically acceptable," as used herein, refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compounds described herein. Such materials are administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
The term "carrier," as used herein, refers to chemical compounds or agents that facilitate the incorporation of a compound described herein into cells or tissues. The term "pharmaceutically acceptable carrier", as used herein, includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts,
preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289- 1329; Remington: The Science and Practice of Pharmacy, 21st Ed. Pharmaceutical Press 2011; and subsequent versions thereof). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is
contemplated.
The term "pharmaceutically acceptable salt," as used herein, refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compounds described herein.
The term "combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non- fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, by way of example, a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, by way of example, a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5) or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients.
The terms "composition" or "pharmaceutical composition," as used herein, refers to a mixture of at least one compound, such as a compound Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), or a pharmaceutically acceptable salt thereof, with at least one and optionally more than one other pharmaceutically acceptable chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
The term "subject" or "patient," as used herein, encompasses mammals and non- mammals. Examples of mammals include, but are not limited to, humans, chimpanzees, apes, monkeys, cattle, horses, sheep, goats, swine; rabbits, dogs, cats, rats, mice, guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like. Frequently the subject is a human, and may be a human who has been diagnosed as in need of treatment for a disease or disorder disclosed herein.
As used herein, a subject is "in need of a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
The term "an optical isomer" or "a stereoisomer", as used herein, refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom. The term "chiral" refers to molecules which have the property of non-superimposability on their mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. "Enantiomers" are a pair of stereoisomers that are non- superimposable mirror images of each other. A 1 : 1 mixture of a pair of enantiomers is a "racemic" mixture. The term is used to designate a racemic mixture where appropriate.
"Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn- lngold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
The term "a therapeutically effective amount" of a compound of the present invention, as used herein, refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the present invention that, when administered to a subject, is effective to: (a) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by EGFR kinase, (ii) associated with EGFR kinase activity, or (iii) characterized by activity (normal or abnormal) of EGFR kinases; (b) reducing or inhibiting the activity of EGFR kinase; or (c) reducing or inhibiting the expression of EGFR kinase. In another non- limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of EGFR kinase; or at least partially reducing or inhibiting the expression of EGFR kinase.
The terms "treat," "treating" or "treatment," as used herein, refers to methods of alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.
In addition, as used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment "treat", "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, "treat", "treating" or
"treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, "treat", "treating" or "treatment" refers to preventing or delaying the onset or development or progression of the disease or disorder.
Unless specified otherwise, the term "compound(s) of the invention" or "compound(s) provided herein" refers to compounds of Formula (1) and subformulae thereof (Formula (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5)), a pharmaceutically acceptable salt thereof, a prodrug thereof, a stereoisomer thereof (including diastereoisomers and enantiomers), a tautomer thereof, an isotopically labeled compound thereof (including deuterium substitutions), as well as inherently formed moieties (e.g., polymorphs, solvates and/or hydrates). As used herein, the term "a," "an," "the" and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
The chemical naming protocol and structure diagrams used herein employ and rely on the chemical naming features as utilized by the ChemDraw program (available from CambridgeSoft Corp., Cambridge, MA). In particular, compound structures and names were derived using Chemdraw Ultra (Version 10.0) and/or ChemAxon Name Generator (JChem Version 5.3.1.0).
Description of the Preferred Embodiments
The invention provides compositions and methods for modulating the activity of the epidermal growth factor receptor (EGFR). In one aspect, the invention provides compounds which act as inhibitors of EGFR. Various embodiments of the invention are described herein.
In one aspect, provided herein is a compound of Formula (1), a tautomer thereof, or a pharmaceutically accep
Figure imgf000044_0001
wherein Ring A is a 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and optionally substituted with oxo;
Ring B is phenyl; a 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S; or a 5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted by oxo;
E is NH or CH2;
Figure imgf000044_0002
Rrand R2 are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl; 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; phenyl, 5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O, S and P, and optionally substituted by oxo; - X1-C(0)OR3; -X1-0-C(0)R3; -X]-C(0)R3;
-X1-C(0)NR4R5; -X1-C(0)NR4-X3-C(0)OR3; -X1-C(O)NR4-X3-S(O)0-2 R6; -X]-NR4R5; -X^R^-C C R3; -X1-NR4-X2-C(0)OR3; -X1-NR4-X2-C(0)NR4R5;
-X1-NR4-X3-S(0)o-2R6; -X1-NR4S(0)2R6; -X^OSCCXhR6; -X]-OR3; -X^O-X^OR3; -X1-0-X4-S(0)o-2R6; -X1-0-X4-NR4R5; -X1-S(O)0-2R6; -X1-S(O)0-2-X3-NR4R5;
-X1-C(0)NR4-X3-P(0)R6aR6b; -X1-NR4-X1-P(0)R6aR6b; -X1-0-X1-P(0)R6aR6b;
-X1-P(0)R6a-X1-NR4R5; -X1-P(0)R6aR6b or -X^SCC zNR ; wherein each phenyl, heteroaryl, or heterocyclyl in R1 or R2 is unsubstituted or substituted by 1-3 groups selected from OH, halo, Ci_6 alkyl, Ci_6 haloalkyl and Ci_6 haloalkoxy;
R3, R4 and R5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R4 and R5 together with N in NR4R5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R7;
R6 is Ci-6 alkyl or Ci_6 haloalkyl;
R6a and R6b are independently hydroxy, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 alkoxy, Ci_6 haloalkoxy, 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and o tionally substituted with oxo;
Figure imgf000045_0001
Figure imgf000046_0001
independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl;
R12 and R13 are independently hydrogen, halo, cyano, Ci_6 alkyl or Ci_6 haloalkyl; R14 and R15 are independently hydrogen, Ci_6 alkyl, -L]-R23, -(CRaRb)2-3-Rc or -L2- Rd; or R14 and R15 together with N in NR14R15 may form a 4-7 membered ring containing
1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R 18 groups;
R and R are independently hydrogen or Ci_6 alkyl; or R and R together with the carbon to which they are attached may form a C3-6 cycloalkyl;
X1 and X2 are independently a bond or Ci_6 alkyl;
X3 is Ci_6 alkyl;
X4 is C2_6 alkyl;
Riy hydrogen, Ci_6 alkyl, COR , COOR , CONRzuRzl or S(0)2R ;
R 20 is Ci-6 alkyl, Ci_6 haloalkyl or cycloalkyl;
R21 is hydrogen or Ci_6 alkyl; or R20 and R21 together with the N in NR20R21 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S, P and optionally substituted with 1-4 R22 groups;
R7, R18 and R22 are independently oxo, halo, hydroxy, Ci_6 alkyl, Ci_6 haloalkyl, Ci-6 alkoxy or Ci_6 haloalkoxy;
R23 is independently C3-7 cycloalkyl, or a 4-10 membered heterocyclyl comprising 1-3 heteroatoms selected from N, O and S, and is optionally substituted with oxo; and R23 is unsubstituted or substituted with Ci_6 alkyl, Ci_6 haloalkyl, -L3-Re or -L4-Rf;
Rc and Re are independently halo, cyano, hydroxy, -OR24, -NRR25, -NR-C02R24, - NR-S02-R26, -NR-COR26, -NR-C(0)-NRR25, -OC(0)-NRR25, or Ci_6 alkyl substituted with halo, Ci_6 alkoxy, hydroxy or cyano;
Rd and Rf are independently -S02NRR25, -CONRR25, -C(0)OR24, -S02R26 or C(0)R26; R24 is C^g alkyl, d_6haloalkyl, -L2-R23aor -(CRaRb)2-3-N(RaRb)2;
R25 is hydrogen, Ci_6 alkyl, Ci_6haloalkyl, -L2-R23b or-(CR2)2_3-N(RaRb)2;
R26 is Ci_6 alkyl, Ci_6haloalkyl, -L2-R23c or -(CRaRb)i_3-N(RaRb)2;
R23a, R23b and R23c are independently selected from R23;
R, Ra and Rb are independently hydrogen or Ci_6 alkyl;
L1, L2, L3 and L4 are independently a bond or -(CRaRb)i_3 ; and
n and m are independently 1-3; and p and q are 1-4;
or a pharmaceutically acceptable salt thereof.
In another embodiment, provided herein is a compound of Formula (2) or a pharmaceutically accep
Figure imgf000047_0001
wherein Ring A is a 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo;
R1 and Rr are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl; -X]-NR4R5; -X]-OR3; -X1-S(O)0-2R6; -X1-P(0)R6aR6b; phenyl unsubstituted or substituted by Ci-6 alkyl; or a 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S;
R2 is selected from hydrogen, halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl;
- X1-C(0)OR3; -X1-C(0)R3; -X1-C(0)NR4R5; -X1-C(0)NR4-X3-C(0)OR3;
-X1-C(0)NR4-X3-S(0)o-2R6; -X]-NR4R5; -X1NR4-X2-C(0)R3; -X1-NR4-X3-S(O)0-2R6;
-X]-OR3; -X^O-X^OR3; -X1-S(O)0-2R6; -X^O-X^NR ; or a 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S and is unsubstituted or substituted by Ci_6 alkyl;
R3, R4 and R5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R4 and R5 together with N in NR4R5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R7 groups;
R6, R6a and R6b are Ci_6 alkyl;
Figure imgf000048_0001
Figure imgf000048_0002
Figure imgf000048_0003
R9, R10, Rlla, Rllb, Rllc, Rlld, Rlle, Rllf, Rllg, Rllh, Rni, Rllj, Rllk and R111 are hydrogen;
R 1i2A, R 1^3 R 1^6 and R I1V' are independently hydrogen or Ci_6 alkyl;
R14 and R15 are independently hydrogen; Ci_6 alkyl; -C(0)0-(Ci_6 alkyl); C3-7 cycloalkyl unsubstituted or substituted with Ci_6 alkyl; or R14 and R15 together with N in NR14R15 may form may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R18 groups;
R7 and R18 are independently oxo, halo, hydroxy, Ci_6 alkyl or Ci_6 alkoxy; R19 hydrogen, COR20 or COOR20;
R20 is Ci_6 alkyl;
p is 1;
m and q are independently 1-2; and Ring B, X1, X2, X3 and X4 and n are as defined in any of the embodiments described herein.
In another embodiment, provided herein is a compound of Formula (2A), (2B), (2C), (2D), (3A), (3B) or (3C) or a pharmaceutically acceptable salt thereof:
Figure imgf000049_0001
or a pharmaceutically acceptable salt thereof;
wherein Y is O or NR19; and
R1, Rr, R2, R8, R19, A, B, Y, m and n are as defined in any of the embodiments described herein.
In yet another embodiment, provided herein is a compound of Formula (4) or a pharmaceutically accep
Figure imgf000050_0001
wherein W1, W2, W3 and W4 are independently CR1 or N; and R1, Rr, R2, R8, Y and m are defined in any of the embodiments described herein. In a particular embodiment, at least two of W1, W2, W3 and W4 are CR1, and the others are N.
In a further embodiment, provided herein is a compound of Formula (5) or a pharmaceutically accep
Figure imgf000050_0002
wherein W1 and W2 are independently CR1 or N; and R1, R1 , R2, R8 and m are as defined in any of the embodiments described herein.
Certain of the compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present invention is meant to include all possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, nC, 13C, 14C, 15N, 18F, 31P, 32P, 35S, 36C1 and 125I respectively. The invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3H, 13C, and 14C, are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
Further, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the present invention. The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Processes using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D20, d6- acetone, d6-DMSO.
Compounds of the invention, i.e. compounds of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5), that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co- crystal formers. These co-crystals may be prepared from the compounds of the invention by known co-crystal forming procedures. Such procedures include grinding, heating, co- subliming, co-melting, or contacting in solution a compound of the invention with the co- crystal former under crystallization conditions and isolating co-crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of Formula (1), (2), (2A), (2B), (2C), (2D), (3A), (3B), (3C), (4) or (5).
Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomeric ally enriched, for example the (R)-, (S)- or (R,S)- configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration. Substituents at atoms with unsaturated bonds may, if possible, be present in cis- (Z)- or trans- (E)- form.
Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof. Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization. Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-0,0'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
The invention also provides for a method of inhibiting EGFR kinase activity in a cell comprising contacting the cell with an effective amount of an EGFR antagonist. In one embodiment, the administered amount is a therapeutically effective amount and the inhibition of EGFR kinase activity further results in the inhibition of the growth of the cell. In a further embodiment, the cell is a cancer cell.
Inhibition of cell proliferation is measured using methods known to those skilled in the art. For example, a convenient assay for measuring cell proliferation is the CellTiter- Glo™ Luminescent Cell Viability Assay, which is commercially available from Promega (Madison, Wis.). That assay determines the number of viable cells in culture based on quantitation of ATP present, which is an indication of metabolically active cells. See Crouch et al (1993) J. Immunol. Meth. 160:81-88, U.S. Pat. No. 6,602,677. The assay may be conducted in 96- or 384-well format, making it amenable to automated high- throughput screening (HTS). See Cree et al (1995) Anticancer Drugs 6:398-404. The assay procedure involves adding a single reagent (CellTiter-Glo® Reagent) directly to cultured cells. This results in cell lysis and generation of a luminescent signal produced by a luciferase reaction. The luminescent signal is proportional to the amount of ATP present, which is directly proportional to the number of viable cells present in culture. Data can be recorded by luminometer or CCD camera imaging device. The luminescence output is expressed as relative light units (RLU). Inhibition of cell proliferation may also be measured using colony formation assays known in the art.
Furthermore, the invention provides for methods of treating a condition mediated by EGFR in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of an EGFR antagonist. In one embodiment, the condition is a cell proliferative disease. Treatment of the cell proliferative disorder by administration of an EGFR antagonist results in an observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of cancer cells or absence of the cancer cells;
reduction in the tumor size; inhibition of cancer cell infiltration into peripheral organs including the spread of cancer into soft tissue and bone; inhibition of tumor metastasis; inhibition, to some extent, of tumor growth; and/or relief to some extent, one or more of the symptoms associated with the specific cancer; reduced morbidity and mortality, and improvement in quality of life issues. To the extent the EGFR antagonist may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. Reduction of these signs or symptoms may also be felt by the patient.
The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician. For cancer therapy, efficacy can be measured, for example, by assessing the time to disease progression (TDP) and/or determining the response rate (RR). Metastasis can be determined by staging tests and by bone scan and tests for calcium level and other enzymes to determine spread to the bone. CT scans can also be done to look for spread to the pelvis and lymph nodes in the area. Chest X-rays and measurement of liver enzyme levels by known methods are used to look for metastasis to the lungs and liver, respectively. Other routine methods for monitoring the disease include transrectal ultrasonography (TRUS) and transrectal needle biopsy (TRNB). In a specific embodiment, the administration of an EGFR antagonist decreases tumor burden (e.g., reduces size or severity of the cancer). In yet another specific embodiment, the administration of an EGFR antagonist kills the cancer.
Processes for Making Compounds of the Invention
Typically, a compound of Formula (1) can be prepared according to any one of the following schemes illustrated below, wherein A, B, R1, R1 , R2, R8, E, n and m are as defined in the Summary of the Invention, and Z* is the same as Z, except each N-R8 moiety has been replaced with an N-H. In particular embodiments, E is NH. In any of the schemes below, it is understood that a radical as defined encompasses any protecting groups thereof. One of skill in the art will also appreciate that these methods are representative, and does not limit other methods for preparing the compounds of the present invention.
In one embodiment, a compound of Formula (1) can be prepared according to Scheme
1:
Figure imgf000055_0001
(1-1 ) (1 )
Scheme 1
In Scheme 1, an intermediate of formula (I-l) is reacted with an intermediate of formula (1-2), in the presence of a base in a suitable solvent. Alternatively, a compound of Formula (1) can be prepared from the reaction of an intermediate of formula (I-l) with an intermediate of formula (1-3), in the presence of a coupling reagent and a base in a suitable solvent. The reaction proceeds in a temperature range of about -30 °C to about 50 °C. Suitable bases include but are not limited to, DIEA, K2CO3, NaHCC>3, and the like.
In another embodiment, a compound of Formula (1) can be prepared according to Scheme 2, wherein A, R1, R1 , R2, E, n and m are as defined in the Summary of the In
Figure imgf000055_0002
In Scheme 2, a compound of Formula (1) is prepared from the reaction of an intermediate of formula (1-8) with an intermediate of formula (1-9) in the presence of a coupling reagent and a base (for example, DIEA, triethylamine, K2CO3, NaHCC>3, and the like) in a suitable solvent. Alternatively, a compound of Formula (1) can be prepared from the reaction of an intermediate of formula (1-8) with an intermediate of formula (I- 10) in the presence of base (for example, DIEA, K2CO3, NaHCC>3, and the like) in a suitable solvent. The reaction proceeds in a temperature range of about -30 °C to about 50
'C.
Suitable coupling agents for use in the schemes described above include, but are not limited to, 2-(7-aza-lH- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium
hexafluorophosphate (HATU), O-benzotriazole-Ν,Ν,Ν' ,N'-tetramethyl-uronium- hexafluoro-phosphate (HBTU), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride/hydroxybenzotriazole (EDCI/HOBt), and the like. Suitable solvents include but are not limited to, CH2CI2, DMF, THF and the like.
Figure imgf000056_0001
Scheme 3 0-11) (1-12)
In Scheme 3, an intermediate of formula (1-4) (where X is a leaving group such as fluoro, chloro, bromo, methoxy, ethoxy and the like) is reacted with an intermediate of the formula (1-5) in the presence or absence of a base (for example, DIEA, triethylamine, K2CO3, NaHCC>3, and the like), either neat or in a suitable solvent such as DMF, DMA, N-methylpyrrolidine and the like, to generate an intermediate of formula (1-6). The reaction proceeds in a temperature range of about room temperature to about 150 °C. An intermediate of formula (1-6) can further be converted to an intermediate of formula (1-7) by means of hydrogenation conditions known in the art (for example H2, Pd/C, MeOH or H2, Raney-Ni, MeOH and the like) or in the presence of a reducing agents such as iron, zinc and the like in a suitable solvent such as acetic acid or the like. An intermediate of formula (1-7) can then be converted to an intermediate of formula (1-8) in the presence of cyanogen bromide in a suitable solvent such as a mixture of water, MeCN and MeOH at a temperature ranging from about room temperature to about 60 °C.
Alternatively, an intermediate of formula (1-11) can be prepared from the reaction of an intermediate of formula (1-7) with a condensation partner such as trimethyl orthoformate, triethyl orthoformate, 1,3,5-triazine, formamide, N,N-dimethylformamide dimethyl acetal, formic acid and the like in the presence or absence of an acid (for example AcOH, p-TSA, H2S04, HC02H and the like) either neat or in a suitable solvent such as DMF, DMA, MeOH, THF, toluene and the like. The reaction proceeds in a temperature range of about room temperature to about 150 °C. An intermediate of formula (1-11) can further be deprotonated with a base such as BuLi, LDA, LHMDS and the like, and reacted with an azide source such as p-toluenesulfonyl azide,
dodecylbenzenesulfonyl azide, methylsulfonylazide and the like in a suitable solvent such as toluene, THF and the like to form an intermediate of formula (1-12). The reaction proceeds in a temperature range of about -80 °C to about -20 °C. An intermediate of formula (1-12) can further be reduced to an intermediate of formula (1-8) by reactions well known in the art (for example H2, Pd/C, MeOH or PPh3,THF/H20 or
Na2S204/THF/H20 and the like). The reaction proceeds in a temperature range of about - 30 °C to about 60 °C.
The invention also relates to those forms of the process in which a compound obtainable as an intermediate at any stage of the process is used as a starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, for example in a protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ. Compounds of the invention and intermediates can also be converted into each other according to methods generally known to those skilled in the art. Intermediates and final products can be worked up and/or purified according to standard methods, e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like.
In the reactions described, reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, may be protected to avoid their unwanted participation in the reactions. A characteristic of protecting groups is that they can be removed readily (i.e. without the occurrence of undesired secondary reactions) for example by solvolysis, reduction, photolysis or alternatively under physiological conditions (e.g. by enzymatic cleavage). Conventional protecting groups may be used in accordance with standard practice (see e.g., T.W.
Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry," 4th Ed., Wiley- Interscience, 2006, and subsequent versions thereof).
All the above-mentioned process steps mentioned herein before and hereinafter can be carried out under reaction conditions that are known to those skilled in the art, including those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, including, for example, solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, for example ion exchangers, such as cation exchangers, e.g. in the H+ form, depending on the nature of the reaction and/or of the reactants at reduced, normal or elevated temperature, for example in a temperature range of from about -100 °C to about 190 °C, including, for example, from approximately -80 °C to approximately 150 °C, for example at from -80 to 60 °C, at room temperature, at from -20 to 40 °C or at reflux temperature, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under an argon or nitrogen atmosphere.
At all stages of the reactions, mixtures of isomers that are formed can be separated into the individual isomers, for example diastereoisomers or enantiomers, or into any desired mixtures of isomers, for example racemates or mixtures of diastereoisomers. Mixtures of isomers obtainable according to the invention can be separated in a manner known to those skilled in the art into the individual isomers; diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallisation and/or chromatographic separation, for example over silica gel or by e.g. medium pressure liquid chromatography over a reversed phase column, and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials.
The solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate; ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydrofuran or dioxane; liquid aromatic hydrocarbons, such as benzene or toluene; alcohols, such as methanol, ethanol or 1- or 2-propanol; nitriles, such as acetonitrile; halogenated hydrocarbons, such as methylene chloride or chloroform; acid amides, such as dimethylformamide or dimethyl acetamide; bases, such as heterocyclic or heteroaromatic nitrogen bases, for example pyridine or N-methylpyrrolidin-2-one; carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic anhydride; cyclic, linear or branched hydrocarbons, such as cyclohexane, hexane or isopentane, methycyclohexane; or mixtures of those solvents, for example aqueous solutions, unless otherwise indicated in the description of the processes. Such solvent mixtures may also be used in working up, for example by chromatography or partitioning.
The compounds of the present invention are either obtained in the free form, as a salt thereof, or as prodrug derivatives thereof. When both a basic group and an acid group are present in the same molecule, the compounds of the present invention may also form internal salts, e.g., zwitterionic molecules.
As used herein, the terms "salt" or "salts" refers to an acid addition or base addition salt of a compound of the invention. "Salts" include in particular "pharmaceutical acceptable salts". The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and
tromethamine.
In one embodiment, the invention provides a compound of Formula (1), (2), (2A),
(2B), (2C), (3A), (3B), (3C), (3D), (4) or (5) in acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, subsalicylate, sulfate, tartrate, tosylate, trifenatate, trifluoroacetate or xinafoate salt form.
The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in "Remington: The Science and Practice of Pharmacy," 21st Ed., Pharmaceutical Press 2011; and in "Pharmaceutical Salts: Properties, Selection, and Use," by Stahl and Wermuth, 2nd Rev. Ed., Wiley- VCH 2011, and subsequent versions thereof).
The present invention also provides pro-drugs of the compounds of the present invention that converts in vivo to the compounds of the present invention. A pro-drug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a subject. The suitability and techniques involved in making and using pro-drugs are well known by those skilled in the art.
Prodrugs can be conceptually divided into two non-exclusive categories, bioprecursor prodrugs and carrier prodrugs. (See, "The Practice of Medicinal Chemistry," Ch. 31-32 Ed. Wermuth, Academic Press, San Diego, Calif., 2001, and subsequent versions thereof). Generally, bioprecursor prodrugs are compounds, which are inactive or have low activity compared to the corresponding active drug compound, that contain one or more protective groups and are converted to an active form by metabolism or solvolysis. Both the active drug form and any released metabolic products should have acceptably low toxicity.
Carrier prodrugs are drug compounds that contain a transport moiety, e.g., that improve uptake and/or localized delivery to a site(s) of action. Desirably for such a carrier prodrug, the linkage between the drug moiety and the transport moiety is a covalent bond, the prodrug is inactive or less active than the drug compound, and any released transport moiety is acceptably non-toxic. For prodrugs where the transport moiety is intended to enhance uptake, typically the release of the transport moiety should be rapid. In other cases, it is desirable to utilize a moiety that provides slow release, e.g., certain polymers or other moieties, such as cyclodextrins. Carrier prodrugs can, for example, be used to improve one or more of the following properties: increased lipophilicity, increased duration of pharmacological effects, increased site-specificity, decreased toxicity and adverse reactions, and/or improvement in drug formulation (e.g., stability, water solubility, suppression of an undesirable organoleptic or physiochemical property). For example, lipophilicity can be increased by esterification of (a) hydroxyl groups with lipophilic carboxylic acids (e.g., a carboxylic acid having at least one lipophilic moiety), or (b) carboxylic acid groups with lipophilic alcohols (e.g., an alcohol having at least one lipophilic moiety, for example aliphatic alcohols).
Exemplary prodrugs are, e.g. , esters of free carboxylic acids and S-acyl derivatives of thiols and O-acyl derivatives of alcohols or phenols, wherein acyl has a meaning as defined herein. Suitable prodrugs are often pharmaceutically acceptable ester derivatives convertible by solvolysis under physiological conditions to the parent carboxylic acid, e.g. , alkyl esters, cycloalkyl esters, alkenyl esters, benzyl esters, mono- or di-substituted alkyl esters, such as the co-(amino, mono- or di- alkylamino, carboxy, alkoxycarbonyl)- alkyl esters, the oc-( alkanoyloxy, alkoxycarbonyl or di- alkylaminocarbonyl)- alkyl esters, such as the pivaloyloxymethyl ester and the like conventionally used in the art. In addition, amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde
(Bundgaard, /. Med. Chem. 2503 (1989)). Moreover, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N- acyloxymethyl groups (Bundgaard, "Design of Prodrugs," Elsevier (1985) and subsequent versions thereof). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.
Furthermore, the compounds of the present invention, including their salts, may also be obtained in the form of hydrates, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present. The compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms. The term "solvate" refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like. The term "hydrate" refers to the complex where the solvent molecule is water. The compounds of the present invention, including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
Compounds of the invention in unoxidized form may be prepared from N-oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C.
General procedures for preparing a compound of the invention are described in the Examples, infra. All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents and catalysts utilized to synthesize the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl Science of Synthesis volumes 1-48, Georg Thieme Verlag, and subsequent versions thereof). All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The examples provided herein are offered to illustrate, but not to limit, the compounds of the invention, and the preparation of such compounds.
Pharmacology and Utility
The invention provides compounds and compositions that are able to modulate the activity of epidermal growth factor receptor (EGFR).
In one aspect, the invention provides a method of inhibiting epidermal growth factor receptor (EGFR) in a subject, comprising administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt, ester, or prodrug thereof.
In another aspect, the invention provides the use of a compound of the invention for treating a condition mediated by EGFR. For example, the invention provides compounds and compositions for treating cancer, including but not limited to the following cancers: non-small cell lung cancer (NSCLC), head and neck cancer, colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, gastric cancer, glioma and prostate cancer.
Other cancers include but are not limited to : epidermoid, Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma,
rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma,
medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes
(carcinoma), breast; Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma] hairy cell; lymphoid disorders; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma;
medullary thyroid carcinoma, undifferentiated thyroid cancer, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and Adrenal glands: neuroblastoma. A cancerous cell includes a cell afflicted by any one of the above-identified conditions.
Other cancers include but are not limited to, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, thyroid cancer (medullary and papillary thyroid carcinoma), renal carcinoma, kidney parenchyma carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, testis carcinoma, urinary carcinoma, melanoma, brain tumors such as glioblastoma, astrocytoma, meningioma,
medulloblastoma and peripheral neuroectodermal tumors, gall bladder carcinoma, bronchial carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroidea melanoma, seminoma, rhabdomyosarcoma, craniopharyngeoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmocytoma.
In one embodiment, the invention provides compounds and compositions for treating lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphoma, myeloma, a solid tumor, or a cancer comprising an EGFR activated tumor. The EGFR activated tumor can be from a mutation of EGFR; for example, from a mutation of EGFR located at G719S, G719C, G719A, L858R, L861Q, an exon 19 deletion mutation or an exon 20 insertion mutation. The EGFR activated tumor can also be from an amplification of EGFR, expression of EGFR, and/or ligand mediated activation of EGFR.
The invention also provides compounds and compositions for treating a condition that is resistant to EGFR targeted therapy. For example, the EGFR targeted therapy may comprise treatment with gefitinib, erlotinib, lapatinib, XL-647, HKI-272 (Neratinib), BIBW2992 (Afatinib), EKB-569 (Pelitinib), AV-412, canertinib, PF00299804, BMS 690514, HM781-36b, WZ4002, AP-26113, cetuximab, panitumumab, matuzumab, trastuzumab, or pertuzumab.
The invention also provides compounds and compositions for treating a condition that is resistant to ALK-targeted therapy. For example, the ALK targeted therapy may comprise treatment with crizotinib, SP-3026, AF802, X-396, or AP-26113.
In another embodiment, the invention provides compounds and compositions for treating a proliferative disease. For example, the compounds of the invention may be used to inhibit cell proliferative disease such as hyperplasias, dysplasias and pre- cancerous lesions. Examples of pre-cancerous lesions may occur in skin, esophageal tissue, breast and cervical intra-epithelial tissue. Inhibition may be assessed by delayed appearance of primary or secondary tumors, slowed development of primary or secondary tumors, decreased occurrence of primary or secondary tumors, slowed or decreased severity of secondary effects of disease, arrested tumor growth and regression of tumors, among others. In the extreme, complete inhibition is observed, and may be referred to as prevention or chemoprevention.
In yet another embodiment, the invention provides compounds and compositions for treating an autoimmune disease, inflammatory disease, immunologically-mediated disease, bone disease, metabolic disease, neurological or neurodegenerative disease, cardiovascular disease, hormone related disease, allergy, or asthma.
Furthermore, the invention provides compounds and compositions for treating a condition selected from inflammation, arthritis, rheumatoid arthritis,
spondylarthropathies, gouty arthritis, osteoarthritis, juvenile arthritis, and other arthritic conditions, systemic lupus erthematosus (SLE), skin-related conditions, psoriasis, eczema, burns, dermatitis, neuroinflammation, allergy, pain, neuropathic pain, fever, pulmonary disorders, lung inflammation, adult respiratory distress syndrome, pulmonary sarcoisosis, asthma, silicosis, chronic pulmonary inflammatory disease, and chronic obstructive pulmonary disease (COPD), cardiovascular disease, arteriosclerosis, myocardial infarction (including post-myocardial infarction indications), thrombosis, congestive heart failure, cardiac reperfusion injury, as well as complications associated with hypertension and/or heart failure such as vascular organ damage, restenosis, cardiomyopathy, stroke including ischemic and hemorrhagic stroke, reperfusion injury, renal reperfusion injury, ischemia including stroke and brain ischemia, and ischemia resulting from cardiac/coronary bypass, neurodegenerative disorders, liver disease and nephritis, gastrointestinal conditions, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, ulcerative diseases, gastric ulcers, viral and bacterial infections, sepsis, septic shock, gram negative sepsis, malaria, meningitis, HIV infection, opportunistic infections, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS),
AIDS, ARC (AIDS related complex), pneumonia, herpes virus, myalgias due to infection, influenza, autoimmune disease, graft vs. host reaction and allograft rejections, treatment of bone resorption diseases, osteoporosis, multiple sclerosis, angiogenesis including neoplasia, metastasis, a central nervous system disorder, a central nervous system disorder having an inflammatory or apoptotic component, Alzheimer's disease,
Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, and peripheral neuropathy, or Canine B-Cell Lymphoma. In a further
embodiment, the condition is inflammation, arthritis, rheumatoid arthritis,
spondylarthropathies, gouty arthritis, osteoarthritis, juvenile arthritis, and other arthritic conditions, systemic lupus erthematosus (SLE), skin-related conditions, psoriasis, eczema, dermatitis, pain, pulmonary disorders, lung inflammation, adult respiratory distress syndrome, pulmonary sarcoisosis, asthma, chronic pulmonary inflammatory disease, and chronic obstructive pulmonary disease (COPD), cardiovascular disease, arteriosclerosis, myocardial infarction (including post-myocardial infarction indications), congestive heart failure, cardiac reperfusion injury, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, leukemia, or lymphoma.
Further, the invention provides compounds and compositions for treating a neurodegenerative disease. Examples of neurodegenerative diseases include, without limitation, Adrenoleukodystrophy (ALD), Alexander's disease, Alper's disease,
Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjoegren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial fatal insomnia,
Frontotemporal lobar degeneration, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado- Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Progressive
Supranuclear Palsy, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer- Vogt-Sjogren-Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson- Olszewski disease, Tabes dorsalis, and Toxic encephalopathy.
In another aspect, the invention also provides a method of preventing resistance to gefitinib or erlotinib in a disease, comprising administering to a subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt, ester, or prodrug thereof.
Administration and Pharmaceutical Compositions
In one aspect, the present invention provides a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier, diluent or excipient. The pharmaceutical compositions can be formulated for oral, intravenous, intradermal, intramuscular, intraperitoneal, subcutaneous, intranasal, epidural, sublingual, intracerebral, intravaginal, intraventricular, intrathecal, epidural, transdermal, rectal, by inhalation, or topical administration.
In one embodiment, the pharmaceutical composition is formulated for oral administration. The pharmaceutical compositions can take the form of solutions, suspensions, emulsions, tablets, pills, pellets, capsules, capsules containing liquids, powders, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. The compositions can be formulated for immediate release, sustained release, or controlled release of the compounds of the invention.
Suitable pharmaceutical excipients include, for example, a) diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine); b) lubricants (e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol); for tablets also c) binders (e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone); if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
Additional suitable pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one embodiment, the pharmaceutically acceptable excipients are sterile when administered to a subject. Water is a useful excipient when the compound of the invention is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, specifically for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
Additional suitable pharmaceutical excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene -block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch;
cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes, oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water, isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
Compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs for example. Orally administered compositions can contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, compositions in tablet or pill forms can be coated to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active substance driving a compound of the invention are also suitable for orally administered compositions. In these latter platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time-delay material such as glycerol monostearate or glycerol stearate can also be useful. Oral compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment, the excipients are of pharmaceutical grade.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
In another embodiment, the compositions can be formulated for parenteral administration by various routes, including but not limited to, intravenous (including bolus injection), subcutaneous, intramuscular, and intra-arterial administration. Such parenteral dosage forms are administered in the form of sterile or sterilizable injectable solutions, suspensions, dry and/or lyophylized products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection (reconstitutable powders) and emulsions. Vehicles used in such dosage forms include, but are not limited to, Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium
Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
In another embodiment, the compositions can be formulated for intranasal form via use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration can be continuous rather than intermittent throughout the dosage regimen. Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention. The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
In another embodiment, the compositions can be formulated for rectal or vaginal administration. Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound. Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
Compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present compositions can contain, in one embodiment, from about 0.1 percent to about 99 percent; and in another embodiment from about 1 percent to about 70 percent of the compound of the invention by weight or volume.
The present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds. Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g., vials), blister packs, and strip packs.
The invention further provides pharmaceutical compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose. Such agents, which are referred to herein as "stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
In another aspect, the pharmaceutical compositions further comprise one or more additional therapeutic agents. The compounds of the invention and the additional therapeutics agent(s) may act additively or synergistically.
In one embodiment, the compounds may be administered in combination with one or more therapeutic agents (e.g. small molecules, monoclonal antibodies, antisense RNA, and fusion proteins) that modulate protein kinase signaling involved in various disease states. Examples of such kinases may include, but are not limited to: serine/threonine specific kinases, phosphatidylinositol-3-kinases (PI3 kinases), Phosphatidylinositol-3 kinase -related kinases, mTOR, receptor tyrosine specific kinases and non-receptor tyrosine specific kinases. Serine/threonine kinases include mitogen activated protein kinases (MAPK), meiosis specific kinase (MEK), AKT, RAF PLK1, and aurora kinase. Examples of receptor kinase families include epidermal growth factor receptor (EGFR) (e.g. HER2/neu, HER3, HER4, ErbB, ErbB2, ErbB3, ErbB4, Xmrk, DER, Let23);
fibroblast growth factor (FGF) receptor (e.g. FGF-R1, GFF-R2/BEK/CEK3 , FGF- R3/CEK2, FGF-R4/TKF, KGF-R); hepatocyte growth/scatter factor receptor (HGFR/SF) (e.g, MET, RON, SEA, SEX); insulin receptor (e.g. Ins-R, IGFI-R, ALK, ROS); Eph (e.g. CEK5, CEK8, EBK, ECK, EEK, EHK-1, EHK-2, ELK, EPH, ERK, HEK, MDK2, MDK5, SEK); Axl (e.g. Mer/Nyk, Rse); RET; and platelet-derived growth factor receptor (PDGFR) (e.g. PDGF alpha -R, PDG beta -R, CSF1-R/FMS, SCF-R/C-KIT, VEGF- R/FLT, NEK FLKl, FLT3/FLK2/STK-1). Non-receptor tyrosine kinase families include, but are not limited to, BCR-ABL (e.g. p43, ARG); BTK (e.g. ITK/EMT, TEC); CSK, FAK, FPS, JAK, SRC, BMX, FER, CDK and SYK.
The compounds of the invention may also be administered in combination with one or more agents that modulate non-kinase biological targets or processes. Such targets include histone deacetylases (HDAC), DNA methyltransferase (DNMT), thrombin, TLR9, hedgehog pathway, COX-2, Aromatase, heat shock proteins (e.g. HSP90), and proteosomes.
In another embodiment, the compounds of the invention may be combined with antineoplastic agents (e.g. small molecules, monoclonal antibodies, antisense RNA, and fusion proteins) that inhibit one or more biological targets such as vorinostat, erlotinib, gefitinib, lapatinib, sunitinib, dasatinib, sorafenib, MGCD265, Pazopanib, Regorafenib, , Rapamycin, Temsirolimus (CCI-779), Ridaforolimus (MK8669), PF-04691502, DS- 7423, Tanespimycin, GDC-0449, PF-04449913, IPI-926, XL139, TAK-441, MK-2206, GSK2110183, AZD6244, GDC-0941, XL765, CAL-101, BAY80-6946, XL147, PX-866, AMG 319, Volasertib, BMS-582664, motesanib, pasireotide, Romidepsin, Exemestane, letrozole, anastrozole, Temlntedanib, bortezomib, XL-518, GSK1120212,
MSC1936369B, Selumetinib (AZD6244), PD-325901, BAY86-9766, RDEA119, TAK- 733, R04987655, , EMD 1214063, AMG 208, XL880, AMG 337, tivantinib (ARQ 197), , AZD6244, BMS-908662, BAY 43-9006, XL281, R05126766, GSK2118436,
Vemurafenib (R05185426, PLX4032), MetMAb, Crizotinib, ASP-3026, AF802, X-396, AP-26113, CNF2024, RG108, BMS387032, Isis-3521, bevacizumab, trastuzumab, pertuzumab, MM-121, U3-1287 (AMG 888), cetuximab, panitumumab, zalutumumab, nimotuzumab, matuzumab, AV-299, PR0143966, IMC-A12, R1507, AVE- 1642, Figitumumab, OSI-906, Intedanib, AMG 102, AMG 900, MLN8237, AG24322, PD325901, ZD6474 (vandetanib), PD184322, Obatodax, ABT737, XL-647, neratinib, afatinib, HM781-36B, AV-412, canertinib (CI-1033), Dacomitinib (PF00299804), or BMS 690514. Such combinations may enhance therapeutic efficacy over efficacy achieved by any of the agents alone and may prevent or delay the appearance of resistant mutational variants.
The compounds of the invention may also be administered in combination with a chemotherapeutic agent at various stages of the disease for the purposes of shrinking tumors, destroying remaining cancer cells left over after surgery, inducing remission, maintaining remission and/or alleviating symptoms relating to the cancer or its treatment. Examples of chemotherapeutic agents include, but are not limited to, alkylating agents such as mustard gas derivatives (Mechlorethamine, cylophosphamide, chlorambucil, melphalan, ifosfamide), ethylenimines (thiotepa, hexamethylmelanine), Alkylsulfonates (Busulfan), Hydrazines and Triazines (Altretamine, Procarbazine, Dacarbazine and Temozolomide), Nitrosoureas (Carmustine, Lomustine and Streptozocin), Ifosfamide and metal salts (Carboplatin, Cisplatin, and Oxaliplatin); plant alkaloids such as
Podophyllotoxins (Etoposide and Tenisopide), Taxanes (Paclitaxel and Docetaxel), Vinca alkaloids (Vincristine, Vinblastine, Vindesine and Vinorelbine), and Camptothecan analogs (Irinotecan, SN38, and Topotecan); anti-tumor antibiotics such as Chromomycins (Dactinomycin and Plicamycin), Anthracyclines (Doxorubicin, Daunorubicin, Epirubicin, Mitoxantrone, Valrubicin and Idarubicin), and miscellaneous antibiotics such as
Mitomycin, Actinomycin and Bleomycin; anti-metabolites such as folic acid antagonists (Methotrexate, Pemetrexed, Raltitrexed, Aminopterin), pyrimidine antagonists (5- Fluorouracil, Floxuridine, Cytarabine, Capecitabine, and Gemcitabine), purine antagonists (6-Mercaptopurine and 6-Thioguanine) and adenosine deaminase inhibitors (Cladribine, Fludarabine, Mercaptopurine, Clofarabine, Thioguanine, Nelarabine and Pentostatin); topoisomerase inhibitors such as topoisomerase I inhibitors (Ironotecan, topotecan) and topoisomerase II inhibitors (Amsacrine, etoposide, etoposide phosphate, teniposide); interferons (interferon-oc, interferon-β, interferon- γ); monoclonal antibodies (for example, Alemtuzumab, Gemtuzumab ozogamicin, Rituximab, Trastuzumab, Ibritumomab Tioxetan, Cetuximab, Panitumumab, Tositumomab, Bevacizumab, zalutumumab, nimotuzumab, matuzumab, pertuzumab, MM-121, U3-1287 (AMG 888), Figitumumab, AMG 102, IMC-A12, R1507, AVE- 1642, MetMAb); and miscellaneous anti-neoplastics such as ribonucleotide reductase inhibitors (Hydroxyurea); adrenocortical steroid inhibitor (Mitotane); enzymes (Asparaginase and Pegaspargase); anti-microtubule agents (Estramustine); glucocorticosteroids (dexamethasone); and retinoids (Bexarotene, Isotretinoin, Tretinoin (ATRA).
In certain embodiments, the compounds of the invention are administered in combination with a chemoprotective agent. Chemoprotective agents act to protect the body or minimize the side effects of chemotherapy. Examples of such agents include, but are not limited to, amfostine, mesna, and dexrazoxane.
In another aspect of the invention, the compounds of the invention are administered in combination with radiation therapy. Radiation is commonly delivered internally
(implantation of radioactive material near cancer site) or externally from a machine that employs photon (x-ray or gamma-ray) or particle radiation. Where the combination therapy further comprises radiation treatment, the radiation treatment may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and radiation treatment is achieved. For example, in appropriate cases, the beneficial effect is still achieved when the radiation treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.
It will be appreciated that compounds of the invention can be used in combination with an immunotherapeutic agent, such as agents used to transfer the immunity of an immune donor, e.g., another person or an animal, to a host by inoculation. The term embraces the use of serum or gamma globulin containing performed antibodies produced by another individual or an animal; nonspecific systemic stimulation; adjuvants; active specific immunotherapy; and adoptive immunotherapy. Adoptive immunotherapy refers to the treatment of a disease by therapy or agents that include host inoculation of sensitized lymphocytes, transfer factor, immune RNA, or antibodies in serum or gamma globulin.
One form of immunotherapy is the generation of an active systemic tumor-specific immune response of host origin by administering a vaccine composition at a site distant from the tumor. Various types of vaccines have been proposed, including isolated tumor- antigen vaccines and anti-idiotype vaccines. Another approach is to use tumor cells from the subject to be treated, or a derivative of such cells (Schirrmacher et al. (1995) J. Cancer Res. Clin. Oncol. 121:487). In U.S. Pat. No. 5,484,596, Hanna Jr. et al. claim a method for treating a resectable carcinoma to prevent recurrence or metastases, comprising surgically removing the tumor, dispersing the cells with collagenase, irradiating the cells, and vaccinating the patient with at least three consecutive doses of about 107 cells. The compounds of the invention can be used in conjunction with such techniques. It will be appreciated that the compounds of the invention may advantageously be used in conjunction with one or more adjunctive therapeutic agents. Examples of suitable agents for adjunctive therapy include a 5HT] agonist, such as a triptan (e.g. sumatriptan or naratriptan); an adenosine Al agonist; an EP ligand; an NMDA modulator, such as a glycine antagonist; a sodium channel blocker (e.g. lamotrigine); a substance P antagonist (e.g. an NKi antagonist); a cannabinoid; acetaminophen or phenacetin; a 5-lipoxygenase inhibitor; a leukotriene receptor antagonist; a DMARD (e.g. methotrexate); gabapentin and related compounds; a tricyclic antidepressant (e.g. amitryptilline); a neurone stabilizing antiepileptic drug; a mono-aminergic uptake inhibitor (e.g. venlafaxine); a matrix metalloproteinase inhibitor; a nitric oxide synthase (NOS) inhibitor, such as an iNOS or an nNOS inhibitor; an inhibitor of the release, or action, of tumor necrosis factor a; an antibody therapy, such as a monoclonal antibody therapy; an antiviral agent, such as a nucleoside inhibitor (e.g. lamivudine) or an immune system modulator (e.g. interferon); an opioid analgesic; a local anesthetic; a stimulant, including caffeine; an H2-antagonist (e.g. ranitidine); a proton pump inhibitor (e.g. omeprazole); an antacid (e.g. aluminum or magnesium hydroxide; an antiflatulent (e.g. simethicone); a decongestant (e.g.
phenylephrine, phenylpropanolamine, pseudoephedrine, oxymetazoline, epinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine); an antitussive (e.g. codeine, hydrocodone, carmiphen, carbetapentane, or dextromethorphan); a diuretic; or a sedating or non-sedating antihistamine.
Other examples of therapeutic agents that may be combined with the compounds of this invention include, without limitation: treatments for Alzheimer's Disease such as ARICEPT® and EXCELON®; treatments for Parkinson's Disease such as L- DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., AVONEX® and REBIF®, COPAXONE®, and mitoxantrone; treatments for asthma such as albuterol and SINGULAIR®; agents for treating schizophrenia such as ZYPREXA®, RISPERDAL®, SEROQUEL®, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, interleukin 1 receptor antagonist (IL-1RA), azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and
immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and antiparkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, antileukemic agents, and growth factors; and agents for treating immunodeficiency disorders such as gamma globulin.
The pharmaceutical composition comprising a compound of the invention and one or more additional therapeutic agent may be provided as a combined preparation for simultaneous, separate or sequential use, by the same or different route of administration, in the treatment of a disease or condition mediated by EGFR kinase activity. Products provided as a combined preparation include a composition comprising a compound of the invention, and the other therapeutic agent(s) together in the same pharmaceutical composition; or a compound of the invention and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
In another aspect, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound provided herein. In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like. The kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the invention typically comprises directions for administration.
In the combination therapies of the invention, the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.
The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed can also depend on the route of administration, and the seriousness of the condition being treated and can be decided according to the judgment of the practitioner and each subject's circumstances in view of, e.g., published clinical studies. In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5 mg/kg per body weight. An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5 mg to about 100 mg, conveniently administered, e.g. in divided doses up to four times a day or in retard form. Suitable unit dosage forms for oral administration comprise from ca. 1 to 50 mg active ingredient.
In certain embodiments, a therapeutic amount or dose of the compounds of the present invention may range from about 0.1 mg/kg to about 500 mg/kg, alternatively from about 1 to about 50 mg/kg. In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in single or multiple doses (such as two, three, or four times daily). Therapeutic amounts or doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.
Upon improvement of a subject's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary.
Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. The subject may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific inhibitory dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. Examples
The following examples were offered to illustrate, but not to limit, the compounds of the present invention, and the preparation of such compounds.
Synthesis of Intermediates
Intermediate 1
(R)-tert-butyl 3-aminoazepane-l-carboxylate
Figure imgf000078_0001
1-1 b Intermediate 1
Step A: To a solution of (R)-lysine HQ salt (100 g, 0.68 mol) in xylene (1 L) was added hexamethyldisilazane (1000 mL, 4.76 mol) and chlorotrimethylsilane (10 mL, 78.8 mmol). The mixture was heated to 120 °C for 24h, then to 180 °C for 48 h. The solvent was then removed under reduced pressure and the crude material was purified by column chromatography (20:1 to 10:1 CH2Cl2/MeOH) to afford (R)-3-aminoazepan-2-one (I-la). ]H-NMR (400 MHz, CDC13): d 6.55 (br s, IH), 3.50-3.46 (m, IH), 3.18-3.10 (m, 2H), 1.98-1.93 (m, IH), 1.81-1.43 (m, 6H), 1.38-1.29 (m, IH); MS calculated for C6H13N20 (M+H+) 129.09, found 129.1.
Step B: To a suspension of L1AH4 (51.13 g, 1.345 mol) in THF (1 L) at 0°C was added dropwise over 30 min a solution of I-la (34.44 g, 0.269 mol) in THF (400 mL). The mixture was then stirred at room temperature overnight, cooled to 0 °C, treated with H20 (52 ml) and 2M NaOH (52 mL) and stirred for 0.5h. The resulting white precipitate was filtered through Celite and the filtrate evaporated under reduced pressure to afford (R)-azepan-3-amine (I- lb). The product was used in the next step without further purification. ]H-NMR (400 MHz, CDC13): d 3.02-2.94 (m, 2H), 2.90-2.81 (m, 2H), 2.61- 2.55 (m, IH), 1.88-1.81 (m, IH), 1.80-1.53 (m, 6H), 1.51-1.40 (m, 2H); MS calculated for C6H15N2 (M+H+) 115.12, found 115.0. Step C: To a solution of I-lb (32.83 g, 0.288 mol) in CH2C12 (1300 mL) at -78°C was added dropwise a solution of BocOSu (51.13 g, 1.345 mol) in CH2C12 (400 mL). The mixture was stirred at room temperature overnight, treated with H20 (400 mL) and the organic phase was separated and discarded. The aqueous layer was basified to pH~13 with solid NaOH and extracted with CH2C12. The combined organic layers were dried over Na2S04 and concentrated under reduced pressure to afford the title compound
(Intermediate 1) as a yellow oil. ]H-NMR (400 MHz, CDC13): d 3.74-3.42 (m, 2H), 3.28-3.18 (m, IH), 3.11-3.01 (m, IH), 2.97-2.88 (m, IH), 1.88-1.50 (m, 4H), 1.48 (s, 9H), 1.45-1.23 (m, 4H); MS calculated for CnH23N202 (M+H+) 215.17, found 215.1.
Intermediate 2
(S, E)-4-(3-hvdroxypyrrolidin-l-yl)but-2-enoic acid hydrochloride
Figure imgf000079_0001
Step A Step B
l-2a
Figure imgf000079_0002
Step C HCI
l-2b Intermediate 2
Step A: To the mixture of (E)-tert-butyl but-2-enoate (10.0 g, 70.4 mmol) and NBS (12.5 g, 70.4 mmol) in CC14 (150 mL) was added benzoyl peroxide (510 mg, 2.11 mmol), and the reaction was refluxed for 12 h. The mixture was cooled to room temperature, and the solid was filtered off. The filtrate was concentrated in vacuo, and purified by column chromatography to afford (E)-tert-butyl 4-bromobut-2-enoate (I-2a). ]H-NMR (400 MHz, CDCI3) δ 7.02 - 6.76 (m, IH), 6.05 - 5.89 (m, IH), 4.06 - 3.95 (m, 2H), 1.56 - 1.40 (m, 9H). MS calculated for C8H14Br02 (M+H+) 221.01, found: 221.0.
Step B: A solution of I-2a (1.0 g, 4.55 mmol), (S)-pyrrolidin-3-ol HCI salt (561.7 mg, 4.55 mmol) and NEt3 (1.27 mL, 9.1 mmol) in THF (35 mL) was stirred at room temperature overnight. The solid was filtered off, the filtrate was concentrated in vacuo, and purified by column chromatography to afford (S,E)-tert-butyl 4-(3- hydroxypyrrolidin-l-yl)but-2-enoate (I-2b). ¾-NMR (400 MHz, CDC13) δ 6.89 (dt, J = 6.1 , 15.7 Hz, 1H), 5.93 (d, 7 = 15.6 Hz, 1H), 4.43 - 4.31 (m, 1H), 3.25 (dd, 7 = 1.6, 6.1 Hz, 2H), 2.93 (d, 7 = 5.2 Hz, 1H), 2.73 (d, 7 = 9.7 Hz, 1H), 2.57 (dd, 7 = 5.1 , 10.1 Hz, 1H), 2.34 (d, 7 = 6.3 Hz, 1H), 2.25 - 2.14 (m, 1H), 1.86 (d, 7 = 7.0 Hz, 1H), 1.82 - 1.73 (m, 1H), 1.56 (s, 9H). MS calculated for C12H22NO3 (M+H+) 228.15, found: 228.1.
Step C: A solution of I-2b (584 mg, 2.57 mmol) in 4N aq. HCl solution was stirred at room temperature for 4 h. The mixture was then concentrated and dried in vacuo to afford (S,E)-4-(3-hydroxypyrrolidin- l-yl)but-2-enoic acid (1-2) as a HCl salt. ]H-NMR (400 MHz, MeOD) δ 6.88 (d, 7 = 15.6 Hz, 1H), 6.26 (d, 7 = 15.6 Hz, 1H), 4.58 (s, 1H), 4.03 (d, 7 = 7.0 Hz, 2H), 3.74 (s, 1H), 3.52 (d, 7 = 11.8 Hz, 1H), 3.46 - 3.36 (m, 1H), 3.19 (s, 1H), 2.45 - 2.28 (m, 1H), 2.14 (s, 1H), 2.10 - 1.95 (m, 1H). MS calculated for C8H14N03 (M+H+) 172.09, found: 172.1.
The following intermediates were obtained following analogous procedures as described for the above Intermediate 2, using the appropriate starting materials.
Figure imgf000080_0001
Intermediate Structure Physical Data (¾ NMR and MS)
Ή-NMR (400MHz, MeOD): d 6.95-6.86 (m, 1H), 6.27 (d, J = 15.6 Hz, 1H), 3.35 (s, 3H), 4.22-4.17 (m, 1H), 4.10-4.04 (m, 2H), 3.79--7 3.68 (m, 2H), 3.30-3.19 (m, 2H) 2.43-2.30
HCI (m, 1H), 2.21-2.07 (m, 1H); MS calculated for C9H16N03 (M+H+) 186.12, found 186.1.
]H-NMR (400 MHz, MeOD) δ 7.01 - 6.80 (m, 1H), 6.27 (d, / = 15.6 Hz, 1H), 4.04 (d, J-8 = 6.9 Hz, 2H), 3.65 (m, 2H), 3.16 (m, 2H),
HCI 2.09 (m, 4H); MS calculated for C8H14N02
(M+H+) 156.09, found: 156.1.
Ή-NMR (400 MHz, MeOD) δ 6.87 - 6.82 (m, 1H), 6.27-6.22 (m, 1H), 4.03 (d, / = 6.8-9 Hz, 2H), 3.83 (t, / = 12.0 Hz, 2H), 3.66-3.61
(m, 2H), 2.67-2.60 (m, 2H); MS calculated
HCI
for C8H12F2N02 (M+H+) 192.08, found: 192.1.
]H-NMR (400 MHz, MeOD) δ 6.83 - 6.65 (m, 1H), 6.22 (dd, / = 15.8, 22.1 Hz, 1H),
0 4.34 - 4.20 (m, 2H), 4.12 (dd, / = 9.6, 19.6-10
HO^^-N J Hz, 2H), 4.03 (d, / = 6.6 Hz, 2H), 3.78 (d, / =
HCI 6.8 Hz, 1H), 2.66 - 2.41 (m, 2H); MS
calculated for C7H12N02 (M+H+) 142.08, found: 142.1.
Ή-NMR (400MHz, DMSO-d6): d 12.9-11.5 (br s, 2H), 6.69 (dt, J = 15.8, 6.4 Hz, 1H), ), 6.16 (d, J = 15.8 Hz, 1H), ), 5.39 (dm, J = 11 57.1 Hz, 1H), 4.47-4.38 (m, 2H), 4.29-4.20
HCI (m, 2H), 4.06 (dd, J = 0.8, 6.3 Hz, 2H); MS calculated for C7HnFN02 (M+H+) 160.08, found 160.1.
]H-NMR (400 MHz, MeOD) δ 6.77 (ddd, / = 6.6, 12.7, 18.9 Hz, 1H), 6.21 (dd, / = 4.0, 15.7 Hz, 1H), 4.57 (dd, / = 6.5, 11.9 Hz, 1H),-12 4.32 (t, J = 7.5 Hz, 2H), 4.20 (d, J = 9.3 Hz,
HCI 1H), 4.08 (dd, / = 7.0, 10.3 Hz, 2H), 4.00 (dd,
/ = 5.4, 12.0 Hz, 1H), 3.35 (t, / = 8.1 Hz, 3H); MS calculated for C8H14N03 (M+H+) 172.09, found: 172.1.
]H-NMR (400 MHz, MeOD) δ 6.85 - 6.69 (m, 1H), 6.21 (dd, / = 5.9, 15.8 Hz, 1H), 4.77 - 4.60 (m, 1H), 4.58 - 4.45 (m, 1H), 4.30 (dd,-13 7 = 6.5, 12.0 Hz, 1H), 4.15 - 4.03 (m, 3H),
HCI 3.92 (dd, J = 4.5, 7.2 Hz, 1H), 3.22 (q, J = 7.3
Hz, 1H); MS calculated for C7H12N03 (M+H+) 158.08, found: 158.1. Intermediate Structure Physical Data (¾ NMR and MS)
Ή-NMR (400 MHz, MeOD) δ 6.82 - 6.75 (m, 1H), 6.22-6.18 (m, 1H), 4.72 - 4.69 (m,
1-14 II 4H), 4.09 (d, J = 6.8 Hz, 2H); MS calculated
HCI for C7H10F2NO2 (M+H+) 178.06, found:
178.1.
Intermediate 15
(S)-tert-buty\ 3-(2-amino-5-methyl-lH-benzordlimidazol-l-yl) piperidine-l-carboxylate
Figure imgf000082_0001
Step A 1-15a tep 1-15b
Figure imgf000082_0002
Intermediate 15
Step A: A stirred solution of (S)-ieri-butyl 3-aminopiperidine-l-carboxylate (0.500 g, 2.49 mmol), l-fluoro-4-methyl-2-nitrobenzene (0.387 g, 2.49 mmol) and N,N- diisopropylethylamine (0.482 g, 3.74 mmol) in DMF under argon was heated to 110°C for 6 h (reaction completion monitored by TLC). The mixture was diluted with water and extracted with EtOAc (3 x 100 rriL). The combined organic layers were dried over anhydrous Na2S04 and concentrated under reduced pressure to afford (S)-ieri-butyl 3-((4- methyl-2-nitrophenyl) amino) piperidine-l-carboxylate (I-15a). MS calculated for C17H24N3O4 (M-H ) 334.18, found 334.0.
Step B: To a stirred solution of I- 15a (0.550 g, 1.64 mmol) in MeOH (35mL) was added Pd/C (0.090 g) and the mixture was stirred at room temperature under hydrogen atmosphere (balloon) for 2h (reaction completion monitored by TLC). The mixture was filtered through Celite, washed with MeOH and concentrated under reduced pressure to afford (S)-ieri-butyl 3-((2-amino-4-methylphenyl)amino)piperidine-l-carboxylate (I- 15b). MS calculated for C17H28N3O2 (M+H+) 306.22, found 306.2.
Step C: To a stirred solution of (5)-tert-butyl 3-((2-amino-4- methylphenyl)amino)piperidine-l-carboxylate (I-15b) (0.500 g, 1.63 mmol) in MeOH (20 rriL) was added a solution of cyanogen bromide (0.208 g, 1.96 mmol) in 1 :2
MeCN:H20 (20 rriL) for a period of 5 min. The mixture was heated to 50°C for 2h (reaction completion monitored by TLC), cooled to 0°C and pH was adjusted to 10 by adding aqueous Na2C03 solution. The mixture was stirred for 30 min at room
temperature, the resulting solid was collected and dried under vacuum to afford the title compound (Intermediate 15). ]H-NMR (400 MHz, CDC13): d 7.24 (s, 1H), 7.17 (d, J = 7.6 Hz, 1H), 6.85 (d, / = 8 Hz, 1H), 4.64 (br s, 2H), 4.17 (t, / = 14.8 Hz, 2H), 3.99-3.93 (m, 1H), 3.32 (d, / = 11.6 Hz, 1H), 2.79 (t, J = 12.4 Hz, 1H), 2.41 (s, 3H), 2.38-2.37 (m, 1H), 2.34 (d, J = 3.2 Hz, 1H), 1.91 (d, J = 13.6 Hz, 3H), 1.69-1.61 (m, 1H), 1.47 (s, 9H); MS calculated for Ci8H27N402 (M+H+) 331.21 , found 331.0.
Intermediate 16
(S)-N-(5-methyl- l-(piperidin-3-yl)- lH-benzordlimidazol-2-yl)-3-
(trifluoromethyl)benzamide
Figure imgf000083_0001
Step A: To the stirred solution of 1-15 (0.350 g, 1.06 mmol) in DMF (8 mL) were added sequentially 3-trifluoromethylbenzoic acid (0.221 g, 1.16 mmol), 2-(7-aza- lH- benzotriazole- l-yl)-l , l,3,3-tetramethyluronium hexafluorophosphate (0.483 g, 1.27 mmol) and Ν,Ν-diisopropylethylamine (0.410g, 3.18mmol). The mixture was stirred at room temperature for 16h (reaction completion monitored by TLC), diluted with H20 (50 mL) and EtOAc (50 mL). The organic layer was washed with saturated aqueous Na2CC>3 solution and brine, dried over anhydrous Na2S04, and concentrated under reduced pressure to afford (S)-tert-butyl 3-(5-methyl-2-(3-(trifluoromethyl)benzamido)-lH- benzo[d]imidazol-l-yl)piperidine- l-carboxylate (I-16a). ]H-NMR (400 MHz, CDC13): d 12.47 (s, 1H), 8.58 (s, 1H), 8.46 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 7.28 (s, 1H), 7.15 (s, 1H), 7.09 (d, / = 8.4 Hz, 1H), 4.60 ( br s, 1H), 4.27 (br s, 2H), 2.9-2.84 (m, 2H), 2.45 (s, 3H), 2.08- 1.96 (m, 2H), 1.93- 1.90 (m, 1H), 1.50 (s, 9H); MS calculated for C26H3oF3N403 (M+H+) 503.22, found 503.0.
Step B: To a stirred solution of I- 16a (0.300g, 0.59 mmol) in CH2C12 (25mL) at room temperature was added TFA (0.170 g, 1.49 mmol) and the mixture was stirred for 2h (reaction completion monitored by TLC). The mixture was then concentrated under reduced pressure, the crude material was basified with saturated aqueous NaHCC>3 solution and extracted with CH2CI2 (2 x 20mL). The combined organic layers were washed with brine, dried over anhydrous Na2S04 and concentrated under reduced pressure to afford the title compound (Intermediate 16) as a brown solid. 1 H-NMR (400
MHz, CDCI3): d 8.59(s, 1H), 8.49 (d, / = 8 Hz, 1H), 7.73 (d, / = 8 Hz, 1H), 7.58 -7.54 (m, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.14 (s, 1H), 7.08 (d, J = 8.4 Hz, 1H), 4.78 (br s, 1H), 3.67 (t, / = 11.2 Hz, 1H), 3.21 (t, / = 9.2 Hz, 2H), 2.80-2.61 (m, 2H), 2.4 (s, 3H), 2.08- 1.95 (m, 3H), 1.78-1.75 (m, 1H); MS calculated for C21H22F3N4O (M+H+) 403.17, found
403.0.
Intermediate 17
fe? -butyl 3-(2-amino-lH-imidazor4,5-clpyridin-l-yl)piperidine-l-carboxylate
Figure imgf000084_0001
Steps A and B: ieri-butyl 3-((3-aminopyridin-4-yl)amino)piperidine-l-carboxylate (I- 17b) was prepared from tert-butyl 3-((3-nitropyridin-4-yl)amino)piperidine-l- carboxylate (I-17a) following procedures analogous to 1-15 Steps A and B. ]H-NMR (400 MHz, DMSO-d6): d 7.65 (s, 1H), 7.57 (d, / = 5.6 Hz, 1H), 6.42 (d, J = 5.2 Hz, 1H), 5.07 (dd, / = 7.2 Hz, 1H), 4.61 (s, 2H), 4.10-3.60 (m, 3H), 2.80 (s, 3H), 1.99-1.97 (m, 1H), 1.79-1.72 (m, 2H), 1.46-1.37 (m, 16H); MS calculated for C15H25N4O2 (M+H+) 293.20, found 293.3.
Step C: A mixture of I-17b (1.5g, 0.34mmol), trimethylorthoformate (15mL) and p- toluene sulfonic acid (0.025g) was heated to reflux for 2h (reaction completion monitored by TLC). The mixture was concentrated under reduced pressure. The residue was diluted with EtOAc, washed with saturated aqueous NaHCC>3 and extracted with EtOAc (2 x 20mL). The combined organic layers were dried over Na2S04 and concentrated under reduced pressure. The crude material was purified by column chromatography to afford tert-butyl 3-(lH-imidazo[4,5-c]pyridin-l-yl)piperidine-l-carboxylate (I- 17c) as a white solid.
Step D: To the stirred solution of I- 17c (0.2g, 0.66mmol) in dry THF (4mL) at -78°C was added sec -butyl lithium (1.38mL, 1.4M in cyclohexane) and the mixture was stirred at -78°C for 50 min. Dodecylbenzenesulfonyl azide (0.28g, 0.79 mmol) in THF (2 rriL) was slowly added over 10 min and allowed to stir at -78°C for 2h (reaction completion monitored by TLC). The mixture quenched with saturated aqueous NH4C1 solution and diluted with EtOAc (20mL). The organic layer was separated, dried over anhydrous Na2S04 and concentrated under reduced pressure to afford tert-butyl 3-(2-azido-lH- imidazo[4,5-c]pyridin-l-yl)piperidine-l-carboxylate (I-17d) as a liquid. ^-NMR (400 MHz, DMSO-d6): d 8.84 (s, IH), 8.56 (s, IH), 7.85 (m, IH), 4.30-4.24 (m, IH), 4.03-3.95 (m, 2H), 2.89-2.67 (m, IH), 2.32-2.22 (m, 2H), 1.98-1.79 (m, 3H), 1.60-1.23 (m, 12H), 0.85-0.83 (m, IH); MS calculated for C16H22N702 (M+H+) 344.18, found 344.2.
Step E: To a stirred solution of I-17d (0.4g) in MeOH (lOmL) was added Pd/C (O. lg) and the mixture was stirred at room temperature under hydrogen atmosphere (balloon) for 2h (reaction completion monitored by TLC). The mixture was filtered through Celite and concentrated under reduced pressure to afford the title compound (Intermediate 17). ]H- NMR (400 MHz, DMSO-d6): d 8.37 (s, IH), 7.99 (d, / = 5.2 Hz, IH), 7.50 (d, / = 6.0 Hz, IH), 6.78 (s, 2H), 4.31-4.25 (m, IH), 3.98-3.95 (m, 2H), 3.40-3.32 (m, IH), 2.90 (s, IH), 2.23-2.19 (m, IH), 1.89-1.79 (m, 2H), 1.58-1.49 (m, 2H), 1.40 (s, 9H), 1.33-1.22 (m,2H); MS calculated for Ci6H24N502 (M+H+) 318.19, found 318.2.
Intermediate 18
N-(l-(piperidin-3-yl)-lH-imidazor4,5-clpyridin-2-yl)-3-(trifluoromethyl)benzamide
Figure imgf000085_0001
Intermediate 18 Steps A and B: The title compound (Intermediate 18) as a white solid was prepared from 1-17 in several steps following procedures analogous to 1-16. MS calculated for Ci9H19F3N50 (M+H+) 390.15, found 390.0.
Intermediate 19
fe? -butyl 3-(2-amino-3H-imidazor4,5-clpyridin-3-yl)piperidine-l-carboxylate
Figure imgf000086_0001
Step A: To a stirred solution of 3-fluoropyridine (20 g, 206 mmol) in AcOH (120 mL) at 85 °C was added under nitrogen concentrated H2S04 (1 mL). The mixture was then treated portion wise with H202 (30% in water, 48 mL, 422 mmol) and stirred at reflux for 24 h (reaction completion monitored by TLC). The mixture was quenched with solid Na2SC>3, the solvent was removed under reduced pressure and the residue was dissolved in CH2C12 (500 mL). The mixture was neutralized with solid NaHCC>3 and stirred for 1 h. The mixture was filtered and concentrated under reduced pressure to afford crude 3-fluoropyridine 1-oxide (I- 19a). ]H-NMR (400 MHz, CDC13): d 8.16 (t, / = 2.0 Hz, 1H), 8.11 (dd, / = 2 and 26.8 Hz, 1H), 7.29-7.23 (m, 1H), 7.10-7.05 (m, 1H); MS calculated for C5H5FNO (M+H+) 114.04, found 114.2.
Step B: A solution of I- 19a in concentrated H2S04 (40 mL) was slowly treated over 15 min with a 2:3 HN03 H2S04 mixture (73 mL). The mixture was then heated to 90 °C and stirred for 4 h. The mixture was cooled to room temperature, poured into ice and extracted with CH2C12 (3x 300 mL). The combined organic phase was dried over Na2S04 and concentrated under reduced pressure. The crude material was washed with pentane and stirred in CH2CI2 (30 mL). The resulting yellow precipitate was collected to afford 3- fluoro-4-nitropyridine 1-oxide (I-19b). ]H-NMR (400 MHz, DMSO-d6): d 8.90 (dd, / = 1.6, 6.0 Hz, 1H), 8.28 (dd, J = 1.2, 6.0 Hz, 1H), 8.23 (dd, J = 7.2, 2.0 Hz, 1H).
Step C: 3-((l-(tert-butoxycarbonyl)piperidin-3-yl)amino)-4-nitropyridine 1-oxide (I-
19c) was prepared following procedures analogous to 1-15 Step A. ]H-NMR (400 MHz, CDCI3): d 8.03 (d, / = 7.2 Hz, 2H), 7.97 (d, / = 1.6 Hz, 1H), 7.46 (dd, / = 2 and 4 Hz, 1H), 3.74 (d, / = 12.8 Hz, 1H), 3.51-3.43 (m, 5H), 2.17-1.97 (m, 1H), 1.80- 1.73 (m, 2H), 1.65-1.62 (m, 2H), 1.46 (s, 10H); MS calculated for C15H21N4O5 (M-H ) 337.15, found 337.4.
Step D: To a stirred solution of I- 19c (7.5g, 22.1 mmol) in MeOH (450mL) was added Raney-Ni (cat.) and AcOH (7 mL) and the mixture was stirred at room temperature under hydrogen atmosphere (balloon) for 2h (reaction completion monitored by TLC). The mixture was filtered through Celite and concentrated under reduced pressure. The residue was dissolved in water, basified with 1M NaOH and extracted with Et20 (2x 100 mL). The combined organic phase was washed with brine, dried over anhydrous Na2S04, and concentrated under reduced pressure to afford tert-butyl 3-((4-aminopyridin-3- yl)amino)piperidine-l-carboxylate (I-19d). MS calculated for C15H25N4O2 (M+H+) 293.20, found 293.3.
Step E: tert-butyl 3-(3H-imidazo[4,5-c]pyridin-3-yl)piperidine-l-carboxylate (I-19e) was prepared following procedures analogous to 1-17, Step C. ]H-NMR (400 MHz, DMSO-d6): d 9.09 (s, 1H), 8.54 (s, 1H), 8.35 (d, / = 6Hz, 1H), 7.68 (d, / = 4.8 Hz, 1H), 4.65-4.58 (m, 1H), 4.11 (br s, 1H), 3.86 (d, / = 12.8 Hz, 1H), 3.05-2.98 (m, 1H), 2.20- 2.19 (m, 2H), 1.84-1.81 (m, 1H), 1.65-1.37 (m, 10H).
Step F: tert-butyl 3-(2-azido-3H-imidazo[4,5-c]pyridin-3-yl)piperidine-l-carboxylate
(I-19f) was prepared following procedures analogous to 1-17, Step D. ]H-NMR (400 MHz, DMSO-d6): d 9.08 (s, 1H0, 8.33 (d, / = 5.2 Hz, 1H), 7.54 (d, / = 5.6 Hz, 1H), 4.29- 4.25 (m, 1H), 4.07-3.95 (m, 2H), 3.40 ( br s, 1H), 2.35-2.25 (m, 1H), 2.01-1.99 (m, 1H), 1.83-1.80 (m, 1H), 1.61-1.48 (m, 1H0, 1.41 (s, 10H); MS calculated for C16H22N7O2 (M+H+) 344.18, found 343.9.
Step G: The title compound (Intermediate 19) was prepared following procedures analogous to 1-17, Step E. ]H-NMR (400 MHz, DMSO-d6): d 8.67 (s, 1H), 8.05 (d, / = 5.2 Hz, 1H), 7.09 (d, / = 5.2 Hz, 1H), 6.95 (s, 2H), 4.32-4.26 (m, 1H), 3.97-3.95 (m, 2H), 3.43 (s, IH), 2.96 (s, IH), 2.25-2.21 (m, IH), 1.90-1.79 (m, 2H), 1.58-1.41 (m, 11H); MS calculated for C16H24N5O2 (M+H+) 318.19, found 318.3.
Intermediate 20
N-(3-(piperidin-3-yl)-3H-imidazo 4,5-clpyridin-2-yl)-3-(trifluoromethyl)benzamide
Figure imgf000088_0001
The title compound (Intermediate 20) was prepared from teri-butyl 3-(2-azido-3H- imidazo[4,5-c]pyridin-3-yl)piperidine-l-carboxylate (1-19) in several steps following procedures analogous to 1-16. ]H-NMR (400 MHz, DMSO-d6): d 8.98 (s, IH), 8.53-8.36 (m, 3H), 7.94-7.92 (m, IH), 7.78-7.75 (m, IH), 7.53-7.52 (m, IH), 4.84-4.81 (m, IH), 3.43-3.32 (m, IH), 3.07-2.95 (m, 2H), 2.69-2.62 (m, 2H), 1.99-1.80 (m, 2H), 1.64-1.61 (m, IH); MS calculated for C19H19F3N5O (M+H+) 390.15, found 390.0.
Intermediate 21
(R)-methyl 2-amino- 1 -( 1 -(tert-butoxycarbonyl)piperidin-3 -yl)- 1 H-benzo rdlimidazole-5 - carboxylate
Figure imgf000088_0002
Intermediate 21
Step A: A mixture of methyl 4-fluoro-3-nitrobenzoate (l.OOg, 5.02mmol) and (R)- ieri-butyl 3-aminopiperidine-l -carboxylate (1.00 g, 5.02mmol) were heated to 130°C for 3h (reaction completion monitored by TLC). The mixture was cooled to room
temperature, the resulting solid was collected and washed with n-hexanes to afford (R)- tert-butyl 3-((4-(methoxycarbonyl)-2-nitrophenyl)amino)piperidine-l-carboxylate (I-21a) as a red solid. ]H-NMR (400 MHz, CDC13): d 8.89 (s, IH), 8.40 (d, J = 7.2 Hz, IH), 8.06 (dd, / = 2 and 6.8 Hz, IH), 6.97 (d, J = 8.8 Hz, IH), 4.75 (d, J = 13.6 Hz, 2H), 3.97-3.90 (m, 4H), 3.69-3.63 (m, 2H), 3.24-3.01 (m, 2H), 2.10-2.06 (m, IH), 1.84-1.73 (m, 2H), 1.46 (s, 9H); MS calculated for C18H24N3O6 (M-H") 378.17, found 378.4.
Steps B and C: The title compound (Intermediate 21) was prepared from I-21a in several steps following procedures analogous to 1-15, Steps B and C. MS calculated for C19H27N4O4 (M+H+) 375.20, found 375.2.
Intermediate 22
R)-tert-butyl 3-(5-(hydroxymethyl)-2-(3-(trifluoromethyl)benzamido)-lH- - 1 -yPpiperidine- 1 -carboxylate
Figure imgf000089_0001
Intermediate 22
Step A: (R)-methyl l-(l-(tert-butoxycarbonyl)piperidin-3-yl)-2-(3-(trifluoromethyl) benzamido)-lH-benzo[d]imidazole-5-carboxylate (I-22a) was prepared from (/?)-methyl 2-amino-l-(l-(tert-butoxycarbonyl)piperidin-3-yl)-lH-benzo[d]imidazole-5-carboxylate (1-21) following procedures analogous to 1-16, Step A. ]H-NMR (400 MHz, CDC13): d 12.63 (br s, IH), 8.58 (s, IH), 8.47 (d, J = 8 Hz, IH), 8.03 (dd, J = 1.2 and 4Hz, 2H), 7.77-7.75 (m, IH), 7.60-7.56 (m, IH), 7.43-7.41 (m, IH), 4.64 (br s, IH), 4.29 (br s, 2H), 3.95 (s, 3H), 3.85-3.79 (m, IH), 3.49 (s, IH), 2.86-2.77 (m, 2H), 2.11-1.96 (m, 2H), 1.76- 1.58 (m, IH), 1.48 (s, 9 H); MS calculated for C27H30F3N4O5 (M+H+) 547.21, found 547.3.
Step B: To a stirred solution of I-22a (l.OOg, 1.83mmol) in THF (20mL) at 0°C was slowly added DIBAL-H (7.28mL, 12.82mmol) and the mixture was stirred for 2h (reaction completion monitored by TLC). The mixture was diluted with water and extracted with EtOAc (2 x 50 mL), the combined organic layers were washed with brine, dried over anhydrous Na2S04 and concentrated under reduced pressure. The crude material was purified by column chromatography (20% EtOAc/Hexanes) to afford the title compound (Intermediate 22); ]H-NMR (400 MHz, DMSO-d6): d 12.90 (s, 1H), 8.48 (d, J = 8.4 Hz, 2H), 7.9 (d, J = 8 Hz, 1H), 7.75-7.7 (m, 2H), 7.56 (s, 1H), 7.20 (d, J = 8.4 Hz, 1H), 4.82 ( br s, 1H), 4.05-4.00 (m, 2H), 3.70 (br s, 1H), 2.90 (br s, 1H), 2.70-2.60 (m, 1H), 1.98 - 1. 86 (m, 3H), 1.63 - 1.40 (m, 1H), 1.5 (s, 9H), 1.19 (s, 1H); MS calculated for C26H30F3N4O4 (M+H+) 519.21, found 519.2.
Intermediate 23
(R) -N- (5 - (morpholinomethyl) - 1 - (piperidin-3 - yl) - 1 H-benzo rdl imidazol-2- yl) - 3 -
(trifluoromethyl)benzamide
Figure imgf000090_0001
l-23b Intermediate 23
Step A: To a stirred solution of 1-22 (0.500g, 0.96mmol) in CH2C12 (30mL) at 0°C was added carbon tetrabromide (1.90g, 5.79mmol). The mixture was stirred for 15 min, PPI13 (0.758g, 2.89mmol) was added and the mixture was further stirred for 45 min at 0°C (reaction completion monitored by TLC). The mixture was diluted with water, extracted with CH2C12 (2 x 20mL), the combined organic layers were washed with brine, dried over anhydrous Na2S04 and concentrated under reduced pressure to afford (R)-ieri-butyl 3 - (5 - (bromomethyl)-2- (3 - (trifluoromethyl)benzamido) - 1 H-benzo [d] imidazol- 1 -yl) piperidine-l-carboxylate (I-23a). MS calculated for
Figure imgf000090_0002
(M-H ) 579.13, found 579.3. Step B: To a stirred solution of I-23a (0.250g, 0.43mmol) in THF (lOmL) at 0°C was added morpholine (0.120g, 1.29mmol) and the mixture was heated to 55°C for 2h (reaction completion monitored by TLC). The mixture was concentrated under reduced pressure and the crude material was purified by column chromatography to afford (R)- tert-butyl 3-(5-(morpholinomethyl)-2-(3-(trifluoromethyl)benzamido)-lH- benzo[d]imidazol-l-yl)piperidine-l-carboxylate (I-23b) as a light yellow solid; MS calculated for C30H37F3N5O4 (M+H+) 588.27, found 588.4.
Step C: The title compound (Intermediate 23) was prepared from I-23b following procedures analogous to 1-16, Step B. MS calculated for C25H29F3N5O2 (M+H+) 488.22, found 488.2.
Intermediate 24
fe? -butyl 3-(2-amino-5-methyl- lH-benzordlimidazol- 1 -yPazepane- 1 -carboxylate
Figure imgf000091_0001
Figure imgf000091_0002
Step C Intermediate 24
Step A, B and C: The title compound (Intermediate 24) was prepared following procedures analogous to 1-15, using the appropriate starting materials. ]H-NMR (400 MHz, DMSO-d6): 57.15-7.12 (m, 1H), 6.93 (s, 1H), 6.66 (d, / = 7.6 Hz, 1H), 6.26 (s, 2H), 4.29 (br s, 1H), 3.81-3.75 (m, 1H), 3.55-3.36 (m, 3H), 2.29 (s, 3H), 2.08 (s, 2H), 1.86-1.68 (m, 5H), 1.40 (s, 9H); MS calculated for C19H29N4O2 (M+H+) 345.22, found 345.1.
Intermediate 25
N-(l-(azepan-3-yl)-5-methyl-lH-benzordlimidazol-2-yl)-3-(trifluoromethyl)benzamide
Figure imgf000092_0001
Step A l-25a
Figure imgf000092_0002
The title compound (Intermediate 25) was prepared from 1-24 in several steps following procedures analogous to 1-16, using the appropriate starting materials. ]H-NMR (400 MHz, DMSO-d6):5 12.85 (s, 1H), 9.1 (br s, 2H), 8.53 (d, / = 8Hz, 1H), 8.43 (s, 1H), 7.92 (d, 7 = 7.6 Hz, 1H), 7.78-7.74 (m, 1H), 7.53 (d, / = 8.4 Hz, 1H), 7.39 (s, 1H), 7.13 (d, J = 8.4 Hz, 1H), 5.21 (br s, 1H), 4.03-3.97 (m, 1H), 3.57 (d, / = 11.6 Hz, 1H), 2.40 (s, 3H), 2.08-2.01 (m, 4H), 1.97-1.72 (m, 1H); MS calculated C22H24F3N4O (M+H+) 417.18, found 417.2.
Intermediate 26
(R)-tert-butyl 3 -(2-amino-7-chloro- 1 H-benzo Tdlimidazol- 1 - vDazepane- 1 - carboxylate
Figure imgf000092_0003
Intermediate 26
Step A: (R)-tert-butyl 3-((2-chloro-6-nitrophenyl)amino)azepane-l-carboxylate (I- 26a) was prepared following procedures analogous to 1-15, Step A, using the appropriate starting materials. 1 H-NMR (400MHz, CDC13): d 8.00-7.91 (m, 1H), 7.58-7.49 (m, 1H), 7.02-6.51 (m, 2H), 4.31-4.03 (m, 1H), 3.84-2.98 (m, 4H), 1.98-1.60 (m, 5H), 1.46-1.39 (m, 10H); MS calculated for C17H25CIN3O4 (M+H+) 370.15, found 370.10. Step B: A mixture of I-26a (7.5 g, 19.5 mmol) and Zn (12.8 mg, 195 mmol) in AcOH (22 mL) was stirred at room temperature for 2 h. The reaction was basified with saturated aqueous Na2CC>3 solution, filtered, and extracted with EtOAc (3 x 80 mL). The combined organic phase was washed with brine, dried with Na2S04 and concentrated in vacuo to afford (R)-tert-butyl 3-((2-amino-6-chlorophenyl)amino)azepane-l-carboxylate (I-26b). MS calculated for Ci7H27ClN302 (M+H+) 340.17, found 340.10. The crude was used in the next step without further purification.
Step C: The title compound (Intermediate 26) was prepared from I-26b following procedures analogous to 1-15, Step C. ]H-NMR (400MHz, CDC13): d 7. ,34-7.26 (m, 1H), 7.04-6.97 (m, 2H), 6.05-5.85 (m, 1H), 5.84-5.72 (m, 1H), 5.50-5.37 (m, 0.5H), 5.10- 4.80(m, 0.5H), 4.41-4.23(m, 1H), 4.09-3.96(m, 0.5H), 3.94-3.81 (m, 1H), 3.76-3.57 (m, 1H), 3.22-3.14 (m, 0.5H), 2.84-2.63 (m, 1H), 2.34-2.17 (m, 1H), 2.07-1.84 (m, 1H), 1.82- 1.64 (m, 2H), 1.53 (s, 9H), 1.48-1.37 (m, 1H); MS calculated for Ci8H26ClN402 (M+H+) 365.17, found 365.10.
Intermediate 27
(R)-N-(l-(azepan-3-yl)-7-chloro-lH-benzordlimidazol-2-yl)-2-methylisonicotinamide hydrochloride
Figure imgf000093_0001
l-27a Intermediate 27
Step A: A mixture of 2-methylisonicotinic acid (3.371 g, 24.6 mmol) and 2-(7-aza- 1H- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (9.345 g, 24.6 mmol) in CH2C12 (120 ml) was treated at room temperature with NEt3 (4.1 mL, 29.4 mmol). The reaction was stirred for 1 hour before it was slowly added into a CH2C12 solution (45 ml) of 1-26 (5.98 g, 16.4 mmol). Ten minutes later, more NEt3 (4.1 mL, 29.4 mmol) was added and the mixture stirred for 2 h. The mixture was then diluted with CH2C12 (240 mL), washed with H20 (2 x 80 mL), saturated aqueous NaHC03 solution (70 mL), and brine (70 mL). The organic phase was dried with Na2S04, and concentrated under reduced pressure. The crude material was purified by column chromatography (55% EtOAc/hexanes) to afford (R)-tert-butyl 3-(7-chloro-2-(2-methylisonicotinamido)- lH-benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-27a) as a light yellow foam. ]H- NMR (400MHz, CDC13): d 12.81 (br s, IH), 8.65-8.62 (m, IH), 7.95-7.85 (m, 2H), 7.27- 7.11 (m, 3H), 5.64 - 5.51 (m, IH), 4.56-4.44 (m, IH), 4.07-3.92 (m, IH), 3.79-3.71 (m, 0.5H), 3.41-3.35 (m, 0.5H), 3.29-3.23 (m, IH), 2.71-2.59 (m, IH), 2.65 (s, 3H), 2.22-2.00 (m, 3H), 1.93-1.80 (m, IH), 1.51-1.45 (m, IH), 1.50 (s, 3.5H), 1.41 (s, 5.5H); MS calculated for C25H31CIN5O3 (M+H+) 484.20, found 484.20.
Step B: A solution of I-27a (8.62 g, 16.4 mmol) in MeOH (67 mL) was treated with HCl in dioxane (4M, 67 mL) and the mixture was stirred at room temperature for 7 h. The mixture was then concentrated under reduced pressure to afford the title compound
(Intermediate 27). The product was used in the next step without further purification. A sample was treated with 1M NaOH, extracted with EtOAc, dried with Na2S04 and concentrated under reduced pressure to afford 1-27 as a free base. ]H-NMR (400MHz, CD3CN): d 8.49 (d, J=5.0 Hz, IH), 7.81 (s, IH), 7.72 (d, J=4.8 Hz, IH), 7.50 (br d, J=7.52 Hz, IH), 7.16 - 7.09 (m, 2H), 5.66-5.59 (m, IH), 3.77 (dd, J = 6.54, 14.3 Hz, IH), 3.18 (dd, J = 5.3, 14.3 Hz, IH), 3.05 - 2.98 (m, IH), 2.76-2.69 (m, IH), 2.63-2.53 (m, IH), 2.47 (s, 3H), 2.10-2.03 (m, IH), 1.96-1.93 (m, 2H), 1.86 - 1.75 (m, 2H), 1.61 - 1.54 (m, 2H); MS calculated for C20H23CIN5O (M+H+) 384.15, found 384.20.
Intermediate 28
(R)-tert-bu \ 3-(2-amino-7-chloro-6-methoxy-lH-benzordlimidazol-l-yl)azepane-l- carboxylate
Figure imgf000094_0001
Step A: To a solution of 2-chloro-l,3-difluoro-4-nitrobenzene (1.3548 g, 7 mmol) in DMF (10 mL) was added N,N-diisopropylethylamine (0.9951 g, 1.341 mL) and 1-1
(1.575 g, 7.35 mmol). The mixture was subjected to microwave irradiation (100 °C, 30 min), the solvent was evaporated and the crude was re-dissolved in a 0.5M sodium methoxide solution in MeOH (5 ml, 2.5 mmol). This mixture was re-subjected to microwave irradiation (100 °C, 30 min). The mixture was then quenched with water and concentrated under reduced pressure. The crude material was purified by column chromatography (AcOEt in hexanes, 0% to 25%) to afford (R)-tert-butyl 3-((2-chloro-3- methoxy-6-nitrophenyl)amino)azepane-l-carboxylate (I-28a). MS calculated for C18H27CIN3O5 (M+H+) 400.16, found 400.1.
Step B: (R)-tert-butyl 3-((6-amino-2-chloro-3-methoxyphenyl)amino)azepane-l- carboxylate (I-28b) was prepared from I -28a following procedures analogous to 1-26, Step B. MS calculated for C18H29CIN3O3 (M+H+) 370.18, found 370.2.
Step C: The title compound (Intermediate 28) was prepared from I-28b following procedures analogous to 1-15, Step C. MS calculated for C19H28CIN4O3 (M+H+) 395.18, found 395.2.
Intermediate 29
(R)-N-(l-(azepan-3-yl)-7-chloro-6-methoxy-lH-benzordlimidazol-2-yl)pyridazine-4-
Figure imgf000095_0001
Intermediate 29
Step A: A solution of pyridazine-4-carboxylic acid (92.5 mg, 0.754) and 2-(7-aza-
1H- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (283 mg, 0.745 mmol) in 1 : 1 CH2C12/DMF (10 mL) was treated with NEt3 (108 mg, 1.06 mmol) and stirred for 10 min. A solution of 1-28 (224 mg, 0.56 mmol) in 1: 1 CH2C12/DMF (10 mL) was then added and the mixture was stirred for lh (reaction completion monitored by LC/MS). The solvent was evaporated under reduced pressure and the residue was dissolved in CH2CI2 (4 mL), treated with Na2CC>3 (178 mg, 1.68 mmol) and stirred for 3 minutes. The mixture was then purified by column chromatography (MeOH in CH2CI2, 0% to 10%) to afford (R)-tert-buty\ 3-(7-chloro-6-methoxy-2-(pyridazine-4- carboxamido)-lH-benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-29a). MS calculated for C24H30CIN6O4 (M+H+) 501.19, found 501.2.
Step B: The title compound (Intermediate 29) was prepared from I-29a following procedures analogous to 1-27, Step B. MS calculated for C19H22CIN6O2 (M+H+) 401.14, found 401.1.
Intermediate 30
(R)-N-(l-(azepan-3-yl)-7-chloro-lH-benzordlimidazol-2-yl)-2,6-dimethylisonicotinamide hydrochloride
Figure imgf000096_0001
Step A
Step A: A mixture of 2,6-dimethylisonicotinic acid (927 mg, 6.1 mmol) and O- benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU) (4.65 g, 12.3 mmol) in DMF (15 ml) was treated with hydroxybenzotriazole (HOBt) (1.82 g, 13.5 mmol) and stirred at room temperature for 10 min. The resulting mixture was then added to a solution of 1-26 (1.12 g, 3.1 mmol) in DMF (4 mL), followed by addition of NEt3 (1.7 mL, 12.3 mmol). The reaction was stirred overnight, quenched with ¾0 (2 mL) and concentrated under reduced pressure. The crude was partitioned between EtOAc and IN NaOH, and extracted with EtOAc. The combined organic phase was dried over Na2S04, and concentrated under reduced pressure. The crude material was purified by column chromatography (0-100% EtOAc/Hexanes) to afford (R)-tert-butyl 3-(7-chloro-2-(2,6- dimethylisonicotinamido)-lH-benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-30a). MS calculated for C26H33CIN5O3 (M+H+) 498.22, found: 498.2.
Step B: A solution of I-30a (951 mg, 1.9 mmol) in CH2C12 (20 mL) was treated with HC1 in dioxane (4M, 20 mL) and the mixture was stirred at room temperature overnight. The yellow solid was filtered, washed with CH2CI2 and dried to afford the title compound (Intermediate 30). MS calculated for C21H25CIN5O (M+H+) 398.17, found: 398.2.
Intermediate 31
(R)-tert-butyl 3-(2-amino-7-methyl-lH-benzordlimidazol-l-yl)azepane-l-carboxylate
Figure imgf000097_0001
Step A: (R)-tert-butyl 3-((2-methyl-6-nitrophenyl)amino)azepane-l-carboxylate (I- 31a) was prepared following procedures analogous to 1-15, Step A, using the appropriate starting materials. ]H-NMR (400MHz, CDC13): d 7.93-7.87 (m, IH), 7.37-7.31 (m, IH), 6.91-6.79 (m, 1.5H), 6.50-6.47 (m, 0.5H), 3.88-3.76 (m, 2H), 3.57-3.52 (m, IH), 3.22- 2.78 (m, 2H), 2.43-2.41 (m, 3H), 1.92-1.60 (m, 5H), 1.47-1.38 (m, 10H); MS calculated for C18H28N3O4 (M+H+) 350.20, found 350.0.
Step B: (R)-tert-butyl 3-((2-amino-6-methylphenyl)amino)azepane-l-carboxylate (I- 31b) was prepared from I-31a following procedures analogous to 1-15, Step B. MS calculated for C18H30N3O2 (M+H+) 320.23, found 320.2.
Step C: The title compound (Intermediate 31) was prepared from I-31b following procedures analogous to 1-15, Step C. ]H-NMR (400MHz, CDC13): d 8.50 (br s, IH), 7.27-7.24 (m, IH), 7.18-7.14 (m, IH), 7.00-6.97 (m, IH), 5.10-5.05 (m, IH), 4.32-4.26 (m, IH), 3.99-3.92 (m, IH), 3.78-3.72 (m, IH), 2.99-2.87 (m, IH), 2.68 (s, 3H), 2.30-2.23 (m, IH), 2.13-2.08 (m, IH), 1.87 (br s, 3H), 1.50 (s, 9H), 1.39-1.38 (m, IH); MS calculated for C19H29N4O2 (M+H+) 345.22, found 345.2.
Intermediate 32
(R)-N-(l-(azepan-3-yl)-7-methyl-lH-benzordlimidazol-2-yl)-2-methylisonicotinamide hydrochloride
Figure imgf000097_0002
'-31 Step A '"32a Intermediate 32
Step A: (R)-tert-butyl 3-(7-methyl-2-(2-methylisonicotinamido)-lH- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-32a) was prepared from 1-31 following procedures analogous to 1-27, Step A. MS calculated for C26H34N5O3 (M+H+) 464.26, found 464.2. Step B: Solid I-32a (363 mg, 0.78 mmol) was treated with 4.0 M HC1 in dioxane (5 mL) and the reaction mixture stirred until complete as determined by LC/MS analysis. The solvent was removed under reduced pressure, the residue was suspended in CH2CI2 (4 mL), and the mixture was concentrated under reduced pressure to afford the title compound (Intermediate 32). MS calculated for C2iH26N50 (M+H+) 364.21, found 364.2.
Intermediate 33 and 34
(R)- and (5)-N-(7-metfayl-l-(l,4-oxazepan-6-yl)-lH-benzord1imidazol-2-yl)-3-
(trifluoromethyl)benzamide
Figure imgf000098_0001
Intermediate 33 Intermediate 34
Step A: A sample of racemate I-33a (prepared in several steps similarly to I- 16a, using the appropriate starting materials) is subjected to chiral chromatography (ChiralPak AD-H) with isocratic elution (75/25 C02/iPrOH) using a Thar Technologies SFC Prep 80 system with SuperChrom v.5.3 software. The first eluting peak is (/?)-tert-butyl 6-(7- methyl-2-(3-(trifluoromethyl)benzamido)-lH-benzo[d]imidazol-l-yl)-l,4-oxazepane-4- carboxylate (I-33b) and the second eluting peak is (S)-tert-butyl 6-(7-methyl-2-(3- (trifluoromethyl)benzamido)- lH-benzo[d]imidazol- 1 -yl)- 1 ,4-oxazepane-4-carboxylate (I- 33c). MS calculated for C26H3oF3N404 (M+H+) 519.21, found 519.2.
Step B: The title compounds (Intermediate 33 and Intermediate 34) were prepared from I-33b and I-33c respectively, following procedures analogous to 1-32, Step B. MS calculated for C2iH22F3N402 (M+H+) 419.16, found 419.2. Intermediate 35
(R)-tert-bu \ 3-(2-amino-5-(hvdroxymethyl)-7-methyl- lH-benzordlimidazol- 1- yPazepane- 1 -carboxylate
Figure imgf000099_0001
Intermediate 35
Step A: Concentrated H2SO4 (17.5 mL) was slowly added to methyl 4-fluoro-3- methylbenzoate (12.8 g, 76 mmol) and the mixture was cooled to 0 °C. A solution of fuming HNO3 (69.5%, 11.6 mL) in concentrated H2SO4 (17.5 mL) was then added drop- wise over 10 min. The mixture was stirred for 80 min while slowly warming up to room temperature (reaction completion monitored by TLC). The mixture was slowly poured into ice, the aqueous layer was extracted with CH2CI2 (3 x 200 mL), dried over anhydrous Na2S04 and concentrated under reduced pressure. The crude was purified by column chromatography to afford methyl 4-fluoro-3-methyl-5-nitrobenzoate (I-35a) as a white solid. MS calculated for C9H9FNO4 (M+H+) 214.04, found 214.0.
Step B: To a solution of I-35a (6.55g, 30.73 mmol) in THF (50 mL) at -10°C was slowly added DIBALH (92.2 mL of 1.0 M solution in hexanes) over 10 min. The mixture was stirred for 40 min at -10°C (reaction completion monitored by TLC) and quenched with Na2S04- IOH2O. The mixture was then treated with Rochelle's salt (19.4 g, 95 mmol) in water (300 mL), CH2C12 (400mL) and EtOAc (200 ml) and stirred overnight. The organic phase was separated and the aqueous phase extracted with EtOAc (200 mL). The combined organic layers were dried over Na2S04, and concentrated under reduced pressure. The crude was purified by column chromatography (EtOAc in Hexanes, 15% to 40%) to afford (4-fluoro-3-methyl-5-nitrophenyl)methanol (I-35b).
Step C: A solution of I-35b (1.516 g, 8.20 mmol), (R)-tert-butyl 3-aminoazepane-l- carboxylate (1.844 g, 8.60 mmol) and N,N-diisopropylethylamine (1.16 g, 9.01 mmol) in DMF (30 rriL) was subjected to microwave irradiation (140 °C, 4.5 h). The solvent was evaporated and the residue was purified by column chromatography (EtOAc in Hexanes, 0% to 25%) to afford (R)-tert-butyl 3-((4-(hydroxymethyl)-2-methyl-6- nitrophenyl)amino)azepane-l-carboxylate (I-35c) as an orange oil. MS calculated for C19H30N3O5 (M+H+) 380.21, found 380.2.
Steps D and E: The title compound (Intermediate 35) was prepared from I-35c in several steps following procedures analogous to 1-26, Steps B and C. MS calculated for C20H31N4O3 (M+H+) 375.23, found 375.2.
Intermediate 36
(R)-N-(l-(azepan-3-yl)-7-methyl-5-(pyrrolidin-l-ylmethyl)-lH-benzordlimidazol-2- vDbenzamide hydrochloride
Figure imgf000100_0001
Intermediate 36
Step A: (R)-tert-butyl 3-(2-benzamido-5-(hydroxymethyl)-7-methyl-lH- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-36a) as a clear oil was prepared from I- 35 following procedures analogous to 1-16, step A. MS calculated for C27H35N4O4 (M+H+) 479.26, found 479.2.
Step B: To a solution of I-36a (540 mg, 1.128 mmol) in CH2C12 (65 rriL) were added N,N-diisopropylethylamine (436 mg, 3.385 mmol) and mesyl chloride (388 mg, 3.385 mmol). The mixture was stirred at RT for 16 h. Pyrrolidine (401 mg, 5.64 mmol) was added and the mixture was stirred for 30 min. The solvent was evaporated and the residue was re-dissolved in DMA. More pyrrolidine ((401 mg, 5.64 mmol) was added and the mixture was subjected to microwave irradiation (80 °C, 40 minutes). A few drops of water were added to quench the reaction and the mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (200 mL), washed with saturated aqueous NaHCC>3 solution and brine, dried over Na2S04, and concentrated under reduced pressure. The crude material was purified by column chromatography (0-10% MeOH in CH2CI2) to afford (R)-tert-butyl 3-(2-benzamido-7-methyl-5-(pyrrolidin-l-ylmethyl)-lH- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-36b). MS calculated for C31H42N5O3 (M+H+) 531.32, found 532.3.
Step C: The title compound (Intermediate 36) was prepared from I-36b following procedures analogous to 1-27, Step B. MS calculated for C26H34N5O (M+H+) 432.27, found 432.2.
Intermediate 37
N-(l-(azepan-3-yl)-7-(pyrrolidin-l-ylmethyl)-lH-benzordlimidazol-2-yl)-3- (trifluoromethyl)benzamide hydrochloride
Figure imgf000101_0001
Intermediate 37
Step A: A solution of I-37a (45 mg, 0.087 mmol; prepared in several steps following procedures analogous to 1-25, using the appropriate starting materials), NBS (23 mg, 0.131 mmol), benzoyl peroxide (3 mg, 0.012 mmol), and carbon tetrachloride (1 mL) in a 2 mL microwave reaction vessel was warmed to 100 °C by irradiation with a heat lamp for 6h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was then suspended in acetonitrile (1 mL) and treated with pyrrolidine (0.014 mL, 0.174 mmol) and N,N-diisopropylethylamine (0.045 mL, 0.261 mL). The reaction mixture was stirred at room temperature until completed as determined by LC/MS analysis. The mixture was concentrated under reduced pressure to afford tert- butyl 3-(7-(pyrrolidin-l-ylmethyl)-2-(3-(trifluoromethyl)benzamido)-lH- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-37b). MS calculated for C31H39F3N5O3 (M+H+) 586.29, found 586.3.
Step B: The title compound (Intermediate 37) was prepared following procedures analogous to 1-32, Step B. MS calculated for C26H31F3N5O (M+H+) 486.24, found 486.2.
Intermediate 38
(R)-N-(l-(azepan-3-yl)-7-methyl-5-(pyrrolidin-l-ylmethyl)-lH-benzordlimidazol-2-yl)-
2,6-dimefhylisonicotinamide hydrochloride
Figure imgf000102_0001
Intermediate 38
Step A: (R)-tert-butyl 3-(2-(2,6-dimethylisonicotinamido)-5-(hydroxymethyl)-7- methyl-lH-benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-38a) was prepared following procedures analogous to 1-16.
Step B: A suspension of I-38a (350 mg, 0.689 mmol) and IBX (386 mg, 1.379 mmol) in MeCN was heated to 90°C in a sealed vessel for lh. The mixture was cooled to room temperature and filtered. The filtrate was concentrated to afford (R)-tert-butyl 3-(2- (2,6-dimethylisonicotinamido)-5-formyl-7-methyl- lH-benzo[d]imidazol- 1 -yl)azepane- 1 - carboxylate (I-38b). The compound was used in the next step without further purification. Step C: To a mixture of I-38b (350 mg, 0.689 mmol), pyrrolidine (146 mg, 2.067 mmol), and N,N-diisopropylethylamine (600 uL, 3.445 mmol) in (CH2C1)2 (20 mL) was added NaHB(OAc)3 (438 mg, 2.067 mmol). The mixture was then heated to 50°C for 30 min., cooled to room temperature, filtered and concentrated. The crude was purified by column chromatography (0-90% [9: 1 :0.175N CHzCyMeOH/NILl/CHzC^) to afford (R)- tert-butyl 3-(2-(2,6-dimethylisonicotinamido)-7-methyl-5-(pyrrolidin- 1-ylmethyl)- 1H- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-38c) as a yellow solid. MS calculated for C32H45N6O3 (M+H+) 560.35, found 560.3.
Step D: The title compound (Intermediate 38) was prepared from I-38c following procedures analogous to 1-30, Step B. MS calculated for C27H37N6O (M+H+) 461.30, found 461.3.
Intermediate 39
N-(l-((R)-azepan-3-yl)-7-((3-hvdroxypyrrolidin-l-yl)methyl)-lH-benzordlimidazol-2- vDbenzamide
Figure imgf000103_0001
-39a l-39b
Figure imgf000103_0002
l-39c Intermediate 39
Step A: To a solution of I-39a (227 mg, 0.488 mmol; prepared following procedures analogous to I-36a, using the appropriate starting materials) in CH2CI2 (20 mL) at 0 °C were added N,N-diisopropylethylamine (152 mg, 1.175 mmol) and mesyl chloride (134 mg, 1.175 mmol). The mixture was stirred for 10 min, 2,4,6-trimethylpyridine (142.4 mg, 1.175 mmol) was added drop-wise and the reaction was stirred at room temperature for 2 h. More N,N-diisopropylethylamine (63 mg, 0.488 mmol) and mesyl chloride (56 mg, 0.488 mmol) were added and the mixture was stirred for lh at room temperature. The mixture was diluted with DMF (5 mL) and stirred overnight, quenched with ice and diluted with EtOAc (300 mL). The organic phase was washed with 0.2 N HC1 (3 x 50 mL), saturated aqueous NaHCC>3 solution, and brine, dried over Na2S04, and concentrated under reduced pressure. The crude material was purified by column chromatography (0-10% MeOH in CH2C12) to afford (R)-tert-butyl 3-(2-benzamido-7- (chloromethyl)-lH-benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-39b). MS calculated for C26H32C1N403 (M+H+) 483.21, found 483.0.
Step B: A solution of I-39b (44 mg, 0.092mmol) in DMF (2 mL) was treated with pyrrolidin-3-ol (16 mg, 0.184 mmol) and the mixture was stirred at 110 °C for 1 h. The solvent was evaporated under reduced pressure. The residue was dissolved with EtOAc (100 mL), washed with 0.2N HCI (2 x 20 mL), saturated aqueous NaHC03 solution and brine, dried over Na2S04 and concentrated under reduced pressure. The crude material was purified by column chromatography (0-10% methanol in CH2C12) to afford (3R)-tert- butyl 3 -(2-benzamido-7-((3 -hydroxypyrrolidin- 1 -yl)methyl)- 1 H-benzo [djimidazol- 1 - yl)azepane-l-carboxylate (I-39c). MS calculated for C3oH40N502 (M+H+) 534.30, found 534.3.
Step C: The title compound (Intermediate 39) was prepared from I-39c following procedures analogous to 1-27, Step B. MS calculated for C25H32N502 (M+H+) 434.25, found 434.2.
Intermediate 40
N-(l-(azepan-3-yl)-7-(l,l-dioxidothiomorpholine-4-carbonyl)-lH-benzordlimidazol-2-
Figure imgf000104_0001
Step A: To a solution of I-40a (49.3 mg, 0.1 mmol; prepared following procedures analogous to I-22a, using the appropriate starting materials) in DMSO (3mL) was added potassium t-butoxide (112 mg, 1.0 mmol). The mixture was stirred at room temperature for 50 minutes, diluted with ice-water, acidified to pH=l with IN HCl, and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine and water, dried over Na2S04 and concentrated under reduced pressure to afford 2-benzamido-l-(l- (tert-butoxycarbonyl)azepan-3-yl)-lH-benzo[d]imidazole-7-carboxylic acid (I-40b). MS calculated for C26H31N4O5 (M+H+) 479.22, found 479.0.
Step B: tert-butyl 3-(2-benzamido-7-(l,l-dioxidothiomorpholine-4-carbonyl)-lH- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-40c) was prepared from I-40a following procedures analogous to 1-16. MS calculated for C30H38N5O6S (M+H+) 596.25, found 595.20.
Step C: The title compound (Intermediate 40) was prepared from I-40c following procedures analogous to 1-27, Step B. MS calculated for C25H30N5O4S (M+H+) 496.19, found 496.20.
Intermediate 41
2- amino- 1 - ( 1 - (tert-butoxycarbonyl) azepan- 3 -yl) -7 -cy ano- 1 H-benzo Tdl imidazole- 5 - carboxylate
Figure imgf000105_0001
'"^c Intermediate 41
Step A: To a stirred solution of methyl-3-cyano-4-methoxy benzoate (0.820g) at 0°C was slowly added fuming HNO3 (15mL) and the mixture was stirred at 5°C for 30 min. The mixture was then poured in ice-cold water, the resulting solid was collected by filtration and dried under vacuum to afford methyl 3-cyano-4-methoxy-5-nitrobenzoate (I-41a); ]H-NMR (400 MHz, DMSO-d6): d 8.66 (d, / = 2Hz, 1H), 8.60 (d, / = 2Hz, 1H), 4.18 (s, 3H), 3.90 (s, 3H). Steps B, C and D: The title compound (Intermediate 41) was prepared in several steps from I-41a following procedures analogous to 1-15. MS calculated for C21H28N5O4 (M+H+) 414.21, found 414.3.
Intermediate 42
N-(l-(azepan-3-yl)-7-cyano-5-(hydroxymethyl)-lH-benzordlimidazol-2-yl)-3-
Figure imgf000106_0001
Intermediate 42
Step A: Methyl l-(l-(tert-butoxycarbonyl)azepan-3-yl)-7-cyano-2-(3- (trifluoromethyl)benzamido)-lH-benzo[d]imidazole-5-carboxylate (I-42a) was prepared from 1-41 following procedures analogous to 1-16. MS calculated for C29H29F3N5O5 (M- H") 584.21, found 584.3.
Step B: A mixture of I-42a (52 mg, 0.09 mmol) and L1BH4 (8.7 mg, 0.4 mmol) in 1:1 THF/toluene (2 mL) was stirred at 100 °C for 1 h (reaction completion monitored by LC- MS). The mixture was then diluted with 1M HC1 and extracted with CH2C12 (3x). The combined organic layers were dried over anhydrous Na2S04 and concentrated under reduced pressure to afford tert-butyl 3-(7-cyano-5-(hydroxymethyl)-2-(3- (trifluoromethyl)benzamido)- lH-benzo[d]imidazol- 1 -yl)azepane- 1 -carboxylate (I-42b). MS calculated for C28H31F3N5O4 (M+H+) 558.22, found 558.2.
Step C: The title compound (Intermediate 42) was prepared from I-42b following procedures analogous to 1-32, Step B. MS calculated for C23H23F3N5O2 (M+H+) 458.17, found 458.20.
Intermediate 43
methyl l-(piperidin-3-yl)-2-(3-(trifluoromethyl)benzamido)-6,7-dihydro-lH-imidazor4,5- clpyridine-5(4H)-carboxylate
Figure imgf000107_0001
l-43b Intermediate 43
Step A: A degassed solution of 1-18 (0.2g, 0.4mmol) in EtOH (l.lmL) and water (0.05mL) was treated drop-wise at -78 °C with methylchloroformate (0.045g, 0.48mmol) and stirred for 50 min. NaBH4 (0.045g) was then added portion wise at the same temperature and the mixture was stirred at room temperature for lh (reaction completion monitored by TLC). The mixture was quenched with water and extracted with EtOAc (2 x 20mL). The combined organic layers were dried over Na2S04 and concentrated under reduced pressure to afford methyl l-(l-(tert-butoxycarbonyl)piperidin-3-yl)-2-(3- (trifluoromethyl)benzamido)-lH-imidazo[4,5-c]pyridine-5(4H)-carboxylate (I-43a) as a greenish yellow solid. MS calculated for Czel^^NsOs (M+H+) 550.22, found 550.2.
Step B: Methyl l-(l-(tert-butoxycarbonyl) piperidin-3-yl)-2-(3- (trifluoromethyl)benzamido)-6,7-dihydro-lH-imidazo[4,5-c]pyridine-5(4H)-carboxylate (I-43b) was prepared from I-43a following procedures analogous to 1-15, Step B. MS calculated for C26H31F3N5O5 (M-H ) 550.24, found 550.5.
Step C: The title compound (Intermediate 43) was prepared from I-43b following procedures analogous to 1-16, Step B. MS calculated for C21H25F3N5O3 (M+H+) 452.18, found 452.2.
Intermediate 44
(R)-N-(l-(azepan-3-yl)-7-chloro-lH-benzordlimidazol-2-yl)pyridazine-4-carboxamide hydrochloride
Figure imgf000108_0001
Intermediate 44
Step A
Steps A and B: The title compound (Intermediate 44) was prepared in several steps from 1-26 following procedures analogous to 1-30. MS calculated for C18H20CIN6O (M+H+) 371.13, found 371.1.
Intermediate 45
(R)-N-(l-(azepan-3-yl)-7-methyl-lH-benzordlimidazol-2-yl)-2- (trifluoromethyl)isonicotinamide hydrochloride
Figure imgf000108_0002
'-31 Step A l_45a Intermediate 45
Step A: (R)-tert-butyl 3-(7-methyl-2-(2-(trifluoromethyl)isonicotinamido)- lH- benzo[d]imidazol-l-yl)azepane- l-carboxylate (I-45a) was prepared from 1-31 following procedures analogous to 1-27, Step A. ]H-NMR (400 MHz, CDC13) δ 12.53 (s, 1H), 8.89 (d, J = 4.6 Hz, 1H), 8.54 (d, / = 7.1 Hz, 1H), 8.27 (d, J = 4.6 Hz, 1H), 7.21 (dt, 7 = 7.8, 21.3 Hz, 2H), 7.08 (t, / = 9.2 Hz, 1H), 5.12 - 4.85 (m, 1H), 4.34 (dd, / = 10.6, 13.6 Hz, 1H), 4.16 - 3.85 (m, 2H), 3.36 - 3.21 (m, 1H), 2.94 - 2.82 (m, 1H), 2.80 (s, 3H), 2.30 - 2.15 (m, 1H), 2.15 - 2.00 (m, 2H), 2.00 - 1.81 (m, 1H), 1.48 (s, 9H), 1.43 - 1.36 (m, 1H). 19F-NMR (376 MHz, CDC13) δ -67.90 (s, 1H); MS calculated for CzeHgjFgNsOg (M+H+) 518.23, found 518.2.
Step B: The title compound (Intermediate 45) was prepared from I-45a following procedures analogous to 1-32, Step B. ]H-NMR (400 MHz, DMSO) δ 9.40 - 9.09 (m, 2H), 8.99 (d, / = 4.9 Hz, 1H), 8.37 (s, 1H), 8.34 (s, 1H), 7.50 (d, / = 7.9 Hz, 1H), 7.18 (d, 7 = 7.8 Hz, 1H), 7.11 (s, 1H), 5.33 - 5.14 (m, 1H), 4.40 - 4.23 (m, 1H), 3.71 - 3.69 (m, 1H), 3.38 - 3.18 (m, 2H), 2.79 (s, 3H), 2.69 - 2.57 (m, 1H), 2.29 - 2.12 (m, 1H), 2.10 - 1.89 (m, 3H), 1.89 - 1.72 (m, 1H). 19F-NMR (376 MHz, DMSO) δ -66.52 (s, 1H); MS calculated for C21H23F3N5O (M+H+) 418.18, found 418.2. Intermediate 46
(R)-N-(l-(azepan-3-yl)-7-methyl-lH-benzordlimidazol-2-yl)-2,6- dimethylisonicotinamide hydrochloride
Figure imgf000109_0001
Step A Step A: (R)-tert-butyl 3-(2-(2,6-dimethylisonicotinamido)-7-methyl-lH- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-46a) was prepared from 1-31 following procedures analogous to 1-27, Step A. MS calculated for C27H36N5O3 (M+H+) 478.27, found 478.3.
Step B: The title compound (Intermediate 46) was prepared from I-46a following procedures analogous to 1-32, Step B. ]H-NMR (400 MHz, DMSO) δ 7.69 (s, 2H), 7.44 (d, 7 = 7.7 Hz, 1H), 7.11 (t, 7 = 7.7 Hz, 1H), 7.07 - 6.99 (m, 1H), 4.91 (s, 1H), 3.79 (s, 1H), 3.20 - 3.04 (m, 1H), 2.94 (s, 1H), 2.86 (s, 1H), 2.71 (s, 3H), 2.70 - 2.68 (m, 2H), 2.52 (s, 6H), 2.06 (s, 1H), 1.84 (s, 2H), 1.72 - 1.56 (m, 1H); MS calculated for
C22H28N5O (M+H+) 378.22, found 378.3.
Intermediate 47
l-methyl-l,2,5,6-tetrahvdropyridine-3-carboxylic acid hydrochloride
Figure imgf000109_0002
l-47a Intermediate 47 l-methyl-l,2,5,6-tetrahydropyridine-3-carboxylate hydrobromide (I-47a, 235 mg, 1.0 mmol) was diluted with concentrated HCl (2.0 mL), and the mixture was heated at 50°C overnight. The reaction mixture was concentrated in vacuo to afford the title compound (Intermediate 47). MS calculated for C7H12N02 (M+H+) 142.08, found: 142.1. The crude was used in the next step without further purification. Intermediate 48
l-methyl-l,2,3,6-tetrahvdropyridine-4-carboxyric acid hydrochloride
Figure imgf000110_0001
I -48a Intermediate 48 l-methyl-l,2,3,6-tetrahydropyridine-3-carboxylate (I-48a, 155 mg, l.Ommol) was diluted with concentrated HCI (2.0 mL), and the mixture was heated at 50°C overnight. The reaction mixture was concentrated in vacuo to afford the title compound
(Intermediate 48). MS calculated for C7H12N02 (M+H+) 142.08, found: 142.2. The crude was used in the next step without further purification.
Intermediate 49
-4-(dimethylamino)-4-methylpent-2- acid hydrochloride
Figure imgf000110_0002
Intermediate 49
Step A and B: To the solution of Ν,Ν-2-trimethylprop-l-en-l-amine (I-49a, 240 mg, 2.42 mmol) in anhydrous Et20 (40 mL) at -78°C was added dropwise Br2 (0.12 mL, 2.42 mmol), whereupon I-49b precipitated as a thick, light yellow solid. This mixture was then warmed and kept at 0°C, and treated dropwise with a -78°C solution of t-butyl lithioacetate, which was prepared in situ by dropwise addition of tert-butyl acetate (I-49c, 0.65 mL, 4.84 mmol) to a solution of LDA at -78°C (prepared by dropwise addition of n- BuLi (3.02 mL, 4.84 mmol) to diisopropylamine (0.65 mL, 4.84 mmol) in Et20 (10 mL) at -78°C). During the addition, the precipitate dissolved, and a pale yellow solution was obtained. The reaction mixture was allowed to warm to room temperature, and stirred for another 1 h. The reaction mixture was partitioned between Et20 and water and extracted with Et20. The combined organic layers were dried over Na2S04 and concentrated under reduced pressure. The crude material was purified by column chromatography (0-10% MeOH in CH2CI2) to afford (E)-tert-butyl 4-(dimethylamino)-4-methylpent-2-enoate (I- 49d). MS calculated for C12H24NO2 (M+H+) 214.17, found: 214.2.
Step C: Intermediate I-49d (133 mg, 0.62 mmol) was diluted with concentrated HCl (5.0 mL), and stirred at room temperature overnight. The reaction mixture was then concentrated in vacuo to afford the title compound (Intermediate 49). MS calculated for C8H16N02 (M+H+) 158.11, found: 158.2. The crude was used in the next step without further purification.
Intermediate 50
-(dimethylphosphoryl)-6-methylisonicotinic acid hydrochloride
Figure imgf000111_0001
Step A: Intermediate I-50b was prepared from Intermediate I-50a following a similar procedure as described in WO2009/143389. A solution of methyl 2-bromo-6- methylisonicotinate (I-50a, 690 mg, 3 mmol) in DMF (12 mL) was treated with dimethylphosphine oxide (515 mg, 6.6 mmol), palladium acetate (39 mg, 0.05 mmol), 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (104 mg, 0.18 mmol) and potassium phosphate (700.5 mg, 3.3 mmol). The mixture was purged with nitrogen and subjected to microwave irradiation (20 min, 150 °C). The reaction mixture was concentrated and purified by column chromatography (9: 1 :0.175N CH2Cl2/MeOH/NH3 in CH2C12, 0% to 100%) to afford methyl 2-(dimethylphosphoryl)-6-methylisonicotinate (I-50b) as an off- white solid. ]H NMR (400 MHz, DMSO) δ 8.14 (s, 1H), 7.87 (s, 1H), 3.93 (s, 3H), 2.64 (s, 3H), 1.67 (d, / = 13.6 Hz, 6H); MS calculated for C10H15NO3P (M+H+) 228.07, found 228.1.
Step B: A solution of I-50b (539 mg, 2.37 mmol) in MeOH (0.5 mL) was treated with 10N NaOH (1 mL) and stirred at room temperature for 80 min. The mixture was then acidified with concentrated HCl, evaporated under reduced pressure and lyophilized. The crude was then triturated in MeOH and filtered to afford the title compound
(Intermediate 50) as a white solid. ]H NMR (400 MHz, DMSO) δ 8.14 (s, 1H), 7.84 (s, 1H), 4.62 (br s, 2H), 2.63 (s, 3H), 1.67 (d, / = 13.6 Hz, 6H); MS calculated for
C9H13N03P (M+H+) 214.06, found 214.1. Intermediate 51
2-(dimethylphosphoryl)isonicotinic acid hydrochloride
Figure imgf000112_0001
Step A: tert-butyl 2-(dimethylphosphoryl)isonicotinate (I-51b) was prepared from I-51a following procedures analogous to 1-50, Step A. ]H NMR (400 MHz, DMSO) δ 8.97 (d, 7 = 4.9 Hz, 1H), 8.36-8.19 (m, 1H), 7.93 (dt, / = 1.9, 4.9 Hz, 1H), 1.69 (d, J = 13.7 Hz, 6H), 1.58 (s, 9H); MS calculated for C12H19N03P (M+H+) 256.10, found 256.1.
Step B: A solution of I-51b (511 mg, 2 mmol) in dichloromethane (4 mL) was treated with trifluoroacetic acid (4 mL) and stirred at room temperature for 5 hours. A solution of HCl in isopropanol (4N, 3 mL) was then added and the mixture was stirred at 55 °C for 2 hours (reaction completion monitored by LC/MS). The solvent was then evaporated and the crude was co-evaporated with HCl in isopropanol (3x) to afford the title compound (Intermediate 50) as a white solid. ]H NMR (400 MHz, DMSO) δ 8.98 (d, / = 4.9 Hz, 1H), 8.33 (d, / = 5.4 Hz, 1H), 7.96 (d, / = 4.9 Hz, 1H), 6.24-4.44 (m, 2H), 1.69 (d, J = 13.7 Hz, 6H); MS calculated for C8HnN03P (M+H+) 200.04, found 200.1.
Intermediate 52
(R)-N-(l-(azepan-3-yl)-7-chloro-lH-benzordlimidazol-2-yl)-2-(dimethylphosphoryl)-6-
Figure imgf000112_0002
1-26 l-52a Intermediate 52
Steps A: A mixture of 1-26 (401 mg, 1.1 mmol) and 1-50 (213 mg, 1 mmol) in ethyl acetate (2 mL) was treated with triethylamine (1.4 mL, 10 mmol) and a 50 w solution of propane phosphonic acid anhydride in ethyl acetate (1.9 g, 3 mmol). The mixture was then stirred at 50 °C for 64 hours. The mixture was washed with saturated aqueous Na2CC>3 (2x). The aqueous phase was re-extracted with ethyl acetate and the combined organics were washed with brine, dried over Na2S04 and concentrated under reduced pressure. The crude was purified by column chromatography (9: 1:0.175N
CH2Cl2/MeOH/NH3 in CH2C12, 0% to 100%) to afford (R)-tert-butyl 3-(7-chloro-2-(2- (dimethylphosphoryl)-6-methylisonicotinamido)-lH-benzo[d]imidazol-l-yl)azepane-l- carboxylate (I-52a) MS calculated for C27H36C1N504P (M+H+) 560.21, found 560.2.
Step B: Solid I-52a (314 mg, 0.56mmol) was treated with HQ in isopropanol (5 mL) and stirred at room temperature for 4 hours, when dichloromethane (2 mL) was added and the mixture was further stirred at 50 °C for 4 hours (reaction completion monitored by LC/MS). The solvent was then evaporated and the crude material was dried under vacuum to afford the title compound (Intermediate 52) as a yellow solid. ]H NMR (400 MHz, DMSO) δ 9.89 (s, 1H), 9.55 (s, 1H), 8.45 (d, / = 5.8 Hz, 1H), 7.99 (s, 1H), 7.60 (dd, / = 1.1, 7.9 Hz, 1H), 7.44-7.10 (m, 2H), 5.88 (s, 1H), 4.82 (s, 1H), 4.35-4.30 (m, 1H), 3.78-3.74 (m, 1H), 3.28 (d, / = 48.9 Hz, 2H), 2.70 (s, 3H), 2.60-2.50 (m, 1H), 2.20-1.95 (m, 4H), 1.88-1.57 (m, 7H); MS calculated for C22H28C1N502P (M+H+) 460.16, found 460.1.
Intermediate 53
(R)-N-(l-(azepan-3-yl)-7-chloro-lH-benzordlimidazol-2-yl)-2- (dimethylphosphoryl)isonicotinamide dihydrochloride
Figure imgf000113_0001
Steps A and B: The title compound (Intermediate 53) was prepared in several steps from 1-26 and 1-51 following procedures analogous to 1-52. ]H NMR (400 MHz,
DMSO) δ 9.85-9.80 (m, 1H), 9.60-9.51 (m, 1H), 8.97 (d, / = 4.9 Hz, 1H), 8.62 (d, / = 5.3 Hz, 1H), 8.17 (d, J = 4.9 Hz, 1H), 7.60 (dd, / = 1.1, 7.9 Hz, 1H), 7.44-7.15 (m, 2H), 5.91- 5.82 (m, 1H), 5.63 (s, 1H), 4.38-4.29 (m, 1H), 3.76-3.71 (m, 1H), 3.40-3.19 (m, 2H), 2.70-2.51 (m, 2H), 2.20-1.93 (m, 4H), 1.87-1.68 (m, 7H); MS calculated for
C2iH26ClN502P (M+H+) 446.14, found 446.1. Intermediate 54
1-benzyl 4-tert-butyl 6-amino-l,4-diazepane-l,4-dicarboxylate
1 ) PhCHO
Figure imgf000114_0001
l-54a Intermediate 54
Step A: A solution of benzyl 6-amino-5-oxo-l,4-diazepane-l-carboxylate (12.86 g, 47.4 mmol) in THF (158 mL) was treated dropwise with BH3 DMS (22.5 mL, 237 mmol). The mixture was warmed to reflux and stirred for 15 hours. The mixture was then cooled to 0 °C, quenched by the slow addition of MeOH (50 mL; vigorous ¾ evolution observed) and treated over 10 min with concentrated HC1 (12 mL). The reaction vessel was then heated to reflux for 8 hours. The volatiles were partially removed under reduced pressure and the mixture was basified to pH 11 with solid Na2C03. The aqueous layer was extracted with CH2CI2 (2x), the organic phase was dried (Na2S04), and concentrated in vacuo to afford benzyl 6-amino-l,4-diazepane-l-carboxylate (I-54a). MS calculated for C13H20N3O2 (M+H+) 250.15, found 250.1. The crude was used in the next step without further purification.
Step B: Anhydrous sodium sulfate (5.92 g, 41.7 mmol) was suspended in a solution of I-54a (8.66 g, 34.7 mmol) in CH2C12. Benzaldehyde (4.4 mL, 43.4 mmol) was added and the mixture was stirred for 24 hours, resulting in a color change from colorless to bright yellow. The mixture was filtered, rinsed with CH2CI2 (100 mL). The filtrate was treated with di-½ri-butyl dicarbonate (9.10 g, 41.7 mmol) and triethylamine (9.7 mL, 69.5 mmol). The reaction mixture was stirred for 80 min and then treated with formic acid (38 mL, 868 mmol). The reaction color changed from bright yellow to cloudy orange. The mixture was stirred for 2 hours, diluted with 1.0 M HC1 (50 mL), and extracted with CH2CI2 (3 x 50 mL). The aqueous layer was made alkaline (~pH 10) with saturated Na2CC>3 and extracted with CH2CI2 (3 x 50 mL). The combined organic phase from all six extractions was then washed with 1.0 M NaHSC>3 (3 x 40 mL), dried over Na2S04 and concentrated under reduced pressure to afford the title compound (Intermediate 54). ]H
NMR (400 MHz, CD2C12) δ 7.39 - 7.34 (m, 5H), 7.34 - 7.23 (m, 2H), 4.65 (s, 2H), 3.69 (m, 1H), 3.53 - 3.21 (m, 1H), 3.21 - 2.96 (m, 1H), 2.96 - 2.77 (m, 3H), 2.73 (m, 1H), 2.66 - 2.54 (m, 1H), 2.47 (m, 1H), 1.78 (s, 9H); MS calculated for C18H28N304 (M+H+) 350.20, found 350.1. Intermediate 55
1-benzyl 4-tert-butyl 6-(2-amino-7-chloro-lH-benzordlimidazol-l-yl)-l,4- diazepane- 1 ,4-dicarboxylate
Figure imgf000115_0001
Step A: 1-benzyl 4-ieri-butyl 6-((2-chloro-6-nitrophenyl)amino)-l,4-diazepane-l,4- dicarboxylate (I- 55a) was prepared following procedures analogous to 1-15, Step A, using the appropriate starting materials. ]NMR (400 MHz, CDC13) δ 7.91 (s, 1H), 7.52 (s, 1H), 7.33 (d, / = 28.3 Hz, 5H), 7.11 - 6.88 (m, 1H), 6.88 - 6.69 (m, 1H), 5.31 - 4.95 (m, 2H), 4.82 - 4.34 (m, 1H), 3.77 - 3.55 (m, 4H), 3.54 - 3.14 (m, 4H), 1.47 - 1.38 (m, 9H); MS calculated for C24H29ClN4Na06 (M+Na+) 527.17, found 527.2.
Step B: 1-benzyl 4-ieri-butyl 6-((2-amino-6-chlorophenyl)amino)-l,4-diazepane-l,4- dicarboxylate (I-55b) was prepared from I-55a following procedures analogous to 1-26, Step B. MS calculated for C24H32CIN4O4 (M+H+) 475.20, found 475.2.
Step C: The title compound (Intermediate 55) was prepared from I-55b following procedures analogous to 1-15, Step C. ]H NMR (400 MHz, CD2C12) δ 7.59 - 7.08 (m, 6H), 7.08 - 6.91 (m, 2H), 5.98 - 5.79 (m, 1H), 5.62 - 5.35 (m, 2H), 5.27 - 4.99 (m, 2H), 4.51 - 3.90 (m, 4H), 3.90 - 3.67 (m, 2H), 3.56 - 2.75 (m, 2H), 1.49 - 1.34 (m, 9H). MS calculated for C25H31CIN5O4 (M+H+) 500.20, found 500.2.
Intermediate 56
fe? -butyl 6-(7-chloro-2-(2-methylisonicotinamido)-lH-benzor(ilimidazol-l-yl)-l,4- diazepane- 1 -carboxylate
Figure imgf000115_0002
l-56a Intermediate 56
1-55 Step A
Step A: 1-benzyl 4-ieri-butyl 6-(7-chloro-2-(2-methylisonicotinamido)-lH- benzo[if|imidazol-l-yl)-l,4-diazepane-l,4-dicarboxylate (I-56a) was prepared from 1-55 following procedures analogous to 1-27, Step A. ]H NMR (400 MHz, DMSO) δ 8.62 (t, J = 4.2 Hz, IH), 7.87 (d, J = 3.5 Hz, IH), 7.80 (d, J = 3.8 Hz, IH), 7.63 - 7.53 (m, IH), 7.49 - 7.33 (m, 3H), 7.33 - 7.24 (m, 4H), 7.24 - 7.06 (m, IH), 5.68 - 5.50 (m, IH), 5.20 - 5.00 (m, 2H), 4.51 - 4.22 (m, 2H), 4.22 - 4.08 (m, 3H), 4.06 - 3.96 (m, IH), 3.45 - 3.37 (m, IH), 3.29 - 3.16 (m, IH), 2.58 (s, 3H), 1.45 - 1.30 (m, 9H); MS calculated for C32H36CIN6O5 (M+H+) 619.24, found 619.2.
Step B: A solution of I-56a (647 mg, 1.05 mmol) in CH2CI2 (5 mL) was evacuated and backfilled with nitrogen (2x) and then treated with palladium(II) chloride (56 mg, 0.314 mmol). To the resulting brick red suspension was added triethylsilane (0.67 mL, 4.18 mmol) followed by NEt3 (0.1 mL, 7.3 mmol) and the mixture was stirred for 30 min. The mixture was then partitioned between CH2CI2 and saturated aqueous NH4CI solution, the layers separated, and the aqueous phase extracted with CH2CI2 (2x). The combined organic phase was washed with brine, dried over Na2S04, and concentrated under reduced pressure. The crude was purified by column chromatography (9: 1:0.175 M CH2CI2 /MeOH/NH3 in CH2C12, 30-75%) to afford the title compound (Intermediate 56). ]H NMR (400 MHz, DMSO) δ 8.63 (d, / = 5.0 Hz, IH), 7.85 (s, IH), 7.82-7.71 (m, IH), 7.57 (d, 7 = 7.8 Hz, IH), 7.31 (s, IH), 7.25 (d, / = 7.9 Hz, IH), 5.55 (br s, IH), 4.38 (br s, IH), 3.95-3.83 (m, IH), 3.83-3.70 (m, IH), 3.63 (s, IH), 3.27-2.96 (m, 3H), 2.96-2.85 (m, IH), 2.58 (s, 3H), 1.38 (m, 9H); MS calculated for C24H30CIN6O3 (M+H+) 485.20, found 485.2.
Intermediate 57
(R)-tert-butyl 3-(2-amino-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH-benzordlimidazol-l- - 1 -carboxylate
Figure imgf000116_0001
Figure imgf000117_0001
Step A: To a solution of 2-chloro-l,3-difluoro-4-nitrobenzene (9 g, 46.5 mmol) in dimethoxyethane (93 mL) was added 1-1 (10.96 g, 51.2 mmol). The mixture was heated under argon to 85 °C for 2 hours and then cooled to room temperature. In a separate flask, 2-(pyrrolidin-l-yl)ethanol (13.39 g, 116 mmol) in dimethoxyethane (30 mL) at 0 °C was treated with LHMDS (0.9M in methyl-cyclohexane, 134 mL, 121 mmol) and stirred at 0 °C for 15 min. The resulting suspension was then added at 0 °C to the first reaction mixture and then stirred at 85 °C for 30 min. After cooling to 0 °C, additional LHMDS (0.9 M in methyl-cyclohexane, 35 mL, 31.5 mmol) was added. The mixture was then stirred 10 minutes at room temperature and 40 minutes at 85°C, before being concentrated under reduced pressure and poured into ice water (300 mL). The aqueous phase was extracted with EtOAc (3x 150 mL), the combined organic layer was dried with Na2SC>4 and concentrated under reduced pressure. The crude was purified by column
chromatography (0-10% MeOH in CH2C12) to afford (R)-tert-butyl 3-((2-chloro-6-nitro- 3-(2-(pyrrolidin-l-yl)ethoxy)phenyl)amino)azepane-l-carboxylate (I-57a) as brown oil. MS calculated for C^ILeCl^Os (M+H+) 483.23, found 483.2.
Step B: (R)-tert-butyl 3-((6-amino-2-chloro-3-(2-(pyrrolidin-l- yl)ethoxy)phenyl)amino)azepane-l-carboxylate (I-57b) was prepared from I-57a following procedures analogous to 1-26, Step B. MS calculated for C23l½ClN4C>3 (M+H+) 453.26, found 453.3.
Step C: (R)-tert-butyl 3-(7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-57c) was prepared from I-57b following procedures analogous to 1-17, Step C. MS calculated for C^ILeCl^Cb (M+H+) 463.24, found 463.2.
Step D: (R)-tert-butyl 3-(2-azido-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-57d) was prepared from I-57c following procedures analogous to 1-17, Step D. MS calculated for C^ILsClNvCb (M+H+) 504.24, found 504.2. Step E: A solution of I-57d (0.83 g, 1.65 mmol) in THF (18 mL) under nitrogen was cooled 0 °C and treated with trimethylphosphine (1M in THF, 17 mL, 17 mmol). The solution was stirred at 0 °C for 120 min. Then, 1M HCl was slowly added until pH 2 and the mixture was stirred for 22 hours at room temperature, before it was basified with IN NaOH to pH 11. THF was evaporated under reduced pressure and the water phase was extracted with 3:1 chloroform/isopropanol (3x 80mL). The combined organic phase was washed with brine (40 mL), dried over Na2SC>4, and concentrated under reduced pressure. The crude was purified by chiral SFC (methanol/liquid C02) to the title compound
(Intermediate 57). MS calculated for C24H37CIN5O3 (M+H+) 478.25, found 478.2.
Intermediate 58
(R)-N-(l-(azepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH-benzordlimidazol-2- yl) -2 , 6-dimethylisonicotinamide
Figure imgf000118_0001
Intermediate 58
Step A: (R)-tert-butyl 3-(7-chloro-2-(2,6-dimethylisonicotinamido)-6-(2-(pyrrolidin- l-yl)ethoxy)-lH-benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-58a) was prepared from 1-57 following procedures analogous to 1-30, Step A. MS calculated for
C32H44C1N604 (M+H+) 611.30, found 611.3.
Step B: The title compound (Intermediate 58) was prepared from I-58a following procedures analogous to 1-16, Step B. MS calculated for C27H36C1N602 (M+H+) 511.25, found 511.2. Example 1
(R,E)-N-(7-chloro-l-(l-(4-(pyrrolidin-l-yl)but-2-enoyl)azepan-3-yl)-lH- benzordlimidazol-2-yl)-2-methylisonicotinamide
Figure imgf000119_0001
To the mixture of 1-7 (76.4 mg, 0.4 mmol) and 2-(7-aza-lH- benzotriazole-l-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (137.5 mg, 0.36 mmol) in DMF (2.0 mL) was added NEt3 (0.11 mL, 0.8 mmol), and was stirred at room temperature for 10 min. The resulting mixture was added to a solution of 1-27 (83.8 mg, 0.2 mmol) in DMF (1 mL), and the mixture was stirred at room temperature for 1 h. The reaction was quenched with H20 (0.2 mL) and the mixture was purified by HPLC to afford the title compound (Example 1). ]H NMR (400 MHz, MeOD) δ 8.58 (d, / = 5.6 Hz, 1H), 8.15 (d, / = 29.6 Hz, 2H), 7.41 (s, 1H), 7.22 (dd, / = 8.9, 17.5 Hz, 2H), 6.87 (s, 1H), 6.70 (s, 1H), 5.69 - 5.44 (m, 1H), 4.76 - 4.48 (m, 1H), 4.23 - 4.06 (m, 1H), 3.96 (d, J = 7.0 Hz, 2H), 3.84 - 3.60 (m, 2H), 3.59 - 3.25 (m, 2H), 3.12 - 2.82 (m, 2H), 2.65 (d, J = 8.9 Hz, 3H), 2.03 (s, 7H), 1.50 - 1.29 (m, 1H), 1.19 (s, 2H), 0.80 (s, 1H). MS calculated for
C28H34CIN6O2 (M+H+) 521.24, found: 521.2.
Example 2
(R.E)-N-(7-chloro-l-(l-(4-(3-fluoroazetidin-l-yl)but-2-enoyl)azepan-3-yl)-lH- benzordlimidazol-2-yl)-2-methylisonicotinamide
Figure imgf000119_0002
1-27 Example 2
To the mixture of 1-11 (87.8 mg, 0.45 mmol) and O-benzotriazole-Ν,Ν,Ν' ,Ν'- tetramethyl-uronium-hexafluoro-phosphate (341 mg, 0.9 mmol) in DMF (2.0 mL) was added hydroxybenzotriazole (162 mg, 1.2 mmol) and stirred at room temperature for 10 min. The resulting mixture was added to a solution of 1-27 (63 mg, 0.15 mmol) in DMF (1 mL), followed by addition of NEt3 (0.2 mL, 1.43 mmol). The resulting mixture was stirred at room temperature for 1 h, quenched with H20 (0.2 mL) and purified by HPLC to afford the title compound (Example 2). ]H NMR (400 MHz, MeOD) δ 8.45 (d, / = 4.4, 1H), 7.92 (d, J = 10.0 Hz, 1H), 7.83 (s, 1H), 7.45 - 7.33 (m, 1H), 7.30 - 7.05 (m, 2H), 6.63 (s, 1H), 6.51 (d, J = 16.0 Hz, 1H), 5.66 - 5.44 (m, 1H), 5.20 - 4.87 (m, 2H), 4.73 - 4.45 (m, 1H), 4.18 - 3.98 (m, 1H), 3.97 - 3.76 (m, 1H), 3.61 (s, 2H), 3.39 (s, 1H), 3.26 (dd, J = 7.2, 20.0 Hz, 2H), 3.07 (d, J = 5.2 Hz, 2H), 2.81 - 2.61 (m, 1H), 2.53 (s, 3H), 2.02 (s, 4H), 1.51 - 1.28 (m, 1H), 1.19 (s, 1H). MS calculated for C27H31CIFN6O2 (M+H+) 525.21, found: 525.0.
Examples 3
The following compounds were prepared following analogous procedures as described in the above examples for Examples 1 and 2, using the appropriate starting materials.
Figure imgf000120_0001
Ex. Compound Structure Physical Data
(1H NMR and MS)
]H NMR (400 MHz, MeOD) δ 8.47 (s, IH), 7.96 (d, / = 16.5 Hz, IH), 7.92 - 7.81 (m, IH), 7.51 - 7.35 (m, IH), 7.19 (dd, / = 8.9, 19.4 Hz, 2H), 6.81 - 6.66 (m, IH), 6.63 (s, IH), 5.69 - 5.49 (m, IH), 4.76 - 4.50 (m, IH), 4.22 - 4.02 (m, IH), 4.02 - 3.86 (m, IH), 3.87 - 3.75 (m,
3-3 IH), 3.72 - 3.56 (m, IH), 3.55 - 3.34 (m,
IH), 3.25 (s, IH), 3.04 (s, IH), 2.90 (s, IH), 2.76 (s, 2H), 2.55 (d, / = 3.9 Hz, 3H), 2.46 - 2.30 (m, IH), 2.29 - 2.14 (m,
F IH), 2.02 (s, 4H), 1.48 - 1.32 (m, IH), 1.19 (s, IH). MS calculated for C28H32CIF2N6O2 (M+H+) 557.22, found: 557.0.
]H NMR (400 MHz, MeOD) δ 8.62 - 8.45 (m, IH), 8.10 - 7.97 (m, IH), 8.00 - 7.87 (m, IH), 7.60 - 7.39 (m, IH), 7.43 - 7.10 (m, 2H), 7.03 - 6.59 (m, 2H), 5.81 - 5.59 (m, IH), 4.83 - 4.59 (m, IH), 4.37 - 3.61 (m, 5H), 3.65 - 3.40 (m, 2H), 3.35
3-4
(s, IH), 3.26 (s, 2H), 3.26 (s, 3H), 2.99 - 2.73 (m, 2H), 2.65 (s, 2H), 2.30 - 1.82 (m, 4H), 1.64 - 1.42 (m, IH), 1.30 (s, IH), 0.96 - 0.84 (m, IH). MS calculated for C29H36CIN6O3 (M+H+) 551.25, found: 551.1.
]H NMR (400 MHz, MeOD) δ 8.62 - 8.45 (m, IH), 8.10 - 7.97 (m, IH), 8.00 - 7.87 (m, IH), 7.60 - 7.39 (m, IH), 7.43 - 7.10 (m, 2H), 7.03 - 6.59 (m, 2H), 5.81 - 5.59 (m, IH), 4.83 - 4.59 (m, IH), 4.37 - 3.61 (m, 5H), 3.65 - 3.40 (m, 2H), 3.35
3-5 (s, IH), 3.26 (s, 2H), 3.26 (s, 3H), 2.99 - 2.73 (m, 2H), 2.65 (s, 2H), 2.30 - 1.82 (m, 4H), 1.64 - 1.42 (m, IH), 1.30 (s,
Figure imgf000121_0001
IH), 0.96 - 0.84 (m, IH). MS calculated for C29H36CIN6O3 (M+H+) 551.25, found: 551.1.
Figure imgf000122_0001
Ex. Compound Structure Physical Data
(1H NMR and MS)
]H NMR (400 MHz, MeOD) δ 8.67 - 8.44 (m, IH), 8.12 - 7.72 (m, 2H), 7.62 - 7.43 (m, IH), 7.42 - 7.05 (m, 2H), 6.97 - 6.61 (m, 2H), 5.42 - 5.04 (m, 2H), 4.75 - 4.46 (m, 2H), 4.38 - 3.89 (m, 2H), 3.87 --10 3.41 (m, 3H), 3.26 - 3.09 (m, 2H), 2.77
(s, 2H), 2.65 (s, IH), 2.41 - 2.03 (m, 3H), 1.99 (s, 3H), 1.65 - 1.39 (m, 2H), 1.30 (s, 4H), 0.98 - 0.84 (m, IH); MS calculated for C29H36F 6O2 (M+H+) 519.28, found: 519.2.
]H NMR (400 MHz, MeOD) δ 9.72 (s, IH), 9.28 (s, IH), 8.21 (s, IH), 7.58 (s, IH), 7.49 - 7.32 (m, IH), 7.29 - 7.10 (m, 2H), 6.84 - 6.66 (m, IH), 6.61 (s, IH), J! γ— ΝΗ 5.71 - 5.41 (m, IH), 5.24 - 4.88 (m, IH),
4.74 - 4.42 (m, IH), 4.27 - 4.03 (m, IH),-11
4.01 - 3.71 (m, IH), 3.55 (s, IH), 3.27 (s, IH), 3.09 (s, IH), 2.95 - 2.78 (m, IH), 2.67 (s, 3H), 1.93 (d, / = 104.5 Hz, 6H), 1.52 - 1.25 (m, IH). MS calculated for C26H30CIFN7O2 (M+H+) 526.21, found: 526.1.
MS calculated for C27H32CIN6O2 (M+H+) 507.22, found: 507.1. -12
]H NMR (400 MHz, MeOD) δ 8.46 (s, IH), 7.98 - 7.87 (m, IH), 7.88 - 7.75 (m, IH), 7.49 - 7.33 (m, IH), 7.20 (s, 2H), 6.70 - 6.41 (m, 2H), 5.69 - 5.46 (m, IH), 4.76 - 4.46 (m, IH), 4.38 - 4.26 (m, IH), 4.22 - 4.01 (m, IH), 3.98 - 3.76 (m, 2H),-13 3.76 - 3.68 (m, IH), 3.67 - 3.57 (m, IH),
3.55 - 3.42 (m, IH), 3.36 (m, IH), 3.14 - 3.08 (m, IH), 3.09 - 3.00 (m, IH), 2.79 (s, IH), 2.54 (s, 3H), 2.13 - 1.78 (m, 4H), 1.49 - 1.29 (m, IH), 1.19 (s, IH). MS calculated for C27H32CIN6O3 (M+H+) 523.21, found: 523.0. Ex. Compound Structure Physical Data
(1H NMR and MS)
]H NMR (400 MHz, MeOD) δ 8.46 (s, IH), 7.94 (s, IH), 7.84 (s, IH), 7.45 - 7.31 (m, IH), 7.20 (s, 2H), 6.78 - 6.62 (m, IH), 6.64 - 6.48 (m, IH), 5.65 - 5.47 (m, IH), 4.66 - 4.50 (m, IH), 4.19 - 3.99 (m, 3H), 4.00 - 3.88 (m, IH), 3.86 - 3.74-14
(m, IH), 3.74 - 3.55 (m, 2H), 3.38 (s, 3H), 3.13 (s, 1H),2.88 - 2.61 (m, 2H), 2.54 (s, 3H), 2.17 - 1.74 (m, 4H), 1.49 - 1.31 (m, IH), 1.19 (s, IH). MS calculated for C28H34CIN6O3 (M+H+) 537.23, found: 537.1.
]H NMR (400 MHz, MeOD) δ 8.52 - 8.36 (m, IH), 7.98 - 7.87 (m, IH), 7.88 - 7.79 (m, IH), 7.47 - 7.36 (m, IH), 7.30 - 7.09 (m, 2H), 6.70 - 6.58 (m, IH), 6.57 - 6.45 (m, IH), 5.70 - 5.47 (m, IH), 4.68 - 4.48 (m, IH), 4.22 - 4.01 (m, IH), 4.01 --15
3.70 (m, 2H), 3.61 (s, 2H), 3.37 (s, 2H), 3.18 - 3.00 (m, IH), 2.97 - 2.63 (m, 2H), 2.54 (s, 3H), 2.16 - 1.74 (m, 4H), 1.48 - 1.31 (m, IH), 1.19 (s, IH). MS calculated for C27H30CIF2N6O2 (M+H+) 543.20, found: 543.0.
]H NMR (400 MHz, MeOD) δ 8.46 (s, IH), 7.92 (s, IH), 7.84 (s, IH), 7.39 (m, IH), 7.19 (m, 2H), 6.02 (s, IH), 5.57 (s, IH), 5.39 (s, IH), 4.60 (m, IH), 4.11 (d, / = 12.9 Hz, IH), 3.85 (m, 2H), 3.52 (dd,-16 / = 14.6, 40.9 Hz, 2H), 3.29 (d, / = 16.8
Hz, IH), 3.08 (m, IH), 2.83 (m, 2H), 2.52 (m, 6H), 2.37 (s, IH), 2.23 (s, IH), 1.99 (m, 3H), 1.46 (m, IH); MS calculated for C27H32CIN6O2 (M+H+) 507.22, found: 507.2.
]H NMR (400 MHz, MeOD) δ 8.47 (s, IH), 7.94 (s, IH), 7.85 (s, IH), 7.41 (t, / = 8.5 Hz, IH), 7.19 (m, 2H), 5.83 (d, / = 9.6 Hz, IH), 5.56 (dt, 7 = 10.4, 14.1 Hz, IH), 4.58 (m, IH), 4.15 (d, / = 12.9 Hz, IH), 3.85 (m, 2H), 3.51 (dd, / = 18.0,-17
28.7 Hz, 2H), 3.27 (s, IH), 3.02 (dd, / = 17.8, 33.2 Hz, 2H), 2.63 (m, 2H), 2.55 (s, 3H), 2.45 (d, / = 17.7 Hz, IH), 2.34 (d, J = 6.0 Hz, 3H), 2.06 (s, 3H), 1.92 (m,
\ 2H); MS calculated for C27H32CIN6O2
(M+H+) 507.22, found: 507.2. Ex. Compound Structure Physical Data
(1H NMR and MS)
]H NMR (400 MHz, MeOD) δ 8.45 (s, IH), 7.92 (d, / = 12.9 Hz, IH), 7.83 (s, IH), 7.38 (s, IH), 7.13 (d, / = 13.3 Hz, 2H), 6.81 (dt, / = 5.8, 11.8 Hz, IH), 6.41 (m, IH), 5.56 (d, 7 = 31.1 Hz, IH), 4.57 (m, 0.5H), 4.19 (d, / = 12.0 Hz, IH), 3.98 (m, 0.5 H), 3.82 (dd, / = 7.2, 15.4
3-18 Hz, 0.5H), 3.60 (dt, 7 = 7.7, 14.1 Hz,
0.5H), 3.32 (m, IH), 2.71 (m, IH), 2.54 (d, / = 3.7 Hz, 2H), 2.20 (s, 2H), 1.91 (m, 7H), 1.39 (m, IH), 1.19 (d, / = 3.4 Hz,
— N 3H), 0.95 (d, J = 24.0 Hz, 3H), 0.82 (d, J
\
= 6.7 Hz, IH); MS calculated for C28H36C1N602 (M+H+) 523.25, found: 523.1
Example 4
(5')-N-(l-(l-acryloylpiperidin-3-yl)-5-methyl-lH-benzordlimidazol-2-yl)-3- (trifluoromethyl) benzamide
Figure imgf000125_0001
1-16 Example 4 To a stirred solution of 1-16 (0.150 g, 0.37 mmol) in CH2C12 (20mL) at 0°C was added acryloyl chloride in CH2C12 (0.050 g, 0.55 mmol) and the mixture was stirred for 30 min (reaction completion monitored by TLC). The mixture was diluted with water and extracted with CH2C12 (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2S04 and concentrated under reduced pressure. The crude material was purified by column chromatography (50% EtOAc/Hexanes) to afford the title compound (Example 4). ]H-NMR (DMSO-d6, 400 MHz): d 12.84 (s, IH), 8.46 (d, J = 8Hz, 2H), 7.89 (d, / = 8 Hz, IH), 7.75-7.63 (m, 2H), 7.39(s, IH), 7.09 (d, / = 8.4 Hz, IH), 6.95-6.79 (m, IH), 6.19-6.13 (m, IH), 5.75-5.59 (m, IH), 4.79-4.56 (m, 2H), 4.23- 4.06 (m, 2H), 3.70-3.65 (m, IH), 3.27-3.21 (m, IH), 2.85-2.66 (m, 2H), 2.39(s, 3H), 2.00- 1.91 (m, 2H), 1.64- 1.5 (m, IH); MS calculated for C24H24F3N4O2 (M+H+) 457.18, found 456.9.
Example 5
(/?,£,)-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)- lH- benzordlimidazol-2-yl)-2-methylisonicotinamide
Figure imgf000126_0001
A mixture of (E)-4-(dimethylamino)but-2-enoic acid hydrochloride (58 mg, 0.35 mmol) and l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (67 mg, 0.35 mmol) in DMF (2 mL) was treated with hydroxybenzotriazole (54 mg, 0.35 mmol) and stirred at room temperature for 1 h. The resulting mixture was added to a solution of 1-27 (100 mg, 0.22 mmol) in DMF (2 mL). Triethylamine (199 mg, 1.97 mmol) was then added and the mixture was stirred for 5 days. Water (2 mL) was added and the mixture was concentrated under reduced pressure. The residue was diluted with IN NaOH (20 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (50 mL) and brine (2 x 50 mL), dried over Na2SC>4, and concentrated under reduced pressure. The crude was purified by column chromatography (9: 1 :0.175N CH2Cl2/MeOH/NH3 in CH2C12, 0% to 100%) to afford the title compound (Example 5). ]H NMR (400 MHz, DMSO-d6) δ 8.59 (d, J = 4.8 Hz, IH), 7.89 (s, IH), 7.79 (d, J = 4.8 Hz, IH), 7.60 (d, / = 7.5 Hz, IH), 7.30-7.22 (m, 2H), 6.71-6.65 (m, IH), 6.57-6.54 (m, IH), 5.54 (br. s, IH), 4.54 (br. s, IH), 4.20 (br s, IH), 3.95 (br s, IH), 3.48 (br s, IH), 2.98 (br s, 2H), 2.72 (d, / = 12.0 Hz, IH), 2.58 (s, 3H), 2.14 (br s, 6H), 2.05 (d, / = 6.7 Hz, 3H), 1.88 (br s, IH), 1.46 (d, 7=11.3 Hz, IH); MS calculated for C26H32CIN6O2 (M+H+) 495.22, found 495.10. Melting point (114.6 °C).
(/?,E)-N-(7-chloro- l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide (1.0 g) was dissolved in acetone (30 mL) by heating to 55°C to form a solution. Methanesulfonic acid (325 μί) was added to acetone (50 mL), and the methanesulfonic acid/acetone (22.2 mL) was added to the solution at 0.05ml/min. Following precipitation, the resulting suspension was cooled to room temperature at 0.5 °C/min, and crystals were collected by filtration, and dried for 4 hours at 40°C under vacuum. The collected crystals (300 mg) were suspended in acetone/H20 (6 mL; v/v=95/5) by heating to 50°C. The suspension was kept slurrying for 16 hours, and cooled to room temperature at 0.5 °C/min. The crystal was collected by filtration and dried for 4 hours at 40°C under vacuum.
The structure of (7?,£')-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)- lH-benzo[d]imidazol-2-yl)-2-methylisonicotinamide mesylate was confirmed by Differential Scanning Calorimetry, X-Ray Powder Diffraction, and Elemental Analyses. Melting point (170.1 °C). Theoretical calculated: C (54.8); H (5.9); N (14.2); 0 (13.5); %S (5.4); and C1 (6.0); C:N ratio: 3.86. Found: C (52.0); H (5.8); N (13.3); C1 (5.9); C:N ratio: 3.91. Stoichiometry: 1.01.
Example 6
(R,E)-N-(7-chloro-l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo rdl imidazol-2- yl) -2 , 6-dimethylisonicotinamide
Figure imgf000127_0001
To a mixture of (E)-4-(dimethylamino)but-2-enoic acid (370 mg, 2.9 mmol) and 1- ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (730 mg, 3.8 mmol) in DMF (15 mL) was added hydroxybenzotriazole (516 mg, 3.8 mmol), and stirred at room temperature 10 min. The resulting mixture was then added to a suspension of 1-30 in DMF (10 mL), followed by the addition of NEt3 (1.86 mL, 13.4 mmol). The mixture was stirred at room temperature overnight, quenched with H20 (2 mL) and concentrated under reduced pressure. The crude was partitioned between EtOAc and 1.0 N NaOH, and extracted with EtOAc. The combined organic layers were dried over Na2S04 and concentrated in vacuo. The crude material was purified by column chromatography (0- 10% MeOH/CH2Cl2) to afford the title compound (Example 6). ]H NMR (400 MHz,
CD2C12) δ 12.69 (s, 1H), 8.75-8.48 (m, 1H), 8.06-7.70 (m, 2H), 7.49-7.06 (m, 2H), 6.88 (dt, J = 4.4, 15.1 Hz, 1H), 6.58 (d, J = 20.2 Hz, 1H), 5.64 (s, 1H), 4.94-4.26 (m, 2H), 4.23-3.96 (m, 1H), 3.97-3.29 (m, 2H), 3.21 (d, J = 5.9 Hz, 1H), 3.03 (dd, J = 18.8, 24.7 Hz, 1H), 2.79 (d, 7 = 12.1 Hz, 1H), 2.64 (s, 7 = 9.8 Hz, 6H), 2.36 (s, 3H), 2.28-1.83 (m, 6H), 1.53 (s, 1H). MS calculated for C28H34CIN6O2 (M+H+) 509.24, found: 509.2.
Example 7
(R,E)-N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-lH- benzordlimidazol-2-yl)-2-methylisonicotinamide
Figure imgf000128_0001
A mixture of 1-32 (313 mg, 0.78 mmol), (E)-4-(dimethylamino)but-2-enoic acid (139 mg, 1.02 mmol) and 2-(7-aza-lH- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (453 mg, 1.18 mmol) in CH2CI2 (7 mL) was treated with NEt3 (0.66 mL, 4.70 mmol) and stirred at room temperature for 10 min. The mixture was then partitioned between half-saturated aqueous Na2CC>3 solution and CH2CI2 and the aqueous layer was extracted with CH2CI2 (2x). The combined organic phase was dried over Na2S04 and concentrated under reduced pressure. The crude was purified by column chromatography (9: 1:0.175N CH2Cl2/MeOH/NH3 in CH2C12, 0% to 60%) to afford the title compound (Example 7). ]H-NMR (400 MHz, DMSO) δ 8.61 (d, 7 = 5.1 Hz, 1H), 7.92 (s, 1H), 7.81 (d, 7 = 5.0 Hz, 1H), 7.46 (d, 7 = 7.2 Hz, 1H), 7.14 (t, 7 = 7.7, 1H), 7.04 (d, 7 = 7.3 Hz, 1H), 6.67 (m, 2H), 4.92 (m, 1H), 4.35 (dd, 7 = 10.7, 12.8 Hz, 1H), 4.16 (m, 1H), 3.95 (m, 1H), 3.60 (t, 7 = 5.8 Hz, 1H), 3.07 (t, 7 = 5.2 Hz, 1H), 2.84 (m, 1H), 2.75 (m, 1H), 2.70 (s, 3H), 2.57 (s, 3H), 2.10 (s, 6H), 1.91 (m, 4H), 1.34 (m, 1H). MS calculated for C27H35N6O2 (M+H+) 475.27, found 475.2.
Example 8
(R,E)-N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-lH- benzordlimidazol-2-yl)-2-(trifluoromethyl)isonicotinamide
Figure imgf000129_0001
The title compound (Example 8) was prepared from 1-45 following procedures analogous to Example 7. ]H-NMR (400 MHz, MeOD) δ 8.88 (d, / = 4.9 Hz, IH), 8.56 (s, IH), 8.34 (d, J = 4.9 Hz, IH), 7.41 (d, J = 8.0 Hz, IH), 7.20 (t, J = 7.8 Hz, IH), 7.12 (m, IH), 6.86 (t, J = 13.8 Hz, IH), 6.78 (m, IH), 5.12 (m, IH), 4.54 (dd, J = 10.8, 13.0 Hz, IH), 4.27 (m, IH), 4.02 (m, IH), 3.65 (m, 3H), 2.92 (m, IH), 2.78 (s, 3H), 2.67 (s, 6H), 2.22 (m, IH), 2.08 (m, 3H), 1.49 (m, IH). MS calculated for C27H32F3N6O2 (M+H+) 529.25, found 529.2.
Example 9
(/?)-N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-methoxy- lH-benzordlimidazol-2- yl)pyridazine-4-carboxamide
Figure imgf000129_0002
1-29 Example 9
Acrylic acid (21.6 mg, 0.30 mmol) and 2-(7-aza-lH- benzotriazole- l-yl)- l , 1,3,3- tetramethyluronium hexafluorophosphate (114 mg, 0.30 mmol) were dissolved in DMF (2 mL). Ν,Ν-diisopropylethylamine (114 mg, 0.885 mmol) was added and the mixture was stirred for 10 min. A solution of 1-29 (88 mg, 0.186 mmol) in DMF (1 mL) was then added and the mixture stirred for lh (reaction completion monitored by LC/MS). The mixture was concentrated under reduced pressure and the residue was diluted with showed that the reaction completed. Reaction mixture was stripped off solvents. The residue was dissolved in CH2CI2 (2 mL), treated with K2CO3 (257 mg, 1.86 mmol) for 5 min and purified by column chromatography (MeOH in CH2CI2, 0% to 10%) to afford a residue that was diluted with CH2C12 (150 mL) and washed with 0.2Ν HC1 (3 x 20mL), brine (20 mL), saturated aqueous NaHCC>3 aq, and water. The organic layer was then dried with Na2S04, and concentrated under reduced pressure to afford the title compound (Example 9) as a light yellow solid. ]H-NMR (400MHz, CD3CN): d 12.33 (br s, IH), 9.71-9.67 (m, IH), 9.27-9.24 (m, IH), 8.09-8.05 (m, IH), 7.38 (d, J=10.0 Hz, 0.4H), 7.36 (d, J = 10.0 Hz, 0.6H), 6.98 (d, J = 8.8 Hz, 0.4H), 6.97 (d, J = 8.8 Hz, 0.6H), 6.68 (dd, J = 10.4, 16.4 Hz, 0.6H), 6.66 (dd, J = 10.4, 16.4 Hz, 0.4H), 6.18-6.12 (m, IH), 5.62(dd, J = 10.4, 2.0 Hz, 0.6H), 5.49 (dd, J = 10.4, 2.0 Hz, 0.6H), 5.64-5.57 (m, IH), 4.65 (dd, J = 14.8, 10.8 Hz,0.4H), 4.45 (dd, J = 14.8, 10.8 Hz, 0.6H), 4.16 (dd, J = 14.8, 10.4 Hz, 0.4H), 4.00 (dd, J = 14.8, 10.4 Hz, 0.6H), 3.96-3.69 (m, IH), 3.84 (s, 1.2H), 3.83 (s, 1.8H), 3.62-3.56 (m, 0.6H), 3.36-3.30 (m, 0.4H), 2.70-2.54 (m, IH), 2.08-1.88 (m, 4H), 1.43-1.31 (m, IH). MS calculated for C22H24CIN6O3 (M+H+) 455.15, found 455.1.
Example 10
N-(7-methyl-l-(l-(vinylsulfonyl)azepan-3-yl)-lH-benzor(ilimidazol-2-yl)-3-
Figure imgf000130_0001
A solution of I-37a (30 mg, 0.066 mmol) in CH2C12 (0.66 mL) was treated with Ν,Ν- diisopropylethylamine (0.046 mL, 0.265 mmol), followed by 2-chloroethanesulfonyl chloride (14 mg, 0.079 mmol). The reaction mixture was stirred at room temperature until completed as determined by LC/MS analysis. The crude reaction mixture was added directly to an ISCO dry loader and purified by column chromatography (0-30%
[9: 1:0.175Ν CHzCyMeOH/N^J/CHzCk) to afford the title compound (Example 10) as a pale beige solid. ]H-NMR (400 MHz, CDC13) δ 12.55 (s, IH), 8.58 (s, IH), 8.38 (m, IH), 7.70 (dd, 7 = 7.5, 23.0, IH), 7.57 (m, IH), 7.15 (m, IH), 7.11 (m, IH), 6.98 (m, IH), 6.24 (ddd, / = 9.9, 60.0, 120.0, IH), 5.10 (s, IH), 4.49 (m, IH), 3.74 (d, / = 9.9, IH), 3.20 (m, IH), 3.06 (m, IH), 2.81 (m, IH), 2.79 (s, 3H), 1.64 (m, IH). 19F-NMR (376 MHz, CDCI3) δ -62.53; MS calculated for C24H26F3N4O3S (M+H+) 507.16, found 507.1.
Example 11 N-(l-(l-acryloylazepan-3-yl)-7-(pyrrolidin-l-ylmethyl)-lH-benzor(ilimidazol-2-yl)-3- enzamide
Figure imgf000131_0001
1-37 Example 11
The title compound as a pale beige solid was prepared following procedures analogous to Example 10, substituting acryloyl chloride for 2-chloroethanesulfonyl. ]H- NMR (400 MHz, CDC13) δ 12.61 (s, IH), 8.67 (s, IH), 8.43 (m, IH), 7.74 (d, / = 7.7 Hz, IH), 7.59 (t, 7 = 7.7 Hz, IH), 7.28 (s, IH), 7.21 (d, / = 19.2 Hz, IH), 7.15 (s, 2H), 6.65 (m, IH), 6.36 (m, IH), 5.74 (m, IH), 5.38 (m, IH), 4.92 (m, IH), 4.46 (m, IH), 4.25 (m, IH), 3.97 (s, IH), 3.58 (m, IH), 2.85 (m, IH), 2.41 (m, 3H), 2.21 (m, 2H), 2.02 (m, 4H), 1.69 (m, 4H). 19F-NMR (376 MHz, CDC13) δ -62.49; MS calculated for C29H33F3N5O2 (M+H+) 540.25, found 540.3.
Example 12
tert-butyl 4-acryloyl-6-(7-chloro-2-(2-methylisonicotinamido)-lH-benzordlimidazol-l- - 1 ,4-diazepane- 1 -carboxylate
Figure imgf000131_0002
The title compound was prepared following procedures analogous to Intermediate 27, step A, by substituting acrylic acid for 2-methylisonicotinic acid. ]H NMR (400 MHz, MeOD) δ 8.58 (d, / = 5.1 Hz, IH), 8.03 - 7.97 (m, IH), 7.97 - 7.90 (m, IH), 7.59 - 7.47 (m, IH), 7.42 - 7.32 (m, IH), 7.32 - 7.23 (m, IH), 6.99 - 6.72 (m, IH), 6.41 - 6.19 (m, IH), 5.95 - 5.82 (m, IH), 5.82 - 5.70 (m, IH), 4.83 - 4.72 (m, 2H), 4.58 - 4.31 (m, 4H), 4.25 - 4.06 (m, 2H), 2.65 (s, 3H), 1.48 - 1.39 (m, 9H); MS calculated for C27H32CIN6O4 (M+H+) 539.21, found 539.2.
Example 13 N-(l-(l-acryloyl-l,4-diazepan-6-yl)-7-chloro-lH-benzordlimidazol-2-yl)-2- methylisonicotinamide
Figure imgf000132_0001
A solution of Example 12 (150 mg, 0.278 mmol) in CH2CI2 (2 mL) was treated with a 1:1 solution of 2,2,2-trifluoroacetic acid in CH2CI2 (4 mL) and stirred for 90 min. The volatiles were removed under reduced pressure, the residue partitioned between CH2CI2 and saturated aqueous Na2CC>3, the layers separated, and the aqueous phase extracted with CH2CI2 (2x). The combined organics were washed with brine, dried over Na2S04, and concentrated under reduced pressure to afford the title compound (Example 13). ]H NMR (400 MHz, MeOD) δ 8.58 (d, J = 5.2 Hz, 1H), 7.96 (d, J = 8.8 Hz, 1H), 7.88 (s, 1H), 7.60 - 7.47 (m, 1H), 7.31 (s, 1H), 7.30-7.21 (m, 1H), 6.83 (dd, J = 10.6, 16.8 Hz, 1H), 6.31 (d, J = 16.7 Hz, 1H), 6.17-5.85 (m, 1H), 5.78 (dd, / = 10.5, 34.2 Hz, 1H), 4.79- 4.39 (m, 1H), 4.37-4.12 (m, 1H), 4.12-3.56 (m, 1H), 3.55-3.34 (m, 1H), 3.25-2.97 (m, 3H), 2.96-2.82 (m, 1H), 2.65 (s, 3H); MS calculated for C22H24C1N602 (M+H+) 439.16, found 439.2.
Example 14
N-(l-(l-acetyl-4-acryloyl-l,4-diazepan-6-yl)-7-chloro-lH-benzordlimidazol-2-yl)-2- ide
Figure imgf000132_0002
Example 14 A solution of Example 13 (30 mg, 0.068 mmol), N,N-dimethylaminopyridine (17 mg, 0.137 mmol), and N,N-diisopropylethylamine (0.024 mL, 0.137 mmol) in CH2C12 (0.75 mL) was treated at room temperature with acetic anhydride (0.01 mL, 0.103 mmol) and stirred for 5 min. The reaction was then added directly to a RediSep dry loader cartridge and purified by column chromatography (9: 1:0.175 M CH2C12 /MeOH/NH3 in CH2C12, 0- 50%) to afford the title compound (Example 14). ]H NMR (400 MHz, MeOD) δ 8.53 - 8.41 (m, IH), 7.96 - 7.88 (m, IH), 7.88 - 7.77 (m, IH), 7.50 - 7.36 (m, IH), 7.31 - 7.13 (m, 2H), 6.91 - 6.60 (m, IH), 6.30 - 6.08 (m, IH), 5.87 - 5.72 (m, IH), 5.72 - 5.65 (m, IH), 4.43 - 4.24 (m, 4H), 4.24 - 3.94 (m, 2H), 3.64 - 3.48 (m, 2H), 2.55 (s, 3H), 2.12 - 1.99 (m, 3H); MS calculated for C24H26C1N603 (M+H+) 481.17, found 481.2.
Example 15
(R)-N-( 1 -( 1 -acryloylazepan-3 -yl)-7-chloro-6-(2-(pyrrolidin- 1 - vDethoxy)- 1 H- benzo rdl imidazol-2- yl) -2 , 6-dimethylisonicotinamide
Figure imgf000133_0001
l_ou Example 15
The title compound was prepared following procedures analogous to Example 9. ]H- NMR (400 MHz, CD2C12): d 7.64-7.54 (m, 2H), 7.16-7.09 (m, IH), 6.90-6.83 (m, IH), 6.64-6.54 (m, IH), 6.34-6.21 (m, IH), 5.65-5.46 (m, 2H), 4.81-4.69 (m, IH), 4.62-4.45 (m, IH), 4.35-4.19 (m, IH), 4.14-4.03 (b m, 2H), 3.92-3.84 (m, IH), 3.80-3.68 (m, IH), 3.59-3.51 (m, IH), 3.46-3.23 (m, IH), 2.92-2.80 (b m, 2H), 2.75-2.63 (m, IH), 2.55 (s, 3H), 2.47 (s, 4H), 2.18-1.81 (m, 4H), 1.70-1.35 (m, 6H). MS calculated for
C30H38CIN6O3 (M+H+) 565.26, found 565.3.
Example 16
(R,E)-N-(7-chloro-l-(l-(4-(dicvclopropylamino)but-2-enoyl)azepan-3-yl)-lH- -2-yl)-2-methylisonicotinamide
Figure imgf000133_0002
A mixture of 1-27 (free base, 340 mg, 0.89 mmol) and diisopropylethylamine (0.2 mL, 1.15 mmol) in THF (15 mL) was treated at 0 °C with (E)-4-chlorobut-2-enoyl chloride (136 mg, 0.98 mmol) and stirred at 0 °C for 10 min, when the reaction was deemed complete as determined by LC/MS (MS calculated for C24H26CI2N5O2 (M+H+) 486.14, found 486.1). One seventh of the reaction mixture (2.2 mL) was diluted with DMA (2 mL), treated with diisopropylethylamine (0.16 mL, 0.91 mmol), followed by dicyclopropylamine hydrochloride (101.4 mg, 0.76 mmol) and subjected to microwave irradiation (100 °C, 45 min). More diisopropylethylamine (0.16 mL, 0.91 mmol) and dicyclopropylamine hydrochloride (101.4 mg, 0.76 mmol) were added and the mixture was further subjected again to microwave irradiation (100 °C, 45 min). The mixture was then passed through a HPLC-filter and purified by HPLC to afford the title compound. ]H NMR (400 MHz, CD2C12) δ 8.67-8.38 (m, IH), 8.06-7.62 (m, 2H), 7.46-7.06 (m, 3H), 7.01-6.78 (m, IH), 6.62-6.22 (m, IH), 5.73-5.41 (m, IH), 4.81-4.63 (m, 0.5H), 4.54-4.39 (m, 0.5H), 4.39-4.21 (m, 0.6H), 4.19-4.00 (m, 0.5H), 3.98-3.88 (m, 0.4H), 3.86-3.69 (m, 0.5H), 3.68-3.50 (m, 0.6H), 3.49-3.35 (m, IH), 3.32-3.27 (m, 0.4H), 3.25-3.20 (m, IH), 2.84-2.63 (m, IH), 2.53 (s, 3H), 2.17-1.80 (m, 4H), 1.63-1.29 (m, 4H), 0.41-0.14 (m, 8H). MS calculated for C30H36CIN6O2 (M+H+) 547.25, found: 547.20.
Examples 17
The following compounds were prepared following analogous procedures as described in the above examples for Examples 4-16, using the appropriate starting materials.
Figure imgf000134_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
0.5H), 4.25-4.04 (m, IH), 3.96-3.94 (m, IH), 3.79 (d, J = 6.8 Hz, 0.8H), 3.74 (d, J = 6.8 Hz, 1.2H), 3.55-3.48 (m, IH), 3.14 (s, 1.5H), 3.01 (s, 1.5H), 2.78 & 2.75 (s & s, 6H), 2.82-2.72 (m, IH), 2.50-1.93 (m, 4H), 1.58-1.25(m, IH); MS calc. for C25H31CIN7O3 (M+H+) 512.21, found 512.2.
]H-NMR (400 MHz, CDC13) δ 12.59 (m, IH), 8.08 (d, / = 7.6 Hz, IH), 7.42 (m, IH), 7.21 (m, 2H), 7.13 (t, / = 9.2 Hz, 3H), 6.97 (t, / = 20.5 Hz, 2H), 6.46 (d, / = 15.3 Hz, IH), 5.00 (m, IH), 4.42 (m, 2H), 3.927-3
(m, IH), 3.45 (m, IH), 3.00 (m, 3H), 2.76 (s, 3H), 2.29 (s, 6H), 2.02 (m, 3H), 1.35 (m, IH). 19F-NMR (376 MHz, CDC13) δ -
\ 111.22. MS calc. for C27H33FN5O2 (M+H+) 478.25, found 478.3.
]H-NMR (400 MHz, DMSO) δ 8.62 (d, / = 5.0 Hz, IH), 7.88 (s, IH), 7.84 (s, IH), 7.47 (s, IH), 7.14 (d, / = 7.8 Hz, IH), 7.06 (s, IH), 6.82 (m, IH), 6.62 (m, IH), 4.79 (m, IH), 4.63 (m, IH), 4.45 (m, IH), 4.137-4 (m, IH), 3.38 (d, J = 7.1 Hz, 2H), 3.15 (m,
3H), 2.67 (s, 4H), 2.58 (s, 3H), 2.33 (s, 4H), 2.00 (m, 2H), 1.60 (m, IH); MS calculated for C26H33N6O2 (M+H+) 461.26, found 461.2.
Figure imgf000135_0001
]H-NMR (400 MHz, MeOD) δ 8.36 (s, IH), 7.74 (d, J = 14.3 Hz, IH), 7.38 (d, J = 8.2 Hz, IH), 7.18 (t, J = 7.8 Hz, IH), 7.08 (d, J = 7.6 Hz, IH), 6.94 (d, J = 15.2 Hz, IH), 6.79 (m, IH), 5.19 (d, J = 94.0 Hz,7-5
IH), 4.61 (m, IH), 4.28 (d, J = 9.7 Hz, IH), 3.97 (s, IH), 3.84 (s, 2H), 3.71 (s, 2H), 2.82 (s, 6H), 2.73 (d, J = 14.4 Hz,
\ 3H), 2.11 (s, 4H), 1.46 (s, IH). MS calc.for C24H31N6O3 (M+H+) 451.24, found 451.1.
CF3 ]H-NMR (400 MHz, CDCI3) δ 12.45 (m,
IH), 8.63 (m, IH), 8.34 (m, IH), 7.70 (m, IH), 7.53 (m, IH), 7.10 (m, IH), 6.96 (m, 2H), 6.80 (m, 2H), 5.18 (m, IH), 4.80 (m,7-6 IH), 4.45 (m, IH), 4.04 (m, 4H), 3.54 (m,
3H), 3.12 (m, IH), 2.74 (s, 3H), 2.59 (s, 6H). 19F- NMR (376 MHz, CDCI3) δ - 62.41. MS calculated for C27H31F3N5O3 (M+H+) 530.23, found 530.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
CF3 ]H-NMR (400 MHz, MeOD) δ 8.81 (s,
IH), 8.48 (m, IH), 7.81 (s, IH), 7.68 (s, IH), 7.39 (s, IH), 7.18 (s, IH), 7.10 (s, IH), 6.83 (s, IH), 5.33 (m, 2H), 5.09 (m,7-7 2H), 4.21 (s, 3H), 3.88 (m, 2H), 3.52 (s,
3H), 2.79 (s, 3H), 2.44 (s, 6H). 19F- NMR (376 MHz, MeOD) δ -63.86. MS calculated for C27H31F3N503 (M+H+)
\ 530.23, found 530.2.
]H-NMR (400 MHz, DMSO-d6): d 13.07 (br s, IH), 8.75 (s, IH), 8.48 (br s, 2H),
CF3 8.39 (d, / = 5.4 Hz, IH), 7.92 (d, J = 7.2
Hz, IH), 7.90-7.80 (m, IH), 7.78-7.74 (m, IH), 6.93-6.78 (m, IH), 6.18-6.14 (m, IH), 5.76-5.61 (m, IH), 4.78 (br s, IH), 4.65-7-8
4.57 (m, IH), 4.34-4.20 (m, IH), 4.07-3.98 (m, 0.5H), 3.68-3.59 (m, 0.5H), 3.28-3.21 (m, 0.5H), 2.87-2.78 (m, 0.5H), 2.74-2.62 (m, IH), 2.07-1.90 (m, 2H), 1.68-1.58 (m, IH); MS calculated for C22H21F3N5O2 (M+H+) 444.16, found 444.2.
]H-NMR (400 MHz, DMSO-d6): d 13.11 (br s, IH), 9.08 (s, IH), 8.46 (d, / = 9.2 Hz,
CF3 2H), 8.39 (d, / = 5.2 Hz, IH), 7.92 (d, J =
7.6 Hz, IH), 7.77-7.73 (m, IH), 7.54 (d, J = 5.6 Hz, IH), 6.95-6.79 (m, IH), 6.20-7-9 6.14 (m, IH), 5.75-5.60 (m, IH), 4.83 (s,
IH), 4.67-4.55 (m, IH), 4.35-4.00 (m, 2H), 3.63-3.57 (m, IH), 2.87-2.84 (m, IH), 2.07-1.91 (m, 2H), 1.64-1.61 (m, IH); MS calculated for C22H21F3N5O2 (M+H+) 444.16, found 444.3.
]H-NMR (DMSO-d6, 400 MHz): d 12.80 (br s, IH), 8.52 (s, IH), 8.42 (d, / = 8 Hz,
CF3 IH), 7.85-7.70 (m, 2H), 7.46 (d, / = 8 Hz,
IH), 7.13 (d, J = 8 Hz, IH), 7.02 (d, 7 = 7.6 Hz, IH), 6.82-6.75 (m, IH), 6.15 (dd, / =7-10 2.4 and 14 Hz, IH), 5.66 (br s, IH), 5.0 (br s, IH), 4.25-4.22 (m, 2H), 4.0 (br s, IH), 3.50 (br s, IH), 2.7-2.65 (m, 4H), 2.10-1.89 (m, 4H), 1.42-1.39 (m, IH); MS calculated for C25H26F3N4O2 (M+H+) 471.19, found 471.3. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400 MHz, DMSO-d6): d 12.91 (m, IH), 8.22-8.20 (m, 2H), 7.54-7.43 (m, 4H), 7.13-6.80 (m, 3H), 6.24-6.20 (m, IH), 5.75-5.72 (m, IH), 4.90 (br s, IH), 4.38-7-11 4.17 (m, 2H), 3.99-3.94 (m, IH), 3.58-3.54
(m, IH), 2.85-2.82 (m, IH), 2.68 (s, 3H), 2.33-1.95 (m, 4H), 1.34-1.32 (m, IH); MS calc. for C24H27N4O2 (M+H+) 403.21, found 403.1.
]H-NMR (400 MHz, DMSO-d6): d 13.38
CF3 (s, IH), 8.52-8.42 (m, 2H), 7.95-7.80 (m, 2H), 7.8-7.66 (m, 2H), 7.46-7.42 (m, IH), 6.84-6.71 (m, IH), 6.18-6.13 (m, IH), 5.73-5.54 (m, IH), 4.79-4.76 (m, IH),7-12
4.52-4.21 (m, 3H), 3.98-3.85 (m, IH),
CF3 Λ-Λ 9 3.61-3.57 (m, IH), 2.80-2.67 (m, IH),
2.08-2.02 (m, 3H), 1.99 (s, IH), 1.32-1.23 (m, 2H); MS calc. for C25H23F6N402 (M+H+) 525.16, found 525.1.
]H-NMR (400 MHz, DMSO-d6): d 12.91
CF3 (d, / = 18.8 Hz, IH), 8.55-8.45 (m, 2H),
7.91-7.89 (m, IH), 7.76-7.58 (m, 3H), 7.30-7.24 (m, 2H), 6.89-6.81 (m, IH), 6.26-6.17 (m, IH), 5.77-5.74 (m, IH),7-13
5.54-5.51 (m, IH), 4.91 (br s, IH), 4.17- 4.09 (m, 3H), 3.92-3.90 (m, IH), 3.88-3.63 (m, IH), 2.08-1.91 (m, 5H); MS calculated for C24H24F3N4O2 (M+H+) 457.18, found 457.2.
]H-NMR (400 MHz, CDC13) δ 12.53 (s, IH), 8.80 (s, IH), 8.42 (dd, / = 7.8, 15.8 Hz, IH), 7.75 (d, J = 7.7 Hz, IH), 7.60 (t, J = 7.7 Hz, IH), 7.18 (m, 2H), 7.05 (m, IH), 6.62 (dd, / = 10.5, 16.7 Hz, IH), 6.41 (m, IH), 5.79 (dd, / = 1.7, 10.5 Hz, IH), 5.307-14 (m, IH), 4.87 (m, IH), 4.59 (dd, / = 4.1,
13.1 Hz, IH), 4.41 (m, IH), 4.13 (dt, J = 5.2, 11.2 Hz, 3H), 3.97 (m, IH), 3.70 (m,
// IH), 2.82 (s, 3H). 19F-NMR (376 MHz,
CDCI3) δ -62.57; MS calculated for C24H24F3N4O3 (M+H+) 473.17, found 473.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400MHz, CDC13): d 12.77 - 12.71 (m, IH), 9.90 (dd, J = 1.2, 2.0 Hz, 0.6H), 9.88 (dd, J = 1.2, 2.0 Hz, 0.4H), 9.42 (dd, J = 1.2, 4.4 Hz, 0.6H), 9.41 (dd, J = 1.2, 4.4 Hz, 0.4H), 8.72 (dd, J = 2.0, 4.4 Hz, 0.6H), 8.65 (dd, J = 2.0, 4.4 Hz, 0.4H), 8.36-8.15 (m, 2H), 7.68 (dd, J = 4.4, 8.6 Hz, 0.6H), 7.37 (dd, J = 4.4, 8.6 Hz, 0.4H), 6.66 (dd, J = 10.4, 16.8 Hz, 0.6H), 6.65 (dd, J = 10.4, 16.8 Hz, 0.4H), 6.43 (dd, J =7-15 16.8, 2.0 Hz, 0.4H), 6.40 (dd, J = 16.8, 2.0
Hz, 0.6H), 5.78 (dd, J = 2.0, 10.8 Hz, 0.6H), 5.70 (dd, J = 2.0, 10.8 Hz, 0.4H),
Figure imgf000138_0001
5.73-5.62 (m, IH), 4.82-4.76 (m, IH),
4.53-4.42 (m, IH), 4.22-4.04 (m, IH), 3.88-3.66 (m, IH), 3.55-3.45 (m, 0.4H), 3.17-3.07 (m, 0.6H), 2.80-2.63 (m, IH), 2.21-1.98 (m, 2H), 1.35-1.20 (m, IH), 0.93-0.82 (m, IH); MS calculated for C21H22CIN6O2 (M+H+) 425.14, found 425.2.
]H-NMR (400MHz, CDC13): d 12.67 (br s, IH), 9.82-9.80 (m, IH), 9.32-9.30 (m, IH),
8.09- 8.05 (m, IH), 7.27-7.11 (m, 2H), 6.94-6.82 (m, 2H), 6.49-6.47 (m, IH), 5.61-5.54 (m, IH), 4.73-4.33 (m, 2H),7-16 4.10- 3.95 (m, IH), 3.80-3.53 (m, IH),
3.44-3.37 (m, IH), 3.20-2.86 (m, 2H), 2.75-2.48 (m, IH), 2.29 & 2.15 (s & s, 6H),
Figure imgf000138_0002
2.10-1.82 (m, 2H), 1.50-1.12 (m, 2H); MS calculated for C24H29CIN7O2 (M+H+) 482.20, found 482.1.
]H-NMR (400MHz, CD3OD): d 8.46 (d, J=5.2Hz, IH), 7.95-7.83 (m, 2H), 7.42- 7.38 (m, IH), 7.25-7.14 (m, 2H), 6.79-6.71 (m, IH), 6.24-6.18 (m, IH), 5.73-5.55 (m, 2H), 4.80-4.56 (m, IH), 4.21-4.08 (m, IH),7-17
4.04-3.80 (m, IH), 3.67-3.38 (m, IH), 2.82-2.64 (m, IH), 2.55 (s, 3H), 2.11-1.84 (m, 3H), 1.52-1.78 (m, 2H); MS calculated for C23H25CIN5O2 (M+H+) 438.16, found 438.1. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400 MHz, DMSO-d6): d 13.17
CF3 (d, 7 = 6Hz, IH), 8.52-8.43 (m, 2H), 7.94- 7.92 (m, IH), 7.79-7.70 (m, IH), 7.60-7.58 (m, IH), 7.32-7.25 (m, 2H), 6.89-6.80 (m, IH), 6.21-6.20 (m, IH), 5.8-5.79 (m, IH),7-18 5.45-5.40 (m, IH), 4.62-4.60 (m, IH), 4.25
CI Λ J> (m, IH), 4.23-4.13 (m, 2H), 3.92-3.90 (m,
IH), 3.5-3.49 (m, IH), 3.20-3.19 (m, IH), 2.10-1.9 (m, 4H), 1.25-1.20 (m, 2H); MS calc. for C24H23CIF3N4O2 (M+H+) 491.14, found 491.2.
]H-NMR (400 MHz, CDCI3) δ 12.59 (s,
CF3 IH), 8.64 (d, J = 10.3 Hz, IH), 8.44 (d, J =
7.6 Hz, IH), 7.78 (m, IH), 7.62 (m, IH), 7.19 (m, 2H), 7.04 (dd, J = 6.6, 14.2 Hz, IH), 5.03 (m, IH), 4.75 (m, IH), 4.35 (m,7-19 2H), 3.41 (m, IH), 2.88 (m, IH), 2.78 (d, J
= 5.0 Hz, 3H), 2.27 (m, IH), 2.13 (m, IH), 2.08 (s, 3H), 2.03 (m, IH), 1.45 (m, 2H); 19F-NMR (376 MHz, CDCI3) δ -62.50; MS calc. for C26H26F3N4O2 (M+H+) 483.19, found 483.2.
]H-NMR (400 MHz, CDCI3) δ 12.61 (s, IH), 8.65 (d, 7 = 19.1 Hz, IH), 8.45 (d, 7 = 7.7 Hz, IH), 7.77 (d, J = 7.3 Hz, IH), 7.62
CF3 (t, 7 = 7.7 Hz, IH), 7.19 (tt, 7 = 7.8, 15.2
Hz, 2H), 7.00 (m, 2H), 6.35 (m, IH), 5.11 (s, IH), 4.50 (dd, 7 = 3.6, 13.1 Hz, IH), 4.39 (dd, 7 = 10.7, 13.1 Hz, IH), 3.98 (dd,7-20
7 = 7.2, 14.2 Hz, IH), 3.61 (m, IH), 2.98 (m, IH), 2.81 (s, 3H), 2.19 (m, IH), 2.06 (m, 3H), 1.94 (dd, 7 = 1.6, 6.8 Hz, 3H), 1.43 (ddd, 7 = 3.8, 12.1, 26.1 Hz, IH). 19F- NMR (376 MHz, CDC13) δ -62.55; MS calculated for C26H28F3N4O2 (M+H+) 485.21, found 485.2.
]H-NMR (400 MHz, CDCI3) δ 12.59 (m, IH), 8.03 (m, IH), 7.91 (m, IH), 7.41 (m, IH), 7.14 (m, 3H), 7.00 (m, IH), 6.88 (m, IH), 6.46 (d, 7 = 15.1 Hz, IH), 4.93 (m, IH), 4.39 (m, IH), 4.03 (m, IH), 3.50 (m,7-21 IH), 3.11 (s, IH), 2.92 (s, IH), 2.71 (d, 7 =
43.6 Hz, 3H), 2.29 (d, 7 = 3.0 Hz, 6H), 2.11 (m, 2H), 2.05 (m, 3H), 1.40 (m, 2H). 19F- NMR (376 MHz, CDCI3) δ -113.83.
Figure imgf000139_0001
MS calculated for C27H33FN5O2 (M+H+)
478.25, found 478.3.
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
O MS calculated for C25H32N7O2 (M+H+)
$ s 462.25, found 462.3. 7-36
\
]H-NMR (400 MHz, CDC13) δ 12.45 (m, IH), 9.33 (d, / = 1.3, IH), 8.85 (d, / = 5.0 Hz, IH), 8.08 (dd, / = 1.4, 5.1 Hz, IH), 7.17 (d, / = 2.7 Hz, IH), 7.10 (t, 7 = 7.8 Hz, IH), 6.97 (d, / = 7.5 Hz, IH), 6.85 (m,7-37 IH), 6.51 (m, IH), 5.02 (m, IH), 4.37 (m, J
= 9.9 Hz, 2H), 3.89 (m, IH), 3.57 (m, IH), 3.21 (m, 2H), 2.83 (m, IH), 2.70 (s, 3H), 2.47 (s, 6H), 2.05 (m, 4H), 1.34 (m, IH).
\ MS calculated for C25H32N7O2 (M+H+) 462.25, found 462.3.
]H-NMR (400 MHz, CDC13) δ 12.62 (s, IH), 9.53 (t, / = 6.2 Hz, IH), 8.76 (dd, / = 1.5, 2.4 Hz, IH), 8.66 (dd, J = 2.4, 7.6 Hz, IH), 7.24 (m, IH), 7.17 (t, / = 7.8 Hz, IH), 7.04 (m, IH), 6.91 (m, IH), 6.53 (m, IH),7-38 5.08 (s, IH), 4.42 (d, / = 10.1 Hz, 2H),
3.91 (s, IH), 3.62 (d, / = 13.7 Hz, IH), 3.11 (m, 2H), 2.86 (m, IH), 2.78 (s, 3H), 2.38 (s, 6H), 2.07 (m, 3H), 1.43 (m, 2H).
\ MS calculated for C25H32N7O2 (M+H+) 462.25, found 462.3.
]H-NMR (400 MHz, CDCI3) δ 12.46 (m, IH), 9.28 (m, IH), 8.32 (m, IH), 7.60 (dd, 7 = 4.9, 8.4 Hz, IH), 7.22 (m, IH), 7.16 (t, / = 7.7 Hz, IH), 7.04 (m, IH), 6.89 (dt, / = 6.1, 15.2 Hz, IH), 6.53 (m, IH), 5.10 (m,7-39 IH), 4.59 (m, IH), 4.41 (dd, / = 3.1, 13.0
Hz, IH), 3.88 (m, IH), 3.57 (m, IH), 3.17 (br d, J = 4.4 Hz, 2H), 2.92 (m, IH), 2.78 (s, 3H), 2.34 (s, 6H), 2.06 (m, 4H), 1.42
Figure imgf000143_0001
(m, IH). MS calculated for C25H32N7O2
(M+H+) 462.25, found 462.3.
Figure imgf000144_0001
Figure imgf000145_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400 MHz, MeOD) δ 8.25 (d, / = 3.3 Hz, IH), 7.67 (s, IH), 7.50 (d, / = 15.2 Hz, IH), 7.38 (d, / = 9.0 Hz, IH), 7.18 (t, J = 8.1 Hz, IH), 7.08 (d, / = 7.7 Hz, IH), 6.99 (d, / = 15.1 Hz, IH), 6.76 (d, / = 7.2 Hz, IH), 5.07 (s, IH), 4.55 (s, IH), 4.32 (d,7-48
/ = 13.0 Hz, IH), 3.99 (s, IH), 3.97 (s, 3H), 3.93 (m, IH), 3.71 (s, 2H), 3.23 (d, J = 7.4 Hz, IH), 2.89 (s, 6H), 2.75 (s, 3H),
Figure imgf000146_0001
2.72 (s, IH), 2.20 (m, IH), 2.10 (m, 2H),
1.50 (m, IH). MS calculated for
C27H35N6O3 (M+H+) 491.27, found 491.2.
]H-NMR (400 MHz, MeOD) δ 7.74 (d, / = 7.0 Hz, IH), 7.36 (m, 2H), 7.18 (m, IH), 7.08 (m, 2H), 6.84 (m, IH), 6.68 (m, IH), 5.04 (m, 2H), 4.50 (m, IH), 4.33 (d, / = 12.8 Hz, IH), 3.99 (m, IH), 3.70 (m, IH),7-49
3.63 (s, 3H), 3.25 (d, J = 6.2 Hz, IH), 3.10 (m, IH), 2.87 (m, IH), 2.75 (s, 3H), 2.34 (s, 6H), 2.09 (m, 3H), 1.45 (m, IH). MS
Figure imgf000146_0002
calculated for C27H35N6O3 (M+H+) 491.27, found 491.2.
1H-NMR (400 MHz, MeOD) δ 8.06 (d, J = 6.3 Hz, IH), 7.77 (s, IH), 7.57 (s, IH), 7.42 (d, J = 7.6, IH), 7.22 (t, J = 7.8 Hz, IH), 7.12 (d, J = 7.4 Hz, IH), 6.99 (d, J = 15.2 Hz, IH), 6.76 (m, IH), 5.10 (m, IH), 4.42 (d, J = 61.8 Hz, IH), 3.98 (d, J = 7.37-50
Hz, 3H), 3.66 (m, IH), 3.34 (s, 6H), 3.11 (d, J = 17.2 Hz, IH), 2.93 (s, 6H), 2.78 (d, J = 10.7 Hz, 3H), 2.12 (s, 3H), 1.48 (m, IH), 1.37 (dd, J = 3.3, 6.7 Hz, 2H). MS
\
calculated for C28H38N7O2 (M+H+) 504.30, found 504.2.
]H-NMR (400 MHz, MeOD) δ 8.27 (d, / = 22.4 Hz, IH), 7.86 (d, / = 4.5 Hz, IH), 7.31 (s, IH), 7.24 (s, IH), 7.14 (t, / = 7.9 Hz, IH), 7.05 (s, IH), 6.82 (s, IH), 6.72 (s, IH), 4.95 (s, 2H), 4.46 (m, IH), 4.00 (m,7-51 IH), 3.68 (m, IH), 3.48 (s, IH), 3.23 (s,
IH), 3.06 (d, J = 61.8 Hz, IH), 2.88 (m, IH), 2.73 (d, / = 13.6 Hz, 3H), 2.26 (m, 6H), 2.01 (m, 2H), 1.49 (m, IH), 1.29 (s,
\ IH). MS calculated for C26H32N7O2S
(M+H+) 506.23, found 506.1. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400 MHz, MeOD) δ 8.94 (t, 7 = 1.6 Hz, IH), 8.51 (d, 7 = 7.8 Hz, IH), 8.10 (d, 7 = 8.2 Hz, IH), 7.76 (t, 7 = 7.8 Hz, IH), 7.39 (m, IH), 7.17 (t, 7 = 7.8 Hz, IH), 7.09 (t, 7 = 7.1, IH), 6.83 (m, IH), 6.73 (m, IH), 5.11 (m, IH), 4.93 (m, IH), 4.57 (m,7-52 x >- IH), 4.37 (d, 7 = 13.1 Hz, IH), 4.05 (m,
IH), 3.76 (m, IH), 3.18 (s, 3H), 2.92 (m, IH), 2.77 (s, 3H), 2.39 (s, 6H), 2.12 (m, 4H), 1.45 (m, IH), 1.37 (d, 7 = 6.6 Hz,
\
IH). MS calculated for C28H36N5O4S (M+H+) 538.24, found 538.2.
]H-NMR (400 MHz, DMSO) 10.22 (s, IH), 10.04 (br s, IH), 8.77 (m, IH), 8.31 (m, IH), 8.09 (ddd, 7 = 0.9, 2.2, 8.0 Hz, IH), 7.80 (t, 7 = 7.9 Hz, IH), 7.48 (d, 7 = 7.8 Hz, IH), 7.14 (t, 7 = 7.7 Hz, IH), 7.05 (t, 7 = 6.0 Hz, IH), 6.89 (d, 7 = 15.0 Hz,7-53
IH), 6.69 (m, IH), 4.86 (m, IH), 4.39 (m, N-N IH), 4.14 (m, IH), 3.96 (m, IH), 3.63 (m,
3H), 2.88 (t, 7 = 12.0 Hz, IH), 2.71 (s, 3H), 2.63 (s, 6H), 2.00 (m, 4H), 1.39 (m, IH). MS calculated for C28H34N9O2 (M+H+) 528.28, found 528.2.
]H-NMR (400 MHz, MeOD) δ 8.88 (d, 7 = 5.0 Hz, IH), 8.08 (d, 7 = 4.9 Hz, IH), 7.42 (d, 7 = 8.1 Hz, IH), 7.21 (t, 7 = 7.8 Hz, IH), 7.11 (d, 7 = 7.8 Hz, IH), 7.01 (d, 7 = 15.1 Hz, IH), 6.76 (m, IH), 4.66 (t, 7 =7-54
11.6 Hz, IH), 4.31 (d, 7 = 12.9 Hz, IH), 3.98 (m, 3H), 3.72 (m, 3H), 3.23 (q, 7 = 7.4 Hz, 2H), 2.93 (s, 6H), 2.80 (s, 3H), 2.77 (s, 3H), 2.12 (m, 3H). MS calculated for
\
C26H34N7O2 (M+H+) 476.27, found 476.3.
]H-NMR (400 MHz, MeOD) δ 8.51 (d, 7 = 7.1 Hz, IH), 8.46 (s, IH), 7.96 (s, IH), 7.71 (s, 2H), 7.36 (d, 7 = 7.9 Hz, IH), 7.16 (t, 7 = 8.5 Hz, IH), 7.08 (t, 7 = 8.1 Hz, IH), 6.80 (m, 2H), 5.08 (m, IH), 4.56 (t, 7 =7-55 11.8 Hz, IH), 4.37 (d, 7 = 13.1 Hz, IH),
4.00 (m, IH), 3.74 (m, IH), 3.41 (m, 3H), 3.04 (m, 2H), 2.76 (s, 3H), 2.44 (s, 6H),
V / 2.10 (m, 2H), 1.51 (m, IH). MS calculated
\ for C28H34N7O2 (M+H+) 500.27, found
500.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400 MHz, MeOD) δ 7.69 (s, IH), 7.34 (d, / = 8.1 Hz, IH), 7.16 (m, 2H), 7.05 (d, / = 7.6 Hz, IH), 6.78 (m, 2H), 6.59 (m, IH), 4.59 (m, IH), 4.29 (d, J = 13.1 Hz, IH), 3.94 (m, IH), 3.68 (m,7-56
IH), 3.40 (m, 2H), 3.23 (m, IH), 2.87 (dd, / = 11.7, 24.7 Hz, IH), 2.74 (s, 3H), 2.46
V / (s, 6H), 2.11 (m, 4H), 1.44 (s, IH). MS
\ calculated for C25H32N5O3 (M+H+) 450.24, found 450.2.
]H-NMR (400 MHz, MeOD) δ 8.18 (d, / = 5.2 Hz, IH), 7.57 (s, IH), 7.36 (m, 2H), 7.17 (t, J = 7.8 Hz, IH), 7.09 (t, J = 8.1 Hz, IH), 6.83 (m, IH), 6.73 (d, / = 14.0 Hz, IH), 5.05 (m, 2H), 4.51 (m, IH), 4.33 (d, J7-57 = 12.8 Hz, IH), 3.93 (m, IH), 3.74 (m,
IH), 3.61 (m, 4H), 3.44 (m, IH), 3.01 (m, 2H), 2.76 (s, 3H), 2.41 (s, 6H), 2.05 (m, 3H), 1.71 (br s, 6H), 1.46 (m, IH). MS
Figure imgf000148_0001
calculated for C31H42N7O2 (M+H+) 544.33, found 544.2.
]H-NMR (400 MHz, MeOD) δ 8.34 (d, / = 5.1 Hz, IH), 8.02 (m, IH), 7.73 (s, IH), 7.39 (d, / = 7.9 Hz, IH), 7.19 (m, IH), 7.10 (t, / = 7.6 Hz, IH), 6.85 (m, IH), 6.68 (m, IH), 5.10 (t, / = 11.0 Hz, IH), 4.51 (dd, / = 10.7, 12.9 Hz, IH), 4.31 (d, / =7-58 a * 13.0 Hz, IH), 3.99 (m, IH), 3.67 (m, IH),
3.22 (d, J = 6.4 Hz, 2H), 2.87 (d, / = 11.7 Hz, IH), 2.77 (s, 3H), 2.32 (s, 6H), 2.14 (s, IH), 2.10 (d, / = 12.8 Hz, 3H), 1.50 (m,
\
IH). MS calculated for C26H32FN6O2 (M+H+) 479.25, found 479.2.
]H-NMR (400 MHz, MeOD) δ 7.24 (m, IH), 7.05 (m, IH), 6.94 (t, 7 = 7.5 Hz, IH), 6.87 (m, IH), 6.70 (m, 2H), 4.52 (m, IH), 4.12 (m, IH), 3.87 (m, IH), 3.54 (m, 2H),7-59 3.26 (d, J = 4.4 Hz, 2H), 3.06 (m, IH),
2.79 (m, IH), 2.63 (s, 3H), 2.27 (s, / = 47.7 Hz, 6H), 2.17 (s, 3H), 2.03 (m, 3H), 1.93 (s, 3H), 1.39 (m, IH). MS calculated for
\ C27H36N5O3 (M+H+) 478.27, found 478.2.
Figure imgf000149_0001
/
= J
= (m,
Figure imgf000150_0001
Figure imgf000151_0001
(M+H+) 491.27, found 491.1.
Figure imgf000152_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
2.03 (m, 4H), 1.46 (s, IH). MS calc. for C32H37N6O2 (M+H+) 537.29, found 537.1.
]H-NMR (400 MHz, MeOD) δ 9.18 (d, 7 = 14.8 Hz, IH), 8.53 (d, 7 = 8.3, IH), 7.59 (d, 7 = 8.3 Hz, IH), 7.37 (d, 7 = 8.0 Hz, IH), 7.18 (t, 7 = 8.6 Hz, IH), 7.08 (d, 7 = 7.7 Hz, IH), 6.83 (dd, 7 = 6.4, 14.9 Hz, IH), 6.74 (d, 7 = 14.2 Hz, IH), 5.08 (s, IH),7-77
4.50 (t, 7 = 11.8 Hz, IH), 4.32 (d, 7 = 12.7 Hz, IH), 3.99 (m, IH), 3.67 (m, IH), 3.15 (m, IH), 2.86 (m, IH), 2.76 (s, 3H), 2.41
\ (s, 6H), 2.12 (s, 2H), 2.04 (m, 3H), 1.48
(m, IH). MS calc. for C26H32CIN6O2 (M+H+) 495.22, found 495.1.
]H-NMR (400 MHz, MeOD) δ 9.09 (m, IH), 8.63 (m, IH), 7.38 (d, 7 = 8.1 Hz, IH), 7.18 (t, 7 = 7.8 Hz, IH), 7.09 (d, 7 = 7.7 Hz, IH), 6.81 (s, 2H), 5.10 (s, IH), 4.53 (m, IH), 4.30 (d, 7 = 13.0 Hz, IH),7-78 3.97 (s, IH), 3.71 (s, IH), 3.53 (s, 2H),
3.14 (m, IH), 2.85 (m, IH), 2.76 (s, 3H), 2.57 (s, 6H), 2.21 (m, IH), 2.10 (m, 2H), 1.49 (m, IH). MS calculated for
C26H31CI2N6O2 (M+H+) 529.18, found 529.0.
]H-NMR (400 MHz, MeOD) δ 9.02 (t, 7 = 1.7 Hz, IH), 8.36 (d, 7 = 2.8 Hz, IH), 8.13 (s, IH), 7.38 (d, 7 = 8.0 Hz, IH), 7.18 (t, 7 = 7.8 Hz, IH), 7.09 (d, 7 = 7.5, IH), 6.84 (m, IH), 6.70 (d, 7 = 15.3 Hz, IH), 5.10 (t, 7 = 11.0 Hz, IH), 4.52 (m, IH), 4.34 (d, 77-79
= 13.0 Hz, IH), 4.03 (m, IH), 3.98 (s, 3H), 3.64 (m, IH), 3.25 (d, 7 = 6.3 Hz, IH), 2.97 (m, 2H), 2.75 (d, 7 = 15.5 Hz, 3H),
Figure imgf000153_0001
2.34 (s, 6H), 2.13 (m, 4H), 1.48 (m, IH).
MS calculated for C27H35N6O3 (M+H+) 491.27, found 491.1.
]H-NMR (400 MHz, MeOD) δ 8.76 (d, 7 = 5.2 Hz, IH), 8.26 (m, IH), 8.11 (d, 7 = 5.2 Hz, IH), 7.42 (m, 2H), 7.34 (m, 3H), 7.19 (t, 7 = 7.8 Hz, IH), 7.09 (d, 7 = 7.5 Hz, IH), 6.81 (m, IH), 6.68 (d, 7 = 15.2 Hz,7-80 IH), 5.09 (t, 7 = 10.7 Hz, IH), 4.50 (m,
IH), 4.33 (d, 7 = 12.7 Hz, IH), 3.92 (m, IH), 3.50 (m, 2H), 3.14 (m, IH), 2.90 (m,
N IH), 2.76 (s, 3H), 2.38 (s, 6H), 2.34 (s,
\ 3H), 2.07 (m, 3H), 1.85 (m, IH), 1.42 (m,
IH). MS calculated for C33H39N6O2
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
]H NMR (400 MHz, CDC13): δ 12.52 (br s, IH), 9.97 - 9.68 (m, IH), 9.31 (dd, / = 1.3, 5.2 Hz, IH), 8.10 - 8.07 (m, IH), 7.18 - 7.05 (m, 2H), 6.98 (d, / = 7.3, IH), 5.29 (s, 0.6H), 5.24 (s, 0.4H), 5.10 (s, 0.6H), 5.07 (s, 0.4H), 5.12 - 4.97 (m, IH), 4.43-4.257-92 (m, IH), 4.07 - 3.76 (m, IH), 3.53-3.25
(m, 2H), 2.93-2.86(m, IH), 2.70(s, 3H), 2.69-2.32 (m, 5H), 2.15 - 1.66 (m, 5H), 1.56-1.46 (m, IH), 1.03 (t, J = 7.1 Hz,
Figure imgf000157_0001
1.8H), 0.96 (t, J = 7.1 Hz, 4.2H); MS calc.
for C27H36N7O2 (M+H+) 490.29, found 490.3.
]H-NMR (400MHz, CDC13): δ 12.49 (s, IH), 9.86 (dd, J = 1.6, 2.0 Hz, IH), 9.31 (dd, / = 1.2, 5.2 Hz, IH), 8.08 (dd, / = 2.0, 5.2 Hz, IH), 7.15 (d, J = 7.2 Hz, IH), 7.12-7.08 (m, IH), 6.97(dd, J = 7.3 Hz, IH), 5.37 (s, IH), 5.18 (s, IH), 5.08-5.007-93 (m, IH), 4.40 - 4.02 (m, 2H), 3.63 (dd, J =
4.4, 4.6 Hz, 4H), 3.54 - 3.49 (m, IH), 3.45 (d, J = 13.4 Hz, IH), 2.93 (d, J = 13.5 Hz, IH), 2.71-2.60 (m, IH), 2.69 (s, 3H), 2.53-
Figure imgf000157_0002
2.39 (m, 4H), 2.14-1.93 (m, 5H), 1.51-1.42
(m, IH); MS calculated for C27H34N7O3 (M+H+) 504.26, found 504.3.
]H-NMR (400 MHz, CDC13) δ 12.59 (br. s, IH), 9.93-9.89 (m, IH), 9.40-9.38 (m, IH), 8.17-8.13 (m, IH), 7.29-7.17 (m, 2H), 7.11-7.07 (m, IH), 6.68-6.58 (m, IH), 6.51-6.36 (m, IH), 5.78-5.70 (m, IH),7-94 5.13-5.07 (m, IH), 4.50-4.46 (m, IH), 4.35
(dd, / = 10.5, 13.6 Hz, IH), 3.97-3.90 (m, IH), 3.68-3.61 (m, IH), 2.93-2.84 (m, IH),
Figure imgf000157_0003
2.79 (s, 3H), 2.18-2.02 (m, 4H), 1.49-1.43
(m, IH). MS calculated for C22H25N6O2 (M+H+) 405.20, found 405.1.
]H-NMR (400 MHz, CDCI3) δ 12.57 (br. s, IH), 9.92-9.88 (m, IH), 9.38-9.37 (m, IH),
0 /=N 8.16- 8.12 (m, IH), 7.24-7.15 (m, 2H),
7.09-7.03 (m, IH), 6.94-6.88 (m, IH), 6.51-6.43 (m, IH), 5.12-5.5.03 (m, IH),7-95 4.48- 4.43 (m, IH), 4.35-4.29 (m, IH),
3.96-3.89 (m, IH), 3.66-3.59 (m, IH),
3.17- 3.07 (m, 2H), 2.96-2.82 (m, IH), 2.77
\ (s, 3H), 2.30 (s, 6H), 2.20-2.02 (m, 4H),
1.49- 1.43 (m, IH). MS calculated for C25H32N7O2 (M+H+) 462.25, found 462.2.
Figure imgf000158_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (DMSO-d6, 400 MHz): d 12.83 (s, IH), 8.46 (d, J = 8.0 Hz, 2H), 7.89 (d, J = 8.0 Hz, IH), 7.75- 7.63 (m, 2H), 7.39 (s, IH), 7.09 (d, J = 8.4 Hz, IH), 6.95-6.79 (m, IH), 6.20-6.13 (m, IH), 5.78-5.59 (m, -100 IH), 4.79-4.56 (m, 2H), 4.23-4.06
(m, 2H), 3.70-3.65 (m, 0.5H), 3.27- 3.21 (m, 0.5H), 2.85-2.66 (m, IH), 2.39 (s, 3H), 2.00- 1.91 (m, 2H), 1.64-
Figure imgf000159_0001
1.5 (m, IH); MS calculated for C24H24F3N4O2 (M+H+) 457.18, found 457.3.
]H-NMR (DMSO-d6, 400 MHz): d
CF3 12.86 (s, IH), 8.46-8.42 (m, 2H),
7.87 (d, / = 7.8 Hz, IH), 7.63 (t, / = 7.8 Hz, IH), 7.42 (d, / = 8.4 Hz, IH), 7.40 (s, IH), 7.13 (d, J = 7.8 Hz, IH), 6.84-675 (m, IH), 6.16-6.12 (m, IH), -101
5.86-5.74 (m, IH), 4.99-4.94 (m, IH), 4.73-4.62 (m, 2H), 4.45-4.40 (m, IH), 2.40 (s, 3H), 1.88 (d, / = 1.0 Hz, 3H); MS calculated for C23H22F3N4O2 (M+H+) 443.16, found 443.0.
]H-NMR (400 MHz, DMSO) δ 8.56 (d, J = 5.1 Hz, IH), 8.05 (d, J = 5.1 ocF3 Hz, IH), 7.79 (s, IH), 7.49 (d, J = 7.6
Hz, IH), 7.16 (m, IH), 7.07 (t, J = 6.2 Hz, IH), 6.70 (m, 2H), 4.86 (m, IH), 4.31 (dd, / = 10.7, 12.8 Hz, IH), -102 4.15 (dd, / = 2.5, 12.7 Hz, IH), 3.90
(m, IH), 3.57 (dt, J = 5.5, 13.8 Hz, IH), 3.07 (m, IH), 2.74 (m, 2H), 2.70 (s, 3H), 2.38 (s, 6H), 1.93 (m, 4H),
\ 1.36 (m, IH). MS calculated for
C27H32F3N6O3 (M+H+) 545.24, found 545.2.
]H-NMR (400 MHz, CD2C12) δ 12.61 ocHF2 (s, IH), 8.31 (d, J = 5.1 Hz, IH), 7.88
(dd, J = 1.3, 5.2 Hz, IH), 7.67 (m, IH), 7.43 (t, J = 73.3 Hz, IH), 7.24 (d, J = 7.3 Hz, IH), 7.17 (t, J = 7.7 -103
Hz, IH), 7.06 (d, J = 7.3 Hz, IH), 6.85 (m, IH), 6.63 (d, J = 15.1 Hz, IH), 5.03 (m, IH), 4.36 (d, J = 7.8 \ Hz, 2H), 3.91 (m, IH), 3.62 (m, IH),
3.30 (br s, 2H), 2.88 (q, J = 11.9 Hz,
Figure imgf000160_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400 MHz, DMSO-d6): d
CF3 12.74 (s, 1H), 8.45-8.37 (m, 2H),
7.87 (d, J = 7.4 Hz, 1H), 7.67 (t, J = 7.8 Hz, 1H), 7.50 (d, / = 8.3 Hz, 1H), 7.38 (s, 1H), 7.08 (d, / = 8.3 Hz, 1H), 6.92-6.81 (m, 1H), 6.29-6.24 (m, -107
1H), 5.78-5.67 (m, 1H), 4.90 (br s, 1H), 3.92-3.43 (m, 4H), 2.60-2.56 (m, 2H), 2.39 (s, 3H), 2.10-1.78 (m, 4H), 1.25-1.21 (m, 1H); MS
0 calculated for C25H26F3N4O2 (M+H+)
471.19, found 471.0.
]H-NMR (400 MHz, DMSO-d6): d 12.94 (s, 1H), 8.21 (d, / = 6Hz, 2H), 7.45-7.43 (m, 4H), 7.13-6.91 (m, 3H), 6.20-6.13 (m, 1H), 5.75-5.65 -108 (m, 1H), 4.71-4.45 (m, 3H), 4.24- 4.07 (m, 1H), 2.74-2.63 (m, 4H), 2.07-1.95 (m, 2H), 1.59-1.56 (m, 2H); MS calculated for C23H25N4O2 (M+H+) 389.19, found 389.2.
]H-NMR (400 MHz, DMSO-d6) δ 8.63 (d, J = 5.0 Hz, 1H), 7.90 (s, 1H), 7.86 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.14 (t, J = 7.7 Hz, 1H), 7.05 (d, J = 7.4 Hz, 1H), 6.93 (m, 1H), 6.17 (s, 1H), 5.76 (s, 1H), 4.73 (s, 1H), 4.63 -109
(m, 1H), 4.47 (m, 1H), 4.11 (m, 1H), 3.20 (m, 1H), 2.74 (m, 1H), 2.65 (d, J = 9.6, 3H), 2.59 (s, 3H), 2.08 (s, 1H), 1.93 (m, 1H), 1.60 (m, 1H); MS calculated for C23H26N5O2 (M+H+) 404.20, found 404.2.
'H-NMR (400 MHz, DMSO-d6): d 13.10 (s, 1H), 8.48 (d, J = 7.8 Hz,
CF3 2H), 8.18 (s, 1H), 7.92-7.89 (m, 3H), 7.76 (d, J = 7.8 Hz, 1H), 6.96-6.79 (m, 1H), 6.20-6.13 (m, 1H), 5.77- 5.61 (m, 1H), 4.85-72 (m, 1H), 4.63- -110 4.55 (m, 1H), 4.40-4.20 (m, 1H),
4.18-4.07 (m, 0.5H), 3.88 (s, 3H), 3.75-3.68 (m, 0.5H), 3.27-3.21 (m, 1H), 2.88-2.68 (m, 1H), 2.06-1.91 (m, 2H), 1.69-1.59 (m, 1H); MS calculated for C25H24F3N4O4 (M+H+) 501.17, found 501.2.
Figure imgf000162_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
2.52-2.35(m, IH), 2.2-1.99(m, 6H), 1.52-1.35(m, IH); MS calculated for C28H34N5O3 (M+H+) 488.26, found 488.2.
]H-NMR (400MHz, CDCI3): d NMR (400 MHz, ) δ 8.36 - 8.21 (m, 2H), 7.51 (m, 3H), 7.41 (dd, 7 = 7.6, 0.8 Hz, IH), 7.26 (dd, J = 7.6 Hz, IH), 7.08 (dd, / = 7.6, 0.8 Hz, IH), 6.67- 6.55 (m, 2H), 5.82 (dd, J = 2.6, 9.5, IH), 4.68 - 4.36 (m, 4H), 4.28 (d, / = -115 11.7, IH), 4.12-4.05 (m, IH), 4.01 - 3.85 (m, 3H), 3.63-3.57 (m, IH), 3.46- 3.40 (m IH), 3.14-3.06 (m,
0 IH), 2.99-2.94 (m, IH), 2.75-2.66
(m, IH), 2.29 - 2.01 (m, 5H), 1.37 - 1.26 (m, IH); MS calculated for C28H32N5O5S (M+H+) 550.20, found 550.2.
]H-NMR (400 MHz, CDCI3): d 8.56 (br s, IH), 8.38-8.30 (m, IH), 7.83- 7.75 (m, IH), 7.68-7.65 (s, 0.3H), 7.60-7.56 (m, 2H), 7.43 (s, 0.7H), 7.05-6.92 (m, IH), 6.58-6.47 (m, IH), 5.32-5.22 (m, IH), 4.83-4.74 (m, 2H), 4.65-4.48 (m, 2H), 4.20- -116 4.05 (m, 0.4H), 3.93-3.82 (m, 0.6H),
3.75-3.67 (m, 0.8H), 3.55-3.49 (m, 0.2H), 3.20-3.12 (m, 2H), 3.02-2.55 (m, 2H), 2.17 (s, 3H), 2.17-2.01 (m,
Figure imgf000163_0001
2H); 19F-NMR (376 MHz, CDCI3) δ - 62.57. MS calculated for C29H32F3N6O3 (M+H+) 569.24, found 569.3.
]H-NMR (400 MHz, DMSO-d6): d 13.10 (s, IH), 10.30 (S, IH), 8.47(d,
CF3 J = 7.2 Hz, 2H), 7.92-7.86 (m, 2H), 7.77-7.69 (m, 2H), 7.46 (br s, IH), 6.96-6.78 (m, IH), 6.19-6.15 (m, IH), 5.76-5.60(m, IH), 4.83-4.60 (m, -117
2H), 4.58 (s, IH), 4.30-4.09 (m, 2H), 3.70 (s, IH), 3.29 (br s, 2H), 2.86- 2.67 (m, 2H), 2.02-1.94 (m, 6H), 1.65-1.62 (m, IH); MS calculated for C28H31F3N5O2 (M+H+) 526.24, found 526.1. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400 MHz, DMSO-d6): d 12.86 (s, IH), 8.46 (d, / = 6.8 Hz,
CF3 2H), 7.90-7.72 (m, 3H), 7.53 (s, IH), 7.19 (d, / = 7.6 Hz, IH), 6.95-6.79 (m, IH), 6.15 (d, J = 16.4 Hz, IH), 5.75-5.60 (m, IH), 4.73-4.57 (m, -118
2H), 4.25-4.08 (m, IH), 3.71-3.49 (m, 2H), 2.81-2.67 (m, 2H), 2.33 (s, 4H), 2.17-1.94 (m, 3H), 1.64-1.23 (m, 7H); MS calculated for C29H33F3N5O2 (M+H+) 540.25, found 540.3.
]H-NMR (400 MHz, DMSO-d6): d 12.88 (d, / = 8.8 Hz, IH), 8.46 (d, / =
CF3 7.6 Hz, 2H), 7.89 (d, / = 7.2 Hz, IH), 7.75-7.47 (m, 2H), 7.47 (s, IH), 7.15- 7.10 (m, IH), 6.90-6.79 (m, IH), 6.19-6.13 (m, IH), 5.75-5.60 (m, -119
IH), 4.76-4.56 (m, 4H), 4.32-4.08 (m, 2H), 2.92 (s, 3H), 2.81 (s, 2H), 2.08 (s, 3H), 1.98-1.91 (m, 2H), 1.59 (s, 2H); MS calculated for C27H29F3N503 (M+H+) 528.21, found 528.3.
CF3 MS calculated for C28H31F3N5O4 (M+H+) 558.22, found 558.2.
-120
HO
]H-NMR (400 MHz, DMSO-d6): d 13.30 (s, IH), 8.47 (d, / = 7.9 Hz, 2H), 7.89 (d, / = 7.8 Hz, IH), 7.76-
CF3 7.69 (m, 2H), 7.57 (s, IH), 7.21 (d, /
= 8.3 Hz, IH), 6.99-6.79 (m, IH), 6.20-6.13 (m, IH), 5.84-5.60 (m, -121 IH), 5.32-5.24 (m, IH), 4.77-4.74
(m, IH), 4.60-56 (m, 2H), 4.31-4.03 (m, 2H), 3.75-3.56 (m, IH), 2.78-
2.70 (m, 2H), 2.05-1.90 (m, 2H), 1.71-1.59 (m, IH); MS calculated for C24H24F3N403 (M+H+) 473.17, found 473.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400 MHz, DMSO-d6): d 12.85 (s, IH), 8.47 (d, J = 6.9 Hz, 2H), 7.88 (d, J = 7.3 Hz, IH), 7.75-
CF3 7.70 (m, 2H), 7.54 (s, IH), 7.19 (d, J
= 7.8 Hz, IH), 6.95-6.80 (m, IH), 6.19-6.13 (m, IH), 5.75-5.59 (m, -122 IH), 4.75 (br. s, IH), 4.60-4.56 (m,
IH), 4.48 (s, 2H), 4.28-4.20 (m, IH), 4.09-3.66 (m, IH), 3.32 (s, 3H), 2.85- 2.67 (m, 2H), 2.01-1.82 (m, 2H), 1.65-1.59 (m, IH); MS calculated for C25H26F3N403 (M+H+) 487.19, found 487.3.
]H-NMR (400 MHz, DMSO-d6): d 12.91 (s, IH), 8.47 (s, 2H), 7.89 (s, IH), 7.74 (s, 2H), 7.56 (s, IH), 7.22
CF3 (d, J = 6.8 Hz, IH), 6.93-6.83 (m,
IH), 6.20-6.16 (m, IH), 5.75-5.60 (m, IH), 4.81-4.71 (m, IH), 4.61- -123 4.52 (m, 3H), 4.28-4.20 (m, IH),
4.09-3.62 (m, IH), 3.50 (d, J = 5.9 Hz, 2H), 2.83-2.71 (m, 2H), 2.09- 1.94 (m, 2H), 1.65-1.59 (m, IH), 1.22-1.16 (m, 3H); MS calculated for C26H28F3N403 (M+H+) 501.20, found 501.2.
]H-NMR (400 MHz, DMSO-d6): d 12.97 (s, IH), 8.46 (s, 2H), 7.87 (s, IH), 7.72 (s, IH), 7.60-7.54 (m, 2H),
CF3 7.21 (s, IH), 6.98-6.78 (m, IH), 6.18- 6.14 (m, IH), 5.72-5.58 (m, IH), 4.80-4.71 (m, IH), 4.54 (s, 2H), 4.23- -124 4.18 (m, IH), 4.10-3.60 (m, IH),
4.09-3.62 (m, IH), 3.55-2.48 (m, 4H), 2.83-2.71 (m, 2H), 2.01-1.92 (m, 2H), 1.65-1.60 (m, IH), 1.32- 1.21 (m, 3H); MS calculated for C27H3oF3N404 (M+H+) 531.21, found 531.1.
CF3 MS calculated for C^H^FsNsC^ (M+H+) 562.22, found 562.3. -125 Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400 MHz, acetonitrile-d3): d 12.33 (s, 1H), 8.50 (d, J = 5.2 Hz, 1H), 7.88 (s, 0.6H), 7.86 (s, 0.4H), 7.84 (s, 0.6H), 7.77 (d, J = 5.2 Hz, 1H), 7.24 (s, 0.6H), 6.93 (s, 1H), 6.66 (dd, / = 10.4, 16.4 Hz, 1H), 6.17(dd, J = 2.0, 16.8 Hz, 0.4H), 6.13 (dd, J = 2.0, 16.8 Hz, 0.6H), 5.63 (dd, / = 2.4, 10.4 Hz, 0.6 H), 5.53 (dd, J = 2.4, 10.4 Hz, 0.4 H), 4.92 - 4.71 (m, 1H), 4.33 (d, J = 10.8 Hz, 0.4H), 4.29 (d, J = 10.8 Hz, 0.6H), 4.19 (dd, J = 3.2, -126
13.2 Hz, 0.6H), 4.02 (dd, J = 3.2, 13.2 Hz, 0.4H), 4.00-3.93 (m, 0.4H), 3.86-3.79 (m, 0.6H), 3.55 (s, 2H), 3.54-3.49 (m, 0.6H), 3.33-3.28 (m, 0.4H), 2.84-2.74 (m, 1.2H), 2.70-2.60 (m, 0.8H), 2.63 (s, 2.1H), 2.56 (s, 0.9H), 2.51 (s, 2.1H), & 2.50 (s, 0.9H), 2.43-2.37 (m, 2H), 2.04-1.86 (m, 5H), 1.68-1.64(m, 4H), 1.39-1.28 (m, 1H); MS calculated for C29H37N6O2 (M+H+) 501.29, found 501.3.
]H-NMR (400MHz, CDC13): d 12.61(s, 1H), 8.22-8.17 (m, 2H), 7.46-7.38 (m, 3H), 7.05 (s, 0.3H), 6.99 (s, 0.7H), 6.86 (s, 0.3H), 6.84 (s, 0.7H), 6.58 (dd, J = 10.0, 17.2 Hz, 0.3H), 6.56 (dd, J = 10.4, 16.8 Hz, 0.7H), 6.39 (dd, J = 2.1, 6.4Hz, 0.3H), 6.29 (dd, J = 2.0, 16.8Hz, 0.7H), 5.67(dd, J = 2.0, 10.8 Hz, ? /=\ 0.7H), 5.64(dd, J = 2.0, 10.4 Hz,
0.3H), 4.99-4.91 (m, 0.7H), 4.74-4.65 -127 (m, 0.3H), 4.40-4.33 (m, 1.6H), 4.15- 4.08 (m, 0.4H), 3.98-3.83 (m, 1H), 3.58-3.50 (m, 0.7H), 3.50 (s, 2H), 3.40-3.34 (m, 0.3H), 3.11 (br t, J = 6.4 Hz, 2H), 2.96(s, 3H), 2.90 (br t, J = 6.4 Hz, 2H), 2.78-2.64 (m, 1H), 2.67 (s, 2.1H), 2.55(s, 0.9H), 2.18 (s, 0.9H), 2.15 (s, 2.1H), 2.06-1.94 (m, 4H), 1.43-1.28 (m, 0.7H), 1.21-1.08 (m, 0.3H); MS calculated for C29H38N5O4S (M+H+) 552.26, found 552.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
Ή-NMR (400MHz, CDC13): d 12.71 (s, IH), 8.32-8.27 (m, 2H), 7.55-7.45 (m, 3H), 7.21(s, 0.3H), 7.17 (s, 0.7H), 6.65 (dd, J = 10.8, 16.8Hz, 0.7H), 6.64 (dd, J = 10.8, 16.8 Hz, 0.3H), 6.48 (dd, J = 16.8, 2.0Hz, 0.3H), 6.38 (dd, J = 16.8, 2.0Hz, 0.7H), 5.76 (dd, J = 10.8, 2.0Hz, 0.7H), 5.72 (dd, J = 10.8, 2Hz, 0.3H), 5.10-4.98 (m, -128 0.7H), 4.82-4.74 (m, 0.3H), 4.602 (s,
2H), 4.51-4.33 (m, 1.8H), 4.27-4.17 (m, 0.2H), 4.04-3.92 (m, IH), 3.68-
Figure imgf000167_0001
3.58 (m, 4H), 3.43(s, 0.6H), 3.42(s,
2.4H), 3.04-2.95 (m, IH), 2.82 (s, IH), 2.77 (s, 2.1H), 2.65 (s, 0.9H), 2.26-1.96 (m, 5H), 1.53-1.37 (m, 0.7H), 0.94-0.88 (m, 0.3H); MS calculated for C28H35N4O4 (M+H+) 491.26, found 491.2.
Ή-NMR (400MHz, CD3OD): d 8.28- 8.25(m, 2H), 7.68(dd, J = 2.4, 8.8 Hz, IH), 7.57-7.48 (m, 3H), 7.42-7.38 (m, 2H), 6.88 (dd, J = 10.8, 16.8 Hz, 0.3H), 6.89 (dd, J = 10.8, 16.8 Hz, 0.7H), 6.44 (dd, J = 1.6, 16.4 Hz, 0.3H), 6.43 (dd, J = 1.6, 16.4 Hz, 0.7H), 5.91 (dd, J = 1.6, 10.4 Hz, 0.3H), 5.89 (dd, J = 1.6 Hz, 10.4 Hz, -129 0.7H), 5.13 (d, J = 14.4 Hz, 0.3H),
5.06 (d, J = 14.4 Hz, 0.7H), 4.82 (d, J = 14.4 Hz, 0.3H), 4.71 (d, J = 14.4 Hz, 0.7H), 4.66-4.63 (m, IH), 4.55- 4.48 (m, IH), 4.42-4.39 (m, IH), 4.15-4.08 (m, IH), 3.70-3.64 (m, IH), 3.06 (s, 1.2H), 3.03(s, 4.8H), 2.28-2.08 (m, 5H), 1.60-1.45 (m, IH); MS calculated for C26H32N5O2 (M+H+) 446.25, found 446.2.
Ή-NMR (400MHz, CDC13): d 8.25- 8.22 (m, 2H), 7.59-7.45 (m, 3H), 7.28-7.20 (m, 3H), 6.69 (dd, J = 10.4, 16.Hz, 0.4H), 6.66 (dd, J = 10.4, 16.4 Hz, 0.6H), 6.40 (dd, J = 1.6, 16.8 Hz, -130 0.4 H), 6.37 (dd, J = 1.6, 16.8 Hz,
0.6H), 5.83 (dd, J = 1.6, 10.4 Hz, 0.6H), 5.66 (dd, J = 1.6, 10.4 Hz, 0.4H), 5.42 (d, J =12 Hz, IH), 5.11- 4.97 (m, IH), 4.58 (d, J = 12 Hz, IH), 4.46(d, J=7.2Hz, IH), 4.03-3.86 (m, Ex. Compound Structure Physical Data (¾ NMR and MS)
IH), 3.80-3.67(m, IH), 3.66-3.54 (m, 4H), 3.35(s, 2.1H), 3.34(s, 0.9H), 2.98-2.87(m, IH), 2.20-1.98 (m, 5H), 1.62-1.44 (m, IH); MS calculated for C27H33N4O4 (M+H+) 477.24, found 477.2.
Ή-NMR (400MHz, CD3OD): d 8.34- 8.29 (m, 2H), 7.66-7.61 (m, IH), 7.53-7.46 (m, 3H), 7.26-7.20 (m, 2H), 6.98 (dd, J = 10.4, 16.8 Hz, 0.3H), 6.85 (dd, J = 10.4, 16.8 Hz, 0.7H), 6.31 (dd, J = 2.4, 16.8 Hz, 0.7H), 6.26 (dd, J = 2.4, 16.8 Hz, 0.3H), 5.75 (dd, J =2.4, 10.4 Hz, 0.7H), 5.56 (dd, J = 2.4, 10.4 Hz, 0.3H), 5.26 (d, J = 12.8 Hz, IH), -131 5.25-5.16 (m, IH), 4.99-4.18 (br s,
IH), 4.92 (d, J=12.8 Hz, IH), 4.54 (dd, J = 13.2, 10.8 Hz, 0.7H), 4.50 (dd, J = 13.2, 10.8 Hz, 0.3H), 4.37(dd, J = 12.8, 3.2 Hz, 0.7H), 4.20 (dd, J = 14, 4.0 Hz, 0.3H), 4.07-3.95 (m, IH), 3.77-3.71 (m, 0.7H), 3.59- 3.55 (m, 0.3H), 3.10-2.87 (m, IH), 2.22-1.90 (m, 5H), 1.63-1.30 (m, IH); MS calculated for C24H27N4O3 (M+H+) 419.20, found 419.2.
Ή-NMR (400MHz, CD3OD): d 8.17-8.12 (m, 2H), 7.42-7.36 (m, 3H), 7.13-7.05 (m, 3H), 6.75 (dd, J = 10.4, 16.4 Hz, IH), 6.24 (d, J = 16.0 Hz, 0.25H), 6.22 (d, J = 16.0 Hz, 0.75H), 5.72(d, J = 10.4 Hz, 0.75H), -132 5.62 (d, J = 10.4 Hz, 0.25H), 5.26- 4.98 (m, IH), 4.53-4.30 (m, 3H), 4.22-3.94 (m, IH), 3.78-3.46 (m,
O 'I 2H), 2.96-2.89 (m, 8H), 2.18-1.96
(m, 4H), 1.33-1.00 (m, 2H); MS calculated for C28H34N5O4S (M+H+) 536.23, found 536.2.
Ή-NMR (400MHz, CDC13): d 12.82 (br s, IH), 8.33-8.26 (m, 2H), 7.56- 7.47 (m, 3H), 7.32-7.27 (m, IH), 7.21-7.15 (m, IH), 7.09-7.05 (m, -133 IH), 6.68 (dd, J = 10.8, 16.8 Hz,
0.7H), 6.62 (dd, J = 10.8, 16.8 Hz, 0.3H), 6.39 (dd, J = 16.8, 2.0 Hz, 0.3H), 6.35 (dd, J = 16.8, 2.0 Hz, 0.7H), 5.76 (dd, J = 2.0, 10.8 Hz, Ex. Compound Structure Physical Data (¾ NMR and MS)
0.7H), 5.63(dd, J = 2.0, 10.8 Hz, 0.3H), 5.22-5.12 (m, 1H), 4.64(d, J = 13.2 Hz, 1H), 4.51-4.35 (m, 2H), 4.07-3.84 (m, 1H), 3.71-3.61 (m, 1H), 3.43 (d, J = 13.2 Hz, 1H), 3.23- 2.91 (m, 4H), 2.94 (s, 0.9H), 2.82 (s, 2.1H), 2.28 (s, 2.1H), 2.24 (s, 0.9H), 2.22-1.97 (m, 4H), 1.55-1.09 (m, 2H); MS calculated for C28H36N5O4S (M+H+) 538.24, found 538.2.
Ή-NMR (400MHz, CDC13): d 12.99 - 12.85 (br s, 1H), 8.28-8.25 (m, 2H), 7.55 - 7.45 (m, 3H), 7.41-7.33 (m, 1H), 7.27-7.16 (m, 2H), 6.78 (dd, J = 10.4, 16.4 Hz, 0.3H), 6.63 (dd, J = 10.4, 16.4 Hz, 0.7H), 6.41 (dd, / = 2.0, 16.4Hz, 0.3H), 6.33 (dd, / = 2.0, 16.4 Hz, 0.7H), 5.75 (dd, J = 10.4, 2.0Hz, 0.7H), 5.64 (dd, J = 10.4, -134
2.0Hz, 0.3H), 5.16 - 4.55 (m, 2H), 4.42-4.36 (m, 1H), 4.17 - 4.14 (m, 1H), 4.01-3.89 (m, 1H), 3.86-3.60 (m, 3H), 3.75(s, 0.9H), 3.74 (s, 2.1H),
COOMe
2.77 (t, J = 6.4, 6.4Hz, 1.4H), 2.71 (t, J = 6.4, 6.4 Hz, 0.6H), 2.30 - 1.88 (m, 5H), 1.46 - 1.36 (m, 1H), MS calc. for C28H32N5O5 (M+H+) 518.24, found 518.2.
]H-NMR (400MHz, CDCI3): d 12.89 (br s, 1H), 8.26 (d, J = 7.9 Hz, 2H), 7.54-7.44 (m, 3H), 7.40-7.28 (m, 2H), 7.23-7.09 (m, 1H), 6.80 (dd, / = 10.5, 16.7 Hz, 0.3H), 6.61 (dd, / = 10.5, 16.7 Hz, 0.7H), 6.36 (dd, / =1.6, 16.4 Hz, 0.3H), 6.25 (dd, J =1.6, 16.4 Hz, 0.7H), 5.71 (dd, J = -135
1.6, 10.4 Hz, 0.7H), 5.59 (dd, J = 2.0, 10.4 Hz, 0.3H), 4.87-4.65 (m, 1H),
MeOOC // 4.41 - 3.89 (m, 4H), 3.82(s, 0.9H),
3.79 (s, 2.1H), 3.66-3.58(m, 2H), 2.88-2.72 (m, 1H), 2.22 - 1.95 (m, 5H), 1.60 - 1.45 (m, 1H); MS calculated for C27H30N5O5 (M+H+) 504.22, found 504.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400MHz, CDCl3): δ 8.23- 8.20 (m, 2H), 7.54-7.36 (m, 4H), 7.25
- 7.10 (m, 2H), 6.60 (dd, / = 10.4, 16.8 Hz, 1H), 6.29 (dd, J = 1.2, 16.8 Hz, 1H), 5.78 (d, J = 15.2 Hz, 1H), 4.79 - 4.68 (m, 1H), 4.48 - 4.43 (m, -136
1H), 4.23 - 4.20 (m, 1H), 3.95- 3.78(m, 2H), 3.71-3.58 (m, 2H), 2.75
- 2.59 (m, 2H), 2.35-1.80 (m, 4H),
COOH 1.68 - 1.40 (m, 2H); MS calculated for C27H30N5O5 (M+H+) 504.22, found 504.2.
]H-NMR (400MHz, CDC13): δ 8.16- 8.14(d, J = 7.6 Hz, 2H), 8.05 (br s, 1H), 7.92 (br s, 1H), 7.44-7.3 l(m, 4H), 7.26-7.16 (m, 1H), 7.05-6.95 (m, 1H), 6.86 (brs, 1H), 6.78 (dd, / = 10.8, 16.4 Hz, 0.3H), 6.29 (dd, / = 10.8, 16.4 Hz, 0.7H), 6.28-6.19 (m, -137 1H), 6.75 (d, J = 10.8 Hz, 0.7H), 5.58
(d, J = 10.8 Hz, 0.3H), 4.77-4.54 (m, 1H), 4.45-4.19 (m, 2H), 4.09-3.92
HOOC (m, 2H), 3.89-3.64 (m, 1H), 3.60- 3.36 (m, 1H), 2.74-2.57 (m, 1H), 2.17-1.67 (m, 3H), 1.62-1.23 (m, 2H); MS calculated for C26H28N5O5 (M+H+) 490.20, found 490.1.
]H NMR (400 MHz, CDC13) δ 8.25 - 8.22 (m, 2H), 7.75 - 7.68 (m, 1H), 7.62 - 7.32 (m, 5H), 6.53 (dd, / = 10.4, 16.8 Hz, 0.6H), 6.46 (dd, / = 10.4, 16.8 Hz, 0.4H), 6.27 (dd, / = 1.6, 16.8 Hz, 0.6H), 6.23 (dd, / = 1.6, 16.8 Hz, 0.4H), 5.71 (dd, / = 10.4, 1.6 Hz, 0.4H), 5.55 (dd, J = 10.4, 1.6 -138
Hz, 0.6H), 5.10-4.83 (m, 1H), 4.41- 4.14 (m, 1H), 4.00-3.70 (m, 1H), 3.62-3.47 (m, 1H), 2.92-2.71 (m, 1H), 2.54-2.42 (m, 1H), 2.47 (s, 1.9H), 2.46 (s, 1.1H), 2.19-1.85(m, 4H), 1.40-1.21(m, 1H); MS calculated for C26H27N6O3 (M+H+) 471.21, found 471.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H NMR (400 MHz, CD3OD) δ 8.27 - 8.22 (m, 2H), 7.67 - 7.59 (m, IH), 7.56 - 7.28 (m, 5H), 6.83 (dd, / = 10.4, 16.8 Hz, IH), 6.31 (dd, J = 2.0, 16.8 Hz, 0.6H), 6.30 (dd, J = 2.0, 16.8 Hz, 0.4H), 5.79 (dd, / = 10.4, 2.0 Hz, 0.6H), 5.68 (dd, / = 10.4Hz, -139
0.4H), 4.70 - 4.50 (m, IH), 4.19 - 4.05 (m, IH), 3.98 - 3.77 (m, 3H), 3.68 - 3.61 (m, IH), 3.56-3.43(m, 2H), 3.09(s, 3H), 2.91-2.79 (m, IH), 2.24 - 1.88 (m, 4H), 1.50-1.41 (m, 2H); MS calculated for C27H32N5O5S (M+H+) 538.20, found 538.1.
]H-NMR (400MHz, CDC13): δ 8.31- 8.28 (m, 2H), 7.54-7.47 (m, 3H), 7.38- 7.35 (m, IH), 7.27-7.20 (m, 2H), 6.59 (dd, J = 10.8,17.2 Hz, IH), 6.31 (d, J = 16.8 Hz, 0.3H), 6.28 (d, J = 16.8 Hz, 0.7H), 5.80 (d, J = 10.8 Hz, 0.3H), 5.78 (d, J = 10.8Hz, 0.7H), 4.77-4.68 (m, IH), 4.61-4.45 -140 (m, IH), 4.39 (s, IH), 4.34-4.25 (m,
IH), 4.19-4.10 (m, 2H), 4.07-3.98 (m, IH), 3.91-3.72 (m, 2H), 3.62-
Figure imgf000171_0001
3.56 (m, IH), 3.53-3.49 (m, IH),
2.85-2.72 (m, IH), 2.31-2.26 (m, IH), 2.23-2.01 (m, 4H), 2.07 (s, 2H), 1.47-1.33 (m, IH); MS calculated for C28H32N5O5 (M+H+) 518.23, found 518.2.
MS calculated for C25H25N6O4 (M+H+) 473.19, found 473.0.
-141
]H NMR (400 MHz, CDC13) δ 8.25 - 8.09 (m, 2H), 7.82 - 7.68 (m, IH), 7.62 - 7.32 (m, 5H), 7.02-6.81 (m, IH), 6.68-6.57 (m, IH), 5.46-5.30 (m, 0.5H), 4.82-4.66 (m, 1.5H), 4.41- -142
4.14 (m, 2H), 4.00-3.80 (m, 4H), 3.50-3.25 (m, 2H), 2.81 (s, 3H), 2.58- 2.47 (m, 6H), 1.49-1.35 (m, IH); MS
— N calculated for C28H32N7O4 (M+H+)
\ 530.24, found 530.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
CF3 MS calculated for C27H31F3N5O3
(M+H+) 530.23, found 530.2. -143
\
]H NMR (400 MHz, CDC13) δ 8.57 (m,lH), 7.91 - 7.70 (m, 2H), 7.17 - 7.10 (m, IH), 7.00 - 6.86 (m, IH),
6.56 (m, IH), 6.46 - 6.21 (m, IH), 5.73 - 5.54 (m, IH), 5.03 - 4.77 (m, 1.6H), 4.79 (m, 0.4H), 4.31 (m, 1.6H), 4.19 - 4.08 (m, 0.4H), 3.98 - -144
3.73 (m, 2H), 3.53 (m, 2.5H), 3.43 -
3.29 (m, 0.5H), 2.91 - 2.73 (m, IH), 2.73 - 2.62 (m, 2H), 2.63 (s, 2H),
2.30 (s, 3H), 2.20 - 1.66 (m, 6H),
1.57 (s, 3H), 1.47 - 1.25 (m, 2H); MS calculated for C30H39N6O2 (M+H+) 515.31, found 515.3.
]H NMR (400 MHz, MeOD) δ 8.55 (d, J = 5.2, IH), 8.01 (d, J = 15.3, IH), 7.93 (dd, J = 5.6, 9.7, IH), 7.36
- 7.27 (m, IH), 7.03 (s, IH), 6.84 (dt, / = 10.2, 16.8, IH), 6.31 (td, / = 1.9, 16.4, IH), 5.80 (dd, J = 1.9, 10.6, 0.6H), 5.70 (dd, J = 1.9, 10.5, 0.4H), 5.10-5.03 (m, IH), 4.54-4.50 (m, -145
IH), 4.33-4.29 (m, 0.6H), 4.25 - 4.16 (m, 0.4H), 4.11 - 3.93 (m, IH), 3.75
- 3.60 (m, 2H), 3.57 - 3.45 (m, IH), 2.88-2,85 (m, IH), 2.75 (s, 3H), 2.73
- 2.66 (m, 4H), 2.67 (s, 3H), 2.26 - 1.95 (m, 6H), 1.57 - 1.36 (m, IH); MS calculated for C28H35N6O2 (M+H+) 487.27, found 487.3. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H NMR (400 MHz, CDC13) δ 12.65 (s, 1H), 11.20 (s, 1H), 8.67 - 8.55 (m, 1H), 7.97 - 7.87 (m, 1H), 7.86 - 7.78 (m, 1H), 7.65 - 7.57 (m, 1H), 6.68 - 6.56 (m, 1H), 6.53 - 6.30 (m, 1H), 5.77 - 5.66 (m, 1H), 5.07-4.89 (m, 1H), 4.65-4.62 (m, 1H), 4.35 - 4.11 -146 (m, 2H), 4.03 - 3.78 (m, 2H),3.69- 3.61 (m, 4H), 2.96 - 2.84 (m, 1H), 2.83 - 2.73 (m, 2H), 2.70 - 2.59 (m, 3H), 2.34 - 2.18 (m, 2H), 2.18 - 2.12 (m, 1H), 2.12 - 1.96 (m, 3H), 1.13- 1.52 (m, 6H); MS calculated for C29H37N6O3 (M+H+) 517.28, found 517.3.
Ή NMR (400 MHz, MeOD) δ 8.56 (d, / = 5.2, 1H), 8.02 (d, / = 15.1 , 1H), 7.93 (dd, / = 5.3, 9.9, 1H), 7.40 (d, / = 5.8, 1H), 7.11 (d, / = 12.8, 1H), 6.85 (dt, / = 11.0, 16.8, 1H), 6.31 (td, / = 1.9, 16.6, 1H), 5.81 (dd, / = 1.9, 10.6, 0.7H), 5.71 (dd, / = 1.9, 10.5, 0.3H), 5.32 - 5.25 (m, 1H), 5.19 -147 - 5.02 (m, 1H), 4.97 - 4.91 (m, 1H),
4.60 - 4.51 (m, 1H), 4.35 - 4.25 (m, 1H), 4.13 - 3.92 (m, 1H), 3.88 - 3.60 (m, 3H), 3.05 - 2.80 (m, 3H), 2.80 (s, 2H), 2.72 (s, 2H), 2.64 (s, 3H), 2.54- 2.50 (m, 1H), 2.32-2.18 (m, 2H), 2.08-2.01 (m, 3H), 1.55 - 1.42 (m, 1H); MS calc. for C29H36FN6O2 (M+H+) 519.28, found 519.3 .
lU NMR (400 MHz, CDC13) δ 8.52 (d, J = 5.1, 1H), 7.97 (d, J = 13.8, 1H), 7.93 - 7.83 (m, 1H), 7.35 (d, / = 11.4, 1H), 7.06 (s, 1H), 6.74 (dd, J = 10.6, 16.8, 1H), 6.42 - 6.22 (m, 1H), 5.83 - 5.67 (m, 1H), 5.29 - 4.99 (m, 2H), 4.94-4.88 (m, 1H), 4.56 - 4.41 -148 (m, 1H), 4.36 (d, J = 10.2, 1H), 4.15
- 3.89 (m, 2H), 3.80-3.64 (m, 3H), 2.98-2.88 (m, 2H), 2.75 (s, 3H), 2.70- 2.65 (m, 1H), 2.62(s, 3H), 2.57 - 2.34 (m, 1H), 2.34 - 1.89 (m, 5H), 1.48- 1.40 (m, 1H); MS calc. for C29H36FN6O2 (M+H+) 519.28, found 519.3. Ex. Compound Structure Physical Data (¾ NMR and MS)
Ή NMR (400 MHz, MeOD) δ 8.55 (d, / = 4.2, IH), 8.02 (d, / = 15.0, IH), 7.93 (dd, / = 5.3, 9.8, IH), 7.46 (s, IH), 7.18 (s, IH), 6.85 (dt, / = 10.3, 16.8, IH), 6.31 (td, / = 1.9, 16.5, IH), 5.82 (dd, J = 1.9, 10.6, 0.6H), 5.71 (dd, J = 1.9, 10.5, 0.4H), 5.09-5.06 (m, IH), 4.99 - 4.91 (m, -149
IH), 4.90 (s, 3H), 4.58-4.52 (m, IH), 4.37 - 4.25 (m, IH), 4.16 - 3.93 (m, 3H), 3.81 - 3.59 (m, IH), 3.16 - 2.83 (m, 4H), 2.79 (s, 3H), 2.71 (s, 2H), 2.63 (s, 3H), 2.30 - 2.15 (m, 2H), 2.15 - 1.94 (m, 3H), 1.57 - 1.41 (m, IH); MS calc. for C30H39N6O3 (M+H+) 531.30, found 531.3.
Ή NMR (400 MHz, CDC13) δ 12.50 (s, IH), 8.67 - 8.49 (m, IH), 7.92- 7.88 (m, IH), 7.81-7.79 (m, IH), 7.23 - 7.11 (m, IH), 6.99 (s, IH), 6.61- 6.56 (m, IH), 6.42- 6.32 (m, IH), 5.77 - 5.60 (m, IH), 5.10 - 4.87 (m, -150 2H), 4.49 - 4.28 (m, 2H), 3.93-3.87
(m, 2H), 3.62-3.57 (m, 4H), 3.25 (s, 3H), 2.91-2.83 (m, IH), 2.72 (s, 3H), 2.62 (s, 3H), 2.78 - 2.39 (m, 3H), 2.14-2.01 (m, 4H), 1.45-1.35 (m, 2H); MS calc. for C30H39N6O3 (M+H+) 531.30, found 531.3.
Ή NMR (400 MHz, MeOD) δ 8.45 (d, J = 5.2, IH), 7.92 (d, J = 15.1, IH), 7.88 - 7.72 (m, IH), 7.33 - 7.22 (m, IH), 6.99 (s, IH), 6.74 (dt, J = 11.2, 16.8, IH), 6.21 (td, J = 1.9, 16.7, IH), 5.71 (dd, J = 1.8, 10.6, 0.6H), 5.61 (dd, J = 1.9, 10.5, 0.4H), 4.99-4.92 (m, IH), 4.85-4.81 (m, IH), 4.48-4.44 (m, IH), 4.28-4.20 -151
(m, 0.6H), 4.15 - 4.07 (m, 0.4H),
7X - 4.05 - 3.82 (m, 2H), 3.64 - 3.52 (m,
IH), 3.60 (s, 3H) 3.45 - 3.36 (m, IH), 2.90 - 2.74 (m, 3H), 2.72 - 2.63 (m, IH), 2.66(s, 2H), 2.54 - 2.49 (s, 3H), 2.31 - 2.05 (m, 3H), 2.05 - 1.92 (m, 3H), 1.44 - 1.27 (m, IH); MS calc. for C29H35F2N6O2 (M+H+) 537.27, found 537.3.
Figure imgf000175_0001
Figure imgf000176_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
(m, IH), 2.34 - 1.97 (m, 6H), 1.89- 1.80 (m, IH), 1.55 - 1.36 (m, IH); MS calculated for C30H38F 6O2 (M+H+) 533.30, found 533.3.
lU NMR (400 MHz, CDC13) δ 12.56 (s, IH), 7.76-7.73 (m, 2H), 7.22-7.17 (m, IH), 7.05-7.04 (m, IH), 6.68- 6.62 (m, IH), 6.62-6.37 (m, IH), 5.82
- 5.70 (m, IH), 5.29 (br, IH), 5.13 - 5.03 (m, 2H), 5.13-4.79 (m, IH), 4.50 -159 - 4.38 (m, 2H), 4.06 - 3.87 (m, 2H),
3.77 - 3.56 (m, 3H), 3.05 - 2.69 (m, 3H), 2.77 (s, 3H), 2.63 (s, 6H), 2.49- 2.45 (m, IH), 2.23-2.05 (m, 4H), 1.49-1.42 (m, IH); MS calculated for C30H38F 6O2 (M+H+) 533.30, found 533.3.
Ή NMR (400 MHz, CDC13) δ 12.51 (d, / = 31.7, IH), 7.92 - 7.74 (m, IH), 7.31-7.25 (m, IH), 7.21 - 6.90 (m, 3H), 6.69 - 6.51 (m, IH), 6.45- 6.32 (m, IH), 5.78 - 5.60 (m, IH), 5.08 - 4.86 (m, 1.6H), 4.76 - 4.64 (m, 0.4H), 4.45-4.38 (m, 1.6H), 4.25- -160 4.19 (m, 0.4H), 4.07 - 3.77 (m, 2H),
3.77 - 3.49 (m, 2H), 3.28 (s, 3H), 2.95-2.90 (m, IH), 2.82 - 2.66 (m, IH), 2.72 (s, 3H), 2.66 - 2.41 (m, 2H), 2.30 - 1.79 (m, 5H), 1.55 (s, 2H), 1.47 - 1.19 (m, 2H); MS calculated for C30H36F2N5O3 (M+H+) 552.27, found 552.3.
Ή NMR (400 MHz, CDC13) δ 12.47 (s, IH), 9.69 (dd, / = 1.7, 10.1, IH), 8.02 - 7.86 (m, IH), 7.22 - 7.15 (m, IH), 7.08 - 6.94 (m, IH), 6.66 - 6.52 (m, IH), 6.43 - 6.27 (m, IH), 5.80 - 5.61 (m, IH), 5.11 - 4.93 (m, IH), 4.52 - 4.12 (m, 2H), 3.87-3.82 -161
(m,lH), 3.76 - 3.50 (m, 2H), 2.91 - 2.76 (m, IH), 2.79 (s, 3H), 2.72 (s, 2H), 2.63 - 2.56 (m, IH), 2.57 (s, 3H), 2.24 - 1.92 (m, 5H), 1.85-1.70 (m, 5H), 1.54 - 1.27 (m, IH); MS calculated for C28H36N7O2 (M+H+) 502.29, found 502.3.
Figure imgf000178_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
(s, 2H), 2.17 - 2.02 (m, 2H), 1.95 (d, / = 6.8, 3H), 1.51 - 1.34 (m, IH); MS calculated for C31H40FN6O2 (M+H+) 547.31, found 547.3.
]H NMR (400 MHz, CDC13) δ 12.58 (s, IH), 8.66 (d, / = 5.1, IH), 7.95 (s, IH), 7.87 (d, J = 5.2, IH), 7.20( br, IH), 7.06-7.01 (m, IH), 6.97 (dd, J = 6.9, 15.0, IH), 6.33 (dd, / = 1.7, 15.0, IH), 5.22-5.10 (m, IH), 4.99-4.90 (m, IH), 4.53 - 4.28 (m, IH), 4.14- -166 4.08 (m, 2H), 4.06 - 3.91 (m, 2H),
3.73 (s, 2H), 3.69 - 3.33 (m, 2H), 3.05-2.94 (m, 3H), 2.79 (s, 3H), 2.67 (s, 3H), 2.19 (s, 2H), 2.20-2.18 (m, IH) 2.15-2.02(m, 2H), 2.01 - 1.74 (d, 3H), 1.45-1.38 (m, IH); MS calculated for C30H38FN6O2 (M+H+) 533.30, found 533.2.
]H-NMR (DMSO-d6, 400 MHz): d
CF3 12.5 (br s, IH), 8.51 (s, IH), 8.36 (s, IH), 7.68 (s, 2H), 7.53 (s, 2H), 7.46 (s, 2H), 6.62-6.60 (m, IH), 6.33 (d, J = 16.8 Hz, IH), 5.74 (s, IH), 4.73 (s, -167
IH), 4.48-4.09 (m, 3H), 3.94-3.76 (m, 7H), 3.19 (s, 2H), 2.69 (s, 3H), 2.03 (s, 3H); MS calculated for C24H27F3N5O4 (M+H+) 506.19, found 506.2.
]H-NMR (400 MHz, DMSO-d6): d
12.5 (s, IH), 8.46-8.40 (m, 2H), 7.80 (d, J = 7.6 Hz, IH), 7.68-7.64 (m, IH), 6.88-6.81 (m, IH), 6.14 (t, J =
15.6 Hz, IH), 5.74-5.60 (m, IH), 4.56 -168 (s, IH), 4.32-4.31 (m, 4H), 3.50-3.40
(m, 3H), 2.98 9s, 3H), 2.86 (s, 3H), 2.11-1.89 (m, 3H), 1.55-1.52 (m, 2H); MS calculated for
Figure imgf000179_0001
C23H27F3N5O4S (M+H+) 526.17, found 526.1. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400 MHz, DMSO-d6): d 12.54 (s, IH), 8.40 (s, 2H), 7.81 (s, IH), 7.67 (s, IH), 6.85 (s, IH), 6.14 (s, IH), 5.71-5.59 (m, IH), 4.53-4.20 -169 (m, 5H), 3.90-3.50 (m, 3H), 2.79- 2.67 (m, 2H), 2.11-1.87 (m, 7H), 1.51-1.33 (m, 2H); MS calculated for C24H27F3N5O3 (M+H+) 490.20,
Figure imgf000180_0001
found 490.4.
]H-NMR (400 MHz, DMSO-d6): d
0 /_/C F3 12.51 (s, IH), 8.39 (s, 2H), 7.82 (d, J
= 7.2 Hz, IH), 7.67 (t, J = 7.2 Hz, IH), 6.86 (d, J = 14 Hz, IH), 6.14 (t, / = 13.2 Hz, IH), 5.73-5.59 (m, IH), -170
4.54-4.21 (m, 4H), 3.66 (s, 5H), 2.67- 2.55 (m, 4H), 2.11-1.86 (m, 2H), 1.57 (s, IH); MS calculated for C24H25F3N5O4 (M-H ) 504.19, found 504.3.
]H-NMR (400 MHz, DMSO-d6): d
0 __ /C F3 12.55 (s, IH), 8.40 (s, 2H), 7.82 (d, J
= 7.2 Hz, IH), 7.68 (t, J = 7.6 Hz, IH), 6.87 (t, / = 8.4 Hz, IH), 6.16 (d, J = 12.8 Hz, IH), 5.75 (s, IH), 4.58- -171
4.23 (m, 5H), 3.55-3.36 (m, 3H), 3.02 (s, 3H), 2.69 (s, 3H), 2.11-1.86 (m, 2H), 1.59-1.56 (m, IH); MS calculated for C23H27F3N5O4S (M+H+) 526.17, found 526.1
]H-NMR (400 MHz, CDCI3): d 8.51 (s, IH), 8.36 (d, / = 7.2 Hz, IH), 7.69 (d, / = 6.8 Hz, IH), 7.53 (t, / = 7.6 Hz, IH), 6.61-6.59 (m, IH), 6.33 (d, / = 16.8 Hz, IH), 5.76-5.74 (m, IH), -172
4.81 (s, 2H), 4.42-4.39 (m, 2H), 4.12- 3.65 (m, 4H), 2.70-2.64 (m, 4H), 2.22 (s, 3H), 2.15-2.09 (m, IH); MS calculated for C24H27F3N5O3 (M+H+) 490.20, found 490.4.
]H-NMR (400 MHz, DMSO-d6): d 12.40 (s, IH), 8.38 (s, 2H), 7.28-7.65 (m, 3H), 6.87-6.83 (m, IH), 6.17- 6.10 (m, 2H), 5.73-5.58 (m, IH), -173 4.54-4.52 (m, IH), 4.28-4.25 (m,
2H), 3.69-3.50 (m, 3H), 2.69-2.08 (m, 6H), 1.98-1.86 (m, 3H), 1.52- 1.29 (m, 3H); MS calculated for C23H27F3N5O2 (M+H+) 462.20, found Ex. Compound Structure Physical Data (¾ NMR and MS)
462.3.
]H NMR (400 MHz, CDC13) δ 12.39 (s, IH), 7.74 (s, IH), 7.72 (s, IH), 7.41-7.36 (m, 2H), 7.26-7.23 (m, IH), 7.10 - 6.91 (m, IH), 6.49 - 6.23 (m, IH), 4.81 (br, IH), 4.38 - 4.02 -174
(m, 2H), 4.02 - 3.58 (m, 5H), 3.27 (s, 3H), 2.85-2.69 (m, 3H), 2.60 (s, 3H), 2.58 (s, 3H), 2.21 - 1.39 (m, 12H); MS calculated for C31H41N6O3 (M+H+) 545.32, found 545.3.
lU NMR (400 MHz, CDC13) δ 12.41 (s, IH), 7.74 (s, IH), 7.72 (s, IH), 7.41-7.37 (m, 2H), 7.32 - 7.21 (m, IH), 6.76 (dd, J = 10.3, 16.7 Hz, 0.4H), 6.65 (dd, J = 10.4, 16.7 Hz, 0.6H), 6.45 (ddd, J = 1.9, 16.7 Hz, 18.6, IH), 5.71 (ddd, J = 1.9, 10.4, -175 50.8 Hz, IH), 4.83 (br, IH), 4.31- 4.34 (m, 2H), 3.98 - 3.88 (m, IH), 3.85-3.65 (m, 4H), 3.27 (s, 3H), 2.88 - 2.70 (m, 2H), 2.60 (s, 3H), 2.59 (s, 3H), 2.16-1.80 (m, 8H), 1.69 - 1.46 (m, 2H). ESMS calculated for C30H39N6O3 (M+H+) 531.30, found 531.2
'H NMR (400 MHz, CDC13) δ 12.52 (s, IH), 8.50-8.45 (m, IH), 7.92-7.74 (m, 2H), 7.20-7.09 (m, IH), 6.99- 6.89 (m, IH), 6.81-6.69 (m, 2H), 6.59-6.39 (m, IH), 5.45-5.30 (m, IH), 4.64-4.58 (m, 0.45H), 4.38-4.28 (m, 0.55H), 4.15-4.01 (m, IH), 3.97 (, 1.65H), 3.87 (s, 1.35H), 3.79-3.65 -176 (m, IH), 3.58-3.47 (m, IH), 3.27- 3.10 (m, IH), 3.07-2.99 (m, IH), 2.87-2.75 (m, IH), 2.72-2.57 (m,
\ IH), 2.53 (s, 1.65H), 2.50 (s, 1.35H),
2.36-2.24 (m, IH), 2.18 (s, 2H), 2.14- 2.05 (m, IH), 2.01 (s, 2H), 1.87 (2H), 1.94- 1.88 (m, IH), 1.49- 1.32 (m, IH); MS calculated for C27H35N6O3 (M+H+) 491.27, found 491.3. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H-NMR (400MHz, CD2C12): δ 12.56 (s, 1H), 8.51-8.49 (m, 1H), 7.84-7.72 (m, 2H), 7.18-7.13 (m, 1H), 6.91- 6.72 (m, 2H), 6.43 (dd, J = 5.3, 15.1 Hz, 1H), 5.63-5.58 (m, 1H), 4.75- 4.69 (m, 0.5H), 4.47-4.41 (m, 0.5H), 4.28-4.23 (m, 0.6H), 4.04-3.95 (m, 0.6H), 3.93-3.89 (m, 0.4H), 3.85 & -177 3.84 (s & s, 3H), 3.79-3.72 (m, 0.4H),
3.59-3.53 (m, 0.6H), 3.35-3.29 (m, 0.4H), 3.05 (br d, J = 5.4 Hz, 1H),
\ 2.87 (br d, J = 5.7Hz, 1H), 2.76-2.59 (m, 1H), 2.52 (s, 3H), 2.21 (s, 3H), 2.04 (s, 3H), 2.10-1.78 (m, 4H), 1.44- 1.35 (m, 1H); MS calc. for C27H34CIN6O3 (M+H+) 525.23, found 525.2.
]H-NMR (400MHz, CD2C12): δ 12.48 (s, 1H), 8.51-8.49 (m, 1H), 7.86-7.76 (m, 2H), 7.42 (s, 0.6H), 7.33 (s, 0.4H), 6.93 (s, 0.4H), 6.89 (s, 0.6H), 6.85-6.73 (m, 1H), 6.60-6.53 (m, 1H), 4.76-4.58 (m, 1H), 4.11-4.01 (m, 2H), 3.85 & 3.83 (s & s, 3H), -178
3.77-3.70 (m, 1H), 3.64-3.58 (m, 1H), 3.27-3.22 (m, 1.4H), 2.87-2.80 (m, 0.6H), 2.53 & 2.52 (s&s, 3H), 2.34 (s, 3.6H), 2.08 (s, 2.4H), 2.05- 1.76 (m, 4H), 1.48-1.40 (m, 2H); MS calculated for C27H34C1N603 (M+H+) 525.23, found 525.2.
]H NMR (400 MHz, CD2C12): δ 12.45 (br s, 1H), 7.66 (s, 1.2H), 7.62 (s, 0.8H), 7.42 (s, 0.6H), 7.30 (s, 0.4H), 6.92 (0.4H), 6.88 (s, 0.6H), 6.85-6.72 (m, 1H), 6.44-6.40 (m, 1H), 4.72-4.57 (m, 1H), 4.13-4.05 (m, 2H), 3.84 & 3.82 (s &s, 3H), -179 3.79-3.69 (m, 1H), 3.60-3.55 (0.6H),
3.24-3.20 (0.4H), 3.03 (d, J = 6.0 Hz, 1H), 2.73-2.53 (m, 1H), 2.48 & 2.47 (s & s, 6H), 2.18 (s, 3.6 H), 1.95 (s,
\ 2.4H), 2.04-1.78 (m, 4H), 1.48-1.39 (m, 2H); MS calculated for
C28H36C1N603 (M+H+) 539.25, found 539.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H NMR (400 MHz, MeOD) δ 7.78 (s, IH), 7.75 (s, IH), 7.35-7.34 (m, IH), 7.08-7.07 (m, IH), 6.86-6.79 (m, IH), 6.31-6.27 (m, IH), 5.82- 5.79 (m, IH), 5.11-5.01 (m, IH),
4.53- 4.51 (m, IH), 4.29-4.26 (m, IH), 4.19-3.93 (m, IH), 3.62 (s, 2H), -180 3.54- 3.45 (m, IH), 3.37-3.32 (m,
2H), 3.11 (s, 2H), 3.04-2.99 (m, IH), 2.95 (s, 3H), 2.92-2.79 (m, IH), 2.71 (s, 3H), 2.58 (br, 2H), 2.26 - 2.15 (m, IH), 2.06 (br, 2H), 1.50-1.35 (m, IH), 1.28 (s, 3H), 1.29 (s, 3H); MS calculated for C31H40N7O3 (M+H+) 558.31, found 558.3.
]H NMR (400 MHz, MeOD) δ 7.77 (s, IH), 7.74 (s, IH), 7.33-7.31 (m, IH), 7.07-7.04 (m, IH), 6.86-4.79 (m, IH), 6.23-6.27 (m, IH), 5.82- 5.79 (m, IH), 5.08-5.01 (m, IH), 4.55-4.49 (m, IH), 4.27 (d, IH), 4.04- 3.93 (m, IH), 3.71-3.62 (m, 2H), -181
3.59-3.52 (m, 4H), 3.20-3.17 (m, IH), 2.88-2.84 (m, IH), 2.73 (s, 2H), 2.68 (br, IH), 2.57 (s, 3H), 2.47-2.42 (m, 2H), 2.21 (br, IH), 2.16 (s, 2H), 2.08 (s, 3H), 2.05 (br, 2H), 1.36 (s, 3H), 1.35 (s, 3H); MS calculated for C32H42N7O3 (M+H+) 572.33, found 572.3.
]H NMR (400 MHz, CD2C12) δ 8.62 (dd, / = 5.8, 21.5 Hz, IH), 8.02 (d, / = 5.8 Hz, IH), 7.40-7.22 (m, 3H), 6.91-6.82 (m, IH), 6.59-6.45 (m,
^P=0 IH), 5.73-5.58 (m, IH), 4.85 (dd, / =
10.7, 14.7 Hz, 0.5H), 4.56 (dd, / = 10.5, 13.0 Hz, 0.5H), 4.44 (dd, / = 3.9, 13.0 Hz, 0.5H), 4.27-4.15 (m, -182 0.5H), 4.06 (dd, 7 = 3.1, 14.6 Hz,
0.5H), 3.98-3.87 (m, IH), 3.83-3.72 (m, IH), 3.49-3.39 (m, 0.5H), 3.04 (dd, / = 6.0, 50.1 Hz, 2H), 2.90-2.74
58% ee x (m, IH), 2.70 (s, 3H), 2.28 (s, 3H),
2.21-1.99 (m, 5H), 1.77 (dd, / = 3.5, 13.5 Hz, 7H), 1.58-1.41 (m, IH), MS calculated for C28H37CIN6O3P (M+H+) 571.23, found 571.3.
Figure imgf000184_0001
found: 481.2.
Figure imgf000185_0001
Ex. Compound Structure Physical Data (¾ NMR and MS)
]H NMR (400 MHz, CD2C12) δ 8.51- 8.47 (m, 1H), 7.83 (d, / = 9.3 Hz, 1H), 7.78-7.70 (s, 1H), 7.25-7.08 (m, 3H), 6.78-6.69 (m, 1H), 6.42-6.37 (m, 1H), 5.59-5.42 (m, 1H), 4.77- 4.68 (m, 0.5H), 4.47-4.36 (m, 0.5H), 4.34-4.21 (m, 0.5H), 4.13-3.96 (m, -189 0.5H), 3.96-3.86 (m, 0.5H), 3.82-3.68
(m, 1H), 3.62-3.47 (m, 1H), 3.36- 3.24 (m, 0.5H), 2.98 (d, / = 5.9 Hz, 1H), 2.81 (d, / = 5.9 Hz, 1H), 2.78- CD3
2.59 (m, 1H), 2.53 (s, 3H), 2.03 (s, 4H), 1.43-1.29 (m, 1H); MS calculated for C26H26D6C1N602 (M+H+) 501.26, found: 501.3.
]H NMR (400 MHz, CD2C12) δ 8.52 (s, 1H), 7.83 (d, / = 7.3 Hz, 1H), 7.74 (s, 1H), 7.26-7.08 (m, 3H), 6.90-6.76 (m, 1H), 6.43-6.29 (m, 1H), 5.60- 5.42 (m, 1H), 4.77-4.66 (m, 0.5H), 4.47-4.37 (m, 0.5H), 4.32-4.22 (m, 0.5H), 4.06-3.95 (m, 0.5H), 3.94-3.84 (m, 0.5H), 3.83-3.70 (m, 0.5H), 3.60- -190 3.50 (m, 0.6H), 3.39 (d, J = 5.4 Hz,
1H), 3.35-3.27 (m, 0.4H), 3.25 (d, / = 5.2 Hz, 1H), 2.77-2.61 (m, 1H), 2.53 (s, 3H), 1.89 (s, 6H), 1.47- 1.31 (m,
Figure imgf000186_0001
2H), 0.38-0.32 (m, 1H), 0.28-0.22
(m, 1H), 0.21-0.15 (m, 1H), 0.04- 0.02 (m, 1H); MS calculated for C27H32C1N602 (M+H+) 507.22, found: 507.2.
]H NMR (400 MHz, CD2C12) δ 8.53- 8.47 (m, 1H), 7.83 (d, 7 = 5.83 Hz, 1H), 7.79-7.70 (m, 1H), 7.28-7.09 (m, 3H), 6.94-6.78 (m, 1H), 6.51- 6.34 (m, 1H), 5.60-5.43 (m, 1H), 4.77-4.68 (m, 0.5H), 4.46-4.34 (m, 0.5H), 4.34-4.21 (m, 0.7H), 4.08-3.96 -191 (m, 0.5H), 3.96-3.85 (m, 0.3H), 3.85- 3.69 (m, 0.5H), 3.59-3.47 (m, 0.7H), -NH 3.34-3.26 (m, 1.3H), 3.17-3.12 (m,
1H), 2.79-2.57 (m, 1H), 2.53 (s, 3H), 1.89 (s, 6H), 1.50- 1.28 (m, 1H), 1.03 (s, 5H), 0.85 (s, 4H); MS calculated for C28H36C1N602 (M+H+) 523.25, found: 523.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H NMR (400 MHz, CD2C12) δ 8.53- 8.50 (m, IH), 7.85-7.81 (m, IH), 7.77-7.73 (m, IH), 7.26-7.07 (m, 3H), 6.87-6.77 (m, IH), 6.47-6.29 (m, IH), 5.59-5.42 (m, IH), 4.78- 4.65 (m, 0.5H), 4.47-4.35 (m, 0.5H), 4.33-4.24 (m, 0.5H), 4.06-3.94 (m, 0.4H), 3.93-3.83 (m, 0.5H), 3.83-3.68 (m, 0.6H), 3.60-3.48 (m, 0.7H), 3.42- -192
3.38 (m, IH), 3.33-3.20 (m, 1.3H), 3.02-2.96 (m, 0.3H), 2.86-2.59 (m,
V-NH . 1.7H), 2.53 (s, 3H), 2.15-1.77 (m,
6H), 1.18 (s, 1.5H), 1.04 (s, 1.5H), 0.49-0.46 (m, IH), 0.30-0.27 (m, IH), 0.24-0.20 (m, IH), 0.16-0.13 (m, IH); MS calculated for
C28H34C1N602 (M+H+) 521.24, found: 521.3.
]H NMR (400 MHz, CD2C12) δ 8.60- 8.41 (m, IH), 7.88-7.79 (m, IH), 7.79-7.68 (m, IH), 7.20-7.15 (m, IH), 7.01-6.81 (m, IH), 6.65-6.49 (m, IH), 6.35-6.16 (m, IH), 5.65- 5.46 (m, 2H), 4.79-4.73 (m, IH), 4.47-4.22 (m, 3H), 4.05-3.50 (m, -193
2H), 3.45-3.27 (m, 2H), 3.27-3.08 (m, 2H), 3.07-2.96 (m, IH), 2.95- 2.77 (m, IH), 2.76-2.57 (m, IH), 2.54 (s, 2H), 1.97-1.31 (m, 8H), 1.30-1.22 (m, IH), 1.21-1.06 (m, IH). MS calculated for C29H36CIN6O3 (M+H+) 551.25, found: 551.2.
Ή NMR (400 MHz, CD2C12) δ 8.50 (s, IH), 7.82 (d, / = 6.63 Hz, IH), 7.73 (s, IH), 7.16-7.11 (m, IH), 6.92- 6.79 (m, 2H), 6.34-6.20 (m, IH), 5.71-5.52 (m, IH), 4.78-4.65 (m, 0.5H), 4.48-4.35 (m, 0.5H), 4.30-4.20 (m, 0.5H), 4.12-3.95 (m, 3H), 3.93- -194 3.84 (m, 0.5H), 3.82-3.65 (m, 0.5H),
3.64-3.39 (m, IH), 3.37-3.22 (m, 0.5H), 2.88-2.82 (m, 2H), 2.78-2.62 (m, IH), 2.56 (s, 3H), 2.52 (s, 3H), 2.13-1.77 (m, 5H), 1.62-1.33 (m, 7H); MS calculated for
C30H38CIN6O3 (M+H+) 565.26, found: 565.2. Ex. Compound Structure Physical Data (¾ NMR and MS)
]H NMR (400 MHz, CD2C12) δ 7.63 (d, / = 6.1 Hz, 2H), 7.16-7.10 (m, IH), 6.93-6.75 (m, 2H), 6.28 (t, / = 14.3 Hz, IH), 5.69-5.56 (m, IH), 4.79-4.69 (m, 0.5H), 4.49-4.39 (m, 0.5H), 4.28-4.20 (m, 0.5 H), 4.12- 4.01 (m, 3H), 3.94-3.85 (m, 0.5H), -195 3.82-3.69 (m, 0.5H), 3.60-3.49 (m,
IH), 3.33-3.24 (m, 0.5H), 2.87 (t, / = 5.7 Hz, 2H), 2.78-2.62 (m, IH), 2.58 (s, 3H), 2.48 (s, 3H), 2.40-2.27 (m, IH), 2.12-1.81 (m, 6H), 1.77-1.51 (m, 7H), 1.45-1.30 (m, IH); MS calc. for C31H40CIN6O3 (M+H+) 579.28, found: 579.3.
]H NMR (400 MHz, CD2C12) δ 8.67- 8.50 (m, IH), 7.90 (dd, / = 10.3, 17.3 Hz, IH), 7.86-7.76 (m, IH), 7.42- 7.10 (m, 3H), 6.94-6.72 (m, IH), 6.62-6.35 (m, IH), 5.73-5.48 (m, IH), 4.83-4.77 (m, 0.5H), 4.59-4.42 (m, 0.5H), 4.40-4.36 (m, 0.5H), 4.19- 3.92 (m, IH), 3.88-3.81 (m, 0.5H), -196
3.68-3.61 (m, 0.5H), 3.46-3.35 (m, 0.5H), 3.07 (dd, / = 6.6, 15.3 Hz, IH), 3.02-2.85 (m, IH), 2.85-2.71
\ (m, IH), 2.57 (s, 3H), 2.27 (s, 3H),
2.20-2.01 (m, 4H), 2.01-1.86 (m, 3H), 1.62-1.38 (m, IH); MS calculated for C26H32C1N602 (M+H+) 495.22, found 495.10.
Ή NMR (400 MHz, CD2C12) δ 7.77- 7.66 (m, 2H), 7.38-7.10 (m, 3H), 6.94-6.75 (m, IH), 6.50 (ddt, / = 1.4, 6.9, 15.2 Hz, IH), 5.74-5.49 (m, IH), 4.86 (ddd, 7 = 5.9, 8.5, 25.4 Hz, 0.5H), 4.61-4.48 (m, 0.5H), 4.43-4.30 (m, 0.5H), 4.22-4.09 (m, 0.5H), 4.01 (dd, / = 3.5, 14.7 Hz, 0.5H), 3.87 (dt, -197 / = 8.6, 14.4 Hz, 0.5H), 3.73-3.53 (m,
0.5H), 3.44-3.28 (m, 0.5H), 3.16-3.05 (m, IH), 2.93 (dd, 7 = 1.3, 6.0 Hz,
\ IH), 2.88-2.70 (m, IH), 2.58 (s, 6H),
2.24 (s, 3H), 2.21-1.85 (m, 7H), 1.57- 1.41 (m, IH); MS calculated for C27H34C1N602 (M+H+) 509.24, found: 509.2. Example 18
(R)-l-(l-acryloylpiperidin-3-yl)-2-(3-(trifluoromethyl)benzamido)-lH-
Figure imgf000189_0001
A solution of Example 17-109 (50 mg, 0.1 mmol) and LiOH- H20 (12 mg, 0.25 mmol) in 1:1 THF/H20 (6 mL) was stirred at room temperature for 14 h (completion of reaction monitored by TLC). The mixture was diluted with water, adjusted to pH 3.5 with aqueous citric acid and extracted with CH2C12 (2x 30 mL). The combined organic phase was washed with brine, dried over Na2S04 and concentrated under reduced pressure. The crude material was purified by preparative TLC (10% MeOH in CH2C12) to afford the title compound (Example 18). ]H-NMR (400 MHz, DMSO-d6): d 13.08 (s, IH), 8.48 (d, / = 7.3 Hz, 2H), 8.18 (s, IH), 7.93-7.87 (m, 3H), 7.76 (d, 7 = 7.8 Hz, IH), 6.96-6.79 (m, IH), 6.22-6.13 (m, IH), 5.77-5.61 (m, IH), 4.85-72 (m, IH), 4.63-4.55 (m, IH), 4.40- 4.20 (m, IH), 4.18-4.07 (m, 0.5H), 3.75-3.68 (m, 0.5H), 3.27-3.21 (m, IH), 2.88-2.68 (m, IH), 2.06-1.90 (m, 2H), 1.71-1.59 (m, IH); MS calculated for C24H22F3N404 (M+H+) 487.15, found 487.3.
Example 19
(R)-l-(l-acryloylpiperidin-3-yl)-2-(3-(trifluoromethyl)benzamido)-lH- benzo rdlimidazole-5 -carboxamide
Figure imgf000189_0002
To a solution of Example 18 (50 mg, 0.1 mmol) and NH4C1 (7 mg, 0.11 mmol) in DMF (4 mL) were added hydroxybenzotriazole (15 mg, 0.11 mmol) and l-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (21 mg, 0.11 mmol) and the mixture was stirred at room temperature for 14 h (completion of reaction monitored by TLC). The mixture was diluted with water and extracted with CH2CI2 (3x 20 mL). The combined organic phase was washed with water and brine, dried over Na2S04 and concentrated under reduced pressure. The crude material was purified by column chromatography (10% MeOH in CH2C12) to afford the title compound (Example 19). ^-NMR (400 MHz, DMSO-d6): d 13.0 (br s, 1H), 8.47 (d, J = 7.2 Hz, 2H), 8.06-7.73 (m, 6H), 7.35 (s, 1H), 6.92-6.79 (m, 1H), 6.17-6.13 (m, 1H), 5.75-5.60 (m, 1H), 4.81-4.60 (m, 2H), 4.29-4.10 (m, 1H), 2.84-2.72 (m, 1H), 2.17-1.94 (m, 3H), 1.65 (s, 2H); MS calculated for
C24H23F3N503 (M+H+) 486.17, found 486.3.
Example 20
l-(l-acryloylazepan-3-yl)-2-(3-(trifluoromethyl)benzamido)-lH-benzordlimidazole-7-
Figure imgf000190_0001
The title compound (Example 20) was prepared following procedures analogous to Example 19, substituting Example 17-95 for Example 17-109. Ή-NMR (400 MHz, CDCI3) δ 8.63 (d, / = 11.0 Hz, 1H), 8.44 (d, / = 7.7 Hz, 1H), 7.80 (dd, / = 7.8, 14.9 Hz, 1H), 7.62 (dd, / = 4.0, 10.7 Hz, 2H), 7.55-7.41 (m, 1H), 7.33-7.26 (m, 1H), 6.84-6.56 (m, 1H), 6.50-6.37 (m, 1H), 5.84-5.66 (m, 1H), 4.88-4.81 (m, 1H), 4.36-4.30 (m, 1H), 4.06-4.02 (m, 1H), 3.70 - 3.28 (m, 1H), 3.01 (d, / = 11.6, 1H), 2.30-2.00 (m, 4H), 1.48- 1.37 (m, 2H). MS calculated for C25H24F3N404 (M+H+) 501.17, found 501.2.
Examples 21
Method A: A sample of racemate or enantioenriched compound is subjected to chiral chromatography with isocratic elution using a Gilson purification system consisting of 306 pump, 806 manometric module, 119 UV/Vis detector, 215 auto sampler fraction collector and UniPoint v3.30 or Trilution v2.1 software. The eluting peaks are collected and reanalyzed accordingly.
Method B : A sample of racemate or enantioenriched compound is subjected to chiral chromatography with isocratic elution using a Thar Technologies SFC Prep 80 system with SuperChrom v.5.3 software. The eluting peaks are collected and reanalyzed accordingly.
By repeating the chiral separations described in Method A or B above, the following Examples are obtained. The eluted compounds in Examples 7 A and 7B; 8 A and 8B; 9 A and 9B; and 10A and 10B were arbitrarily designated as Peak 1 and 2 respectively, without confirmation of absolute configuration. One skilled in the art can use any known methods to determine the absolute stereochemistry of the enantiomers.
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Assays
EGFR Biochemical Assays
ICjn determinations. All EGFR biochemical assays were carried out by HTRF method. The EGFR(L858R/T790M) enzyme were purchased from Carna (GST-a.a. 669- 1210). The substrate peptide Biotin-TK-peptide was purchased from Cis-Bio. The reaction mixtures contained 1 μΜ peptide substrate, 10 μΜ ATP, and 0.036 nM
EGFR(L858R/T790M) in the reaction buffer (50 mM HEPES pH 7.1, lOmM MgCl2, 0.01 BSA, 1 mM TCEP and 0.1 mM Na3V04) at a final volume of 10 μί. All reactions were carried out at room temperature in white ProxiPlate™ 384-well Plus plates
(PerkinElmer) and were quenched with 5 μΕ of 0.2 M EDTA at 60 min. Five μΕ of the detection reagents (2.5 ng PT66K and 0.05 μg SAXL per well) were added, the plates were incubated at room temperature for 1 h and then read in En Vision reader.
Compounds were diluted into assay mixture (final DMSO 0.5%), and IC50 values were determined by 12-point (from 50 to 0.000282 μΜ) inhibition curves in duplicate under the assay conditions as described above. For no-preincubation condition, the compounds were added to the assay solution containing ATP and peptide, and the reaction was initiated by addition of enzyme. For pre-incubation conditions, the compounds were added to the assay solution containing enzyme and peptide, and pre-incubated at room temperature for desired period of time, then the reaction was initiated by addition of ATP.
EGFR Target Modulation in Engineered NIH/3T3 Cell Lines
Tissue Culture. NIH/3T3 cell lines expressing human EGFR (WT, L858R, and L858R/T790M) (obtained from Matthew Meyerson's Lab at DFCI) were maintained in 10% FBS/DMEM supplemented with 100 μg/ml Penicillin/Streptomycin (Hyclone #SV30010) and 2 μg/ml Puromycin. The cells were harvested with 0.05% Trypsin/EDTA (Hyclone #SH30236.01), re-suspended in 5% FBS/DMEM Pen/Strep without Puromycin and plated at 9,000 cells per well in 50 μΐ of media in a 384-well black plate with clear bottoms (Greiner #789068G). The cells were allowed to incubate overnight in a 37°C, 5% C02 humidified tissue culture incubator. A 12-point test compound curve was prepared by serial diluting a 10 μΜ stock 1:3 in DMSO in a 384-well compound plate (Greiner #789201L). The serial diluted compounds were transferred to the plate containing cells by using a 50 nl Pin Head device (Perkin Elmer) and the cells were placed back in the incubator for 3 hours. Only the EGFR WT-expressing cells were induced with 50 ng/ml EGF (Preprotech #AF-100-15) for 5 minutes before lysis. The media was removed and cells were lysed in 25 μΐ of Lysis buffer containing protease and phosphatase inhibitors (1% Triton X-100, 20 mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, IX complete cocktail inhibitor (Roche #11 697 498 001), IX Phosphatase Inhibitor Cocktail Set II and Set III (Sigma #P5726 and #P0044)). The plates were shaken at 4°C for 5 minutes with foil top at maximum speed. An aliquot of 5 μΐ from each well was transferred to ProxiPlate™ 384-well Plus plates (PE #6008289). The plates were sealed with a foil top and frozen at -80°C and thawed when needed.
AlphaLISA. The frozen aliquots were thawed and briefly centrifuged. All antibodies and beads were diluted in IX AlphaLISA HiBlock Buffer (PE #AL004C). Biotinylated anti-phospho-EGFR (Y1068) (Cell Signaling #4031) was incubated with the lysate for 1 hour at room temperature at 1 nM final concentration. Goat anti-total EGFR (R&D Systems #AF231) was added and allowed to equilibrate for 1 hour at room temperature at 1 nM final concentration. Then, 10 μΐ of mixed beads (AlphaScreen Streptavidin Donor Beads (PE #6760002S) and AlphaLISA anti-goat IgG Acceptor Beads (PE #AL107Q) was equilibrated for 1.5 hours before reading on En Vision plate reader using the built-in settings for AlphaScreen.
Data Analysis. Cells untreated (L858R and L858R/T790M) or EGF-induced (WT) were set to 100% maximum response. For a negative control, 10 μΜ HKI-272 was used to normalize data to 0% of maximum response. With these parameters, the ICso's for each compound in each cell line was calculated using non-linear curve fitting analysis.
EGFR Target Modulation in H1975. H3255 and HCC827 Cell Lines
Tissue Culture. Cells were maintained in 10% FBS/RPMI supplemented with 100 μg/ml Penicillin/Streptomycin (Hyclone #SH30236.01). The cells were harvested with 0.25% Trypsin/EDTA (Hyclone #SH30042.1), re-suspended in 5% FBS/DMEM
Pen/Strep and plated at 10,000 cells per well in 50 ul of media in a 384-well black plate with clear bottoms (Greiner #789068G). The cells were allowed to incubate overnight in a 37 °C, 5% CO2 humidified tissue culture incubator. A 12-point test compound curve was prepared by serial diluting a 10 uM stock 1:3 in DMSO in a 384-well compound plate (Greiner #789201L). The serial diluted compounds were transferred to the plate containing cells by using a 50 nl Pin Head device (Perkin Elmer) and the cells were placed back in the incubator for 3 hours.
Phospho-EGFR (Y1173) Target Modulation Assay. The media was reduced to 20 ul using a Bio-Tek ELx 405 Select™ plate washer. Cells were lysed with 20 ul of 2X Lysis buffer containing protease and phosphatase inhibitors (2% Triton X-100, 40 mM Tris, pH 7.5, 2 mM EDTA, 2 mM EGTA, 300 mM NaCl, 2X complete cocktail inhibitor (Roche #11 697 498 001), 2X Phosphatase Inhibitor Cocktail Set II and Set III (Sigma #P5726 and #P0044)). The plates were shaken at 4°C for 20 minutes. An aliquot of 25 ul from each well was transferred to pEGFR(Y1173) ELISA plates for analysis.
Phospho-EGFR Of 1173) ELISA. Solid white high-binding ELISA plates (Greiner #781074) were coated with 5 ug/ml anti-EGFR capture antibody (R&D Systems #AF231) overnight in 50 mM carbonate/bicarbonate pH 9.5 buffer. Plates were blocked with 1% BSA (Sigma #A7030) in PBS for 1 hour at room temperature. Wash steps were carried out with a Bio-Tek ELx405 Select™ using 4 cycles of 100 ul TBS-T (20 mM Tris, 137 mM NaCl, 0.05% Tween-20) per well. Media was drained and cells were lysed in 40 ul Lysis buffer containing protease and phosphatase inhibitors (1% Triton X-100, 20 mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, IX complete cocktail inhibitor (Roche #11 697 498 001), IX Phosphatase Inhibitor Cocktail Set II and Set III (Sigma #P5726 and #P0044)). Lysis was allowed to occur for 20 minutes on ice. A 25 ul aliquot was added to each well of the blocked ELISA plate and incubated overnight at 4°C with gentle shaking. A 1:500 anti-phospho-EGFR (Cell Signaling #4407) in 0.2% BSA/TBS-T was added and incubated for 1 hour at room temperature. After washing, 1:2,000 anti- rabbit-HRP (Cell Signaling #7074) in 0.2% BSA/TBS-T was added and incubated for 1 hour at room temperature. Chemiluminescent detection was carried out with SuperSignal ELISA Pico substrate (ThermoScientific #37069). Signal was read on En Vision plate reader using built-in UltraLUM setting.
Data Analysis. Control cells treated with EGF were set to 100% maximum response. For a negative control, 10 uM CHV999 was used to normalize data to 0% of maximum response. With these parameters, the IC50's for each compound in each cell line was calculated using non- linear curve fitting analysis. EGFR Target Modulation in HEKn (EGFR-WT) Cell Line
Tissue Culture. Human neonatal epithelial keratinocytes (Invitrogen #C-001-5C) were maintained in EpiLife media (Invitrogen #M-EPI-500-CA) supplemented with growth factors (Invitrogen #S-001-5). Cells were harvested with 0.05% Trypsin/EDTA (Hyclone #SH30236.01) and quenched with 5% FBS/EpiLife media. A density of 7500 cells in 50 ul of EpiLife media (no growth factors) was plated in each well of a 384-well solid black tissue culture plate (Greiner #7891680) and incubated overnight at 37°C, 5% C02 in a humidified tissue culture incubator. A 12-point test compound curve was prepared by serial diluting a 10 uM stock 1:3 in DMSO in a 384-well compound plate (Greiner #789201L). The serial diluted compounds were transferred to the plate containing cells by using a 50 nl Pin Head device (Perkin Elmer) and the cells were placed back in the incubator for 3 hours. Stimulation of EGFR autophosphorylation was carried out with 10 ng/ml EGF (Preprotech #AF-100-15) for 5 minutes in the tissue culture incubator.
Phospho-EGFR (Y1173) ELISA. Solid white high-binding ELISA plates (Greiner #781074) were coated with 5 ug/ml anti-EGFR capture antibody (R&D Systems #AF231) overnight in 50 mM carbonate/bicarbonate pH 9.5 buffer. Plates were blocked with 1% BSA (Sigma #A7030) in PBS for 1 hour at room temperature. Wash steps were carried out with a Bio-Tek ELx405 Select™ using 4 cycles of 100 ul TBS-T (20 mM Tris, 137 mM NaCl, 0.05% Tween-20) per well. Media was drained and cells were lysed in 40 ul Lysis buffer containing protease and phosphatase inhibitors (1% Triton X-100, 20 mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, IX complete cocktail inhibitor (Roche #11 697 498 001), IX Phosphatase Inhibitor Cocktail Set II and Set III (Sigma #P5726 and #P0044)). Lysis was allowed to occur for 20 minutes on ice. A 25 ul aliquot was added to each well of the blocked ELISA plate and incubated overnight at 4°C with gentle shaking. A 1:500 anti-phospho-EGFR (Cell Signaling #4407) in 0.2% BSA/TBS-T was added and incubated for 1 hour at room temperature. After washing, 1:2,000 anti- rabbit-HRP (Cell Signaling #7074) in 0.2% BSA/TBS-T was added and incubated for 1 hour at room temperature. Chemiluminescent detection was carried out with SuperSignal ELISA Pico substrate (ThermoScientific #37069). Signal was read on En Vision plate reader using built-in UltraLUM setting.
Data Analysis. Control cells treated with EGF were set to 100% maximum response. For a negative control, 10 uM CHV999 was used to normalize data to 0% of maximum response. With these parameters, the IC50's for each compound in each cell line was calculated using non- linear curve fitting analysis. EGFR Target Modulation in HaCaT (EGFR-WT) Cell Line
Tissue Culture. HaCaT cells were maintained in 10% FBS/RPMI supplemented with 100 μg/ml Penicillin/Streptomycin (Hyclone #SH30236.01). The cells were harvested with 0.25% Trypsin/EDTA (Hyclone #SH30042.1), re-suspended in 5% FBS/DMEM Pen/Strep and plated at 10,000 cells per well in 50 ul of media in a 384-well black plate with clear bottoms (Greiner #789068G). The cells were allowed to incubate overnight in a 37°C, 5% C02 humidified tissue culture incubator, with A 12-point test compound curve was prepared by serial diluting a 10 uM stock 1:3 in DMSO in a 384-well compound plate (Greiner #789201L). The serial diluted compounds were transferred to the plate containing cells by using a 50 nl Pin Head device (Perkin Elmer) and the cells were placed back in the incubator for 3 hours. Stimulation of EGFR autophosphorylation was carried out with 10 ng/ml EGF (Preprotech #AF-100-15), prepared in 2% FBS/PBS for 5 minutes in the tissue culture incubator.
Phospho-EGFR (Y1173) ELISA. Solid white high-binding ELISA plates (Greiner #781074) were coated with 5 ug/ml anti-EGFR capture antibody (R&D Systems #AF231) overnight in 50 mM carbonate/bicarbonate pH 9.5 buffer. Plates were blocked with 1% BSA (Sigma #A7030) in PBS for 1 hour at room temperature. Wash steps were carried out with a Bio-Tek ELx405 SelectTM using 4 cycles of 100 ul TBS-T (20 mM Tris, 137 mM NaCl, 0.05% Tween-20) per well. Media was drained and cells were lysed in 40 ul Lysis buffer containing protease and phosphatase inhibitors (1% Triton X-100, 20 mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, IX complete cocktail inhibitor (Roche #11 697 498 001), IX Phosphatase Inhibitor Cocktail Set II and Set III (Sigma #P5726 and #P0044)). Lysis was allowed to occur for 20 minutes on ice. A 25 ul aliquot was added to each well of the blocked ELISA plate and incubated overnight at 4oC with gentle shaking. A 1:500 anti-phospho-EGFR (Cell Signaling #4407) in 0.2% BSA/TBS-T was added and incubated for 1 hour at room temperature. After washing, 1:2,000 anti- rabbit-HRP (Cell Signaling #7074) in 0.2% BSA/TBS-T was added and incubated for 1 hour at room temperature. Chemiluminescent detection was carried out with SuperSignal ELISA Pico substrate (ThermoScientific #37069). Signal was read on En Vision plate reader using built-in UltraLUM setting.
Data Analysis. Control cells treated with EGF were set to 100% maximum response. For a negative control, 10 uM CHV999 was used to normalize data to 0% of maximum response. With these parameters, the IC50's for each compound in each cell line was calculated using non- linear curve fitting analysis. Biological Results
Table 1 sets forth the IC50 determinations obtained from a EGFR biochemical assay described above. In Table 1 , Column A and B represent IC50 determinations obtained from EGFR (L858R/T790M) without and with 90-minute pre-incubation, respectively. Representative compounds of the invention show an inhibition IC50 in the range of < 1 nM to 10 μΜ, more particularly in the range of < 1 nM to 1 μΜ.
Table 1
Figure imgf000198_0001
Example IC50 (μΜ) IC50 (μΜ) Example IC50 (μΜ) IC50 (μΜ) Column A* Column B** Column A* Column B**
17-4 0.135 0.006 17-127 0.002 <0.001
17-5 0.022 0.001 17-128 0.007 <0.001
17-6 0.189 0.010 17-129 0.002 <0.001
17-7 0.005 <0.001 17-130 0.119 0.006
17-8 7.000 0.137 17-131 0.005 <0.001
17-9 4.100 0.218 17-132 0.041 0.001
17-10 0.014 <0.001 17-133 0.018 0.001
17-11 <0.001 <0.001 17-134 0.930 0.010
17-12 0.064 0.003 17-135 0.620 0.008
17-13 0.006 <0.001 17-136 1.760 0.030
17-14 0.033 0.005 17-137 1.550 0.044
17-15 0.012 <0.001 17-138 0.147 0.009
17-16 0.007 <0.001 17-139 0.147 0.005
17-17 0.004 <0.001 17-140 0.940 0.043
17-18 0.014 <0.001 17-141 0.247 0.010
17-19 0.330 0.007 17-142 0.320 0.010
17-20 0.430 0.032 17-143 0.233 0.014
17-21 0.005 <0.001 17-144 0.002 <0.001
17-22 0.003 <0.001 17-145 0.001 <0.001
17-23 0.003 <0.001 17-146 0.002 <0.001
17-24 0.006 <0.001 17-147 0.002 <0.001
17-25 <0.002 <0.001 17-148 0.002 <0.001
17-26 0.005 <0.001 17-149 0.002 <0.001
17-27 0.021 0.002 17-150 0.003 <0.001
17-28 0.014 <0.001 17-151 0.001 <0.001
17-29 0.020 <0.001 17-152 0.002 <0.001
17-30 0.005 <0.001 17-153 0.002 <0.001
17-31 0.016 <0.001 17-154 0.002 <0.001
17-32 0.014 <0.001 17-155 0.002 <0.001
17-33 0.008 <0.001 17-156 0.001 <0.001
17-34 1.050 0.038 17-157 0.003 <0.001
17-35 0.006 <0.001 17-158 0.002 <0.001
17-36 10.6 0.350 17-159 0.002 <0.001
17-37 0.062 0.005 17-160 0.007 <0.001
17-38 0.117 0.006 17-161 0.008 <0.001
17-39 0.120 0.007 17-162 0.054 0.004
17-40 0.007 <0.001 17-163 0.070 0.005
17-41 0.008 <0.001 17-164 0.055 0.005
17-42 <0.002 <0.001 17-165 0.054 0.004
17-43 0.006 <0.001 17-166 0.039 0.003
17-44 0.007 <0.001 17-167 2.620 0.128
17-45 0.006 <0.001 17-168 1.110 0.095
17-46 0.092 0.005 17-169 1.750 0.186
17-47 0.009 <0.001 17-170 0.660 0.006
17-48 0.007 <0.001 17-171 2.400 0.316
17-49 0.029 0.001 17-172 1.750 0.268
17-50 0.009 <0.001 17-173 6.600 0.285 Example IC50 (μΜ) IC50 (μΜ) Example IC50 (μΜ) IC50 (μΜ) Column A* Column B** Column A* Column B**
17-51 1.950 0.048 17-174 0.210 0.010
17-52 0.002 <0.001 17-175 0.004 <0.001
17-53 0.002 <0.001 17-176 0.018 <0.001
17-54 0.090 0.005 17-177 0.003 <0.001
17-55 0.007 <0.001 17-178 0.097 0.006
17-56 0.020 0.002 17-179 0.230 0.012
17-57 <0.001 <0.001 17-180 0.003 <0.001
17-58 0.005 <0.001 17-181 0.003 <0.001
17-59 0.105 0.006 17-182 0.472 0.022
17-61 0.004 <0.001 17-184 16.13 5.84
17-62 0.140 0.006 17-185 0.002 <0.001
17-63 0.003 <0.001 17-186 0.004 <0.001
17-64 0.020 0.001 17-187 0.022 0.001
17-65 0.004 <0.001 17-188 0.04 0.003
17-66 0.005 <0.001 17-189 0.005 <0.001
17-67 0.003 <0.001 17-190 0.003 <0.001
17-68 0.003 <0.001 17-191 0.004 <0.001
17-69 0.002 <0.001 17-192 0.003 <0.001
17-70 <0.001 <0.001 17-193 0.002 <0.001
17-71 0.002 <0.001 17-194 0.068 0.006
17-72 0.004 <0.001 17-195 0.116 0.007
17-73 <0.001 <0.001 17-196 0.374 0.025
17-74 0.003 <0.001 17-197 1.666 0.117
17-75 0.017 <0.001 18 2.590 0.041
17-76 <0.001 <0.001 19 0.218 0.010
17-77 0.003 <0.001 20 0.110 0.005
17-78 0.006 <0.001 21-1 0.171 0.012
17-79 0.005 <0.001 21-3 0.700 0.098
17-80 <0.001 <0.001 21-4 0.006 <0.001
17-81 0.002 <0.001 21-7A 2.010 0.560
17-82 0.007 <0.001 21-7B 0.008 <0.001
17-83 0.020 0.001 21-8A 0.620 0.033
17-84 0.049 0.003 21-8B 0.006 <0.001
17-85 0.038 0.003 21-9A 32.35 3.7
17-86 0.040 0.004 21-9B 0.894 0.024
17-87 <0.001 <0.001 21-10A 6.05 0.572
17-88 0.390 0.040 21-10B 0.222 0.014
17-89 1.010 2.320
* Column A - EGFR (L858R/T790M) with no pre-incubation
**Column B - EGFR (L858R/T790M) with 90 min pre-incubation
Table 2 sets forth the IC50 determinations obtained from EGFR target modulation in engineered NIH/3T3 cell lines. Compounds of the invention show an inhibition IC50 for L858R/T790M and L858R in the range of 1 nM to 10 uM, more particularly in the range of 1 nM to 1 μΜ. Furthermore, compounds of the invention show an inhibition IC50 for NIH3T3 EGFR WT cell lines in the range of 1 nM to 10 μΜ, and in some instances in the range of 1 nM to >10 μΜ.
Table 2
Figure imgf000201_0001
Example NIH3T3 IC50 (μΜ) NIH3T3 IC50 (μΜ) NIH3T3 IC50 (μΜ) EGFR (L858R/T790M) EGFR (L858R) EGFR (WT)
17-23 0.003 0.004 0.149
17-24 0.006 0.005 0.094
17-25 <0.001 0.002 0.057
17-26 0.005 0.003 0.139
17-27 0.005 0.012 0.670
17-28 0.010 0.004 0.283
17-29 0.017 0.028 0.820
17-30 0.004 0.003 0.167
17-31 0.005 0.019 0.750
17-32 0.004 0.007 0.206
17-33 0.005 0.002 0.224
17-34 0.221 0.530 >10.0
17-35 0.005 0.005 0.140
17-36 2.960 3.500 >10.0
17-37 0.042 0.032 1.650
17-38 0.049 0.093 1.920
17-39 0.072 0.221 5.200
17-40 0.008 0.017 0.490
17-41 0.004 0.012 0.440
17-42 0.002 0.002 0.053
17-43 0.004 0.014 0.480
17-44 0.003 0.015 0.390
17-45 0.003 0.002 0.057
17-46 0.031 0.002 0.057
17-47 0.003 0.002 0.052
17-48 0.004 0.005 0.122
17-49 0.027 0.006 0.330
17-50 0.009 0.005 0.086
17-51 0.650 0.470 7.600
17-52 <0.001 0.003 0.103
17-53 0.002 0.003 0.058
17-54 0.041 0.022 0.560
17-55 0.003 0.002 0.022
17-56 0.008 0.017 0.263
17-57 0.002 <0.001 0.020
17-58 0.002 0.002 0.026
17-59 0.019 0.020 0.370
17-60 0.002 0.002 0.012
17-61 0.003 <0.001 0.011
17-62 0.234 2.500
17-63 0.003 0.038
17-64 0.005 0.002 0.021
17-65 0.002 0.002 0.012
17-66 0.009 0.005 0.129
17-67 0.001 0.004 0.050
17-68 0.001 0.002 0.023
17-69 <0.001 0.001 0.020 Example NIH3T3 IC50 (μΜ) NIH3T3 IC50 (μΜ) NIH3T3 IC50 (μΜ) EGFR (L858R/T790M) EGFR (L858R) EGFR (WT)
17-70 <0.001 0.001 0.035
17-71 0.002 0.002 0.029
17-72 0.001 0.004 0.063
17-73 <0.001 0.001 0.016
17-74 0.002 0.004 0.076
17-75 0.007 0.025 0.218
17-76 <0.001 <0.001 0.004
17-77 0.001 0.001 0.008
17-78 0.006 0.005 0.152
17-79 0.002 0.005 0.062
17-80 <0.001 <0.001 0.002
17-81 0.002 0.003 0.067
17-82 0.007 0.007 0.187
17-83 0.027 0.022 0.600
17-84 0.028 0.040 1.940
17-85 0.020 0.043 0.600
17-86 0.008 0.030 0.450
17-87 <0.001 <0.001 0.013
17-88 0.209 0.158 8.400
17-89 7.500 0.460 0.700
17-90 0.055 0.054 0.760
17-91 0.042 0.033 1.010
17-92 0.057 0.043 1.830
17-93 0.350 0.281 4.200
17-94 <0.001 0.001 0.031
17-95 0.002 0.002 0.026
17-96 0.004 0.016 1.980
17-100 0.026 0.340 >10.0
17-102 0.002 0.001 0.047
17-103 <0.001 <0.001 0.019
17-104 0.020 0.023 0.610
17-105 0.012 0.149 >10.0
17-106 0.007 0.124 >10.0
17-108 0.021 0.306 >10.0
17-109 0.028 0.032 0.880
17-110 0.460 4.700 >10.0
17-111 0.001 0.003 0.047
17-112 0.006 0.040 >10.0
17-113 0.001 0.001 0.081
17-114 <0.001 0.002 0.143
17-115 0.165 1.600 >10.0
17-116 0.008 0.019 0.470
17-117 0.006 0.050 6.400
17-118 0.005 0.156 >10.0
17-119 0.008 0.051 5.000
17-120 0.860 8.200 >10.0
17-121 0.016 0.259 >10.0 Example NIH3T3 IC50 (μΜ) NIH3T3 IC50 (μΜ) NIH3T3 IC50 (μΜ) EGFR (L858R/T790M) EGFR (L858R) EGFR (WT)
17-122 0.020 0.176 >10.0
17-123 0.017 0.174 >10.0
17-124 0.023 0.271 >10.0
17-125 0.013 0.087 >7.6
17-126 <0.001 <0.001 0.024
17-127 0.001 0.004 0.099
17-128 0.002 0.006 0.186
17-129 0.002 0.002 0.045
17-130 0.016 0.094 1.410
17-131 0.002 0.010 0.311
17-132 0.012 0.047 2.870
17-133 0.006 0.041 1.290
17-134 0.073 0.630 >10.0
17-135 0.045 0.400 >10.0
17-136 6.500 >10.0 8.200
17-137 7.900 >10.0 >10.0
17-138 0.067 0.450 >10.0
17-139 0.043 0.305 >9.1
17-140 0.181 1.640 7.900
17-141 0.097 0.680 7.800
17-142 0.090 0.340 5.200
17-143 0.046 0.313 >10.0
17-144 <0.001 <0.001 0.029
17-145 0.001 <0.001 0.026
17-146 0.004 0.003 0.137
17-147 <0.001 <0.001 0.025
17-148 0.002 0.001 0.083
17-149 <0.001 <0.001 0.015
17-150 0.001 0.001 0.042
17-151 0.001 <0.001 0.014
17-152 0.001 <0.001 0.032
17-153 0.001 0.001 0.037
17-154 0.001 <0.001 0.010
17-155 0.002 0.002 0.065
17-161 0.009 0.006 0.281
17-167 0.140 4.800 >10.0
17-168 0.072 0.600 >2.77
17-169 0.140 1.750 8.200
17-170 0.010 0.390 >10.0
17-171 0.160 1.860 9.900
17-172 0.173 1.400 8.700
17-173 0.840 0.670 >10.0
18 6.300 >10.0 >10.0
19 0.026 0.226 >10.0
20 0.820 3.300 >10.0
21-1 0.120 2.230 >10.0
21-3 0.450 2.200 >10.0 Example NIH3T3 IC50 (μΜ) NIH3T3 IC50 (μΜ) NIH3T3 IC50 (μΜ) EGFR (L858R/T790M) EGFR (L858R) EGFR (WT)
21-4 0.002 0.004 0.239
21-7A 0.490 3.200 >10.0
21-7B 0.002 0.012 0.650
21-8A 0.138 0.211 0.980
21-8B 0.002 0.001 0.016
Table 3 sets forth the IC50 determinations obtained from EGFR target modulation in
H1975 (EGFR L858/T790M), H3255 (EGFR L858R), HCC827 (Del E746-A750), HEKn (EGFR WT) and HaCaT (EGFR WT) cell lines. Compounds of the invention show an inhibition IC50 in the range of 1 nM to 10 μΜ, more particularly in the range of 1 nM to 1 μΜ. Furthermore, compounds of the invention show an inhibition IC50 for HEKn (EGFR WT) and/or HaCaT (EGFR WT) cell lines in the range of 0.01 μΜ to 10 μΜ, and in some instances in the range of 0.01 μΜ to >10 μΜ.
Table 3
Figure imgf000205_0001
Example H1975 H3255 HCC827 HEKn (HaCaT)
IC50 (μΜ) IC50 (uM) IC50 (μΜ) IC50 (uM)
16 0.058 0.06 (1.099)
17-1 0.005 0.033 0.014 0.730
17-2 0.076 0.170 2.340
17-4 0.105 0.156 >10.0
17-12 0.010 0.147 0.030 >10.0
17-15 0.006 0.022 0.259
17-16 0.010 0.028 0.295
17-17 0.003 0.008 0.176
17-24 0.007 0.009 0.225
17-25 0.002 0.026 0.251
17-26 0.005 0.015 0.190
17-27 0.012 0.088 1.000
17-28 0.024 0.081 0.370
17-29 0.093 0.290 2.610
17-30 0.010 0.037 0.313
17-33 0.005 0.065 0.259
17-35 0.004 0.005 0.285
17-37 0.128 0.135 >10.0
17-40 0.007 0.130 0.760
17-42 0.002 0.013 0.206
17-45 0.007 0.003 0.142
17-46 0.132 0.005 0.212
17-47 0.017 0.004 0.186
17-48 0.010 0.007 0.380
17-52 0.002 0.005 0.320
17-53 0.002 0.004 0.261
17-54 0.078 0.081 4.900
17-58 0.003 0.009 0.154
17-67 0.002 0.015 0.249
17-68 0.002 0.008 0.203
17-69 0.001 0.006 0.071
17-70 <0.001 0.007 0.185
17-71 0.002 0.003 0.134
17-72 0.003 0.012 0.220
17-74 0.002 0.011 0.261
17-75 0.026 0.085 3.140
17-76 <0.001 0.001 0.014
17-77 0.002 0.001 0.024
17-78 0.134 0.037 1.680
17-79 0.002 0.007 0.176
17-80 <0.001 <0.001 0.004
17-81 0.002 0.004 0.162
17-82 0.010 0.029 0.370
17-83 0.029 0.072 2.330
17-84 0.037 0.137 1.660
17-85 0.038 0.111 2.080 Example H1975 H3255 HCC827 HEKn (HaCaT)
IC50 (μΜ) IC50 (uM) IC50 (μΜ) IC50 (uM)
17-86 0.012 0.057 0.710
17-87 0.002 <0.001 0.037
17-94 0.001 0.002 0.045
17-95 0.003 0.003 0.127
17-103 0.001 0.002 <0.001 0.098
17-105 0.027 0.243 0.207 >10.0
17-106 0.009 0.083 0.153 >10.0
17-108 0.014 0.044 >10.0
17-109 0.014 0.043 1.680
17-111 <0.001 0.008 0.203
17-112 0.015 0.155 0.135 >10.0
17-113 0.002 0.004 <0.001 0.265
17-114 <0.001 0.004 0.100
17-117 0.013 0.290 0.243 >10.0
17-118 0.640 >10.0 >10.0
17-119 0.010 0.118 0.071 >6.9
17-122 0.016 0.390 0.090 >10.0
17-123 0.022 0.199 0.291 >10.0
17-124 0.022 0.490 >10.0
17-126 <0.001 0.002 <0.001 0.065
17-129 0.001 0.004 0.028
17-132 0.009 0.108 2.850
17-142 0.105 0.640 >10.0
17-144 <0.001 0.001 <0.001 0.072
17-145 0.001 0.002 <0.001 0.095
17-147 <0.001 0.002 <0.001 0.079 (0.044)
17-148 0.001 0.002 <0.001 0.077 (0.052)
17-149 <0.001 0.002 <0.001 0.076 (0.048)
17-150 0.002 0.003 <0.001 0.129 (0.059)
17-151 <0.001 0.001 <0.001 0.036
17-152 0.001 0.002 <0.001 0.112 (0.046)
17-153 <0.001 0.002 <0.001 0.061
17-154 <0.001 0.002 <0.001 0.079 (0.038)
17-155 0.002 0.002 <0.001 0.061
17-156 <0.001 0.002 <0.001 0.128
17-157 0.002 0.007 0.002 0.308
17-158 <0.001 0.002 0.082 (0.067)
17-159 <0.001 0.002 0.070 (0.084)
17-160 0.001 0.017 0.237
17-161 0.008 0.009 0.269
17-162 0.038 0.145 0.023 4.600
17-163 0.043 0.051 0.011 1.260
17-164 0.058 0.073 0.009 2.270
17-165 0.039 0.050 0.031 4.500
17-166 0.033 0.060 0.007 1.540
17-174 0.093 0.202 >10.0 (>10.0)
17-175 0.002 0.004 0.289 (0.522) Example H1975 H3255 HCC827 HEKn (HaCaT)
IC50 (nM) IC50 (uM) IC50 (uM) IC50 (uM)
17-176 0.014 0.020 0.004 0.870
17-177 0.004 0.004 0.093
17-178 0.117 0.106 0.038 4.200
17-179 0.234 0.188 5.400
17-180 0.001 0.001 0.001 (0.092)
17-181 0.001 0.001 0.001 (0.077)
17-182 0.77 0.422 (>10.0)
17-184 3.74 4.84 (>10.0)
17-185 0.001 0.002 0.001 0.044 (0.044)
17-186 0.002 0.01 0.002 0.291 (0.213)
17-187 0.013 0.014 0.002 (0.475)
17-188 0.016 0.039 0.01 (0.87)
17-189 0.003 0.005 (0.083)
17-190 0.002 0.003 (0.047)
17-191 0.002 0.003 (0.059)
17-192 0.002 0.002 (0.037)
17-193 0.001 0.002 0.001 (0.044)
17-194 0.041 0.067 0.016 (0.576)
17-195 0.036 0.181 0.045 (7.12)
17-196 0.277 0.295 (>10.0)
17-197 0.935 2.0 (>10.0)
19 0.168 2.020 >10.0
21-4 0.001 0.013 0.285
21-8B 0.004 0.002 0.095
21-9A >10 6.58 (>10.0)
21-9B 0.314 0.312 (>10.0)
21-10A >10 1.539 (>10.0)
21-10B 0.421 0.077 (6.09)
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the range and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes

Claims

1. A compound havi
Figure imgf000209_0001
wherein Ring A is a 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and optionally substituted with oxo;
Ring B is phenyl; a 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S; or a 5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted by oxo;
E is NH or CH2;
Figure imgf000209_0002
Rrand R2 are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl;
5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; phenyl,
5-6 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O, S and P, and optionally substituted by oxo; - X1-C(0)OR3; -X1-0-C(0)R3; -X1-C(0)R3;
-X1-C(0)NR4R5; -X1-C(0)NR4-X3-C(0)OR3; -X1-C(O)NR4-X3-S(O)0-2 R6; -X]-NR4R5;
-X1NR4-X2-C(0)R3; -X1-NR4-X2-C(0)OR3; -X1-NR4-X2-C(0)NR4R5;
-X1-NR4-X3-S(0)o-2R6; -X1-NR4S(0)2R6; -X^OSCCXhR6; -X]-OR3; -X^O-X^OR3;
-X1-0-X4-S(0)o-2R6; -X1-0-X4-NR4R5; -X1-S(O)0-2R6; -X1-S(O)0-2-X3-NR4R5;
-X1-C(0)NR4-X3-P(0)R6aR6b; -X1-NR4-X1-P(0)R6aR6b; -X1-0-X1-P(0)R6aR6b;
-X1-P(0)R6a-X1-NR4R5; -X1-P(0)R6aR6b or -X^SCC zNR ; wherein each phenyl, heteroaryl, or heterocyclyl in R1 or R2 is unsubstituted or substituted by 1-3 groups selected from OH, halo, Ci_6 alkyl, Ci_6 haloalkyl and Ci_6 haloalkoxy;
R3, R4 and R5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R4 and R5 together with N in NR4R5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R7;
R6 is Ci-6 alkyl or Ci_6 haloalkyl;
R6a and R6b are independently hydroxy, Ci_6 alkyl, Ci_6 haloalkyl, Ci_6 alkoxy, Ci_6 haloalkoxy, 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 4-12 membered monocyclic or bicyclic heterocyclyl comprising 1-4 heteroatoms selected from N, O and S, and o tionally substituted with oxo;
Figure imgf000210_0001
R9 and R10 are independently hydrogen, halo, Ci_6 alkyl, Ci_6 haloalkyl, OH, cyano, Ci_6 alkoxy, Ci_6 haloalkoxy;
Rlla, Rllb, Rllc, Rlld, Rlle, Rllf, Rllg, Rllh, Rni, Rn\ Rllk and R111 are
independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl;
R12 and R13 are independently hydrogen, halo, cyano, Ci_6 alkyl or Ci_6 haloalkyl;
R14 and R15 are independently hydrogen, Ci_6 alkyl, -L]-R23, -(CRaRb)2-3-Rc or -L2 Rd; or R14 and R15 together with N in NR14R15 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R groups;
R 116D and R 1"V are independently hydrogen or Ci_6 alkyl; or R 16 and R1V together with the carbon to which they are attached may form a C3-6 cycloalkyl;
X1 and X2 are independently a bond or Ci_6 alkyl;
X3 is Ci_6 alkyl;
X4 is C2-6 alkyl;
R19 hydrogen, Ci_6 alkyl, COR20, COOR20, CONR20R21 or S(0)2R2°;
R 20 is Ci-6 alkyl, Ci_6 haloalkyl or cycloalkyl;
R21 is hydrogen or Ci_6 alkyl; or R20 and R21 together with the N in NR20R21 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S, P and optionally substituted with 1-4 R 22 groups;
R V', R 1180 and R 2^2 are independently oxo, halo, hydroxy, Ci_6 alkyl, Ci_6 haloalkyl, Ci-6 alkoxy or Ci_6 haloalkoxy;
R23 is independently C3_7 cycloalkyl, or a 4-10 membered heterocyclyl comprising 1-3 heteroatoms selected from N, O and S, and is optionally substituted with oxo; and R23 is unsubstituted or substituted with Ci_6 alkyl, Ci_6 haloalkyl, -L3-Re or -L4-Rf;
Rc and Re are independently halo, cyano, hydroxy, -OR24, -NRR25, -NR-C02R24, - NR-SO2-R26, -NR-COR26, -NR-C(0)-NRR25, -OC(0)-NRR25, or Ci_6 alkyl substituted with halo, Ci_6 alkoxy, hydroxy or cyano;
Rd and Rf are independently -S02NRR25, -CONRR25, -C(0)OR24, -S02R26 or C(0)R26;
R24 is Ci_6 alkyl, Ci_6haloalkyl, -L2-R23aor -(CRaRb)2_3-N(RaRb)2;
R25 is hydrogen, Ci_6 alkyl, Ci_6haloalkyl, -L2-R23b or-(CR2)2_3-N(RaRb)2;
R26 is Ci_6 alkyl, Ci_6haloalkyl, -L2-R23c or -(CRaRb)i_3-N(RaRb)2;
R23a, R23b and R23c are independently selected from R23;
R, Ra and Rb are independently hydrogen or Ci_6 alkyl;
L1, L2, L3 and L4 are independently a bond or -(CRaRb)i_3; and
n and m are independently 1-3; and p and q are 1-4;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said compound is of Formula (2):
Figure imgf000212_0001
wherein Ring A is a 6-10 membered monocyclic or bicyclic aryl; a 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S; or a 5- membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo;
R1 and Rr are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl; -X]-NR4R5; -X]-OR3; -X1-S(O)0-2R6; -X1-P(0)R6aR6b; phenyl unsubstituted or substituted by Ci-6 alkyl; or a 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S;
selected from hydrogen, halo; cyano; Ci_6 alkyl; Ci_6 haloalkyl;
- X1-C(0)OR3; -X1-C(0)R3; -X1-C(0)NR4R5; -X1-C(0)NR4-X3-C(0)OR3;
-X1-C(0)NR4-X3-S(0)o-2R6; -X]-NR4R5; -X1NR4-X2-C(0)R3; -X1-NR4-X3-S(O)0-2R6; -X]-OR3; -X^O-X^OR3; -X1-S(O)0-2R6; -X^O-X^NR ; or a 5-6 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S and is unsubstituted or substituted by Ci_6 alkyl;
R3, R4 and R5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R4 and R5 together with N in NR4R5 may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R7 groups;
R6, R6a and R6b are Ci_6 alkyl;
Z is ; provided Z is a 4-7 membered
heterocyclic
Figure imgf000212_0002
ring when Z is
Y is O or NR 19.
Figure imgf000213_0001
Figure imgf000213_0002
R9, R10, Rlla, Rllb, Rllc, Rlld, Rlle, Rllf, Rllg, Rllh, Rni, Rllj, Rllk and R111 are hydrogen;
R12, R13, R16 and R17 are independently hydrogen or d-6 alkyl;
R14 and R15 are independently hydrogen; Ci_6 alkyl; -C(0)0-(Ci_6 alkyl); C3-7 cycloalkyl unsubstituted or substituted with Ci_6 alkyl; or R14 and R15 together with N in NR14R15 may form may form a 4-7 membered ring containing 1-2 heteroatoms selected from N, O, S and P, and optionally substituted with 1-4 R18 groups;
R7 and R18 are independently oxo, halo, hydroxy, Ci_6 alkyl or Ci_6 alkoxy;
R19 hydrogen, COR20 or COOR20;
R20 is Ci_6 alkyl;
p is 1;
m and q are independently 1-2; and
Ring B, X1, X2, X3 and X4 and n are as defined in claim 1.
3. The compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein said compound is of Formula (2A), (2B), (2C), (2D), (3 A), (3B) or (3C):
Figure imgf000213_0003
Figure imgf000214_0001
The compound of any one of claims 1-3 or a pharmaceutically acceptable salt thereof, wherein Ring B together with the atoms to which it is attached forms a fused phenyl, pyridyl or piperidyl, each of which is unsubstituted or substituted by (R2)m; and
m and R2 are as defined in claim 1 or 2.
The compound of any one of claims 1-4 or a pharmaceutically acceptable salt thereof, wherein:
Ring A is phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyridin-2-onyl, Lzolyl, furanyl, thiazolyl, imidazole[2,l-^]thiazolyl, imidazo[l,2-a]pyridinyl, imidazo[l,5-a]pyridinyl or naphthyl, each of which is unsubstituted or substituted by (R^ and Rr;
R1, R1 and n are as defined in claim 1 or 2.
6. The compound of any one of claims 1-5 or a pharmaceutically acceptable salt
thereof, wherein said compound is of Formula (4):
Figure imgf000215_0001
wherein W1, W2, W3 and W4 are independently CR1 or N; and
R1, Rr, R2, R8, Y and m are defined in claim 1 or 2.
The compound of any one of claims 1-5 or a pharmaceutically acceptable salt thereof, wherein said compound is of Formula (5):
Figure imgf000215_0002
wherein W1 and W2 are independently CR1 or N; and
R1, R1 , R2, R8 and m are as defined in claim 1 or 2.
8. The compound of any one of claims 1-7 or a pharmaceutically acceptable salt
thereof, wherein R1 and R1 are independently hydrogen; halo; cyano; Ci_6 alkyl; Ci_ ehaloalkyl; -X]-NR4R5; -X]-OR3; -X1-S(O)0-2R6; phenyl unsubstituted or substituted by C 1-6 alkyl; tetrazolyl or pyrrolyl;
each X1 is a bond or CH2;
R3, R4 and R5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R4 and R5 together with N in NR4R5 form piperidinyl; and
R6 is as defined in claim 1 or 2.
9. The compound of any one of claims 1-7 or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, halo, cyano, Ci_6 alkyl, Ci_6 haloalkyl, tetrazolyl, pyrrolyl, -X]-NR4R5, -X^OR3, -X1-S(O)0-2R6 or phenyl unsubstituted or substituted by Ci_6 alkyl;
R1 is hydrogen, halo or Ci_6 alkyl;
R3, R4 and R5 are independently hydrogen, Ci_6 alkyl or Ci_6 haloalkyl; or wherein R4 and R5 together with N in NR4R5 form piperidinyl;
X1 is a bond or CH2; and
R6 is as defined in claim 1 or 2.
10. The compound of any one of claims 1-7 or a pharmaceutically acceptable salt thereof, wherein R1 and R1 are independently hydrogen; methyl; t-butyl;
trifluoromethyl; methoxy; ethoxy; trifluoromethoxy; difluoromethoxy; fluoro; chloro; cyano; dimethylamino; methylsulfonyl; dime thy lphosphoryl; tetrazolyl; pyrrolyl; phenyl unsubstituted or substituted by methyl; or piperidinyl.
11. The compound of any one of claims 1-10 or a pharmaceutically acceptable salt thereof, wherein:
R2 is hydrogen; chloro; methyl; trifluoromethyl; methoxy; isoproproxy; cyano; hydroxy methyl; methoxy methyl; ethoxymethyl; methylsulfonyl; methylcarbonyl;
carboxy; methoxycarbonyl; carbamoyl; dimethylaminomethyl; pyrrolidinylmethyl unsubstituted or substituted by 1-2 hydroxy, halo or methoxy; morpholinomethyl;
azeditinylmethyl unsubstituted or substituted by 1-2 halo or methoxy; piperidinylmethyl; ((4-methyl-3-oxo-piperazin- lyl)methyl); ((4-acetylpiperazin- 1 -yl)methyl); (1,1- dioxidothiomorpholine-4-carbonyl); pyrrolidinyl carbonyl unsubstituted or substituted by 1-2 hydroxy; pyrrolidinylethoxy; (l,l-dioxidothiomorpholino)methyl; or 1,2,4- oxadiazolyl unsubstituted or substituted by Ci_6 alkyl;
alternatively, R2 is -CH2-N(CH3)-C(0)-CH3; -CH2-0-(CH2)2-OCH3;
-CH2-N(CH3)-(CH2)2-S02(CH3); -C(0)NH-(CH2)1.2-C(0)-OCH3;
-C(0)NH-(CH2)1.2-C(0)OH; or -C(0)NH-(CH2)2-S02(CH3).
12. The compound of any ally acceptable salt
Figure imgf000216_0001
thereof, wherein R is
Figure imgf000217_0001
wherein R and R are independently hydrogen, Ci_6 alkyl or C3-7 cycloalkyl; or R14 and R15 together with N in NR14R15 may form an azetidinyl, piperidyl, pyrrolidinyl or morpholinyl; where said azetidinyl or pyrrolidinyl can be optionally substituted with 1-2 halo, methoxy or hydroxyl; and
R12, R13, R16, R17 and q are as defined in claim 1 or 2.
13. The compound of any one of claims 1- 12 or a pharmaceutically acceptable salt thereof, wherein said compound is selected from:
(R,E)-N-(7-chloro- l-(l-(4-(pyrrolidin- l-yl)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro- l-(l-(4-(pyrrolidin- l-yl)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2-methylisonicotinamide;
(R,E)-N-(7-chloro- l-(l-(4-(3-fluoroazetidin-l-yl)but-2-enoyl)azepan-3-yl)- lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro- l-(l-(4-(3-fluoroazetidin-l-yl)but-2-enoyl)azepan-3-yl)- lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(5')-N-(l-(l-acryloylpiperidin-3-yl)-5-methyl-lH-benzo[d]imidazol-2-yl)-3- (trifluoromethyl) benzamide;
N-(l-(l-acryloylpiperidin-3-yl)-5-methyl- lH-benzo[d]imidazol-2-yl)-3- (trifluoromethyl) benzamide;
(/?,£')-N-(7-chloro- l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro- l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)- lH-benzo[d]imidazol- 2-yl)-2-methylisonicotinamide;
(R,E)-N-(7-chloro- l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
N-(7-chloro- l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-lH-benzo[d]imidazol- 2-yl)-2,6-dimethylisonicotinamide; (R,E)-N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-lH-benzo[d]imidazol- 2-yl)-2-methylisonicotinamide;
(R,E)-N-(l-(l-(4- (dimethylamino)but-2-enoyl)azepan- 3 -yl) -7 -methyl- 1 H- benzo[d]imidazol-2-yl)-2-(trifluoromethyl)isonicotinamide;
N-(l-(l-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-lH-benzo[d]imidazol- 2-yl)-2-(trifluoromethyl)isonicotinamide;
(/?)-N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-methoxy-lH-benzo[d]imidazol-2- yl)pyridazine-4-carboxamide;
N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-methoxy-lH-benzo[d]imidazol-2- yl)pyridazine-4-carboxamide;
N-(7-methyl-l-(l-(vinylsulfonyl)azepan-3-yl)-lH-benzo[ii|imidazol-2-yl)-3- (trifluoromethyl)benzamide ;
N-(l-(l-acryloylazepan-3-yl)-7-(pyrrolidin-l-ylmethyl)-lH-benzo[(i]imidazol-2-yl)-3- (trifluoromethyl)benzamide ;
tert-butyl 4-acryloyl-6-(7-chloro-2-(2-methylisonicotinamido)-lH-benzo[d]imidazol- 1 -yl)- 1 ,4-diazepane- 1 -carboxylate ;
N-(l-(l-acryloyl-l,4-diazepan-6-yl)-7-chloro-lH-benzo[d]imidazol-2-yl)-2- methylisonicotinamide;
N-(l-(l-acetyl-4-acryloyl-l,4-diazepan-6-yl)-7-chloro-lH-benzo[d]imidazol-2-yl)-2- methylisonicotinamide;
(R)-N-( 1 -( 1 -acryloylazepan-3 -yl)-7-chloro-6-(2-(pyrrolidin- 1 -yl)ethoxy)- 1 H- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
N-(l-(l-acryloylazepan-3-yl)-7-chloro-6-(2-(pyrrolidin-l-yl)ethoxy)-lH- benzo [d] imidazol-2-yl) -2 , 6-dimethylisonicotinamide ;
(R,E)-N-(7-chloro-l-(l-(4-(dicyclopropylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
N-(7-chloro-l-(l-(4-(dicyclopropylamino)but-2-enoyl)azepan-3-yl)-lH- benzo[d]imidazol-2-yl)-2-methylisonicotinamide;
(R)- 1 -( 1 -acryloylpiperidin-3-yl)-2-(3-(trifluoromethyl)benzamido)- 1H- benzo[d]imidazole-5-carboxylic acid;
1 -( 1 - acryloylpiperidin- 3 -yl) -2- (3 - (trifluoromethyl)benzamido) - 1 H- benzo[d]imidazole-5-carboxylic acid; (R)-l-(l-acryloylpiperidin-3-yl)-2-(3-(trifluoromethyl)benzamido)-lH- benzo[d]imidazole-5-carboxamide;
1 -( 1 -acryloylpiperidin- 3 -yl) -2- (3 - (trifluoromethyl)benzamido) - 1 H- benzo[d]imidazole-5-carboxamide; and
l-(l-acryloylazepan-3-yl)-2-(3-(trifluoromethyl)benzamido)-lH- benzo[d]imidazole-7-carboxylic acid.
14. A pharmaceutical composition comprising a compound of any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
15. A combination comprising a compound of any one of claims 1-13 or a
pharmaceutically acceptable salt thereof, and a chemotherapeutic agent.
16. A method for inhibiting epidermal growth factor (EGFR), comprising administering to a system or subject a therapeutically effective amount of a compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof.
17. A method for treating a condition mediated by epidermal growth factor receptor (EGFR), comprising administering to a system or subject in need of such treatment an effective amount of a compound of any one of claims 1 to 13, or a
pharmaceutically acceptable salt thereof.
18. Use of a compound of any one of claims 1-13 or a pharmaceutically acceptable salt thereof, for inhibiting epidermal growth factor receptor (EGFR).
19. Use of a compound of any one of claims 1-13 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a condition mediated by epidermal growth factor receptor (EGFR).
20. Use of a compound of any one of claims 1-13 or a pharmaceutically acceptable salt thereof, for treating a condition mediated by epidermal growth factor receptor (EGFR).
21. The method of claim 17 or the use of a compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein the condition mediated by EGFR is selected from non-small cell lung cancer (NSCLC), head and neck cancer, colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, gastric cancer, glioma and prostate cancer.
22. The method of claim 16 or 17, or the use of a compound of any one of claims 18-20 or a pharmaceutically acceptable salt thereof, wherein the EGFR is a mutant EGFR.
23. The method of claim 22, or the use of a compound of claim 22 or a
pharmaceutically acceptable salt thereof, wherein the mutant EGFR comprises G719S, G719C, G719A, L858R, L861Q, an exon 19 deletion mutation or an exon
20 insertion mutation.
24. The method of claim 23, or the use of a compound of claim 23 or a
pharmaceutically acceptable salt thereof, wherein the mutant EGFR further comprises an EGFR T790M, T854A or D761Y resistance mutation.
PCT/US2013/044247 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity WO2013184757A1 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
LTEP13729219.9T LT2773635T (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
AP2014008083A AP3909A (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating EGFR activity
PL13729219T PL2773635T3 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
BR112014030386-0A BR112014030386B1 (en) 2012-06-06 2013-06-05 COMPOUND, ITS USE, PHARMACEUTICAL COMPOSITION AND COMBINATION FOR INHIBITING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
KR1020147037047A KR101817829B1 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
MA37739A MA37739B1 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating the activity of egfr
AU2013271733A AU2013271733B2 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating EGFR activity
JP2015516156A JP6039800B2 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating EGFR activity
MX2014014961A MX345630B (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity.
ES13729219.9T ES2645973T3 (en) 2012-06-06 2013-06-05 Compounds and compositions to modulate EGFR activity
CA2875966A CA2875966C (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
UAA201412612A UA113543C2 (en) 2012-06-06 2013-06-05 COMPOUNDS AND COMPOSITIONS FOR MODULATION OF EGFR ACTIVITY
NZ627661A NZ627661A (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
SG11201407793TA SG11201407793TA (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
EP13729219.9A EP2773635B1 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
DK13729219.9T DK2773635T3 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating EGFR activity
RS20170954A RS56396B1 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
MEP-2017-232A ME02844B (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
SI201330801T SI2773635T1 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
CN201380029790.XA CN104379575B (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating EGFR activity
US14/405,773 US9440957B2 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating EGFR Activity
EA201492219A EA026269B1 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity
TN2014000487A TN2014000487A1 (en) 2012-06-06 2014-11-21 Compounds and compositions for modulating egfr activity
IL235974A IL235974A (en) 2012-06-06 2014-11-27 Compounds and compositions for modulating egfr activity
PH12014502704A PH12014502704A1 (en) 2012-06-06 2014-12-03 Compounds and compositions for modulating egfr activity
CR20140563A CR20140563A (en) 2012-06-06 2014-12-05 COMPOUNDS AND COMPOSITIONS THAT MODULATE THE ACTIVITY OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR
CUP2014000139A CU20140139A7 (en) 2012-06-06 2014-12-05 COMPOUNDS AND COMPOSITIONS TO MODULATE EGFR ACTIVITY
HRP20171670TT HRP20171670T1 (en) 2012-06-06 2017-10-31 Compounds and compositions for modulating egfr activity
CY20171101147T CY1119531T1 (en) 2012-06-06 2017-11-02 UNITS AND COMPOSITIONS FOR REGULATING THE EGFR ACTIVITY

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1741DE2012 2012-06-06
IN1741/DEL/2012 2012-06-06
US201361770752P 2013-02-28 2013-02-28
US61/770,752 2013-02-28

Publications (1)

Publication Number Publication Date
WO2013184757A1 true WO2013184757A1 (en) 2013-12-12

Family

ID=54193706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/044247 WO2013184757A1 (en) 2012-06-06 2013-06-05 Compounds and compositions for modulating egfr activity

Country Status (42)

Country Link
US (1) US9440957B2 (en)
EP (2) EP3257848A1 (en)
JP (1) JP6039800B2 (en)
KR (1) KR101817829B1 (en)
CN (1) CN104379575B (en)
AP (1) AP3909A (en)
AR (1) AR091368A1 (en)
AU (1) AU2013271733B2 (en)
BR (1) BR112014030386B1 (en)
CA (1) CA2875966C (en)
CL (1) CL2014003227A1 (en)
CO (1) CO7160047A2 (en)
CR (1) CR20140563A (en)
CU (1) CU20140139A7 (en)
CY (1) CY1119531T1 (en)
DK (1) DK2773635T3 (en)
DO (1) DOP2014000277A (en)
EA (1) EA026269B1 (en)
ES (1) ES2645973T3 (en)
GE (1) GEP201606555B (en)
GT (1) GT201400282A (en)
HR (1) HRP20171670T1 (en)
HU (1) HUE034759T2 (en)
IL (1) IL235974A (en)
JO (1) JO3300B1 (en)
LT (1) LT2773635T (en)
MA (1) MA37739B1 (en)
MX (1) MX345630B (en)
MY (1) MY165036A (en)
NZ (1) NZ627661A (en)
PE (1) PE20150726A1 (en)
PH (1) PH12014502704A1 (en)
PL (1) PL2773635T3 (en)
PT (1) PT2773635T (en)
RS (1) RS56396B1 (en)
SG (1) SG11201407793TA (en)
SI (1) SI2773635T1 (en)
TN (1) TN2014000487A1 (en)
TW (1) TWI650319B (en)
UA (1) UA113543C2 (en)
UY (1) UY34849A (en)
WO (1) WO2013184757A1 (en)

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015083059A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Forms of the egfr inhibitor
WO2015081463A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Egfr inhibitor forms
WO2015085482A1 (en) * 2013-12-10 2015-06-18 Novartis Ag Egfr inhibitor forms
JP2015526520A (en) * 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Benzimidazole derivatives as ITK inhibitors
WO2015134210A1 (en) * 2014-03-03 2015-09-11 Principia Biopharma, Inc. BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015143148A1 (en) * 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
WO2015143161A1 (en) * 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
WO2016040882A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
WO2016055916A1 (en) 2014-10-06 2016-04-14 Novartis Ag Therapeutic combination for the treatment of cancer
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2016185333A1 (en) 2015-05-15 2016-11-24 Novartis Ag Methods for treating egfr mutant cancers
WO2016189435A1 (en) 2015-05-22 2016-12-01 Novartis Ag Pharmaceutical compositions
WO2017004383A1 (en) 2015-06-30 2017-01-05 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017049069A1 (en) * 2015-09-18 2017-03-23 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
WO2017053537A1 (en) * 2015-09-23 2017-03-30 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017175144A1 (en) 2016-04-08 2017-10-12 Novartis Ag New therapeutic uses
US9873671B2 (en) 2014-01-16 2018-01-23 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9884818B2 (en) 2013-05-17 2018-02-06 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108235685A (en) * 2015-07-29 2018-06-29 诺华股份有限公司 The combination of PD-1 antagonists and EGFR inhibitor
WO2018140513A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US10071961B2 (en) 2013-10-23 2018-09-11 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10077239B2 (en) 2015-09-29 2018-09-18 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
US10111874B2 (en) 2014-09-18 2018-10-30 Araxes Pharma Llc Combination therapies for treatment of cancer
WO2018198076A1 (en) 2017-04-28 2018-11-01 Aduro Biotech, Inc. Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018234879A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
US10196376B2 (en) 2011-12-21 2019-02-05 Novira Therapeutics, Inc. Hepatitis B antiviral agents
WO2019026006A1 (en) 2017-08-03 2019-02-07 Novartis Ag Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
WO2019026007A1 (en) 2017-08-03 2019-02-07 Novartis Ag Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
CN109369620A (en) * 2018-12-22 2019-02-22 山东大学 Pyridine compounds and their and preparation method thereof and anti-gastric cancer application
US10213420B2 (en) 2014-02-05 2019-02-26 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10273207B2 (en) 2013-03-15 2019-04-30 Araxes Pharma Llc Covalent inhibitors of kras G12C
CN109721605A (en) * 2017-10-31 2019-05-07 维眸生物科技（上海）有限公司 A kind of immunocyte migrates inhibitor
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
CN109983009A (en) * 2016-08-17 2019-07-05 Gb005股份有限公司 Containing whorled compound and its medicinal usage
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
US10370386B2 (en) 2013-10-10 2019-08-06 Araxes Pharma Llc Substituted quinolines as inhibitors of KRAS G12C
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2019162323A1 (en) 2018-02-21 2019-08-29 Boehringer Ingelheim International Gmbh New benzimidazole compounds and derivatives as egfr inhibitors
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10441589B2 (en) 2016-04-15 2019-10-15 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
US10450270B2 (en) 2013-07-25 2019-10-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2019202527A1 (en) 2018-04-18 2019-10-24 Novartis Ag Nazartinib for use in the treatment of cns metastasis
US10472419B2 (en) 2014-01-31 2019-11-12 Novartis Ag Antibody molecules to TIM-3 and uses thereof
WO2019229658A1 (en) 2018-05-30 2019-12-05 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019229701A2 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
US10537580B2 (en) 2015-03-19 2020-01-21 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10676429B2 (en) 2012-08-28 2020-06-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2020260252A1 (en) 2019-06-24 2020-12-30 Boehringer Ingelheim International Gmbh New macrocyclic compounds and derivatives as egfr inhibitors
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11096947B2 (en) 2012-04-03 2021-08-24 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2021224867A1 (en) 2020-05-08 2021-11-11 Novartis Ag Pharmaceutical combination comprising tno155 and nazartinib
WO2021239786A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab Egfr tkis for use in the treatment of non-small cell lung cancer
US11220494B2 (en) 2018-04-26 2022-01-11 Pfizer Inc. Cyclin dependent kinase inhibitors
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2022081478A1 (en) * 2020-10-12 2022-04-21 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
WO2022090481A1 (en) 2020-11-02 2022-05-05 Boehringer Ingelheim International Gmbh Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
WO2022265950A1 (en) 2021-06-15 2022-12-22 Genentech, Inc. Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023244587A1 (en) * 2022-06-14 2023-12-21 Genzyme Corporation Methods of making tolebrutinib
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3019628A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
US20170321285A1 (en) * 2016-05-03 2017-11-09 The Texas A&M University System Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
CN107663170B (en) * 2016-07-29 2020-02-11 广东东阳光药业有限公司 Method for preparing besifloxacin intermediate compound
CN110234773B (en) * 2016-12-13 2024-07-02 匹兹堡大学联邦系统高等教育 Methods of treating cancer comprising fusion genes
CN106946779A (en) * 2017-02-13 2017-07-14 广州仁恒医药科技股份有限公司 A kind of amino hexahydro azepine * of R 3 preparation method
CN111747950B (en) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 Pyrimidine derivatives for the treatment of cancer
EP4045506A4 (en) * 2019-10-15 2023-08-30 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions
KR102267662B1 (en) * 2019-11-19 2021-06-22 한국화학연구원 Benzamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
EP4154892A4 (en) * 2020-05-18 2023-12-06 Wellmarker Bio Co., Ltd. Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same
EP4154891A4 (en) * 2020-05-18 2023-12-06 Wellmarker Bio Co., Ltd. Pharmaceutical composition for preventing or treating non-small cell lung cancer associated with ron mutation, and method using same
EP4154890A4 (en) * 2020-05-18 2023-12-06 Wellmarker Bio Co., Ltd. Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same
CN113880804A (en) * 2020-07-01 2022-01-04 微境生物医药科技(上海)有限公司 Novel benzimidazole compounds
WO2022242712A1 (en) * 2021-05-21 2022-11-24 深圳市塔吉瑞生物医药有限公司 Substituted macrocyclic compound, composition comprising compound, and use thereof
AU2022371404A1 (en) * 2021-10-18 2024-05-23 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
KR102572664B1 (en) * 2022-02-07 2023-08-30 주식회사 인터엠 Audio clock adjustment and network based public address using the same
TW202416963A (en) * 2022-09-02 2024-05-01 大陸商迪哲（江蘇）醫藥股份有限公司 Egfr inhibitors and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039051A2 (en) 1980-04-24 1981-11-04 Merck & Co. Inc. Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them
US5484596A (en) 1984-01-31 1996-01-16 Akzo N.V. Active specific immunotherapy
WO2003041708A1 (en) * 2001-11-09 2003-05-22 Boehringer Ingelheim Pharmaceuticals, Inc. Benzimidazoles useful as protein kinase inhibitors
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
WO2004014905A1 (en) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA26659A1 (en) 1998-08-06 2004-12-20 Pfizer NOVEL BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION.
CA2350415A1 (en) 1998-11-18 2000-05-25 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
CA2458533C (en) 2001-10-09 2011-01-04 Tularik Inc. Imidazole derivates as anti-inflammatory agents
US20080146536A1 (en) 2005-08-16 2008-06-19 Pharmacopeia, Inc. 2-Aminoimidazopyridines for treating neurodegenerative diseases
WO2010030857A2 (en) 2008-09-11 2010-03-18 The Regents Of The University Of Colorado Egfr inhibitor therapy responsiveness
US9150577B2 (en) 2009-12-07 2015-10-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
CN102134275B (en) 2010-01-26 2013-12-04 上海市肿瘤研究所 Epidermal growth factor receptor variant
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
US8221644B2 (en) * 2010-07-20 2012-07-17 Miller Chemical & Fertilizer Corporation Compositions and methods for anti-icing/de-icing
RU2013109143A (en) 2010-08-05 2014-09-10 Амджен Инк. Benzimidazole- and azabenzimidazole-containing compounds that inhibit the kinase of anaplastic lymphoma
CA2854936A1 (en) 2011-11-14 2013-05-23 Tesaro, Inc. Modulating certain tyrosine kinases
JP2015526520A (en) 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Benzimidazole derivatives as ITK inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039051A2 (en) 1980-04-24 1981-11-04 Merck & Co. Inc. Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them
US5484596A (en) 1984-01-31 1996-01-16 Akzo N.V. Active specific immunotherapy
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
WO2003041708A1 (en) * 2001-11-09 2003-05-22 Boehringer Ingelheim Pharmaceuticals, Inc. Benzimidazoles useful as protein kinase inhibitors
WO2004014905A1 (en) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy, 21st Ed.", 2011, PHARMACEUTICAL PRESS
"Remington's Pharmaceutical Sciences, 18th Ed.", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329
"The Practice of Medicinal Chemistry", 2001, ACADEMIC PRESS
BUNDGAARD, J. MED. CHEM., vol. 2503, 1989
BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER
CREE ET AL., ANTICANCER DRUGS, vol. 6, 1995, pages 398 - 404
CROUCH ET AL., J. IMMUNOL. METH., vol. 160, 1993, pages 81 - 88
HOUBEN-WEYL: "Science of Synthesis", vol. 1-48, GEORG THIEME VERLAG
SCHIRRMACHER ET AL., J. CANCER RES. CLIN. ONCOL., vol. 121, 1995, pages 487
STAHL; WERMUTH: "Pharmaceutical Salts: Properties, Selection, and Use, 2" Rev. Ed.", 2011, WILEY-VCH
T.W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Chemistry" 4th Ed.,", 2006, WILEY-INTERSCIENCE

Cited By (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10196376B2 (en) 2011-12-21 2019-02-05 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US11096947B2 (en) 2012-04-03 2021-08-24 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US10995064B2 (en) 2012-08-28 2021-05-04 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10676429B2 (en) 2012-08-28 2020-06-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
JP2015526520A (en) * 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Benzimidazole derivatives as ITK inhibitors
US9573958B2 (en) 2012-08-31 2017-02-21 Principia Biopharma, Inc. Benzimidazole derivatives as ITK inhibitors
EP2890691A4 (en) * 2012-08-31 2016-03-23 Principia Biopharma Inc Benzimidazole derivatives as itk inhibitors
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10941113B2 (en) 2013-02-28 2021-03-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10919850B2 (en) 2013-03-15 2021-02-16 Araxes Pharma Llc Covalent inhibitors of KRas G12C
US10273207B2 (en) 2013-03-15 2019-04-30 Araxes Pharma Llc Covalent inhibitors of kras G12C
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10398677B2 (en) 2013-04-03 2019-09-03 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9884818B2 (en) 2013-05-17 2018-02-06 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10457638B2 (en) 2013-05-17 2019-10-29 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10450270B2 (en) 2013-07-25 2019-10-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US11708412B2 (en) 2013-09-26 2023-07-25 Novartis Ag Methods for treating hematologic cancers
US10927125B2 (en) 2013-10-10 2021-02-23 Araxes Pharma Llc Substituted cinnolines as inhibitors of KRAS G12C
US11878985B2 (en) 2013-10-10 2024-01-23 Araxes Pharma Llc Substituted quinazolines as inhibitors of KRAS G12C
US10370386B2 (en) 2013-10-10 2019-08-06 Araxes Pharma Llc Substituted quinolines as inhibitors of KRAS G12C
US10377709B2 (en) 2013-10-23 2019-08-13 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10071961B2 (en) 2013-10-23 2018-09-11 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2015083059A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Forms of the egfr inhibitor
WO2015081463A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Egfr inhibitor forms
WO2015085482A1 (en) * 2013-12-10 2015-06-18 Novartis Ag Egfr inhibitor forms
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9873671B2 (en) 2014-01-16 2018-01-23 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
US10752687B2 (en) 2014-01-24 2020-08-25 Novartis Ag Antibody molecules to PD-1 and uses thereof
US11827704B2 (en) 2014-01-24 2023-11-28 Novartis Ag Antibody molecules to PD-1 and uses thereof
US11155620B2 (en) 2014-01-31 2021-10-26 Novartis Ag Method of detecting TIM-3 using antibody molecules to TIM-3
EP4324518A2 (en) 2014-01-31 2024-02-21 Novartis AG Antibody molecules to tim-3 and uses thereof
US10981990B2 (en) 2014-01-31 2021-04-20 Novartis Ag Antibody molecules to TIM-3 and uses thereof
US10472419B2 (en) 2014-01-31 2019-11-12 Novartis Ag Antibody molecules to TIM-3 and uses thereof
US10632112B2 (en) 2014-02-05 2020-04-28 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
US10213420B2 (en) 2014-02-05 2019-02-26 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2015134210A1 (en) * 2014-03-03 2015-09-11 Principia Biopharma, Inc. BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
US9932329B2 (en) 2014-03-03 2018-04-03 Principia Biopharma, Inc. Benzimidazole derivatives as RLK and ITK inhibitors
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
KR102663309B1 (en) 2014-03-20 2024-05-03 카펠라 테라퓨틱스, 인크. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US10202398B2 (en) 2014-03-20 2019-02-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US10683304B2 (en) 2014-03-20 2020-06-16 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
KR20170004968A (en) * 2014-03-20 2017-01-11 카펠라 테라퓨틱스, 인크. Benzimidazole derivatives as tyrosine kinase inhibitors for the treatment of cancer
WO2015143148A1 (en) * 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US11713322B2 (en) 2014-03-20 2023-08-01 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
WO2015143161A1 (en) * 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US10005765B2 (en) 2014-03-20 2018-06-26 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
AU2015231202B2 (en) * 2014-03-20 2019-08-22 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US11787788B2 (en) 2014-03-20 2023-10-17 Capella Therapeutics, Inc. Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
JP2020007327A (en) * 2014-03-20 2020-01-16 カペラ セラピューティクス，インコーポレーテッド Benzimidazole derivatives as erbb tyrosine kinase inhibitors for treatment of cancer
RU2741914C2 (en) * 2014-03-20 2021-01-29 Капелла Терапьютикс, Инк. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for treating cancer
TWI683813B (en) * 2014-03-20 2020-02-01 美商卡佩拉醫療公司 Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
TWI807150B (en) * 2014-03-20 2023-07-01 美商卡佩拉醫療公司 Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
CN114989140A (en) * 2014-03-20 2022-09-02 卡佩拉医疗公司 Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
CN114940673A (en) * 2014-03-20 2022-08-26 卡佩拉医疗公司 Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
KR20220100081A (en) * 2014-03-20 2022-07-14 카펠라 테라퓨틱스, 인크. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
CN106536506A (en) * 2014-03-20 2017-03-22 卡佩拉医疗公司 Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
JP2017508816A (en) * 2014-03-20 2017-03-30 カペラ セラピューティクス，インコーポレーテッド Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
KR102416358B1 (en) * 2014-03-20 2022-07-07 카펠라 테라퓨틱스, 인크. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
EP3922630A1 (en) * 2014-03-20 2021-12-15 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
AU2015231202B9 (en) * 2014-03-20 2019-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
JP7073316B2 (en) 2014-03-20 2022-05-23 カペラ セラピューティクス，インコーポレーテッド Benzimidazole derivative as an ERBB tyrosine kinase inhibitor for the treatment of cancer
JP2017512833A (en) * 2014-03-20 2017-05-25 カペラ セラピューティクス，インコーポレーテッド Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US10647707B2 (en) 2014-03-20 2020-05-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US11242352B2 (en) 2014-03-20 2022-02-08 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
CN106661027A (en) * 2014-03-20 2017-05-10 卡佩拉医疗公司 Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
CN107207510A (en) * 2014-07-31 2017-09-26 诺华股份有限公司 Conjoint therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
JP2017521474A (en) * 2014-07-31 2017-08-03 ノバルティス アーゲー Combination therapy
RU2695230C2 (en) * 2014-07-31 2019-07-22 Новартис Аг Combined therapy
WO2016040882A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
US10111874B2 (en) 2014-09-18 2018-10-30 Araxes Pharma Llc Combination therapies for treatment of cancer
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
EP3662903A2 (en) 2014-10-03 2020-06-10 Novartis AG Combination therapies
WO2016055916A1 (en) 2014-10-06 2016-04-14 Novartis Ag Therapeutic combination for the treatment of cancer
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
EP4245376A2 (en) 2014-10-14 2023-09-20 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
US11040053B2 (en) 2015-03-10 2021-06-22 Chinook Therapeutics, Inc. Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US10537580B2 (en) 2015-03-19 2020-01-21 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10829458B2 (en) 2015-04-10 2020-11-10 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
JP2018515544A (en) * 2015-05-15 2018-06-14 ノバルティス アーゲー Method for treating EGFR mutant cancer
WO2016185333A1 (en) 2015-05-15 2016-11-24 Novartis Ag Methods for treating egfr mutant cancers
US10881664B2 (en) 2015-05-15 2021-01-05 Novartis Ag Methods for treating EGFR mutant cancers
AU2016268477B2 (en) * 2015-05-22 2018-12-20 Novartis Ag Pharmaceutical compositions
WO2016189435A1 (en) 2015-05-22 2016-12-01 Novartis Ag Pharmaceutical compositions
JP2018515566A (en) * 2015-05-22 2018-06-14 ノバルティス アーゲー Pharmaceutical composition
US10836722B2 (en) 2015-06-30 2020-11-17 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
EP3317273A4 (en) * 2015-06-30 2019-03-20 Dana Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
US10385019B2 (en) 2015-06-30 2019-08-20 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
WO2017004383A1 (en) 2015-06-30 2017-01-05 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10351550B2 (en) 2015-07-22 2019-07-16 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN108235685A (en) * 2015-07-29 2018-06-29 诺华股份有限公司 The combination of PD-1 antagonists and EGFR inhibitor
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
CN108602776A (en) * 2015-09-18 2018-09-28 默克专利有限公司 Heteroaryl compound and application thereof as IRAK inhibitor
RU2743360C2 (en) * 2015-09-18 2021-02-17 Мерк Патент Гмбх Heteroaryl compounds as irak inhibitors and use thereof
US9969710B2 (en) 2015-09-18 2018-05-15 Merck Patent Gmbh Heteroaryl compounds as IRAK inhibitors and uses thereof
KR20180063145A (en) * 2015-09-18 2018-06-11 메르크 파텐트 게엠베하 Heteroaryl compounds as IRAK inhibitors and uses thereof
IL258081B (en) * 2015-09-18 2022-10-01 Merck Patent Gmbh Benzimidazole derivatives and their use
IL258081B2 (en) * 2015-09-18 2023-02-01 Merck Patent Gmbh Benzimidazole derivatives and their use
AU2016323613B2 (en) * 2015-09-18 2020-12-10 Merck Patent Gmbh Heteroaryl compounds as IRAK inhibitors and uses thereof
CN108602776B (en) * 2015-09-18 2021-12-03 默克专利有限公司 Heteroaryl compounds as IRAK inhibitors and uses thereof
KR102650026B1 (en) * 2015-09-18 2024-03-22 메르크 파텐트 게엠베하 Heteroaryl compounds as IRAK inhibitors and uses thereof
WO2017049069A1 (en) * 2015-09-18 2017-03-23 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
US10590108B2 (en) 2015-09-23 2020-03-17 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
WO2017053537A1 (en) * 2015-09-23 2017-03-30 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
US11427565B2 (en) 2015-09-23 2022-08-30 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10077239B2 (en) 2015-09-29 2018-09-18 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US11021470B2 (en) 2015-11-16 2021-06-01 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
EP4424322A2 (en) 2015-12-17 2024-09-04 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017175144A1 (en) 2016-04-08 2017-10-12 Novartis Ag New therapeutic uses
US10441589B2 (en) 2016-04-15 2019-10-15 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
US11129834B2 (en) 2016-04-15 2021-09-28 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN109983009A (en) * 2016-08-17 2019-07-05 Gb005股份有限公司 Containing whorled compound and its medicinal usage
US10723738B2 (en) 2016-09-29 2020-07-28 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018140513A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
WO2018198076A1 (en) 2017-04-28 2018-11-01 Aduro Biotech, Inc. Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof
US10975114B2 (en) 2017-04-28 2021-04-13 Chinook Therapeutics, Inc. Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof
US11377441B2 (en) 2017-05-25 2022-07-05 Araxes Pharma Llc Covalent inhibitors of KRAS
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2018234879A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019026006A1 (en) 2017-08-03 2019-02-07 Novartis Ag Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
WO2019026007A1 (en) 2017-08-03 2019-02-07 Novartis Ag Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
CN109721605B (en) * 2017-10-31 2022-03-11 维眸生物科技（上海）有限公司 Immune cell migration inhibitor
CN109721605A (en) * 2017-10-31 2019-05-07 维眸生物科技（上海）有限公司 A kind of immunocyte migrates inhibitor
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
US11174245B2 (en) 2018-02-21 2021-11-16 Boehringer Ingelheim International Gmbh Benzimidazole compounds and derivatives as EGFR inhibitors
WO2019162323A1 (en) 2018-02-21 2019-08-29 Boehringer Ingelheim International Gmbh New benzimidazole compounds and derivatives as egfr inhibitors
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
WO2019202527A1 (en) 2018-04-18 2019-10-24 Novartis Ag Nazartinib for use in the treatment of cns metastasis
US11220494B2 (en) 2018-04-26 2022-01-11 Pfizer Inc. Cyclin dependent kinase inhibitors
WO2019229658A1 (en) 2018-05-30 2019-12-05 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019229701A2 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
CN109369620A (en) * 2018-12-22 2019-02-22 山东大学 Pyridine compounds and their and preparation method thereof and anti-gastric cancer application
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
WO2020260252A1 (en) 2019-06-24 2020-12-30 Boehringer Ingelheim International Gmbh New macrocyclic compounds and derivatives as egfr inhibitors
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021224867A1 (en) 2020-05-08 2021-11-11 Novartis Ag Pharmaceutical combination comprising tno155 and nazartinib
WO2021239786A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab Egfr tkis for use in the treatment of non-small cell lung cancer
WO2022081478A1 (en) * 2020-10-12 2022-04-21 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
WO2022090481A1 (en) 2020-11-02 2022-05-05 Boehringer Ingelheim International Gmbh Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
WO2022265950A1 (en) 2021-06-15 2022-12-22 Genentech, Inc. Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023244587A1 (en) * 2022-06-14 2023-12-21 Genzyme Corporation Methods of making tolebrutinib

Also Published As

Publication number Publication date
EP2773635A1 (en) 2014-09-10
TN2014000487A1 (en) 2016-03-30
EP2773635B1 (en) 2017-08-02
BR112014030386A8 (en) 2021-09-28
BR112014030386A2 (en) 2017-06-27
ES2645973T3 (en) 2017-12-11
EA201492219A1 (en) 2015-05-29
MA37739A1 (en) 2018-09-28
UY34849A (en) 2014-01-31
JO3300B1 (en) 2018-09-16
DOP2014000277A (en) 2015-03-15
NZ627661A (en) 2016-02-26
MX2014014961A (en) 2015-07-17
EA026269B1 (en) 2017-03-31
PL2773635T3 (en) 2018-01-31
PH12014502704B1 (en) 2015-02-02
DK2773635T3 (en) 2017-11-06
KR20150023555A (en) 2015-03-05
AP2014008083A0 (en) 2014-11-30
CN104379575B (en) 2018-04-17
HRP20171670T1 (en) 2017-12-15
LT2773635T (en) 2017-10-10
HUE034759T2 (en) 2018-02-28
UA113543C2 (en) 2017-02-10
AP3909A (en) 2016-11-24
BR112014030386B1 (en) 2022-09-27
CL2014003227A1 (en) 2015-02-06
US20150197505A1 (en) 2015-07-16
CO7160047A2 (en) 2015-01-15
GEP201606555B (en) 2016-10-10
IL235974A0 (en) 2015-02-01
CU20140139A7 (en) 2015-04-29
JP6039800B2 (en) 2016-12-07
AR091368A1 (en) 2015-01-28
PH12014502704A1 (en) 2015-02-02
TWI650319B (en) 2019-02-11
JP2015518894A (en) 2015-07-06
MA37739B1 (en) 2018-10-31
RS56396B1 (en) 2017-12-29
SG11201407793TA (en) 2014-12-30
MY165036A (en) 2018-02-28
CN104379575A (en) 2015-02-25
SI2773635T1 (en) 2017-11-30
EP3257848A1 (en) 2017-12-20
US9440957B2 (en) 2016-09-13
CR20140563A (en) 2015-01-16
PT2773635T (en) 2017-09-26
PE20150726A1 (en) 2015-05-17
CA2875966C (en) 2019-02-26
AU2013271733B2 (en) 2017-02-16
CA2875966A1 (en) 2013-12-12
IL235974A (en) 2016-11-30
GT201400282A (en) 2015-06-02
TW201350476A (en) 2013-12-16
KR101817829B1 (en) 2018-01-11
MX345630B (en) 2017-02-08
CY1119531T1 (en) 2018-03-07
AU2013271733A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
EP2773635B1 (en) Compounds and compositions for modulating egfr activity
US20200325138A1 (en) P2X7 Modulators
JP6545199B2 (en) 3-Amino-1,5,6,7-tetrahydro-4H-indol-4-ones
AU2014240388B2 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
WO2013184766A1 (en) Compounds and compositions for modulating egfr activity
BR112016011024B1 (en) COMPOUND, PHARMACEUTICAL COMPOSITION AND USES OF THE SAME
KR20150028999A (en) 5-azaindazole compounds and methods of use
TW202031657A (en) Azalactam compounds as hpk1 inhibitors
KR20180032611A (en) TGF beta receptor antagonist
WO2024054832A1 (en) CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
WO2020116662A1 (en) Cycloalkane-1,3-diamine derivative
TW202321239A (en) Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
WO2024028169A1 (en) Novel specifically substituted thiophenolic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13729219

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2013729219

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013729219

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013271733

Country of ref document: AU

Date of ref document: 20130605

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDP00201407412

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 2014003227

Country of ref document: CL

Ref document number: 235974

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 002377-2014

Country of ref document: PE

Ref document number: 14405773

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2015516156

Country of ref document: JP

Kind code of ref document: A

Ref document number: 13656

Country of ref document: GE

Kind code of ref document: P

Ref document number: 2875966

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: CR2014-000563

Country of ref document: CR

Ref document number: MX/A/2014/014961

Country of ref document: MX

Ref document number: 14268955

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201492219

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20147037047

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201412612

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 37739

Country of ref document: MA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014030386

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014030386

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141204

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112014030386

Country of ref document: BR

Kind code of ref document: A2

Free format text: EXPLIQUE A DIVERGENCIA NO NOME DE UM DOS INVENTORES (MATTHEW H MCNEILL ) QUE CONSTA NA PUBLICACAO INTERNACIONAL WO 2013/184757 E O CONSTANTE DA PETICAO INICIAL NO 860140203201 .

ENP Entry into the national phase

Ref document number: 112014030386

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141204